var title_f38_20_39232="Metacarpal fracture with malrotation";
var content_f38_20_39232=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=EM%2F71612&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=EM%2F71612&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Malrotation due to metacarpal fracture",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 429px; height: 321px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    The axes of the fingers normally converge when the metacarpophalangeal and proximal interphalangeal joints are both flexed. In this photograph, while the 2nd, 3rd, and 4th fingers converge as they should, the 5th does not. The divergence of the 5th digit is the result of a 5th metacarpal shaft fracture complicated by malrotation.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Kevin Burroughs, MD",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f38_20_39232=[""].join("\n");
var outline_f38_20_39232=null;
var title_f38_20_39233="Saline in occult constriction";
var content_f38_20_39233=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=CARD%2F70708&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=CARD%2F70708&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Saline loading unmasks occult constrictive pericarditis",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 370px; height: 351px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Right atrial pressure tracings before (top panel) and after (bottom panel) saline loading in a patient with occult constrictive pericarditis. The previously normal right atrial pressure developed the characteristics of constrictive pericarditis (with equalization of pressures after fluid challenge.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Redrawn from: Bush CA, Stang JM, Wooley CF, Kilman JW. Circulation 1977; 56:924.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f38_20_39233=[""].join("\n");
var outline_f38_20_39233=null;
var title_f38_20_39234="Myomectomy with hysteroscope";
var content_f38_20_39234=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=OBGYN%2F58947&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=OBGYN%2F58947&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 527px\">",
"   <div class=\"ttl\">",
"    Myomectomy with hysteroscope",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 507px; height: 232px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Resection of uterine leiomyoma.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f38_20_39234=[""].join("\n");
var outline_f38_20_39234=null;
var title_f38_20_39235="Carboxymethylcellulose: Patient drug information";
var content_f38_20_39235=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/wk_utd-rgb.myextg\" width=\"220px\">",
"   </img>",
"  </div>",
"  <div id=\"printHeaderText\">",
"   Official reprint from  UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"   <a href=\"file://www.uptodate.com\">",
"    www.uptodate.com",
"   </a>",
"   <br>",
"    &copy;2013 UpToDate",
"    <sup>",
"     &reg;",
"    </sup>",
"   </br>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"disclaimer\">",
"   The content on the UpToDate website is not intended nor recommended as a substitute",
"for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or",
"other qualified health care professional regarding any medical questions or conditions.  The",
"use of this website is governed by the",
"   <a href=\"/home/terms-use\" target=\"_blank\">",
"    UpToDate Terms of Use",
"   </a>",
"   &copy;2013 UpToDate, Inc.",
"  </div>",
"  <div id=\"drugTitle\">",
"   Carboxymethylcellulose: Patient drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   <p>",
"    (For additional information",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?28/34/29218?source=see_link\">",
"     see \"Carboxymethylcellulose: Drug information\"",
"    </a>",
"    )",
"   </p>",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F146317\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Optive&trade; [OTC];",
"     </li>",
"     <li>",
"      Refresh Liquigel&trade; [OTC];",
"     </li>",
"     <li>",
"      Refresh Plus&reg; [OTC];",
"     </li>",
"     <li>",
"      Refresh Tears&reg; [OTC];",
"     </li>",
"     <li>",
"      Tears Again&reg; Night &amp; Day&trade; [OTC];",
"     </li>",
"     <li>",
"      Theratears&reg; [OTC]",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F146318\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Celluvisc&trade;;",
"     </li>",
"     <li>",
"      Refresh Plus&reg;;",
"     </li>",
"     <li>",
"      Refresh Tears&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yya-os drugH1Div\" id=\"F10016627\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What is this drug used for?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2691824",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used to treat dry eyes.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt coi-os drugH1Div\" id=\"F10016626\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I need to tell my doctor before I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2701722",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have an allergy to carboxymethylcellulose or any other part of this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2705171",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are allergic to any drugs, foods, or other substances. Tell your doctor about the allergy and what signs you had, like rash; hives; itching; shortness of breath; wheezing; cough; swelling of face, lips, tongue, or throat; or any other signs.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yye-os drugH1Div\" id=\"F10016631\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some things I need to know or do while I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696947",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not use this drug to treat contact lens irritation.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696717",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Check all drugs you are taking with your doctor. This drug may not mix well with some other drugs.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyf-os drugH1Div\" id=\"F10016632\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects of this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697912",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Blurred eyesight. Use care when driving or doing other tasks that call for clear eyesight.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698333",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Short-term pain after use.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyh-os drugH1Div\" id=\"F10016634\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects that I need to call my doctor about right away?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698721",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you think there has been an overdose, call 1-800-222-1222 (the American Association of Poison Control Centers), your local poison control center (file://www.aapcc.org), or emergency room (ER) right away.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699066",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Signs of an allergic reaction, like rash; hives; itching; red, swollen, blistered, or peeling skin with or without fever; wheezing; tightness in the chest or throat; trouble breathing or talking; unusual hoarseness; or swelling of the mouth, face, lips, tongue, or throat.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699086",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Sudden change in eyesight, eye pain, or irritation.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698603",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Any rash.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698977",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Side effect or health problem is not better or you are feeling worse.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyc-os drugH1Div\" id=\"F10016629\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How is this drug best taken?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2694913",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       For the eye only.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695783",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Take out contact lenses before using this drug. Lenses may be put back in 15 minutes after this drug is given. Do not put contacts back in if your eyes are irritated or infected.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2694779",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not touch the container tip to the eye, lid, or other skin.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696124",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tilt your head back and drop drug into the eye.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2694401",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       After use, keep your eyes closed. Put pressure on the inside corner of the eye. Do this for 1 to 2 minutes. This keeps the drug in your eye.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695618",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Space each eye drug by 5 minutes.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyd-os drugH1Div\" id=\"F10016630\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I do if I miss a dose?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696583",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Use a missed dose as soon as you think about it.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696496",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If it is close to the time for your next dose, skip the missed dose and go back to your normal time.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696485",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not use 2 doses or extra doses.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696549",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Many times this drug is used on an as needed basis.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyi-os drugH1Div\" id=\"F10016635\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How do I store and/or throw out this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699336",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Store at room temperature.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyj-os drugH1Div\" id=\"F10016636\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     General drug facts",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699675",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If your symptoms or health problems do not get better or if they become worse, call your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699673",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not share your drugs with others and do not take anyone else's drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699678",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep all drugs out of the reach of children and pets.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699709",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have any questions about this drug, please talk with your doctor, pharmacist, or other health care provider.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s3302581",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       In Canada, take any unused drugs to the pharmacy. Also, visit file://www.hc-sc.gc.ca/hl-vs/iyh-vsv/med/disposal-defaire-eng.php#th to learn about the right way to get rid of unused drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699671",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       These are not all of the side effects that may occur. If you have questions about side effects, call your doctor. Call your doctor for medical advice about side effects.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699683",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Talk with the doctor before starting any new drug, including prescription or OTC, natural products, or vitamins.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 11699 Version 33.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.3 - C21.34",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Morehouse School of Medicine",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1002-210.101.131.232-2A3F076F4F-S473950.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f38_20_39235=[""].join("\n");
var outline_f38_20_39235=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F146317\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F146318\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10016627\">",
"      What is this drug used for?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10016626\">",
"      What do I need to tell my doctor before I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10016631\">",
"      What are some things I need to know or do while I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10016632\">",
"      What are some side effects of this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10016634\">",
"      What are some side effects that I need to call my doctor about right away?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10016629\">",
"      How is this drug best taken?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10016630\">",
"      What do I do if I miss a dose?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10016635\">",
"      How do I store and/or throw out this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10016636\">",
"      General drug facts",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"mobipreview.htm?28/34/29218?source=related_link\">",
"      Carboxymethylcellulose: Drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f38_20_39236="US geographic distribution";
var content_f38_20_39236=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=EM%2F56537&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=EM%2F56537&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 577px\">",
"   <div class=\"ttl\">",
"    US geographic distribution of verified widespread populations of six native Loxosceles species",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 557px; height: 410px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Dr. Rick Vetter. For more information, please visit",
"     <a href=\"file://spiders.ucr.edu/\" target=\"_blank\">",
"      file://spiders.ucr.edu/",
"     </a>",
"     . Copyright &copy; 2011 Regents of the University of California.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f38_20_39236=[""].join("\n");
var outline_f38_20_39236=null;
var title_f38_20_39237="Dapsone (systemic): Pediatric drug information";
var content_f38_20_39237=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Dapsone (systemic): Pediatric drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_general\" href=\"mobipreview.htm?29/7/29814?source=see_link\">",
"    see \"Dapsone (systemic): Drug information\"",
"   </a>",
"   and",
"   <a class=\"drug drug_patient\" href=\"mobipreview.htm?9/22/9573?source=see_link\">",
"    see \"Dapsone (systemic): Patient drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"mobipreview.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"list_set htclist drugH1Div drugBrandNames\" id=\"F10483704\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Therapeutic Category",
"    </span>",
"    <ul>",
"     <li>",
"      <span class=\"list-set-name\">",
"       Antibiotic, Sulfone",
"      </span>",
"     </li>",
"     <li>",
"      <span class=\"list-set-name\">",
"       Leprostatic Agent",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block dos drugH1Div\" id=\"F10483725\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Usual",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_general\" href=\"mobipreview.htm?29/7/29814?source=see_link\">",
"      see \"Dapsone (systemic): Drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Oral:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Children &ge;1 month of age:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Prophylaxis for first episode of opportunistic disease due to",
"     <i>",
"      Toxoplasma gondii",
"     </i>",
"     : 2 mg/kg or 15 mg/m",
"     <sup>",
"      2",
"     </sup>",
"     (maximum dose: 25 mg) once daily in combination with pyrimethamine 1 mg/kg once daily and leucovorin 5 mg every 3 days",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Primary and secondary PCP prophylaxis: 2 mg/kg/day once daily (maximum dose: 100 mg/day), or 4 mg/kg/dose once weekly (maximum dose: 200 mg)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Children: Leprosy: 1-2 mg/kg/day given once daily in combination therapy; maximum dose: 100 mg/day",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Adults:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Leprosy: 50-100 mg once daily; combination therapy with one or more antileprosy drugs is recommended to avoid dapsone resistance",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Dermatitis herpetiformis: Initial: 50 mg once daily; maintenance dosage range: 25-400 mg/day",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     PCP treatment: 100 mg once daily in combination with trimethoprim",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Primary and secondary PCP prophylaxis: 50 mg twice daily; or dapsone 50 mg once daily plus pyrimethamine 50 mg orally every week plus leucovorin 25 mg orally every week; or dapsone 200 mg orally plus pyrimethamine 75 mg orally plus leucovorin 25 mg orally every week",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     <i>",
"      Toxoplasma gondii",
"     </i>",
"     prophylaxis: 50 mg once daily plus pyrimethamine 50 mg orally every week, plus leucovorin 25 mg orally every week",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F8015379\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Tablet, oral: 25 mg, 100 mg",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F9490508\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Yes",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F10483764\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Administer with water. Separate buffered didanosine administration from dapsone by at least 2 hours.",
"    </p>",
"   </div>",
"   <div class=\"block sta drugH1Div\" id=\"F10483711\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Stability",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Store at room temperature. Protect from light.",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F10483705\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Treatment of leprosy due to susceptible strains of",
"     <i>",
"      M. leprae",
"     </i>",
"     ; treatment of dermatitis herpetiformis; prophylaxis against",
"     <i>",
"      Pneumocystis jirovecii",
"     </i>",
"     pneumonia (PCP) in patients who cannot tolerate sulfamethoxazole and trimethoprim or aerosolized pentamidine; prophylaxis against toxoplasmic encephalitis in patients who cannot tolerate sulfamethoxazole and trimethoprim",
"    </p>",
"   </div>",
"   <div class=\"block mst drugH1Div\" id=\"F8015264\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Medication Safety Issues",
"    </span>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      Sound-alike/look-alike issues:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;\">",
"       Dapsone may be confused with Diprosone&reg;",
"      </p>",
"     </div>",
"    </div>",
"   </div>",
"   <div class=\"block arm drugH1Div\" id=\"F8015299\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Cardiovascular: Tachycardia",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Central nervous system: Fever, headache, insomnia, psychosis (oral/topical), vertigo",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Dermatologic: Bullous and exfoliative dermatitis, erythema nodosum, exfoliative dermatitis, morbilliform and scarlatiniform reactions, phototoxicity, Stevens-Johnson syndrome, toxic epidural necrolysis, urticaria",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Endocrine &amp; metabolic: Hypoalbuminemia (without proteinuria), male infertility",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Gastrointestinal: Abdominal pain, nausea, pancreatitis, vomiting",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Hematologic:  Agranulocytosis, anemia, leukopenia,  pure red cell aplasia (case report); hemolysis (dose related; seen in patients with and without G6PD deficiency), hemoglobin decrease (1-2 g/dL), reticulocyte increase, methemoglobinemia, red cell life span shortened",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Hepatic: Cholestatic jaundice, hepatitis",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Neuromuscular &amp; skeletal: Drug-induced lupus erythematosus, lower motor neuron toxicity (prolonged therapy), peripheral neuropathy (rare, nonleprosy patients)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ocular:  Blurred vision",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Otic: Tinnitus",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Renal: Albuminuria, nephrotic syndrome, renal papillary necrosis",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Respiratory: Interstitial pneumonitis, pulmonary eosinophilia",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Miscellaneous: Infectious mononucleosis-like syndrome (rash, fever, lymphadenopathy, hepatic dysfunction)",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F10483706\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hypersensitivity to dapsone or any component; patients with severe anemia",
"    </p>",
"   </div>",
"   <div class=\"block pre drugH1Div\" id=\"F10483707\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Precautions",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Use with caution in patients with G-6-PD deficiency, methemoglobin reductase deficiency or hemoglobin M; in patients receiving drugs capable of inducing hemolysis and in patients with severe cardiopulmonary disease; hypersensitivity to other sulfonamides; obtain G-6-PD levels prior to initiating dapsone therapy",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F8015301\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      Substrate",
"     </b>",
"     of CYP2C19 (minor), CYP2C8 (minor), CYP2C9 (major), CYP2E1 (minor), CYP3A4 (major);",
"     <b>",
"      Note:",
"     </b>",
"     Assignment of Major/Minor substrate status based on clinically relevant drug interaction potential",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F8015302\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Antimalarial Agents: May enhance the adverse/toxic effect of Dapsone (Systemic). Specifically, concomitant use of antimalarial agents with dapsone may increase the risk of hemolytic reactions. Dapsone (Systemic) may enhance the adverse/toxic effect of Antimalarial Agents. Specifically, concomitant use of dapsone with antimalarial agents may increase the risk for hemolytic reactions. Management: Closely monitor patients for signs/symptoms of hemolytic reactions with concomitant use of dapsone and antimalarial agents, particularly in patients deficient in glucose-6-phosphate dehydrogenase (G6PD), methemoglobin reductase, or with hemoglobin M.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     BCG: Antibiotics may diminish the therapeutic effect of BCG.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Conivaptan: May increase the serum concentration of CYP3A4 Substrates.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP2C9 Inducers (Strong): May increase the metabolism of CYP2C9 Substrates. Management: Consider an alternative for one of the interacting drugs. Some combinations may be specifically contraindicated. Consult appropriate manufacturer labeling.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP2C9 Inhibitors (Moderate): May decrease the metabolism of CYP2C9 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP2C9 Inhibitors (Strong): May decrease the metabolism of CYP2C9 Substrates.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP3A4 Inducers (Strong): May increase the metabolism of CYP3A4 Substrates. Management: Consider an alternative for one of the interacting drugs. Some combinations may be specifically contraindicated. Consult appropriate manufacturer labeling.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP3A4 Inhibitors (Moderate): May decrease the metabolism of CYP3A4 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP3A4 Inhibitors (Strong): May decrease the metabolism of CYP3A4 Substrates.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Dasatinib: May increase the serum concentration of CYP3A4 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Deferasirox: May decrease the serum concentration of CYP3A4 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Herbs (CYP3A4 Inducers): May increase the metabolism of CYP3A4 Substrates. Management: Consider avoiding CYP3A4 inducing herbs in order to avoid therapeutic failure of the substrate. Some combinations may be specifically contraindicated. Consult appropriate manufacturer labeling.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ivacaftor: May increase the serum concentration of CYP3A4 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Mifepristone: May increase the serum concentration of CYP2C9 Substrates. Management: Use CYP2C9 substrates at the lowest recommended dose, and monitor closely for adverse effects, during and in the 2 weeks following mifepristone treatment.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Mifepristone: May increase the serum concentration of CYP3A4 Substrates. Management: Minimize doses of CYP3A4 substrates, and monitor for increased concentrations/toxicity, during and 2 weeks following treatment with mifepristone. Avoid cyclosporine, dihydroergotamine, ergotamine, fentanyl, pimozide, quinidine, sirolimus, and tacrolimus.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Peginterferon Alfa-2b: May decrease the serum concentration of CYP2C9 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Prilocaine: Methemoglobinemia Associated Agents may enhance the adverse/toxic effect of Prilocaine. Combinations of these agents may increase the likelihood of significant methemoglobinemia.  Management: Monitor patients for signs of methemoglobinemia (e.g., hypoxia, cyanosis) when prilocaine is used in combination with other agents associated with development of methemoglobinemia.  Avoid lidocaine/prilocaine in infants receiving such agents.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Probenecid: May increase the serum concentration of Dapsone (Systemic).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Rifamycin Derivatives: May increase the metabolism of Dapsone (Systemic).",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Sodium Picosulfate: Antibiotics may diminish the therapeutic effect of Sodium Picosulfate.  Management: Consider using an alternative product for bowel cleansing prior to a colonoscopy in patients who have recently used or are concurrently using an antibiotic.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tocilizumab: May decrease the serum concentration of CYP3A4 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Trimethoprim: Dapsone (Systemic) may increase the serum concentration of Trimethoprim. Trimethoprim may increase the serum concentration of Dapsone (Systemic).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Typhoid Vaccine: Antibiotics may diminish the therapeutic effect of Typhoid Vaccine. Only the live attenuated Ty21a strain is affected.  Management: Vaccination with live attenuated typhoid vaccine (Ty21a) should be avoided in patients being treated with systemic antibacterial agents.  Use of this vaccine should be postponed until at least 24 hours after cessation of antibacterial agents.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"   </div>",
"   <div class=\"block foi drugH1Div\" id=\"F10483710\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Food Interactions",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Do not administer with antacids, alkaline foods, or alkaline drugs; may decrease dapsone absorption",
"    </p>",
"   </div>",
"   <div class=\"block prf drugH1Div\" id=\"F8015289\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Risk Factor",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     C (",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?16/42/17068\">",
"      show table",
"     </a>",
"     )",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F8015290\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Because of adverse events observed in some animal studies, dapsone is classified as pregnancy category C. Per the manufacturer, dapsone has not shown an increased risk of congenital anomalies when given during all trimesters of pregnancy. Several reports have described adverse effects in the newborn after",
"     <i>",
"      in utero",
"     </i>",
"     exposure to dapsone, including neonatal hemolytic disease, methemoglobinemia, and hyperbilirubinemia. Dapsone is an alternative for prophylaxis and treatment of",
"     <i>",
"      Pneumocystis jirovecii",
"     </i>",
"     pneumonia (PCP) in pregnant, HIV-infected patients. Dapsone is also recommended for pregnant women requiring maintenance therapy of either leprosy or dermatitis herpetiformis",
"    </p>",
"   </div>",
"   <div class=\"block mop drugH1Div\" id=\"F10483765\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Monitoring Parameters",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     CBC with differential, platelet count, hemoglobin, reticulocyte count, hematocrit, liver function tests, and urinalysis; check G-6-PD levels prior to initiation of dapsone",
"    </p>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F10483712\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Dapsone is a sulfone antimicrobial. The mechanism of action of the sulfones is similar to that of the sulfonamides. Sulfonamides are competitive antagonists of para-aminobenzoic acid (PABA) and inhibit folic acid synthesis in susceptible organisms.",
"    </p>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F10483724\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacokinetics (Adult data unless noted)",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Absorption: 86% to 100%",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Distribution: Distributes into skin, muscle, kidneys, liver, sweat, sputum, saliva, tears, and bile; crosses the placenta",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     V",
"     <sub>",
"      d",
"     </sub>",
"     : Adults: 1.5-2.5 L/kg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Protein binding: 50% to 90%",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Metabolism: Acetylated and hydroxylated in the liver",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Half-life:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Children: 15.1 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Adults: 13-83 hours (mean: 20-30 hours)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Time to peak serum concentration: Within 2-8 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Elimination: 5% to 20% of dose excreted in urine as unchanged drug; 70% to 85% excreted in urine as metabolites; small amount excreted in feces",
"    </p>",
"   </div>",
"   <div class=\"block pai drugH1Div\" id=\"F10483766\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Patient Information",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_patient\" href=\"mobipreview.htm?9/22/9573?source=see_link\">",
"      see \"Dapsone (systemic): Patient drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Notify physician if fever, sore throat, pallor, fatigue, muscle weakness, rash, purpura, or jaundice occurs. May cause photosensitivity reactions (eg, exposure to sunlight may cause severe sunburn, skin rash, redness, itching); avoid exposure to sunlight and artificial light sources (sunlamps, tanning booth/bed); wear protective clothing, wide-brimmed hats, sunglasses, and lip sunscreen (SPF &ge;15); use a sunscreen [broad-spectrum sunscreen or physical sunscreen (preferred) or sunblock with SPF &ge;15]; contact physician if reaction occurs. Dapsone distributes into breast milk and may harm your baby. A decision should be made to discontinue breast-feeding or the drug.",
"    </p>",
"   </div>",
"   <div class=\"block adi drugH1Div\" id=\"F10483767\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Additional Information",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      Note:",
"     </b>",
"     Guidelines for prophylaxis of",
"     <i>",
"      Pneumocystis jirovecii",
"     </i>",
"     pneumonia: Initiate PCP prophylaxis in the following patients: In all HIV-exposed children at 4-6 weeks of age and continue through the first year of life or until HIV infection has been reasonably excluded; children 1-5 years of age with CD4+ count &lt;500 or CD4+ percentage &lt;15%; children 6-12 years of age with CD4+ count &lt;200 or CD4+ percentage &lt;15%; adolescents and adults with CD4+ count &lt;200 or oropharyngeal candidiasis. Folinic acid (leucovorin) should be given if bone marrow suppression occurs.",
"    </p>",
"   </div>",
"   <div class=\"block exp drugH1Div\" id=\"F8015382\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Extemporaneous Preparations",
"    </span>",
"    <p style=\"text-indent:0em;margin-top:2em;display:inline\">",
"     A 2 mg/mL oral suspension may be made with tablets and a 1:1 mixture of Ora-Sweet&reg; and Ora-Plus&reg;. Crush eight 25 mg tablets in a mortar and reduce to a fine powder. Add small portions of vehicle and mix to a uniform paste; mix while adding the vehicle in incremental proportions to",
"     <b>",
"      almost",
"     </b>",
"     100 mL; transfer to a calibrated bottle, rinse mortar with vehicle, and add quantity of vehicle sufficient to make 100 mL. Label \"shake well\". Stable for 90 days at room temperature or refrigerated.",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;\">",
"     Jacobus Pharmaceutical Company makes a 2 mg/mL proprietary liquid formulation available under an IND for the prophylaxis of",
"     <i>",
"      Pneumocystis jirovecii",
"     </i>",
"     pneumonia.",
"    </p>",
"    <div class=\"reference\">",
"     Nahata MC, Morosco RS, and Trowbridge JM, \"Stability of Dapsone in Two Oral Liquid Dosage Forms,\"",
"     <i>",
"      Ann Pharmacother",
"     </i>",
"     , 2000, 34(7-8):848-50.",
"     <span class=\"pubmed-id\">",
"      10928393",
"     </span>",
"    </div>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <div class=\"reference\">",
"      Barnett ED, Pelton SI, Mirochnick M, et al, \"Dapsone for Prevention of",
"      <i>",
"       Pneumocystis",
"      </i>",
"      Pneumonia in Children With Acquired Immunodeficiency Syndrome\"",
"      <i>",
"       Pediatr Infect Dis J",
"      </i>",
"      , 1994, 13(1):72-4.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?38/20/39237/abstract-text/8170736/pubmed\" id=\"8170736\" target=\"_blank\">",
"        8170736",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Centers for Disease Control and Prevention (CDC), \"Guidelines for the Prevention and Treatment of Opportunistic Infections Among HIV-Exposed and HIV-Infected Children,\"",
"      <i>",
"       MMWR Recomm Rep",
"      </i>",
"      , 2009, 58(RR-11):1-166. Available at",
"      <a href=\"file://aidsinfo.nih.gov/contentfiles/Pediatric_OI.pdf%20\" target=\"_blank\">",
"       file://aidsinfo.nih.gov/contentfiles/Pediatric_OI.pdf",
"      </a>",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?38/20/39237/abstract-text/19730409/pubmed\" id=\"19730409\" target=\"_blank\">",
"        19730409",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Kaplan JE, Masur H, Holmes KK, et al, \"Guidelines for Preventing Opportunistic Infections Among HIV-Infected Persons &minus; 2002. Recommendations of the U.S. Public Health Service and the Infectious Diseases Society of America,\"",
"      <i>",
"       MMWR Recomm Rep",
"      </i>",
"      , 2002, 51(RR-8):1-52.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?38/20/39237/abstract-text/12081007/pubmed\" id=\"12081007\" target=\"_blank\">",
"        12081007",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Mirochnick M, Michaels M, Clarke D, et al, \"Pharmacokinetics of Dapsone in Children,\"",
"      <i>",
"       J Pediatr",
"      </i>",
"      , 1993, 122(5 Pt 1):806-9.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?38/20/39237/abstract-text/8496767/pubmed\" id=\"8496767\" target=\"_blank\">",
"        8496767",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Stavola JJ and Noel GJ, \"Efficacy and Safety of Dapsone Prophylaxis Against",
"      <i>",
"       Pneumocystis carinii",
"      </i>",
"      Pneumonia in Human Immunodeficiency Virus-Infected Children,\"",
"      <i>",
"       Pediatr Infect Dis J",
"      </i>",
"      , 1993, 12(8):644-7.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?38/20/39237/abstract-text/8414776/pubmed\" id=\"8414776\" target=\"_blank\">",
"        8414776",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 15963 Version 31.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1003-122.72.76.133-D31E40A6FC-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f38_20_39237=[""].join("\n");
var outline_f38_20_39237=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10483704\">",
"      Therapeutic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10483725\">",
"      Dosing: Usual",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8015379\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9490508\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10483764\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10483711\">",
"      Stability",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10483705\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8015264\">",
"      Medication Safety Issues",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8015299\">",
"      Adverse Reactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10483706\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10483707\">",
"      Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8015301\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8015302\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10483710\">",
"      Food Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8015289\">",
"      Pregnancy Risk Factor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8015290\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10483765\">",
"      Monitoring Parameters",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10483712\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10483724\">",
"      Pharmacokinetics (Adult data unless noted)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10483766\">",
"      Patient Information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10483767\">",
"      Additional Information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8015382\">",
"      Extemporaneous Preparations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_PED/15963\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_PED/15963|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"mobipreview.htm?29/7/29814?source=related_link\">",
"      Dapsone (systemic): Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"mobipreview.htm?9/22/9573?source=related_link\">",
"      Dapsone (systemic): Patient drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"mobipreview.htm?43/34/44579?source=related_link\">",
"      Dapsone (topical): Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"mobipreview.htm?1/51/1844?source=related_link\">",
"      Dapsone (topical): Patient drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?10/40/10883?source=related_link\">",
"      Dapsone (topical): Pediatric drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f38_20_39238="Advanced case 16 with answer";
var content_f38_20_39238=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=CARD%2F61287&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=CARD%2F61287&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Inverted U waves",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 379px; height: 240px; background-image: url(data:image/jpeg;base64,/9j/4AAQSkZJRgABAQAAAQABAAD/2wBDAAYEBQYFBAYGBQYHBwYIChAKCgkJChQODwwQFxQYGBcUFhYaHSUfGhsjHBYWICwgIyYnKSopGR8tMC0oMCUoKSj/2wBDAQcHBwoIChMKChMoGhYaKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCj/wAARCADwAXsDASIAAhEBAxEB/8QAHwAAAQUBAQEBAQEAAAAAAAAAAAECAwQFBgcICQoL/8QAtRAAAgEDAwIEAwUFBAQAAAF9AQIDAAQRBRIhMUEGE1FhByJxFDKBkaEII0KxwRVS0fAkM2JyggkKFhcYGRolJicoKSo0NTY3ODk6Q0RFRkdISUpTVFVWV1hZWmNkZWZnaGlqc3R1dnd4eXqDhIWGh4iJipKTlJWWl5iZmqKjpKWmp6ipqrKztLW2t7i5usLDxMXGx8jJytLT1NXW19jZ2uHi4+Tl5ufo6erx8vP09fb3+Pn6/8QAHwEAAwEBAQEBAQEBAQAAAAAAAAECAwQFBgcICQoL/8QAtREAAgECBAQDBAcFBAQAAQJ3AAECAxEEBSExBhJBUQdhcRMiMoEIFEKRobHBCSMzUvAVYnLRChYkNOEl8RcYGRomJygpKjU2Nzg5OkNERUZHSElKU1RVVldYWVpjZGVmZ2hpanN0dXZ3eHl6goOEhYaHiImKkpOUlZaXmJmaoqOkpaanqKmqsrO0tba3uLm6wsPExcbHyMnK0tPU1dbX2Nna4uPk5ebn6Onq8vP09fb3+Pn6/9oADAMBAAIRAxEAPwD13RLS2fRdOZrhwxtbMkDVp1wc88A4GPQcL1FF9aWyWNuRcPndYjDatP8A891zxngj0/g6jmjRNV06PRdOSTUbBXW1s1ZW1MqQQeQR2I7j+HqKL3VdOext1XUbAsGsSQNTORicE8dsDkj+Ecin7vKfXNVvbPSVuZdX3XmW3srXdF/pEn+sf/mMTn/lsp9eOOc9x83UVVubS2+3xoJ3wbW9P/IWnJz5keMc989Oj9T0FWn1jTN0X/Ez0/8A1j/8xMn/AJbKfw9c9x83UVUudW0438bDUbAqLW9UkamTyZI8D3JwcD+LGTTfKRSVa60l16vs/Mt3NlamW8IuJDmOTGNYnbPyR9Dn5voevI/hFR2dratql9m4bC3wwRrM44+zJyWzk8nG7r/D0qS51jTDLeY1PTzmOTGNTLZ+SPof4voevI/hFR2eraauqXzNqWnhWvgyk6qcEfZkGQ3pkEbvUbaHy6ExVbkekvh7vuvMksbK1C2+biQYkXrrE6Y/c47Nx6Z7H5elVNEtLZ9F05muHDG1syQNWnXBzzwDgY9BwvUVbsdY0wLb51PTxiReuplMfucdunPGex+XpVTRNV06PRdOSTUbBXW1s1ZW1MqQQeQR2I7j+HqKHy3Karcr0lvHq/PzC+tLZLG3IuHzusRhtWn/AOe654zwR6fwdRzVt7K13Rf6RJ/rH/5jE5/5bKfXjjnPcfN1FVL3VdOext1XUbAsGsSQNTORicE8dsDkj+Ecirb6xpm6L/iZ6f8A6x/+YmT/AMtlP4eue4+bqKPduDVay0lu+r7LzKtzaW32+NBO+Da3p/5C05OfMjxjnvnp0fqegq1c2VqZbwi4kOY5MY1ids/JH0Ofm+h68j+EVUudW0438bDUbAqLW9UkamTyZI8D3JwcD+LGTVu51jTDLeY1PTzmOTGNTLZ+SPof4voevI/hFC5bg1W93SWz6vv6kdna2rapfZuGwt8MEazOOPsycls5PJxu6/w9KksbK1C2+biQYkXrrE6Y/c47Nx6Z7H5elR2eraauqXzNqWnhWvgyk6qcEfZkGQ3pkEbvUbaksdY0wLb51PTxiReuplMfucdunPGex+XpQuWxM1WttL4V1fb1KmiWls+i6czXDhja2ZIGrTrg554BwMeg4XqKL60tksbci4fO6xGG1af/AJ7rnjPBHp/B1HNGiarp0ei6ckmo2CutrZqytqZUgg8gjsR3H8PUUXuq6c9jbquo2BYNYkgamcjE4J47YHJH8I5FL3eU1are2ekrcy6vuvMtvZWu6L/SJP8AWP8A8xic/wDLZT68cc57j5uoqrc2lt9vjQTvg2t6f+QtOTnzI8Y5756dH6noKtPrGmbov+Jnp/8ArH/5iZP/AC2U/h657j5uoqpc6tpxv42Go2BUWt6pI1MnkyR4HuTg4H8WMmm+Uikq11pLr1fZ+ZbubK1Mt4RcSHMcmMaxO2fkj6HPzfQ9eR/CKjs7W1bVL7Nw2FvhgjWZxx9mTktnJ5ON3X+HpUlzrGmGW8xqennMcmMamWz8kfQ/xfQ9eR/CKjs9W01dUvmbUtPCtfBlJ1U4I+zIMhvTII3eo20Pl0Jiq3I9JfD3fdeZJY2VqFt83EgxIvXWJ0x+5x2bj0z2Py9KqaJaWz6LpzNcOGNrZkgatOuDnngHAx6Dheoq3Y6xpgW3zqenjEi9dTKY/c47dOeM9j8vSqmiarp0ei6ckmo2CutrZqytqZUgg8gjsR3H8PUUPluU1W5XpLePV+fmF9aWyWNuRcPndYjDatP/AM91zxngj0/g6jmrb2Vrui/0iT/WP/zGJz/y2U+vHHOe4+bqKqXuq6c9jbquo2BYNYkgamcjE4J47YHJH8I5FW31jTN0X/Ez0/8A1j/8xMn/AJbKfw9c9x83UUe7cGq1lpLd9X2XmVbm0tvt8aCd8G1vT/yFpyc+ZHjHPfPTo/U9BVq5srUy3hFxIcxyYxrE7Z+SPoc/N9D15H8IqvfajYx6jGZL6yX/AEO866if4niZeD13DkD+Mc1YudY0wy3mNT085jkxjUy2fkj6H+L6HryP4RQuW4v3z5WlLZ9X39SOztbVtUvs3DYW+GCNZnHH2ZOS2cnk43df4elSWNlahbfNxIMSL11idMfucdm49M9j8vSo7PVtNXVL5m1LTwrXwZSdVOCPsyDIb0yCN3qNtSWOsaYFt86np4xIvXUymP3OO3TnjPY/L0oXLYU1WttL4V1fb1KmiWls+i6czXDhja2ZIGrTrg554BwMeg4XqKL60tksbci4fO6xGG1af/nuueM8Een8HUc0aJqunR6LpySajYK62tmrK2plSCDyCOxHcfw9RRe6rpz2Nuq6jYFg1iSBqZyMTgnjtgckfwjkUvd5TVqt7Z6StzLq+68y29la7ov9Ik/1j/8AMYnP/LZT68cc57j5uoqrc2lt9vjQTvg2t6f+QtOTnzI8Y5756dH6noKtPrGmbov+Jnp/+sf/AJiZP/LZT+HrnuPm6iqlzq2nG/jYajYFRa3qkjUyeTJHge5ODgfxYyab5SKSrXWkuvV9n5lu5srUy3hFxIcxyYxrE7Z+SPoc/N9D15H8IqOztbVtUvs3DYW+GCNZnHH2ZOS2cnk43df4elSXOsaYZbzGp6ecxyYxqZbPyR9D/F9D15H8IqOz1bTV1S+ZtS08K18GUnVTgj7MgyG9Mgjd6jbQ+XQmKrcj0l8Pd915kljZWoW3zcSDEi9dYnTH7nHZuPTPY/L0qpolpbPounM1w4Y2tmSBq064OeeAcDHoOF6irdjrGmBbfOp6eMSL11Mpj9zjt054z2Py9KqaJqunR6LpySajYK62tmrK2plSCDyCOxHcfw9RQ+W5TVblekt49X5+YX1pbJY25Fw+d1iMNq0//Pdc8Z4I9P4Oo5q29la7ov8ASJP9Y/8AzGJz/wAtlPrxxznuPm6iql7qunPY26rqNgWDWJIGpnIxOCeO2ByR/CORVt9Y0zdF/wATPT/9Y/8AzEyf+Wyn8PXPcfN1FHu3BqtZaS3fV9l5lW5tLb7fGgnfBtb0/wDIWnJz5keMc989Oj9T0FWrmytTLeEXEhzHJjGsTtn5I+hz830PXkfwiqlzq2nG/jYajYFRa3qkjUyeTJHge5ODgfxYyat3OsaYZbzGp6ecxyYxqZbPyR9D/F9D15H8IoXLcGq3u6S2fV9/Ujs7W1bVL7Nw2FvhgjWZxx9mTktnJ5ON3X+HpUljZWoW3zcSDEi9dYnTH7nHZuPTPY/L0qOz1bTV1S+ZtS08K18GUnVTgj7MgyG9Mgjd6jbUljrGmBbfOp6eMSL11Mpj9zjt054z2Py9KFy2Jmq1tpfCur7epU0S0tn0XTma4cMbWzJA1adcHPPAOBj0HC9RRfWlsljbkXD53WIw2rT/APPdc8Z4I9P4Oo5o0TVdOj0XTkk1GwV1tbNWVtTKkEHkEdiO4/h6ii91XTnsbdV1GwLBrEkDUzkYnBPHbA5I/hHIpe7ymrVb2z0lbmXV915lt7K13Rf6RJ/rH/5jE5/5bKfXjjnPcfN1FVbm0tvt8aCd8G1vT/yFpyc+ZHjHPfPTo/U9BVp9Y0zdF/xM9P8A9Y//ADEyf+Wyn8PXPcfN1FVLnVtON/Gw1GwKi1vVJGpk8mSPA9ycHA/ixk03ykUlWutJder7PzLdzZWplvCLiQ5jkxjWJ2z8kfQ5+b6HryP4RXlnxCRE8YagsT70Hl4b7Q0+f3a/xtyfx6dO1ep3OsaYZbzGp6ecxyYxqZbPyR9D/F9D15H8Iryz4hTQ3HjDUJbeWKaJvLw8U5mU/u1HDnr/AJFZ1rcqsetkCqfWPfT+F7+sfM9T0G7UaFpg+0TDFpZjG+Hjac9/Tt3H8XFGoXaiwtx9omGHsBgPDxtnU9/TtnkfxcVHod1erommqthqrKLSyAZWtsEZ4Iy+cemef71F7dXrWFuPsOqqM6eQd1tj/XjaB8+evC57/e4rS65Tx3Be2fw/Euq7o0HuwWi/0iY4kc/fh4zMp/pnnjI4+XNU7q7B1KIfaJjm0vhgvDzuliPb179z/DxU8l3fb4P+Jdq3+tkxlrXr9oTp8/XOPbOMcZqpdXV79uRjY6rxaX42lrbkebHuPD9M9e+SNvGabaM6VNXXw9eq7M0Lm7Vprw/aJjujkGS8POUjHOPp254GOc1FY3y/2rqLfap/+P8ADZ8y3z/x6xjPpnt6Y96Lu7vvPv8Adp2rZ8qXdua1zjZFnOH6dM45xjHOaZZ3V+NWvyLDVyx1AEgNa7gfsqcH58bsfhg+tJtaExguR/D8Pdd0WLG8CLb/AOkTLtkU8PCMfudvf8ueMf7VU9Bu1GhaYPtEwxaWYxvh42nPf07dx/FxU+nXd9sttunat/rVxsa16/Zx0y/XHrxj3qpod1erommqthqrKLSyAZWtsEZ4Iy+cemef71NtXKdNcr+HePVeZJqF2osLcfaJhh7AYDw8bZ1Pf07Z5H8XFXHuwWi/0iY4kc/fh4zMp/pnnjI4+XNZ97dXrWFuPsOqqM6eQd1tj/XjaB8+evC57/e4q3Jd32+D/iXat/rZMZa16/aE6fP1zj2zjHGaLq4OCsvh3fVdkQXV2DqUQ+0THNpfDBeHndLEe3r37n+Hirlzdq014ftEx3RyDJeHnKRjnH07c8DHOaz7q6vftyMbHVeLS/G0tbcjzY9x4fpnr3yRt4zVu7u77z7/AHadq2fKl3bmtc42RZzh+nTOOcYxzmhNXBwXu/Ds+q/mCxvl/tXUW+1T/wDH+Gz5lvn/AI9Yxn0z29Me9S2N4EW3/wBImXbIp4eEY/c7e/5c8Y/2qr2d1fjVr8iw1csdQBIDWu4H7KnB+fG7H4YPrT9Ou77ZbbdO1b/WrjY1r1+zjpl+uPXjHvSjJWJnBW+z8K6rsQaDdqNC0wfaJhi0sxjfDxtOe/p27j+LijULtRYW4+0TDD2AwHh42zqe/p2zyP4uKj0O6vV0TTVWw1VlFpZAMrW2CM8EZfOPTPP96i9ur1rC3H2HVVGdPIO62x/rxtA+fPXhc9/vcUXXKbOC9s/h+JdV3RoPdgtF/pExxI5+/DxmZT/TPPGRx8uap3V2DqUQ+0THNpfDBeHndLEe3r37n+Hip5Lu+3wf8S7Vv9bJjLWvX7QnT5+uce2cY4zVS6ur37cjGx1Xi0vxtLW3I82PceH6Z698kbeM020Z0qauvh69V2ZoXN2rTXh+0THdHIMl4ecpGOcfTtzwMc5qKxvl/tXUW+1T/wDH+Gz5lvn/AI9Yxn0z29Me9F3d33n3+7TtWz5Uu7c1rnGyLOcP06ZxzjGOc0yzur8atfkWGrljqAJAa13A/ZU4Pz43Y/DB9aTa0JjBcj+H4e67osWN4EW3/wBImXbIp4eEY/c7e/5c8Y/2qp6DdqNC0wfaJhi0sxjfDxtOe/p27j+Lip9Ou77ZbbdO1b/WrjY1r1+zjpl+uPXjHvVTQ7q9XRNNVbDVWUWlkAytbYIzwRl849M8/wB6m2rlOmuV/DvHqvMk1C7UWFuPtEww9gMB4eNs6nv6ds8j+Lirj3YLRf6RMcSOfvw8ZmU/0zzxkcfLms+9ur1rC3H2HVVGdPIO62x/rxtA+fPXhc9/vcVbku77fB/xLtW/1smMta9ftCdPn65x7ZxjjNF1cHBWXw7vquyK91dqdTiH2iY5tL4YLw/xSxH9e+OT/DxXM/GrxNqHh/wB4g1XRb6SK/jVFjlYQScPJbo2RyDlSw4HYejV0d1dXv25GNjqvFpfjaWtuR5se48P0z175I28Zrhf2jbi7k+FnidZrPUY1Pk7nma3wP39r97YxPp0H93/AGqSa1M68bU7q20uq7s9Fsb5f7V1FvtU/wDx/hs+Zb5/49Yxn0z29Me9S2N4EW3/ANImXbIp4eEY/c7e/wCXPGP9quY+GOp6ld+F9JupbbVLie4S1leSNrb5nOnxEn5mByRzz/CRn5s10WnXd9sttunat/rVxsa16/Zx0y/XHrxj3ppqw5QTV/d+FdV2INBu1GhaYPtEwxaWYxvh42nPf07dx/FxRqF2osLcfaJhh7AYDw8bZ1Pf07Z5H8XFR6HdXq6JpqrYaqyi0sgGVrbBGeCMvnHpnn+9Re3V61hbj7DqqjOnkHdbY/142gfPnrwue/3uKV1ym7gvbP4fiXVd0aD3YLRf6RMcSOfvw8ZmU/0zzxkcfLmqd1dg6lEPtExzaXwwXh53SxHt69+5/h4qeS7vt8H/ABLtW/1smMta9ftCdPn65x7ZxjjNVLq6vftyMbHVeLS/G0tbcjzY9x4fpnr3yRt4zTbRnSpq6+Hr1XZmhc3atNeH7RMd0cgyXh5ykY5x9O3PAxzmud8PeLBffEHxbo/7+NdMurWcXHnwEy+daY6YCgjZjOSCD2OM7t3d33n3+7TtWz5Uu7c1rnGyLOcP06ZxzjGOc1wfgy4vB8cfiQy2eptK0ul7lVrbzFP2OTG7LbckZxgkYznnFDa0Oea5VFLl1T6rtf8AQ9BsbwItv/pEy7ZFPDwjH7nb3/LnjH+1VPQbtRoWmD7RMMWlmMb4eNpz39O3cfxcVPp13fbLbbp2rf61cbGtev2cdMv1x68Y96qaHdXq6JpqrYaqyi0sgGVrbBGeCMvnHpnn+9Q2rnQ6a5X8O8eq8yTULtRYW4+0TDD2AwHh42zqe/p2zyP4uKuPdgtF/pExxI5+/DxmZT/TPPGRx8uaz726vWsLcfYdVUZ08g7rbH+vG0D589eFz3+9xVuS7vt8H/Eu1b/WyYy1r1+0J0+frnHtnGOM0XVwcFZfDu+q7IgursHUoh9omObS+GC8PO6WI9vXv3P8PFXLm7Vprw/aJjujkGS8POUjHOPp254GOc1n3V1e/bkY2Oq8Wl+Npa25Hmx7jw/TPXvkjbxmrd3d33n3+7TtWz5Uu7c1rnGyLOcP06ZxzjGOc0Jq4OC934dn1X8xjav4vsvD2qI97NfyDUdegsYjCbdisklsiqzZIAHGCRkAe9b1jeBFt/8ASJl2yKeHhGP3O3v+XPGP9qvM/i1Pdtf+GS9rqSn/AITnTWw5t87/ACFwvDY345H8OMZOc16Pp13fbLbbp2rf61cbGtev2cdMv1x68Y96UZKxi1dyXu6Rj1XYg0G7UaFpg+0TDFpZjG+Hjac9/Tt3H8XFGoXaiwtx9omGHsBgPDxtnU9/TtnkfxcVHod1erommqthqrKLSyAZWtsEZ4Iy+cemef71F7dXrWFuPsOqqM6eQd1tj/XjaB8+evC57/e4ouuU6nBe2fw/Euq7o0HuwWi/0iY4kc/fh4zMp/pnnjI4+XNU7q7B1KIfaJjm0vhgvDzuliPb179z/DxU8l3fb4P+Jdq3+tkxlrXr9oTp8/XOPbOMcZqpdXV79uRjY6rxaX42lrbkebHuPD9M9e+SNvGabaM6VNXXw9eq7M0Lm7Vprw/aJjujkGS8POUjHOPp254GOc15H8SJfO8aai4dpAfL+ZihJ/dr3T5fyr1e7u77z7/dp2rZ8qXdua1zjZFnOH6dM45xjHOa8o+JDyyeNNRaeOeKQ+XlJym8fu167CV/I/rWVZrlR7HD0UsR0+F7NPrE9Q0GCQ6Fph+xwnNpZnPkJzk8H7/fofXvt60ahBIbC3Is4Tl7A58hDnM64P3+/Q+vfb1qpokF0dF04pJYBTa2ZAbSpGPJ7nfyfU/xdBS31vdfYYC8lgw3WPTSpM5M685389sn+McDFaXfKea1++fvL4l0fdGs8Em6L/Q4RmRx/qE5/fKMff8AXj6HHIORTuoJBqURNnCMWl8c+QnGJYsn7/boPTtu60Pb3m6L97p/+sf/AJhMo/5bKP8AnpzxxjsPl6mqlzBdC/j/AHlhv+y3pBGlSADEkf8At9emD/D0Oc0232M6S1XvLr0fZmvcwSCa8Bs4V2xyEgQINuEj5Hz8YznjOMnrkgRWNtL/AGrqA+wQZ+3gbfs6Yz9ljOMeZ074zjPOc8VBc294JbzEunjEcmMaTKuPkj6DzPl+p6ZJ/iFR2dvc/wBqX4V9PH+nANnR5SD/AKMh4XzOB0+Xrn5unFDb0JivcfvL4e0u6NCxgkZbfFnC+ZFHMCHP7nOOXGeOe3PPXiqegwSHQtMP2OE5tLM58hOcng/f79D699vWixt7wrb5l085kXOdJlfP7nPaTn1x3PzdKqaJBdHRdOKSWAU2tmQG0qRjye538n1P8XQUNu5TXuv3lvHo/Mt6hBIbC3Is4Tl7A58hDnM64P3+/Q+vfb1q48Em6L/Q4RmRx/qE5/fKMff9ePoccg5GTfW919hgLyWDDdY9NKkzkzrznfz2yf4xwMVae3vN0X73T/8AWP8A8wmUf8tlH/PTnjjHYfL1NF3fYGvdXvLd9H2QXUEg1KImzhGLS+OfITjEsWT9/t0Hp23dauXMEgmvAbOFdschIECDbhI+R8/GM54zjJ65IGRcwXQv4/3lhv8Ast6QRpUgAxJH/t9emD/D0Oc1bube8Et5iXTxiOTGNJlXHyR9B5ny/U9Mk/xChN3egNfD7y2fR9yextpf7V1AfYIM/bwNv2dMZ+yxnGPM6d8ZxnnOeKlsYJGW3xZwvmRRzAhz+5zjlxnjntzz14rPs7e5/tS/Cvp4/wBOAbOjykH/AEZDwvmcDp8vXPzdOKksbe8K2+ZdPOZFznSZXz+5z2k59cdz83ShN2JmtPiXwrpLsGgwSHQtMP2OE5tLM58hOcng/f79D699vWjUIJDYW5FnCcvYHPkIc5nXB+/36H177etVNEgujounFJLAKbWzIDaVIx5Pc7+T6n+LoKW+t7r7DAXksGG6x6aVJnJnXnO/ntk/xjgYpXfKbNfvn7y+JdH3RrPBJui/0OEZkcf6hOf3yjH3/Xj6HHIORTuoJBqURNnCMWl8c+QnGJYsn7/boPTtu60Pb3m6L97p/wDrH/5hMo/5bKP+enPHGOw+XqaqXMF0L+P95Yb/ALLekEaVIAMSR/7fXpg/w9DnNNt9jOktV7y69H2Zr3MEgmvAbOFdschIECDbhI+R8/GM54zjJ65IEVjbS/2rqA+wQZ+3gbfs6Yz9ljOMeZ074zjPOc8VBc294JbzEunjEcmMaTKuPkj6DzPl+p6ZJ/iFR2dvc/2pfhX08f6cA2dHlIP+jIeF8zgdPl65+bpxQ29CYr3H7y+HtLujQsYJGW3xZwvmRRzAhz+5zjlxnjntzz14qnoMEh0LTD9jhObSzOfITnJ4P3+/Q+vfb1osbe8K2+ZdPOZFznSZXz+5z2k59cdz83SqmiQXR0XTiklgFNrZkBtKkY8nud/J9T/F0FDbuU17r95bx6PzLeoQSGwtyLOE5ewOfIQ5zOuD9/v0Pr329auPBJui/wBDhGZHH+oTn98ox9/14+hxyDkZN9b3X2GAvJYMN1j00qTOTOvOd/PbJ/jHAxVp7e83RfvdP/1j/wDMJlH/AC2Uf89OeOMdh8vU0Xd9ga91e8t30fZBdQSDUoibOEYtL458hOMSxZP3+3Qenbd1rhf2joXT4UeJ91rFHjyc7YlXb+/tumHOOo9fvH1OOvuYLoX8f7yw3/Zb0gjSpABiSP8A2+vTB/h6HOa5n4x6bdX3g/ULJpLIrcXdpDhNNkiPzXVqBjLnHXuD3/vCi71MsQv3XxLaXR92aPwhgkbwToWLOF829mBmBDn/AIl8Jxy4zxz25568V1ljBIy2+LOF8yKOYEOf3OccuM8c9ueevFcV8JoLhvBWhGNrED7PZ58zS5JCf9AhPUOM9uO5+bocV1Njb3hW3zLp5zIuc6TK+f3Oe0nPrjufm6URbsU17vxL4V0fYNBgkOhaYfscJzaWZz5Cc5PB+/36H177etGoQSGwtyLOE5ewOfIQ5zOuD9/v0Pr329aqaJBdHRdOKSWAU2tmQG0qRjye538n1P8AF0FLfW919hgLyWDDdY9NKkzkzrznfz2yf4xwMUrvlN2v3z95fEuj7o1ngk3Rf6HCMyOP9QnP75Rj7/rx9DjkHIp3UEg1KImzhGLS+OfITjEsWT9/t0Hp23daHt7zdF+90/8A1j/8wmUf8tlH/PTnjjHYfL1NVLmC6F/H+8sN/wBlvSCNKkAGJI/9vr0wf4ehzmm2+xnSWq95dej7M17mCQTXgNnCu2OQkCBBtwkfI+fjGc8Zxk9ckDzb4cyx33xo+Jj2kFtMqXVhAypEGVXS3mRlwWGMMjZGSMr1OBnvbm3vBLeYl08YjkxjSZVx8kfQeZ8v1PTJP8Qrx/4Gx3EnxO+KAR7XcNaCt5mnvKp+e76IHBUcfdJJ6f3TQ2zkq70/e79H2PbLGCRlt8WcL5kUcwIc/uc45cZ457c89eKp6DBIdC0w/Y4Tm0sznyE5yeD9/v0Pr329aLG3vCtvmXTzmRc50mV8/uc9pOfXHc/N0qpokF0dF04pJYBTa2ZAbSpGPJ7nfyfU/wAXQUNu51te6/eW8ej8y3qEEhsLcizhOXsDnyEOczrg/f79D699vWrjwSbov9DhGZHH+oTn98ox9/14+hxyDkZN9b3X2GAvJYMN1j00qTOTOvOd/PbJ/jHAxVp7e83RfvdP/wBY/wDzCZR/y2Uf89OeOMdh8vU0Xd9ga91e8t30fZBdQSDUoibOEYtL458hOMSxZP3+3Qenbd1q5cwSCa8Bs4V2xyEgQINuEj5Hz8YznjOMnrkgZFzBdC/j/eWG/wCy3pBGlSADEkf+316YP8PQ5zVu5t7wS3mJdPGI5MY0mVcfJH0HmfL9T0yT/EKE3d6A18PvLZ9H3OA+LUDrf+GQbOFf+K501cCBBz5C/L988Hrjp7jpXpdjBIy2+LOF8yKOYEOf3OccuM8c9ueevFeR/Gt5rCPRbpntB5HjGxfMenyQ4Itwc5L8L/sdSecjOK9Qsbe8K2+ZdPOZFznSZXz+5z2k59cdz83SlFvUw3lP3ltHo/5Q0GCQ6Fph+xwnNpZnPkJzk8H7/fofXvt60ahBIbC3Is4Tl7A58hDnM64P3+/Q+vfb1qpokF0dF04pJYBTa2ZAbSpGPJ7nfyfU/wAXQUt9b3X2GAvJYMN1j00qTOTOvOd/PbJ/jHAxRd8p1tfvn7y+JdH3RrPBJui/0OEZkcf6hOf3yjH3/Xj6HHIORTuoJBqURNnCMWl8c+QnGJYsn7/boPTtu60Pb3m6L97p/wDrH/5hMo/5bKP+enPHGOw+XqaqXMF0L+P95Yb/ALLekEaVIAMSR/7fXpg/w9DnNNt9jOktV7y69H2Zr3MEgmvAbOFdschIECDbhI+R8/GM54zjJ65IHkfxIRo/Gmoq0SxEeX8ioEA/dr2BIH516hc294JbzEunjEcmMaTKuPkj6DzPl+p6ZJ/iFeWfENWTxhqCyeUWHl58qAwL/q16IxJH589e9Z1n7qPY4f8A943v7r6NdY9z1PQVb+wtM/ezf8eln0im9f8Ae7dscH+HBrkvi9JqGn+Codb027uw2izWOpS2sZmiW8ijkO6Fn3YVed2cEEoAozXRaJaWz6LpzNcOGNrZkgatOuDnngHAx6DheoovrS2SxtyLh87rEYbVp/8AnuueM8Een8HUc1evKeRVpxnUlFt6y7LuvM8f8R3niNPgHqfil9d1ixv9RvG1e3himkY2sEtzEscCzEn5MESZXYQSFPcH2u6Vv7Si/ezH/RL7/llN/wA9Yv8Aa7988D+LJoeytd0X+kSf6x/+YxOf+Wyn1445z3HzdRVW5tLb7fGgnfBtb0/8hacnPmR4xz3z06P1PQU3czw9OMZbvr0XaXma1yredefvZj+7k6xTDPyR9ctx+ORwM8EYisUb+1dR/fz/APH+OfJuM/8AHrHz97Oe2OuOc44rmNO8QaHrPizxPodjcXL3WkxgTSf2xK0chdF+WNg5LlSpVgQOeD0rcs7W1bVL7Nw2FvhgjWZxx9mTktnJ5ON3X+HpQ29ApuMqbab+Hsu68zQsVJW3/ezDMi9Ipjj9z7N+HHOOfu8VT0FW/sLTP3s3/HpZ9IpvX/e7dscH+HBosbK1C2+biQYkXrrE6Y/c47Nx6Z7H5elVNEtLZ9F05muHDG1syQNWnXBzzwDgY9BwvUUO9y2o8r1e8ei8/Mt6grfYLf8AezD57D/llN/z3X0bt2xwf4cGrjqd0X72b/WP/wAspv8Ansv+1+PHOeD82DWRfWlsljbkXD53WIw2rT/891zxngj0/g6jmrb2Vrui/wBIk/1j/wDMYnP/AC2U+vHHOe4+bqKNbg1HlWr3fRdl5hdK39pRfvZj/ol9/wAspv8AnrF/td++eB/Fk1cuVbzrz97Mf3cnWKYZ+SPrluPxyOBngjGTc2lt9vjQTvg2t6f+QtOTnzI8Y5756dH6noK4H41a3c+G5ba50zVZre1tw17exxX0txJdQrNZwmFS7gKGE7NuxkmPHAGaE2rk1JQpxjKTdrPov5vU9PsUb+1dR/fz/wDH+OfJuM/8esfP3s57Y645zjipbFSVt/3swzIvSKY4/c+zfhxzjn7vFZ9na2rapfZuGwt8MEazOOPsycls5PJxu6/w9KksbK1C2+biQYkXrrE6Y/c47Nx6Z7H5elCvYKiVt38K6Lt6hoKt/YWmfvZv+PSz6RTev+927Y4P8ODRqCt9gt/3sw+ew/5ZTf8APdfRu3bHB/hwaqaJaWz6LpzNcOGNrZkgatOuDnngHAx6DheoovrS2SxtyLh87rEYbVp/+e654zwR6fwdRzS15TZpe2er+JdF3Xma7qd0X72b/WP/AMspv+ey/wC1+PHOeD82DVO6Vv7Si/ezH/RL7/llN/z1i/2u/fPA/iyaQ2dqTCfPlH7xyR/bE5x++U8/Nx9e4+bqKrXNpbfb40E74Nren/kLTk58yPGOe+enR+p6Cm7mdJRutX16Ls/M1rlW868/ezH93J1imGfkj65bj8cjgZ4IxFYo39q6j+/n/wCP8c+TcZ/49Y+fvZz2x1xznHFQXNlamW8IuJDmOTGNYnbPyR9Dn5voevI/hFcn8LPE+meO9NvNZtI7yyh/tWSERXOsTK4CwIAzEN3BBzyQTsyQAaHfQzUoKNm3dx7Ly8zuLFSVt/3swzIvSKY4/c+zfhxzjn7vFU9BVv7C0z97N/x6WfSKb1/3u3bHB/hwaLGytQtvm4kGJF66xOmP3OOzcemex+XpVTRLS2fRdOZrhwxtbMkDVp1wc88A4GPQcL1FDvc0ajyvV7x6Lz8zh/jZe6x4d07QPFemz309ho7wtf6ckksEVwjnCM7FiCEkVAuAeZMrjaa4n4hz/EPwz8KtLt5LvV4/stp9q1HWBOTP9pe7H+jsxl3KqblzIgbcdi4A3Gvbr60tksbci4fO6xGG1af/AJ7rnjPBHp/B1HNW3srXdF/pEn+sf/mMTn/lsp9eOOc9x83UUa3MalBSXxPVvouyv19Pu8yIO88tnLIl3byvY3rvDMkhaPMkXyNtcrkHOSCVz1z1rK+JW5NHLCWRiNT08/NHKM/6ZZ9dxP6+g9VxeuLa1OoKgnk/49b3P/E2nJz5kWMZPOc9OjdTyKwPiktlb6ZAhmuHe51axhj2alNMM/abZjnc3IwjYPqP9kGhX1NKijyq7ez6Lu/Mt/CFWPgnQ/3swzb2XSKY4/4l8Po34cc45+7xXWWKkrb/AL2YZkXpFMcfufZvw45xz93ivPfgdJb6n8P9GnlleMoYocf2nNDxHaomcKxwPl6/8BwBgDtrGytQtvm4kGJF66xOmP3OOzcemex+XpRG9iXyuKd38Mei7eoaCrf2Fpn72b/j0s+kU3r/AL3btjg/w4NGoK32C3/ezD57D/llN/z3X0bt2xwf4cGqmiWls+i6czXDhja2ZIGrTrg554BwMeg4XqKL60tksbci4fO6xGG1af8A57rnjPBHp/B1HNLXlOhpe2er+JdF3Xma7qd0X72b/WP/AMspv+ey/wC1+PHOeD82DVO6Vv7Si/ezH/RL7/llN/z1i/2u/fPA/iyaHsrXdF/pEn+sf/mMTn/lsp9eOOc9x83UVVubS2+3xoJ3wbW9P/IWnJz5keMc989Oj9T0FN3M6Sjdavr0XZ+ZrXKt515+9mP7uTrFMM/JH1y3H45HAzwRjxb4ESAfFj4oweeyyNrJYALKXIEl0Cdobd3GcnIz1659dubK1Mt4RcSHMcmMaxO2fkj6HPzfQ9eR/CK8X+FzWyfHLxBZKWCTrfXEkpvZYyGS/uEAEqtkqVcZLAkkdRzkbehyVY35Gm9E+i7W7nulipK2/wC9mGZF6RTHH7n2b8OOcc/d4qnoKt/YWmfvZv8Aj0s+kU3r/vdu2OD/AA4NFjZWoW3zcSDEi9dYnTH7nHZuPTPY/L0qpolpbPounM1w4Y2tmSBq064OeeAcDHoOF6ih3udbUeV6vePRefmW9QVvsFv+9mHz2H/LKb/nuvo3btjg/wAODVx1O6L97N/rH/5ZTf8APZf9r8eOc8H5sGsi+tLZLG3IuHzusRhtWn/57rnjPBHp/B1HNW3srXdF/pEn+sf/AJjE5/5bKfXjjnPcfN1FGtwajyrV7vouy8wulb+0ov3sx/0S+/5ZTf8APWL/AGu/fPA/iyauXKt515+9mP7uTrFMM/JH1y3H45HAzwRjJubS2+3xoJ3wbW9P/IWnJz5keMc989Oj9T0FWrmytTLeEXEhzHJjGsTtn5I+hz830PXkfwihXuDUfd1ez6Lv6nhX7V2q/ZdJt9M/evJcaybtXdZFA8q1iXBDseT5w9/l9CK+gbFSVt/3swzIvSKY4/c+zfhxzjn7vFfPP7TOnWs8dxKGMrWiXE0R+2SXGDu01M5b2kcZ/Door3qxsrULb5uJBiReusTpj9zjs3Hpnsfl6Uo31OZL95O7e0e38vqGgq39haZ+9m/49LPpFN6/73btjg/w4NGoK32C3/ezD57D/llN/wA919G7dscH+HBqpolpbPounM1w4Y2tmSBq064OeeAcDHoOF6ii+tLZLG3IuHzusRhtWn/57rnjPBHp/B1HNGvKdrS9s9X8S6LuvM13U7ov3s3+sf8A5ZTf89l/2vx45zwfmwap3St/aUX72Y/6Jff8spv+esX+13754H8WTQ9la7ov9Ik/1j/8xic/8tlPrxxznuPm6iqtzaW32+NBO+Da3p/5C05OfMjxjnvnp0fqegpu5nSUbrV9ei7PzNa5VvOvP3sx/dydYphn5I+uW4/HI4GeCMeR/EgEeNNRBZmP7vllZT/q17OS35mvULmytTLeEXEhzHJjGsTtn5I+hz830PXkfwivLPiEiJ4w1BYn3oPLw32hp8/u1/jbk/j06dqzrX5Vc9jh9L6xo38L3t3j2Z6Romq6dHounJJqNgrra2asramVIIPII7Edx/D1FF7qunPY26rqNgWDWJIGpnIxOCeO2ByR/CORVvQbtRoWmD7RMMWlmMb4eNpz39O3cfxcUahdqLC3H2iYYewGA8PG2dT39O2eR/FxV2fKeW1H2z0fxL7XmvIH1jTN0X/Ez0//AFj/APMTJ/5bKfw9c9x83UVUudW0438bDUbAqLW9UkamTyZI8D3JwcD+LGTR4q8TxeH9NjvZINZ1DE7Ktvp1vHcysTMrZCr0GFJyxAyABnOD5vL8TdesPEcl14m0qSw0K903U5dHg3RfbGEaJO32kbsR7lU/LjcGIUZ6lu5ze2pUneSfXq+t12Oe+Dt1JJ8QLrWb6K3sv7V8OXeoXJW42RmSW/LruYE72CSxjaxzgqDjpXuFnq2mrql8zalp4Vr4MpOqnBH2ZBkN6ZBG71G2vL9TsdSsfBfw816wtLi41Pw7awrcWRVWlNvLaRQTokYwTKBjAOMbT3DCul8JfFfRNV8V3mm3ba1omozXSXMEGsQwWrzKYViG3ccF9y4C9wRgE5wmnoZUeWnCUZrdd7fy+Xkzr7HWNMC2+dT08YkXrqZTH7nHbpzxnsfl6VU0TVdOj0XTkk1GwV1tbNWVtTKkEHkEdiO4/h6inax4p0/wvoTapqt9LDb2x8zasluHcrb/AHIwxGXOCAD16feritH8ZeODoFpJZ+CPMgSGzSBZdetYpZYxkq5QxnZjAyrNuUsM7gDhu9zec6cU00/s9X59kdne6rpz2Nuq6jYFg1iSBqZyMTgnjtgckfwjkVbfWNM3Rf8AEz0//WP/AMxMn/lsp/D1z3HzdRXBXHif4gXuleUnhWw0qffZxwy3muQTIrCQsjMkceSoZVUjcGG8E5GSseneLfHHinTdNg07Tn0C5UMuo6lqkUYWKYshb7NbltzjcysrOdh2sOxo1uS6sGkuV7vq+y8jr9W8RaJZXcU15rWlW8Jtr1A8urbV3GSMheTgkgEgfxAEnpXnXiO2g1XxN8VdZk1KxugNEk0bTbeO/wBxb/Ro5nA4zITI67QT1Dr/AAir+ofDTSJbXV2vHXWPFOrabfedqmo+Q265yixuifMIVG44EYyAAFLYzVj4AaDceFPh1JY6iLm21Caa8e5gZ4iFfKRgKe6lYlOQTnOVJFJJtmVSEqkoxlH3bPr5vf5nQ/DzxbZ65odpq17qOnLc3skU8w/tFogJDaRiQAHlQHDLnnBG3pW/Y6xpgW3zqenjEi9dTKY/c47dOeM9j8vSuE0v4VeBV1bW3uNOa7We6lhVZ5oClvDLEshSFAQkeHdtrKAVzgNmrNr4c1rw0qz+A9flVcRRrpOt3P2i0QLGijynLl4cL5o6OpyqkDaMNJ2NJaRSlF/CvteXodPomq6dHounJJqNgrra2asramVIIPII7Edx/D1FF7qunPY26rqNgWDWJIGpnIxOCeO2ByR/CORXI+CPDmpXejQXnjbxFqd1eSRW4gttL1JrK2toA52IBG6F2CkEs/zA4B4G5nW/gs6QkNzb+OfGssm6zTZdanb3EY/fqThJEIG3AK8ZHfgnK15TXm/e35H8S+15ryO3fWNM3Rf8TPT/APWP/wAxMn/lsp/D1z3HzdRWbqXiLRLfVLVZ9Z0qJpba9jjD6tguxliwqgn5iew/i6mud1vRvEOj3Wn6t4R1y/1O8inuZL+z1fUVZL6N5ldVjwfKgcFRtKxqvPOVBBoeHfAen/b7nVPG1rp+r+J9VjvLi+kfybi3RhIgiWFZBlVCHHTcexIAw3czptt2jFp67y02fkdb438Q2tl4Z8TXen6pYC8h067kgZdR8w+YIVK4B++cjoRhsEH7orzb4D6jb+Hdfv8Aw3ezQadC9lp2owWstw0KiU2apdOWx8r+aFDKTkMCAMbjWP8AHnw8fD17Bc+ArOCy/wCEgjPh66htxBCjB2ikQKseAGco6sx42gDg5r0PxLY6lZ+NU8WeEYIr3UrGV7Geyee1t2u7Z7eHaomIKp5bruAxggkAg5DJ3OZx55OXK/dXfe+nbz/A7Sx1jTAtvnU9PGJF66mUx+5x26c8Z7H5elVNE1XTo9F05JNRsFdbWzVlbUypBB5BHYjuP4eorI0X4iWkGraRo3iKDUtA1a78t4I7hrd4Jm8nayxzqShYEBcOVJDJ8u5sV0Wg3ajQtMH2iYYtLMY3w8bTnv6du4/i4p63O1OEoysnvH7T8/IqXuq6c9jbquo2BYNYkgamcjE4J47YHJH8I5FW31jTN0X/ABM9P/1j/wDMTJ/5bKfw9c9x83UVi6r438NwQpbTeJ9OjuIZbJJImv7RWjMc4LAgtkbcHg8jHzcV0UWpQXUVrcW1680EjNIkiSwMrK0yMGUg4II5z0PBHy5oV7hzU5JJLq/teS8jMudW0438bDUbAqLW9UkamTyZI8D3JwcD+LGTXC/G/WLRm8KpaX9rIr+JbPzRFe+cNgCtkk9sqOfUY7CuuvfFOkW/iV7C41+EXa2WoSvA9zbAwpmJzuAOQCoLnPJAYr8oOOK+Mmtabrv/AAhlxpmpw6hbL4ts1aWCeGYKdgyMxnGcY4z6d80K9zKdSm0kul/tX+12sL+zVqlrD8LtMF/f20cv22bAuNQMLbQpUcdhxgN7belel2OsaYFt86np4xIvXUymP3OO3TnjPY/L0rj/AIF28OheFLjS7e5mEFjrl9ChEkXKozoGy2DnjqQB+Nddo/iLTLhpI7bWIZJLGVRcrFdWxNuRCV+cE/Kcqw+bHQg/MDRFOw/dUFdfZj9q3T0K2iarp0ei6ckmo2CutrZqytqZUgg8gjsR3H8PUUXuq6c9jbquo2BYNYkgamcjE4J47YHJH8I5FeZW3i7xV4rDn4bavFDpugWNrDIt3bRFdSvVO7yEdiAIlAALgggsM5Vg69/4e8VWvifwTo+sWk06R3IsMxl4v3bpcAOnzAEhWDAHHOMngilrymkalOddpJ/F331XkbL6xpm6L/iZ6f8A6x/+YmT/AMtlP4eue4+bqKqXOracb+NhqNgVFreqSNTJ5MkeB7k4OB/FjJqK78c+Gba6EFx4o02KeGaRZI5NQtFZGE6kgjdweMnPcf3c1naL4+8PeJvEV3YaHrL3lzZWt6syr5YU75Y8FWIAkU45KE9scEZbuKlOlzJev2vJ+R0NzrGmGW8xqennMcmMamWz8kfQ/wAX0PXkfwivE/hPe6bL8W5NcF4ixX0erFZpZmhhZPtodCsp5JO9sjrjbnrXvFzdq014ftEx3RyDJeHnKRjnH07c8DHOa8I/ZuuBFZ+DsyOmyDWWLKyAjMtmP4jjt3/Dmhp6GTStovsvr5x8j2ux1jTAtvnU9PGJF66mUx+5x26c8Z7H5elVNE1XTo9F05JNRsFdbWzVlbUypBB5BHYjuP4eorXsbwItv/pEy7ZFPDwjH7nb3/LnjH+1XnGpfEebSrnQPDnhrTptf1yXT7eWe2S7hgW1RAGBkkKMq5yMBiCMjd95QR3uazcIwbae8ftevkdhe6rpz2Nuq6jYFg1iSBqZyMTgnjtgckfwjkVbfWNM3Rf8TPT/APWP/wAxMn/lsp/D1z3HzdRWTovimx8S+ENL1fTLm6+y3Bsdok8lGUpcgMpB/usCPwySVINdE92C0X+kTHEjn78PGZlP9M88ZHHy5oV7j9yUE0na7+15LyMi51bTjfxsNRsCotb1SRqZPJkjwPcnBwP4sZNW7nWNMMt5jU9POY5MY1Mtn5I+h/i+h68j+EUXV2DqUQ+0THNpfDBeHndLEe3r37n+Hirlzdq014ftEx3RyDJeHnKRjnH07c8DHOaEndjaj7uj2f2vP0PEfjo9rqT6vHBPDcA6dfyqILxZs7RpzZy5AI/dtyOTtYAEqBXsVjrGmBbfOp6eMSL11Mpj9zjt054z2Py9K8s+Jmsx3Hi/xVYCZ2eDwxqtwWLIWIlt7VBkj5cfuSODn8cZ9fsbwItv/pEy7ZFPDwjH7nb3/LnjH+1SinYxai5S0+zHr5d7GRomq6dHounJJqNgrra2asramVIIPII7Edx/D1FF7qunPY26rqNgWDWJIGpnIxOCeO2ByR/CORVvQbtRoWmD7RMMWlmMb4eNpz39O3cfxcUahdqLC3H2iYYewGA8PG2dT39O2eR/FxRZ8p1NR9s9H8S+15ryB9Y0zdF/xM9P/wBY/wDzEyf+Wyn8PXPcfN1FVLnVtON/Gw1GwKi1vVJGpk8mSPA9ycHA/ixk1rvdgtF/pExxI5+/DxmZT/TPPGRx8uap3V2DqUQ+0THNpfDBeHndLEe3r37n+Him0zOko3Wj6/a8n5Bc6xphlvManp5zHJjGpls/JH0P8X0PXkfwivLPiFNDceMNQlt5Ypom8vDxTmZT+7UcOev+RXr9zdq014ftEx3RyDJeHnKRjnH07c8DHOa8j+JEvneNNRcO0gPl/MxQk/u17p8v5VnWT5Vc9jh9L6xovsvrfrHyPTNDur1dE01VsNVZRaWQDK1tgjPBGXzj0zz/AHqL26vWsLcfYdVUZ08g7rbH+vG0D589eFz3+9xUmgwSHQtMP2OE5tLM58hOcng/f79D699vWjUIJDYW5FnCcvYHPkIc5nXB+/36H177etXb3dzyXKHtnpH4l37rzJ5Lu+3wf8S7Vv8AWyYy1r1+0J0+frnHtnGOM1x/xJ8K2vjuzt9O17Ttb8qBLy5haGa2R0kWVAWHzEEYJDAg/e+Udx2rwSbov9DhGZHH+oTn98ox9/14+hxyDkU7qCQalETZwjFpfHPkJxiWLJ+/26D07butNrTcypum3ZqP2u/Z+ZPd3d959/u07Vs+VLu3Na5xsiznD9Omcc4xjnNY2uaNb+KF1PTPEGg6jqFnLqIZopDa7kf7IgBBDja+OhU9D1zmt65gkE14DZwrtjkJAgQbcJHyPn4xnPGcZPXJAisbaX+1dQH2CDP28Db9nTGfssZxjzOnfGcZ5znihrbUUZU/ZvSPw+fdeZyek+CNITUtF1F9D8QXd1p0oNmbvUVukgJgU5jSaZlB+VSDjgKvRlGOh0O6vV0TTVWw1VlFpZAMrW2CM8EZfOPTPP8AerQsYJGW3xZwvmRRzAhz+5zjlxnjntzz14qnoMEh0LTD9jhObSzOfITnJ4P3+/Q+vfb1oa13HemoytGO8f18yO9ur1rC3H2HVVGdPIO62x/rxtA+fPXhc9/vcVbku77fB/xLtW/1smMta9ftCdPn65x7ZxjjNQahBIbC3Is4Tl7A58hDnM64P3+/Q+vfb1q48Em6L/Q4RmRx/qE5/fKMff8AXj6HHIOQW13G5QstI7vv2XmZ91dXv25GNjqvFpfjaWtuR5se48P0z175I28Zq3d3d959/u07Vs+VLu3Na5xsiznD9Omcc4xjnNQXUEg1KImzhGLS+OfITjEsWT9/t0Hp23dauXMEgmvAbOFdschIECDbhI+R8/GM54zjJ65IAlq9Qcoe7pHZ9/5vUr2d1fjVr8iw1csdQBIDWu4H7KnB+fG7H4YPrT9Ou77ZbbdO1b/WrjY1r1+zjpl+uPXjHvRY20v9q6gPsEGft4G37OmM/ZYzjHmdO+M4zznPFS2MEjLb4s4XzIo5gQ5/c5xy4zxz25568UorTcmcoW2j8K79vUz9Dur1dE01VsNVZRaWQDK1tgjPBGXzj0zz/eovbq9awtx9h1VRnTyDutsf68bQPnz14XPf73FSaDBIdC0w/Y4Tm0sznyE5yeD9/v0Pr329aNQgkNhbkWcJy9gc+QhzmdcH7/fofXvt60W93c2coe2ekfiXfuvMnku77fB/xLtW/wBbJjLWvX7QnT5+uce2cY4zVS6ur37cjGx1Xi0vxtLW3I82PceH6Z698kbeM1oPBJui/wBDhGZHH+oTn98ox9/14+hxyDkU7qCQalETZwjFpfHPkJxiWLJ+/wBug9O27rTa8zOlKF1pHr37PzJ7u7vvPv8Adp2rZ8qXdua1zjZFnOH6dM45xjHOaZZ3V+NWvyLDVyx1AEgNa7gfsqcH58bsfhg+tWLmCQTXgNnCu2OQkCBBtwkfI+fjGc8Zxk9ckCKxtpf7V1AfYIM/bwNv2dMZ+yxnGPM6d8ZxnnOeKGttSYyhyPSPw+fdeZn31kniDRDpWr6HqN5p10ypLAxtSrfuARjL5DDAIPGMA5DCuL07wLPeeEdO0i71PxrcaGILQizju7ONJImLAws4xK0RDsFUsMDAONqkek2MEjLb4s4XzIo5gQ5/c5xy4zxz25568VT0GCQ6Fph+xwnNpZnPkJzk8H7/AH6H177etDWu4pxpSTk1HS3fz8zEfQ9PtvDZ0u28LNb6ZdPYyT2qW9kIZmM68sgOGJ2gAsM5A3cVgP8ACrwxDqceoad4Z1vTdQN1JMs+n38ds6nzlUqmyXCKQShCgAbvl2jkd1qEEhsLcizhOXsDnyEOczrg/f79D699vWrjwSbov9DhGZHH+oTn98ox9/14+hxyDkFtdxyVJxXux3f5LzOHt/A/h3T7K10qHwcz2NtBfSww3MVpPtcyRh3JdmJOAilidwAAXI6Nb4b+FrXxPPrVt4LuINQt1eSPYbdIo2WNAG8lZPLBG7OVXOcMPmBNdfdW7jUIW+yQD/RL7OIFBGJIufv9ug9OwPWrdzBIJrwGzhXbHISBAg24SPkfPxjOeM4yeuSAJa7iSpLl92PXv39TxvWlvtT+F3inS9KOoQ3WoeLLmxkkEkIEck195bRttYHJRwCB8hDHnBruLHwV4bkjgB8A2jb5EBK6fp/P7kNxk+ozzxjrzmvLfDTSXvjWPw35BiS9+IGqX7vEqgt9jjSUQsu7DIWKEgnA2jBJ6e/WMEjLb4s4XzIo5gQ5/c5xy4zxz25568Ukjlo1ITi+ZRdklr5X8zH8LRtp3hrTLXTtHvoLVLW0ZEtltI48s5bco3DGWJIyMkklq85n8OePPDk+sL4Mig/sfWbiPUmN+8S3FveysBGUILq0YmCMAy5Iypx98+paDBIdC0w/Y4Tm0sznyE5yeD9/v0Pr329aNQgkNhbkWcJy9gc+QhzmdcH7/fofXvt60W93c7pKm6rVkveXfy8znvhxpyeH/CemWulJqOpLJJJNNqKPaE3krXCb5SwkO4k4GWZjwoyQCab4y8N2viW+tptQ0vWYr63tr57e8tp4ILiFg4G5ZEcHA3tlTkEtwpGa+fPi0mv/AAq+Jlxf+H55LLT9Uke8hhCKYCwciRDGSV4YdOwYAHvXu/wz1jWfFHhnStZ1zSrC2murK9kjNvECHjEkWJMFsqc5wOcDGM5wDyObDVqcp+ycErX79n5lK4+Gdu1yk15d/EC8vbCSW4hu7nWo2mVTFGrx5EgARgcMUAcjA3cECXw1o8HhX4h6NpGg6TqdrZW0GpeTb+bC8iFlsGb5mcgnJyckjDDHOQPQ7mCQTXgNnCu2OQkCBBtwkfI+fjGc8Zxk9ckDgPFd++g+ObrVTp0EpsNL1a6+zmNUWTy4LB9pwxwOPfGc8nihrbUuPs403ZR+Hz7rzM7RdKTx34yuvEN3H4jkttJuTo+nxWV0LPyZEgH2iQOJlJctmPK4UpHgljjb0vw98PWXhfR92haHqcL6gtpd3UwmgkaeQt94tJIWxnJUHGCTkDJpPg5pctn8OvDYZWvpblFvJJrmNZHeSeIzsCS4yMyE8+xJzxXQaDBIdC0w/Y4Tm0sznyE5yeD9/v0Pr329aLa7hTdP2bk1G7cfxv5/I808Vxax4Hv5vFWjWVzB4VmWzvNfsNsJdpFmXFzAFYgOQBuBChtpLkk5DNO1L/hb2ttdiDVLrwRpsxhgt45Y0Go3DSRSP9ojZlBRN0W1CpBY53bcqPTtQgkNhbkWcJy9gc+QhzmdcH7/AH6H177etXHgk3Rf6HCMyOP9QnP75Rj7/rx9DjkHIdtdwlCDs3a3Nt8l531/T1v5X/wqHwfaajby23hXWYZIYbmaMrqOGRopU2spE+RtJOcEHJyM9r914S8WadcH+wPFPi1BBb3MUq6yLTUPMRlibJPmIdwJzuJYgbVHG4HubqCQalETZwjFpfHPkJxiWLJ+/wBug9O27rVy5gkE14DZwrtjkJAgQbcJHyPn4xnPGcZPXJAFHXcqUKL5fdjs9rrr5M8b8U+F9chufHHivXbme7vToN3pMghsobdQPsok3t/pD846hQRg5BB+Wu68b+MLvwh4Dv8AXTY6ijWoXyWcW7xiZoAke4B9xXcy5x/Dn+Km/EKCRfBPj7NnCmLe6HECDH/EvBxw5x69+eevFUNds0134jeDtFka3aKzSXWprJYkLyvEkK27NhwwUNI7YJCsVOQeipLTczquEYtRS+GPft5so6ZefFiHQlis9M0K63Wlh9iuGl8lYxwcPHli43ZCkMh4DMOdopahYfFi30xdQi11bu5C2kselSaZax2xcyjy4hMJvM2q33WIy2Bv2jJr0rQYJDoWmH7HCc2lmc+QnOTwfv8AfofXvt60ahBIbC3Is4Tl7A58hDnM64P3+/Q+vfb1ot7u5tKEHVa0+Jd+689znNO+IltceDf+Ej1G31Gwt7Npf7Qjke3LWcyzx+ZEykh94YjClQxJTC4bFcva6h8WLiB76PTrEyX9tdXFtbagyxNYRNMhlicKAZcKI+SI3Du3BC4PS618MtI1TxPBq89pLEryZutPgSOO0v2S4JU3EYb96Q0nc44UHIya6a6gkGpRE2cIxaXxz5CcYliyfv8AboPTtu602vMyoK8lzW0v89Hrv/WpHbX+uS290+r6Ne218YpvNigubedFG2P+M7CRt2k4UEZAGeSfM/iQ8snjTUWnjnikPl5ScpvH7teuwlfyP6165cwSCa8Bs4V2xyEgQINuEj5Hz8YznjOMnrkgeR/EhGj8aairRLER5fyKgQD92vYEgfnWVZe6tT3uHnF4jRL4Xt6x82ei6JBdHRdOKSWAU2tmQG0qRjye538n1P8AF0FLfW919hgLyWDDdY9NKkzkzrznfz2yf4xwMVa0FW/sLTP3s3/HpZ9IpvX/AHu3bHB/hwaNQVvsFv8AvZh89h/yym/57r6N27Y4P8ODWlvdPNdV+2ev2l0XdeQPb3m6L97p/wDrH/5hMo/5bKP+enPHGOw+XqaqXMF0L+P95Yb/ALLekEaVIAMSR/7fXpg/w9DnNa7qd0X72b/WP/yym/57L/tfjxzng/Ng1Tulb+0ov3sx/wBEvv8AllN/z1i/2u/fPA/iyabRnSqu6179F2fkFzb3glvMS6eMRyYxpMq4+SPoPM+X6npkn+IVHZ29z/al+FfTx/pwDZ0eUg/6Mh4XzOB0+Xrn5unFaFyredefvZj+7k6xTDPyR9ctx+ORwM8EYisUb+1dR/fz/wDH+OfJuM/8esfP3s57Y645zjihrYmNV8j1+z2XdeRBY294Vt8y6ecyLnOkyvn9zntJz647n5ulVNEgujounFJLAKbWzIDaVIx5Pc7+T6n+LoK17FSVt/3swzIvSKY4/c+zfhxzjn7vFU9BVv7C0z97N/x6WfSKb1/3u3bHB/hwaGtSnVfK/WPRefkVb63uvsMBeSwYbrHppUmcmdec7+e2T/GOBirT295ui/e6f/rH/wCYTKP+Wyj/AJ6c8cY7D5epo1BW+wW/72YfPYf8spv+e6+jdu2OD/Dg1cdTui/ezf6x/wDllN/z2X/a/HjnPB+bBotqDqvlWvV9F2XkZFzBdC/j/eWG/wCy3pBGlSADEkf+316YP8PQ5zVu5t7wS3mJdPGI5MY0mVcfJH0HmfL9T0yT/EKLpW/tKL97Mf8ARL7/AJZTf89Yv9rv3zwP4smrlyredefvZj+7k6xTDPyR9ctx+ORwM8EYEtQdV+7r0fRd/Qz7O3uf7Uvwr6eP9OAbOjykH/RkPC+ZwOny9c/N04qSxt7wrb5l085kXOdJlfP7nPaTn1x3PzdKnsUb+1dR/fz/APH+OfJuM/8AHrHz97Oe2OuOc44qWxUlbf8AezDMi9Ipjj9z7N+HHOOfu8UJaEzqu2/2V9ldvQyNEgujounFJLAKbWzIDaVIx5Pc7+T6n+LoKW+t7r7DAXksGG6x6aVJnJnXnO/ntk/xjgYq1oKt/YWmfvZv+PSz6RTev+927Y4P8ODRqCt9gt/3sw+ew/5ZTf8APdfRu3bHB/hwaVvdNnVftnr9pdF3XkD295ui/e6f/rH/AOYTKP8Also/56c8cY7D5epqpcwXQv4/3lhv+y3pBGlSADEkf+316YP8PQ5zWu6ndF+9m/1j/wDLKb/nsv8Atfjxzng/Ng1Tulb+0ov3sx/0S+/5ZTf89Yv9rv3zwP4smm0Z0qrute/Rdn5Bc294JbzEunjEcmMaTKuPkj6DzPl+p6ZJ/iFR2dvc/wBqX4V9PH+nANnR5SD/AKMh4XzOB0+Xrn5unFaFyredefvZj+7k6xTDPyR9ctx+ORwM8EYisUb+1dR/fz/8f458m4z/AMesfP3s57Y645zjihrYmNV8j1+z2XdeRBY294Vt8y6ecyLnOkyvn9zntJz647n5ulVNEgujounFJLAKbWzIDaVIx5Pc7+T6n+LoK17FSVt/3swzIvSKY4/c+zfhxzjn7vFU9BVv7C0z97N/x6WfSKb1/wB7t2xwf4cGhrUp1Xyv1j0Xn5FW+t7r7DAXksGG6x6aVJnJnXnO/ntk/wAY4GKtPb3m6L97p/8ArH/5hMo/5bKP+enPHGOw+XqaNQVvsFv+9mHz2H/LKb/nuvo3btjg/wAODVx1O6L97N/rH/5ZTf8APZf9r8eOc8H5sGi2oOq+Va9X0XZeRkXMF0L+P95Yb/st6QRpUgAxJH/t9emD/D0Oc1bube8Et5iXTxiOTGNJlXHyR9B5ny/U9Mk/xCluQw1CNfNlINpek5hm7SR9y3AOeew/iycVbuVbzrz97Mf3cnWKYZ+SPrluPxyOBngjAlqHtZe76Pou/ofPfwon+2/HXXtKaCyM2nalrN6k0lg0g3SyQRnEYYMMCNsDPAc9a94sbe8K2+ZdPOZFznSZXz+5z2k59cdz83SvJfg1oSWvxq+JVzchvt8WoARTKk5IinM8pGAQcnbHnOTxwcbs+zWKkrb/AL2YZkXpFMcfufZvw45xz93ihLQ48NUapv8AyXn5GRokF0dF04pJYBTa2ZAbSpGPJ7nfyfU/xdBS31vdfYYC8lgw3WPTSpM5M685389sn+McDFWtBVv7C0z97N/x6WfSKb1/3u3bHB/hwaNQVvsFv+9mHz2H/LKb/nuvo3btjg/w4NK3unoOq/bPX7S6LuvIy9c8MW2tXOmS6rbaTdPZXMksHmaRLhW81V5HmYYYP3TnHA64I5TWNM1HwbrM2q6NDDeabdR3cl7YRabIBajzE3zwJv68qWUEAAEgFiQ3pbqd0X72b/WP/wAspv8Ansv+1+PHOeD82DVO6Vv7Si/ezH/RL7/llN/z1i/2u/fPA/iyabSMYSu79dei7PyIUMt5DLdWd1pkttNbvLFImlSBWUxxlWX95xwcg9s5/iFeRfHM6pBc30Wl/Z3vrq1urJIobAxtN5zaZEURGJyxEmABkg5YdQV9vuVbzrz97Mf3cnWKYZ+SPrluPxyOBngjHjnxTtr+7+L/AIEtNOmuS0msyPMoEy74oksZmyC2WwIt2OuUU/3cKS2MatWXsJa9Oy7x8j1ext7wrb5l085kXOdJlfP7nPaTn1x3PzdKqaJBdHRdOKSWAU2tmQG0qRjye538n1P8XQVr2Kkrb/vZhmRekUxx+59m/DjnHP3eKp6Crf2Fpn72b/j0s+kU3r/vdu2OD/Dg02tTodV8r9Y9F5+RVvre6+wwF5LBhusemlSZyZ15zv57ZP8AGOBirT295ui/e6f/AKx/+YTKP+Wyj/npzxxjsPl6mjUFb7Bb/vZh89h/yym/57r6N27Y4P8ADg1cdTui/ezf6x/+WU3/AD2X/a/HjnPB+bBotqDqvlWvV9F2XkZFzBdC/j/eWG/7LekEaVIAMSR/7fXpg/w9DnNW7m3vBLeYl08YjkxjSZVx8kfQeZ8v1PTJP8Qoulb+0ov3sx/0S+/5ZTf89Yv9rv3zwP4smrlyredefvZj+7k6xTDPyR9ctx+ORwM8EYEtQdV+7r0fRd/Q4r4gQXA8FeOjusgBb3W/bpciE/6ADwS/y9uDnB+bpxVbwfLc6n8SPEk0Mdk1vZRWGnre/wBnSTRXDiGaVwmGGCvnIGXJJIVuOlaXxCVh4J8ffvZji3uusUwz/wAS8erfhzzjn7vFc9+zZZNH8PlvzfSTHVNXurvclvKADgx5G1gDny84ABG70HKSOatVk6kUv5U9l29PM7bRILo6LpxSSwCm1syA2lSMeT3O/k+p/i6Clvre6+wwF5LBhusemlSZyZ15zv57ZP8AGOBirWgq39haZ+9m/wCPSz6RTev+927Y4P8ADg0agrfYLf8AezD57D/llN/z3X0bt2xwf4cGi3una6r9s9ftLou68ge3vN0X73T/APWP/wAwmUf8tlH/AD0544x2Hy9TVS5guhfx/vLDf9lvSCNKkAGJI/8Ab69MH+Hoc5rXdTui/ezf6x/+WU3/AD2X/a/HjnPB+bBqndK39pRfvZj/AKJff8spv+esX+13754H8WTTaM6VV3Wvfouz8gube8Et5iXTxiOTGNJlXHyR9B5ny/U9Mk/xCvLPiGrJ4w1BZPKLDy8+VAYF/wBWvRGJI/Pnr3r1+5VvOvP3sx/dydYphn5I+uW4/HI4GeCMeR/EgEeNNRBZmP7vllZT/q17OS35ms6y91HscPzcsRZ/yvol1j5I9F0S0tn0XTma4cMbWzJA1adcHPPAOBj0HC9RRfWlsljbkXD53WIw2rT/APPdc8Z4I9P4Oo5o0TVdOj0XTkk1GwV1tbNWVtTKkEHkEdiO4/h6ii91XTnsbdV1GwLBrEkDUzkYnBPHbA5I/hHIqvd5Tzmq3tnpK3Mur7rzLb2Vrui/0iT/AFj/APMYnP8Ay2U+vHHOe4+bqKq3Npbfb40E74Nren/kLTk58yPGOe+enR+p6CrT6xpm6L/iZ6f/AKx/+YmT/wAtlP4eue4+bqKqXOracb+NhqNgVFreqSNTJ5MkeB7k4OB/FjJpvlIpKtdaS69X2fmW7mytTLeEXEhzHJjGsTtn5I+hz830PXkfwio7O1tW1S+zcNhb4YI1mccfZk5LZyeTjd1/h6VJc6xphlvManp5zHJjGpls/JH0P8X0PXkfwio7PVtNXVL5m1LTwrXwZSdVOCPsyDIb0yCN3qNtD5dCYqtyPSXw933XmSWNlahbfNxIMSL11idMfucdm49M9j8vSqmiWls+i6czXDhja2ZIGrTrg554BwMeg4XqKt2OsaYFt86np4xIvXUymP3OO3TnjPY/L0qpomq6dHounJJqNgrra2asramVIIPII7Edx/D1FD5blNVuV6S3j1fn5hfWlsljbkXD53WIw2rT/wDPdc8Z4I9P4Oo5q29la7ov9Ik/1j/8xic/8tlPrxxznuPm6iql7qunPY26rqNgWDWJIGpnIxOCeO2ByR/CORVt9Y0zdF/xM9P/ANY//MTJ/wCWyn8PXPcfN1FHu3BqtZaS3fV9l5lW5tLb7fGgnfBtb0/8hacnPmR4xz3z06P1PQVaubK1Mt4RcSHMcmMaxO2fkj6HPzfQ9eR/CKqXOracb+NhqNgVFreqSNTJ5MkeB7k4OB/FjJq3c6xphlvManp5zHJjGpls/JH0P8X0PXkfwihctware7pLZ9X39SOztbVtUvs3DYW+GCNZnHH2ZOS2cnk43df4elSWNlahbfNxIMSL11idMfucdm49M9j8vSo7PVtNXVL5m1LTwrXwZSdVOCPsyDIb0yCN3qNtSWOsaYFt86np4xIvXUymP3OO3TnjPY/L0oXLYmarW2l8K6vt6lTRLS2fRdOZrhwxtbMkDVp1wc88A4GPQcL1FF9aWyWNuRcPndYjDatP/wA91zxngj0/g6jmjRNV06PRdOSTUbBXW1s1ZW1MqQQeQR2I7j+HqKL3VdOext1XUbAsGsSQNTORicE8dsDkj+Ecil7vKatVvbPSVuZdX3XmW3srXdF/pEn+sf8A5jE5/wCWyn1445z3HzdRVW5tLb7fGgnfBtb0/wDIWnJz5keMc989Oj9T0FWn1jTN0X/Ez0//AFj/APMTJ/5bKfw9c9x83UVUudW0438bDUbAqLW9UkamTyZI8D3JwcD+LGTTfKRSVa60l16vs/Mt3NlamW8IuJDmOTGNYnbPyR9Dn5voevI/hFR2dratql9m4bC3wwRrM44+zJyWzk8nG7r/AA9KkudY0wy3mNT085jkxjUy2fkj6H+L6HryP4RUdnq2mrql8zalp4Vr4MpOqnBH2ZBkN6ZBG71G2h8uhMVW5HpL4e77rzJLGytQtvm4kGJF66xOmP3OOzcemex+XpVTRLS2fRdOZrhwxtbMkDVp1wc88A4GPQcL1FW7HWNMC2+dT08YkXrqZTH7nHbpzxnsfl6VU0TVdOj0XTkk1GwV1tbNWVtTKkEHkEdiO4/h6ih8tymq3K9Jbx6vz8wvrS2SxtyLh87rEYbVp/8AnuueM8Een8HUc1beytd0X+kSf6x/+YxOf+Wyn1445z3HzdRVS91XTnsbdV1GwLBrEkDUzkYnBPHbA5I/hHIq2+saZui/4men/wCsf/mJk/8ALZT+HrnuPm6ij3bg1WstJbvq+y8yrc2lt9vjQTvg2t6f+QtOTnzI8Y5756dH6noKo+Ogmn+FvFF9ZXckdzb6bdzQuNWmfDrCpUjJw/I6Hg4IPCirtzq2nG/jYajYFRa3qkjUyeTJHge5ODgfxYyazPiPqunSeCvF6x6jYOz6TeqoXUy24m3UAD+8fbv0/hFC5dSKvtlBNKW0ur7vzOZ+DNzYatc6pc3cpOuTf2bdXtz/AGhJC0qyaZEV3Mpz/rPOPTgsVHBOPRLGytQtvm4kGJF66xOmP3OOzcemex+XpXH/AAhm0Wz8L6VcmbS7e8uLawWaU33lSSKmnxqoYjnCksB6ElRxXYWOsaYFt86np4xIvXUymP3OO3TnjPY/L0oXLYyp060Kdve2vu+t33KmiWls+i6czXDhja2ZIGrTrg554BwMeg4XqKL60tksbci4fO6xGG1af/nuueM8Een8HUc0aJqunR6LpySajYK62tmrK2plSCDyCOxHcfw9RRe6rpz2Nuq6jYFg1iSBqZyMTgnjtgckfwjkUvd5Trare2ekrcy6vuvMtvZWu6L/AEiT/WP/AMxic/8ALZT68cc57j5uoqrc2lt9vjQTvg2t6f8AkLTk58yPGOe+enR+p6CrT6xpm6L/AImen/6x/wDmJk/8tlP4eue4+bqKqXOracb+NhqNgVFreqSNTJ5MkeB7k4OB/FjJpvlIpKtdaS69X2fmW7mytTLeEXEhzHJjGsTtn5I+hz830PXkfwivO7jSLrVvj7ayxXVomk+H18+Qvqlx50jXVs8fyy5PAMC5PynnBLDAHolzrGmGW8xqennMcmMamWz8kfQ/xfQ9eR/CK5bQ9TsE+LniuV7+xWKS307ZIdSIVsJdA4k6nB4J7HjvQ+XQycKsoWkpbd30afc6mxsrULb5uJBiReusTpj9zjs3Hpnsfl6VU0S0tn0XTma4cMbWzJA1adcHPPAOBj0HC9RVux1jTAtvnU9PGJF66mUx+5x26c8Z7H5elVNE1XTo9F05JNRsFdbWzVlbUypBB5BHYjuP4eoofLc1arcr0lvHq/PzC+tLZLG3IuHzusRhtWn/AOe654zwR6fwdRzVt7K13Rf6RJ/rH/5jE5/5bKfXjjnPcfN1FVL3VdOext1XUbAsGsSQNTORicE8dsDkj+Ecirb6xpm6L/iZ6f8A6x/+YmT/AMtlP4eue4+bqKPduDVay0lu+r7LzKtzaW32+NBO+Da3p/5C05OfMjxjnvnp0fqegq1c2VqZbwi4kOY5MY1ids/JH0Ofm+h68j+EVUudW0438bDUbAqLW9UkamTyZI8D3JwcD+LGTVu51jTDLeY1PTzmOTGNTLZ+SPof4voevI/hFC5bg1W93SWz6vv6nn/xmv4tF+H/AIvuYopbwPMbQhNYlOxZrVIxIQT84DOOvJ+793pufCjS9Otvh74VWAi3R7S3mZI9UmhXe9sGdtqnC5dmJI7kisD43X9jL8OfFbrPa3US6jZzOkd6Z90YNsCdp6rnjd6/LXf6TqOj2trZQQX2mQQQsiJGuo+UqKIAAABwoGMcdPu9KS5TmlGq6ra5tIrrrqvXyINEtLZ9F05muHDG1syQNWnXBzzwDgY9BwvUUX1pbJY25Fw+d1iMNq0//Pdc8Z4I9P4Oo5o0TVdOj0XTkk1GwV1tbNWVtTKkEHkEdiO4/h6ii91XTnsbdV1GwLBrEkDUzkYnBPHbA5I/hHIo93lOxqt7Z6StzLq+68y29la7ov8ASJP9Y/8AzGJz/wAtlPrxxznuPm6iqtzaW32+NBO+Da3p/wCQtOTnzI8Y5756dH6noKtPrGmbov8AiZ6f/rH/AOYmT/y2U/h657j5uoqpc6tpxv42Go2BUWt6pI1MnkyR4HuTg4H8WMmm+Uikq11pLr1fZ+ZbubK1Mt4RcSHMcmMaxO2fkj6HPzfQ9eR/CK8s+ISInjDUFifeg8vDfaGnz+7X+NuT+PTp2r1O51jTDLeY1PTzmOTGNTLZ+SPof4voevI/hFeWfEKaG48YahLbyxTRN5eHinMyn92o4c9f8is61uVWPWyBVPrHvp/C9/WPmep6DdqNC0wfaJhi0sxjfDxtOe/p27j+LijULtRYW4+0TDD2AwHh42zqe/p2zyP4uKj0O6vV0TTVWw1VlFpZAMrW2CM8EZfOPTPP96i9ur1rC3H2HVVGdPIO62x/rxtA+fPXhc9/vcVpdcp47gvbP4fiXVd0aD3YLRf6RMcSOfvw8ZmU/wBM88ZHHy5qndXYOpRD7RMc2l8MF4ed0sR7evfuf4eKnku77fB/xLtW/wBbJjLWvX7QnT5+uce2cY4zVS6ur37cjGx1Xi0vxtLW3I82PceH6Z698kbeM020Z0qauvh69V2ZoXN2rTXh+0THdHIMl4ecpGOcfTtzwMc5qKxvl/tXUW+1T/8AH+Gz5lvn/j1jGfTPb0x71x/wv8Yaz4w8CQa7qVjcPd3cV15jWYhSIhWVOA77gMKue/p3rrbO6vxq1+RYauWOoAkBrXcD9lTg/Pjdj8MH1obWhEIp02/d+HuvIsWN4EW3/wBImXbIp4eEY/c7e/5c8Y/2qp6DdqNC0wfaJhi0sxjfDxtOe/p27j+Lip9Ou77ZbbdO1b/WrjY1r1+zjpl+uPXjHvVTQ7q9XRNNVbDVWUWlkAytbYIzwRl849M8/wB6htXLdNcr+HePVeZJqF2osLcfaJhh7AYDw8bZ1Pf07Z5H8XFXHuwWi/0iY4kc/fh4zMp/pnnjI4+XNZ97dXrWFuPsOqqM6eQd1tj/AF42gfPnrwue/wB7ircl3fb4P+Jdq3+tkxlrXr9oTp8/XOPbOMcZourg4Ky+Hd9V2RBdXYOpRD7RMc2l8MF4ed0sR7evfuf4eKkudZs21W8sv7RBvXtpJfIM9v5hjIjXcVBztyMZHoAOc1Xurq9+3IxsdV4tL8bS1tyPNj3Hh+mevfJG3jNcLPcXf/DRmqubPUfN/wCERYMha38zb9oXlvm27f8AdO6hSVyKi5VD4evVfzHotjfL/auot9qn/wCP8NnzLfP/AB6xjPpnt6Y96lsbwItv/pEy7ZFPDwjH7nb3/LnjH+1Vezur8atfkWGrljqAJAa13A/ZU4Pz43Y/DB9afp13fbLbbp2rf61cbGtev2cdMv1x68Y96UZKw5wVvs/Cuq7EGg3ajQtMH2iYYtLMY3w8bTnv6du4/i4o1C7UWFuPtEww9gMB4eNs6nv6ds8j+Lio9Dur1dE01VsNVZRaWQDK1tgjPBGXzj0zz/eovbq9awtx9h1VRnTyDutsf68bQPnz14XPf73FF1ymzgvbP4fiXVd0aMl0u6Ai5lPzux+eH5czqfz4z6dMfLmqV1dg6lEPtExzaXwwXh53SxHt69+5/h4qeS7vt8H/ABLtW/1smMta9ftCdPn65x7ZxjjNVLq6vftyMbHVeLS/G0tbcjzY9x4fpnr3yRt4zTbRnSpq6+H7XVdmaFzdq014ftEx3RyDJeHnKRjnH07c8DHOaisb5f7V1FvtU/8Ax/hs+Zb5/wCPWMZ9M9vTHvWR451bVLDw14pvLa01WC5t9NvJUlf7K2xlgQhmG4ggYBIAPGMDOa534FeKNd8TeCbTWNWW/v8AULrUJfNntlto1Zlj2D5SVw21R2xj3pOS0Mo2s4WXw33Vt0d9Y3gRbf8A0iZdsinh4Rj9zt7/AJc8Y/2qp6DdqNC0wfaJhi0sxjfDxtOe/p27j+Lip9Ou77ZbbdO1b/WrjY1r1+zjpl+uPXjHvVTQ7q9XRNNVbDVWUWlkAytbYIzwRl849M8/3qbauaumuV/DvHqvMk1C7UWFuPtEww9gMB4eNs6nv6ds8j+Lirj3YLRf6RMcSOfvw8ZmU/0zzxkcfLms+9ur1rC3H2HVVGdPIO62x/rxtA+fPXhc9/vcVbku77fB/wAS7Vv9bJjLWvX7QnT5+uce2cY4zRdXBwVl8O76rsiC6uwdSiH2iY5tL4YLw87pYj29e/c/w8Vl/Eu8DeB/GJ+0THfpF8Ml4ec26jnH07c8DHOa0Lq6vftyMbHVeLS/G0tbcjzY9x4fpnr3yRt4zWZ8Sbq9bwX4yV7DVVzpF8GZ2tuB9nTJbD9MYzjnGMc5pJrUirBci+HaXVd2VvhDdqngnQx9omXbb2Z4eEY/4l8K9/y54x/tV1ljeBFt/wDSJl2yKeHhGP3O3v8Alzxj/arkfhHcXieCtBEVnqcg8izwYjbY/wCQdCBjcw5xyM8bSM/Nmup067vtltt07Vv9auNjWvX7OOmX649eMe9EWrBKCcfs/Cuq7EGg3ajQtMH2iYYtLMY3w8bTnv6du4/i4o1C7UWFuPtEww9gMB4eNs6nv6ds8j+Lio9Dur1dE01VsNVZRaWQDK1tgjPBGXzj0zz/AHqL26vWsLcfYdVUZ08g7rbH+vG0D589eFz3+9xRdcpu4L2z+H4l1XdGg92C0X+kTHEjn78PGZlP9M88ZHHy5qndXYOpRD7RMc2l8MF4ed0sR7evfuf4eKnku77fB/xLtW/1smMta9ftCdPn65x7ZxjjNVLq6vftyMbHVeLS/G0tbcjzY9x4fpnr3yRt4zTbRnSpq6+Hr1XZmhc3atNeH7RMd0cgyXh5ykY5x9O3PAxzmuH0bVxH8d/Etv58uJ7Cyn37ot37tZl6/c/5aY6/rXZ3d3feff7tO1bPlS7tzWucbIs5w/TpnHOMY5zXm8UsiftTTSQW+pPdv4eBmizB5qN5gA/i8vG0Kep6+vQbWhjK0IpO2qtuvJ/dpuem2N4EW3/0iZdsinh4Rj9zt7/lzxj/AGqp6DdqNC0wfaJhi0sxjfDxtOe/p27j+Lip9Ou77ZbbdO1b/WrjY1r1+zjpl+uPXjHvVTQ7q9XRNNVbDVWUWlkAytbYIzwRl849M8/3qG1c2dNcr+HePVeZJqF2osLcfaJhh7AYDw8bZ1Pf07Z5H8XFXHuwWi/0iY4kc/fh4zMp/pnnjI4+XNZ97dXrWFuPsOqqM6eQd1tj/XjaB8+evC57/e4q3Jd32+D/AIl2rf62TGWtev2hOnz9c49s4xxmi6uDgrL4d31XZEF1dg6lEPtExzaXwwXh53SxHt69+5/h4q5c3atNeH7RMd0cgyXh5ykY5x9O3PAxzms+6ur37cjGx1Xi0vxtLW3I82PceH6Z698kbeM1bu7u+8+/3adq2fKl3bmtc42RZzh+nTOOcYxzmhNXBwXu/Ds+q/mPKv2jtURPhh4phMjSm71S2RfMkh4xHC24Bckn5COMDGfQg+tWN4EW3/0iZdsinh4Rj9zt7/lzxj/arw39qqa5k8Bzie3volPiKAkzmAgN9iIwdhJ3Y54+XHvXtunXd9sttunat/rVxsa16/Zx0y/XHrxj3pRa1OfkTnP4fhj1VvhINBu1GhaYPtEwxaWYxvh42nPf07dx/FxRqF2osLcfaJhh7AYDw8bZ1Pf07Z5H8XFR6HdXq6JpqrYaqyi0sgGVrbBGeCMvnHpnn+9Re3V61hbj7DqqjOnkHdbY/wBeNoHz568Lnv8Ae4ouuU7HBe2fw/Euq7o0HuwWi/0iY4kc/fh4zMp/pnnjI4+XNU7q7B1KIfaJjm0vhgvDzuliPb179z/DxU8l3fb4P+Jdq3+tkxlrXr9oTp8/XOPbOMcZqpdXV79uRjY6rxaX42lrbkebHuPD9M9e+SNvGabaM6VNXXw9eq7M0Lm7Vprw/aJjujkGS8POUjHOPp254GOc15H8SJfO8aai4dpAfL+ZihJ/dr3T5fyr1e7u77z7/dp2rZ8qXdua1zjZFnOH6dM45xjHOa8o+JDyyeNNRaeOeKQ+XlJym8fu167CV/I/rWVZrlR7HD0UsR0+F7NPrE9Q0GCQ6Fph+xwnNpZnPkJzk8H7/fofXvt60ahBIbC3Is4Tl7A58hDnM64P3+/Q+vfb1qpokF0dF04pJYBTa2ZAbSpGPJ7nfyfU/wAXQUt9b3X2GAvJYMN1j00qTOTOvOd/PbJ/jHAxWl3ynmtfvn7y+JdH3RrPBJui/wBDhGZHH+oTn98ox9/14+hxyDkZ+pbbS6+0XUFtBbw2N/JLK0CgRoske5iQ5Pyjvg4HQN1qR7e83RfvdP8A9Y//ADCZR/y2Uf8APTnjjHYfL1NcP8Y719G8D63c3QtJFfTL62Aj0x0OZZooRy0mBgyLz/CARgkinJuxinypyUl9ro+zMH9l37bJ8MruG6g3rb3NysPmRKSkbRQSAglgeshYHBxv4znj12xtpf7V1AfYIM/bwNv2dMZ+yxnGPM6d8ZxnnOeK4jwD4eXw5/wk+j6XNAbayuBErXGnO0jEWFl8xwy7ckk5I4ySSd1dZZ29z/al+FfTx/pwDZ0eUg/6Mh4XzOB0+Xrn5unFK70MsMrUX73R9H3RoWMEjLb4s4XzIo5gQ5/c5xy4zxz25568VT0GCQ6Fph+xwnNpZnPkJzk8H7/fofXvt60WNveFbfMunnMi5zpMr5/c57Sc+uO5+bpVTRILo6LpxSSwCm1syA2lSMeT3O/k+p/i6Cm27m7Xuv3lvHo/Mt6hBIbC3Is4Tl7A58hDnM64P3+/Q+vfb1q48Em6L/Q4RmRx/qE5/fKMff8AXj6HHIORk31vdfYYC8lgw3WPTSpM5M685389sn+McDFWnt7zdF+90/8A1j/8wmUf8tlH/PTnjjHYfL1NF3fYGvdXvLd9H2QXUEg1KImzhGLS+OfITjEsWT9/t0Hp23da850nRp4v2g/FmqPHGUm06a1WDyVxD5UOnOWA3nGftHbOOTzkgd3cwXQv4/3lhv8Ast6QRpUgAxJH/t9emD/D0Oc15Z4Zmv7D4hO+ovavLreoeIYbSRrJzhYTbKONw2gC1ZQM/IBkk5pX1OfE/wDLr3uvZ/zM9lsbaX+1dQH2CDP28Db9nTGfssZxjzOnfGcZ5znipbGCRlt8WcL5kUcwIc/uc45cZ457c89eKz7O3uf7Uvwr6eP9OAbOjykH/RkPC+ZwOny9c/N04qSxt7wrb5l085kXOdJlfP7nPaTn1x3PzdKabsbTWnxL4V0l2DQYJDoWmH7HCc2lmc+QnOTwfv8AfofXvt60ahBIbC3Is4Tl7A58hDnM64P3+/Q+vfb1qpokF0dF04pJYBTa2ZAbSpGPJ7nfyfU/xdBS31vdfYYC8lgw3WPTSpM5M685389sn+McDFK75TZr98/eXxLo+6NZ4JN0X+hwjMjj/UJz++UY+/68fQ45ByKd1BINSiJs4Ri0vjnyE4xLFk/f7dB6dt3Wh7e83RfvdP8A9Y//ADCZR/y2Uf8APTnjjHYfL1NVLmC6F/H+8sN/2W9II0qQAYkj/wBvr0wf4ehzmm2+xnSWq95dej7MrfEuCQeB/GINnCu3SL4kCBBtxbryPn4xnPGcZPXJA539n/SJ9L8EnTpbaOeWz1m8tXZ4FJZkLAjlxxxnH69qX433l5o/w48U3INhIrWzWxVdNeLAlMMRILOdpAkJGR/6EKufDKC4a11ny3sRjxLqStv0uSTJ82ToA4wv+xyR1zSb1Rzw+OXvfY7PuvmdrYwSMtvizhfMijmBDn9znHLjPHPbnnrxVPQYJDoWmH7HCc2lmc+QnOTwfv8AfofXvt60WNveFbfMunnMi5zpMr5/c57Sc+uO5+bpVTRILo6LpxSSwCm1syA2lSMeT3O/k+p/i6Cm27nQ17r95bx6PzLeoQSGwtyLOE5ewOfIQ5zOuD9/v0Pr329auPBJui/0OEZkcf6hOf3yjH3/AF4+hxyDkZN9b3X2GAvJYMN1j00qTOTOvOd/PbJ/jHAxVp7e83RfvdP/ANY//MJlH/LZR/z0544x2Hy9TRd32Br3V7y3fR9kF1BINSiJs4Ri0vjnyE4xLFk/f7dB6dt3Wsv4lwSDwP4xBs4V26RfEgQINuLdeR8/GM54zjJ65IFm5guhfx/vLDf9lvSCNKkAGJI/9vr0wf4ehzmsz4jwXQ8FeL90lgUGk3pIXSpEP/HuvTLnaevJ6Zz/ABChN6kVl7i95bS6PuxfhJaTjwP4fZrCMrLbWZQvbqd4+wRdMuMjgn6gnOflrqbGCRlt8WcL5kUcwIc/uc45cZ457c89eK4b4Ps174H0OWz+xpGIrWJhLpzzksljErcqwBGVJ24zn5q62xt7wrb5l085kXOdJlfP7nPaTn1x3PzdKIt2FvBNyXwro+waDBIdC0w/Y4Tm0sznyE5yeD9/v0Pr329aNQgkNhbkWcJy9gc+QhzmdcH7/fofXvt61U0SC6Oi6cUksAptbMgNpUjHk9zv5Pqf4ugpb63uvsMBeSwYbrHppUmcmdec7+e2T/GOBild8p0Nfvn7y+JdH3RrPBJui/0OEZkcf6hOf3yjH3/Xj6HHIORTuoJBqURNnCMWl8c+QnGJYsn7/boPTtu60Pb3m6L97p/+sf8A5hMo/wCWyj/npzxxjsPl6mqlzBdC/j/eWG/7LekEaVIAMSR/7fXpg/w9DnNNt9jOktV7y69H2Zr3MEgmvAbOFdschIECDbhI+R8/GM54zjJ65IHj2gNPN+1v4lt5LeMmHSUjSDyl2hdlu+Nu/HVifvd8+1eq3NveCW8xLp4xHJjGkyrj5I+g8z5fqemSf4hXj3hyGf8A4a08Uxq1oJP7NTdnT3MZHlW3SHfuHbv70Ns46y0h7y+59j22xgkZbfFnC+ZFHMCHP7nOOXGeOe3PPXiqegwSHQtMP2OE5tLM58hOcng/f79D699vWixt7wrb5l085kXOdJlfP7nPaTn1x3PzdKqaJBdHRdOKSWAU2tmQG0qRjye538n1P8XQUNu52Ne6/eW8ej8y3qEEhsLcizhOXsDnyEOczrg/f79D699vWrjwSbov9DhGZHH+oTn98ox9/wBePoccg5GTfW919hgLyWDDdY9NKkzkzrznfz2yf4xwMVZe2vPMhPnWI/eONo0mQA/v06/Pk+gAPAJU5JGC7vsEvhXvdX0fZC3UEg1KImzhGLS+OfITjEsWT9/t0Hp23dauXMEgmvAbOFdschIECDbhI+R8/GM54zjJ65IGRcwXQv4/3lhv+y3pBGlSADEkf+316YP8PQ5zVu5t7wS3mJdPGI5MY0mVcfJH0HmfL9T0yT/EKE3d6A18PvLZ9H3PGv2qYmj8CTl7SKMDxFCuViVMH7CeMhzx3x09+1e42MEjLb4s4XzIo5gQ5/c5xy4zxz25568V4R+1LFKngWYyG1IHiCEHyrB4Dn7EehZjgf7PUn5s44r2uxt7wrb5l085kXOdJlfP7nPaTn1x3PzdKUW9Tnt78/e+zHo/5Q0GCQ6Fph+xwnNpZnPkJzk8H7/fofXvt60ahBIbC3Is4Tl7A58hDnM64P3+/Q+vfb1qpokF0dF04pJYBTa2ZAbSpGPJ7nfyfU/xdBS31vdfYYC8lgw3WPTSpM5M685389sn+McDFF3ynY1++fvL4l0fdGs8Em6L/Q4RmRx/qE5/fKMff9ePoccg5FO6gkGpRE2cIxaXxz5CcYliyfv9ug9O27rQ9vebov3un/6x/wDmEyj/AJbKP+enPHGOw+XqaqXMF0L+P95Yb/st6QRpUgAxJH/t9emD/D0Oc0232M6S1XvLr0fZmvcwSCa8Bs4V2xyEgQINuEj5Hz8YznjOMnrkgeR/EhGj8aairRLER5fyKgQD92vYEgfnXqFzb3glvMS6eMRyYxpMq4+SPoPM+X6npkn+IV5Z8Q1ZPGGoLJ5RYeXnyoDAv+rXojEkfnz171nWfuo9jh//AHje/uvo11j3PU9BVv7C0z97N/x6WfSKb1/3u3bHB/hwa5L4vSahp/gqHW9Nu7sNos1jqUtrGZolvIo5DuhZ92FXndnBBKAKM10WiWls+i6czXDhja2ZIGrTrg554BwMeg4XqKL60tksbci4fO6xGG1af/nuueM8Een8HUc1evKeRVpxnUlFt6y7LuvM8fvrzVZvhxZapqHiGbSdW8S3t1e6fJqGp30FtpsUjK6xiaIlHIVA6K+0ZZuCy7Tc1yP/AISn4I6HEZdWg/tO3jiZ9SaaebL6jaKZGkZsOCTuBAAIK8DIA9feytd0X+kSf6x/+YxOf+Wyn1445z3HzdRXIfEq1t1sLFUmdt15D/zEppT/AMhO06An0JPv97qooadjnp0Iq+r2ktl2fmVvChf/AIXP8VIzNMVWCwblJeSbbnILZHQcsSOB7V39ijf2rqP7+f8A4/xz5Nxn/j1j5+9nPbHXHOccVwekaNb2fxc8eSNe71v9NsrmMJqUwK4WSIqXzmU5jzg8fMB2rsbO1tW1S+zcNhb4YI1mccfZk5LZyeTjd1/h6Ua6Dw6XspavZ9F/MvM0LFSVt/3swzIvSKY4/c+zfhxzjn7vFU9BVv7C0z97N/x6WfSKb1/3u3bHB/hwaLGytQtvm4kGJF66xOmP3OOzcemex+XpVTRLS2fRdOZrhwxtbMkDVp1wc88A4GPQcL1FN3ubNR5Xq949F5+Zb1BW+wW/72YfPYf8spv+e6+jdu2OD/Dg1cdTui/ezf6x/wDllN/z2X/a/HjnPB+bBrIvrS2SxtyLh87rEYbVp/8AnuueM8Een8HUc1beytd0X+kSf6x/+YxOf+Wyn1445z3HzdRRrcGo8q1e76LsvMLpW/tKL97Mf9Evv+WU3/PWL/a7988D+LJrxnxPe2nh268K+KdSmdNOsPEWv2VwVWQybriWcK4UnlRs+bncBjIfIFeuXNpbfb40E74Nren/AJC05OfMjxjnvnp0fqegrxr4l+HYtY+DuvXEDTzXGna1qV7Ekd48oYLfOjEq2dwEbSNuGCdpJPBBWupz4lLli03dJvp0l6nu1ijf2rqP7+f/AI/xz5Nxn/j1j5+9nPbHXHOccVLYqStv+9mGZF6RTHH7n2b8OOcc/d4rPs7W1bVL7Nw2FvhgjWZxx9mTktnJ5ON3X+HpUljZWoW3zcSDEi9dYnTH7nHZuPTPY/L0pq9jaolbd/Cui7eoaCrf2Fpn72b/AI9LPpFN6/73btjg/wAODRqCt9gt/wB7MPnsP+WU3/PdfRu3bHB/hwaqaJaWz6LpzNcOGNrZkgatOuDnngHAx6DheoovrS2SxtyLh87rEYbVp/8AnuueM8Een8HUc0teU2aXtnq/iXRd15mu6ndF+9m/1j/8spv+ey/7X48c54PzYNU7pW/tKL97Mf8ARL7/AJZTf89Yv9rv3zwP4smh7K13Rf6RJ/rH/wCYxOf+Wyn1445z3HzdRVW5tLb7fGgnfBtb0/8AIWnJz5keMc989Oj9T0FN3M6Sjdavr0XZ+Zz3xv006t4F1XTftMqG8ubS2DtFLxvurVc4Zu2c4J7D1XEvwnvWvYvEcHzRCx8U6lbBo4ZsyZd5N7YbJb95tx97CjJwDVH4p6U1/f8Ahqzsb9oVm1tJJi2ozTq8cMBnK5Y9SYQAeu7A7VX+DdtbvN403zsu3xhqAGNVmj42LySDz/vnk9DRqcUkudNN7W6dvU9IsVJW3/ezDMi9Ipjj9z7N+HHOOfu8VT0FW/sLTP3s3/HpZ9IpvX/e7dscH+HBosbK1C2+biQYkXrrE6Y/c47Nx6Z7H5elVNEtLZ9F05muHDG1syQNWnXBzzwDgY9BwvUUO9ztajyvV7x6Lz8zh/jZe6x4d07QPFemz309ho7wtf6ckksEVwjnCM7FiCEkVAuAeZMrjaa5HXINW8KeHNKufEnjjUI9bg0SeY6ZqEl9FHc3C3BlZVuI7lFeUb1jwGY4UHbkqR7NfWlsljbkXD53WIw2rT/891zxngj0/g6jmrb2Vrui/wBIk/1j/wDMYnP/AC2U+vHHOe4+bqKLNswqUIz1bdr9l2V+vp93mZmhST3Om6LcXMN7ZTy6TcSSWtx9okkhYtCTG7s2WIPBZu4+bJqH4pssPgPxg007Bf7Lu1zKJUBJhQAZZjySQAD1OB3XF+5tLb7fGgnfBtb0/wDIWnJz5keMc989Oj9T0FcV+0DDaW/wv8TS7nm+SNVU6pNKMmW3AOCfmwecHrg/3RRrqVXSVLd/DLou78xn7Mwmb4X6cJ5J0kS/njK+XMSu1SMfKRyAMY6/hxXp1ipK2/72YZkXpFMcfufZvw45xz93iuE+Elhaw6RqMBlSJYPEOoRqsOoy26BRJIBhUOAPRuT0HSuvsbK1C2+biQYkXrrE6Y/c47Nx6Z7H5elEb2HZciu38Mei7eoaCrf2Fpn72b/j0s+kU3r/AL3btjg/w4NGoK32C3/ezD57D/llN/z3X0bt2xwf4cGqmiWls+i6czXDhja2ZIGrTrg554BwMeg4XqKL60tksbci4fO6xGG1af8A57rnjPBHp/B1HNLXlOhpe2er+JdF3Xma7qd0X72b/WP/AMspv+ey/wC1+PHOeD82DVO6Vv7Si/ezH/RL7/llN/z1i/2u/fPA/iyaHsrXdF/pEn+sf/mMTn/lsp9eOOc9x83UVVubS2+3xoJ3wbW9P/IWnJz5keMc989Oj9T0FN3M6Sjdavr0XZ+ZrXKt515+9mP7uTrFMM/JH1y3H45HAzwRjyXw/p88f7UviO+bzhDPZtAk22XLNHBZMw2538CRf4u/pXp1zZWplvCLiQ5jkxjWJ2z8kfQ5+b6HryP4RXm8E1la/HVLdnA+2Xd9AJG1GYPxp+myD96Dux8jYJyDkjHQ0NvQ4sQ4pQ1f3Lt6nqlipK2/72YZkXpFMcfufZvw45xz93iqegq39haZ+9m/49LPpFN6/wC927Y4P8ODRY2VqFt83EgxIvXWJ0x+5x2bj0z2Py9KqaJaWz6LpzNcOGNrZkgatOuDnngHAx6Dheood7na1Hler3j0Xn5lvUFb7Bb/AL2YfPYf8spv+e6+jdu2OD/Dg1cdTui/ezf6x/8AllN/z2X/AGvx45zwfmwayL60tksbci4fO6xGG1af/nuueM8Een8HUc1beytd0X+kSf6x/wDmMTn/AJbKfXjjnPcfN1FGtwajyrV7vouy8wulb+0ov3sx/wBEvv8AllN/z1i/2u/fPA/iyauXKt515+9mP7uTrFMM/JH1y3H45HAzwRjJubS2+3xoJ3wbW9P/ACFpyc+ZHjHPfPTo/U9BVq5srUy3hFxIcxyYxrE7Z+SPoc/N9D15H8IoV7g1H3dXs+i7+p41+1UpHgO4zJK3/FRQcNHKuf8AQTz87EZ9jz74r2zR5o7y0srm1nmMExSSMiKf7pgBB4I7HsAcc/d4ryr442ME/h2+RLhcrf3LjdqMswITR536MfmJIxuPP8PTiuw+Glrbv4D8KySXEgdrK0Zs6vPH/wAuiZ4B+XnjI6H5elKNzlf8aSu/hXbsvM3tBVv7C0z97N/x6WfSKb1/3u3bHB/hwaNQVvsFv+9mHz2H/LKb/nuvo3btjg/w4NVNEtLZ9F05muHDG1syQNWnXBzzwDgY9BwvUUX1pbJY25Fw+d1iMNq0/wDz3XPGeCPT+DqOaNeU7ml7Z6v4l0XdeZrup3RfvZv9Y/8Ayym/57L/ALX48c54PzYNU7pW/tKL97Mf9Evv+WU3/PWL/a7988D+LJoeytd0X+kSf6x/+YxOf+Wyn1445z3HzdRVW5tLb7fGgnfBtb0/8hacnPmR4xz3z06P1PQU3czpKN1q+vRdn5mtcq3nXn72Y/u5OsUwz8kfXLcfjkcDPBGPI/iQCPGmogszH93yysp/1a9nJb8zXqFzZWplvCLiQ5jkxjWJ2z8kfQ5+b6HryP4RXlnxCRE8YagsT70Hl4b7Q0+f3a/xtyfx6dO1Z1r8quexw+l9Y0b+F727x7M9I0TVdOj0XTkk1GwV1tbNWVtTKkEHkEdiO4/h6ii91XTnsbdV1GwLBrEkDUzkYnBPHbA5I/hHIq3oN2o0LTB9omGLSzGN8PG057+nbuP4uKNQu1Fhbj7RMMPYDAeHjbOp7+nbPI/i4q7PlPLaj7Z6P4l9rzXkVdR8U+H7Brc32vaPbbpJCvm6wF3YmQnGT+OR1HzdQK8o+I/xC0fXtb8K6T4X1aG8kbU45L4RySOgt/OjuAd7qFGDGhOCTkEMAcivbXuwWi/0iY4kc/fh4zMp/pnnjI4+XNU7q7B1KIfaJjm0vhgvDzuliPb179z/AA8VTTsc0ITc1y7a9W+j/rbQ4fVLnSrP42x6tJrNgV1LQLnToo1vS2HieGX/AFn8W5XbCtgfuyM9K7Sz1bTV1S+ZtS08K18GUnVTgj7MgyG9Mgjd6jbXHfFab7N4p8Ha/El3dyWuqPYsBJFtSO7gWAyMUU9G2DsD0yCcjZ+H/wAQtC8Y3uqz6FqV7KIr5ZHEsccTKphMat8wA+bymIx0UjIDHFS09CKbhFSi1utPe/w+XkzcsdY0wLb51PTxiReuplMfucdunPGex+XpXNX3jzw14T8MaXNrWrW0Ra2tY1iiu5JZWZQWYbEBIxjnOAhI5yQDreIvGWleDfD41bWr24htoJEwkRhaSR/I2hI1PJY4xzwACSQQSOU+FnhqK3jfxP4htoT4kv5IJopGNtJJZW6/u4olk9RCq5ZQpJJ35ABpu9y6ktHCC106uy38v6+RmTfE/UtW0yxuvD/g+e40+VbV1lvdfgs5CUnz/qi7EKdowTjaDuxjBNjVPilqWkadFd6r4Pnd3DtFDpmtpfMsnmkhJQmCgxGDvUOCHU/eG2vRdQu1Fhbj7RMMPYDAeHjbOp7+nbPI/i4q492C0X+kTHEjn78PGZlP9M88ZHHy5os77j9nom29318l/d/U8wfxB4y1LULC7g/4Q7RbZre5We2vtXmvZowZl3cxMiFmUKVUNhsMS3Pyul07TvCnwZ1/QF12y1KWDSdRzcfbtpmkkj3khQTklmOBznGCTtzXoN1dg6lEPtExzaXwwXh53SxHt69+5/h4q5c3atNeH7RMd0cgyXh5ykY5x9O3PAxzmhJ3YnRjZXu7p/a8/Q5rwP4ms9U0q11O8vLG3mvmgunR9UZdpeyjJHrw2Rnrkba2bHWNMC2+dT08YkXrqZTH7nHbpzxnsfl6V4T4A8AbfHPiDQ31zWLCx8PA22ny2GoCOQfaS8wlEgZUD+WsSOoBU+owtdr4Q+LdnZ+Hhb+Lm1Gx8T6XJHBc6eqRPPdyeV5aPboAPM3kdFG1c8nGHZK9jL20JR1i9kvi6pWfQs658T9D8H2Hh+yniu9UvrqzgIttLufOljEfLb13Db3AHbBI6GsaX4p6lq1qh0HwVfSWsT2qO+pazFYSb0lDYWJySUIx8w4XJPGDW78J9Ju4LZvE3iG8eXWdTtrNYYgYsWForZjt1LfMDjazgBQX5Ycbm7TULtRYW4+0TDD2AwHh42zqe/p2zyP4uKLPlN0nUqt6q8tNfNd0zzS21r4lz29rNLqHw4t5Hy7QyX90XiYyKSrFXK5B7qSCATkkA1FbfFtBDbNrHhzWU1hPtdhcW1m7zRh3dCJVlJEbRHaR985PJyMMfXHuwWi/0iY4kc/fh4zMp/pnnjI4+XNU7q7B1KIfaJjm0vhgvDzuliPb179z/DxTaYqNNKWl+v2vJ+R5fY+N5fHXjfTZrbTJ9E0TSRPe3EutXBhlnle3eBI4gSdxG8seeRwcYG7qvCOv6JF438aadDd2UJj1aG8LDUCkTiWxjG5Xz8x3xvuOMgkDJ3cdlc3atNeH7RMd0cgyXh5ykY5x9O3PAxzmvLIPE1n4T+JnxT8QaxNepYw/2VLviWJ5JB9mkjG0D5SS525HyjnJBos0c84qKi7Pr9ry9PxPR7HWNMC2+dT08YkXrqZTH7nHbpzxnsfl6VU0TVdOj0XTkk1GwV1tbNWVtTKkEHkEdiO4/h6imeBfGGn+JdLju9Onv4fs919nuILhIoZLeVIAGRlf+IZAzyvvurF8ReLpvD/gvSodHJvPEd7a2lvpli7xYllXklsciOMfMSSoGMMy7gaHe51OVP2blZ2937Xr5GtrniDRrPRkuLnVtOjhiNizs2pkYAnUngenoPu9RXMD4yeFd8kl4NVsrCJhJDfXFvdeTdI8oIeMhCwHykZYLkjIyRSy+FbvUJbe78da+viGG3ltjZ6d9jtoLS33ybH3Rlm84qjFUMmSm5iRk5r0R7sFov8ASJjiRz9+HjMyn+meeMjj5c0K9zKSqSScVZXe7bey7WODvfir4Jj1prL/AISOwaWOG4jd1uZXi3SSReXtlC7GBycgNtwMuRt4wvj34i0TV/hZ4oj0nWtKvpB5GVtdUFwf9fbdgefut19D/cFem3V2DqUQ+0THNpfDBeHndLEe3r37n+HiuK8YfCnwN4hgmhbSo9PeNXaGfTRb2zg4jPIQbXHBGCG6nbg7jRZ6kTpVHFLR3Uu/d+v9aeZd+GepadDaauZNS09fM8SalIA2pMnymWXBz3B6h++QO9dRY6xpgW3zqenjEi9dTKY/c47dOeM9j8vSuF+FWt2+mWfj2+1G+nhsrPxZqdzJIDE3lxhAzNtGST1+6CDnjJxVPwhN8UrWwtrqTV9I1Rbuximjh1JUsJbG6MPRlRG3ooIUhtpJGPkOciuKFRSik4tu3ftp2M/VfFGt6/eWnh7wH4h0jSF0vTrZ9Q1G4u/M/wBIIYR26q4xwcM5UNsweQylH6TwZ47s/E/heM309jZ61ZXFpa6hZ/2kw8qWO5wzL2KELuBUsqgnDEg1pfC3QbDwl4QtbWxurqSW6Fve3c8ksJaa4Ygu5yeMYGB1GBuz1NHxZpGow6ta674RuNPttQmggtr9L2Xy4rplZTbSN5ectFIiDlNxR3UugC0rPlNrSjV55J35tVfzW3mvncPGHxT8O+Hb6KyjN3rOoqzSPaaRK9y8aGXcGY8Ko+XH3tx3KxHINYUPxo8NzXLXGrWet6FBHb3ESyajFNtleV1ZVXyw/ICHIbAPU12Hgfw/F4atpZrq9a+13ULl7nU9SCwo1zJ56leNx2qq8Bc7RgkAAtW3dXYOpRD7RMc2l8MF4ed0sR7evfuf4eKbTClGT1tZ69Xpo/v+9HN6d8T/AAVrKX09n4l0xIwki4u7+S3YnZH0WYKzflg4I/hFefeBnsdQ8ax+I5dUtZBbeN9Wt45Pt5EbQzWLbH8wfw4t1Ct/F+Fe26jLBdrqMNw7TwTwyxukhgZZFZIwVYdCDgggdQOOd1cJpGi6L4P1XQdM8OJcWmnp4lkmWMTxykFtJmBbLMT+OdoHvRK+hyVKM5RUpWstd33XqdnY6xpgW3zqenjEi9dTKY/c47dOeM9j8vSqWk6zpdtoFibnVNOhEVnaeYZNUKbNp+bOfu47j+DqK5jxbrPiW+1+08OeC9YOk3sFk2pTXk9pFNEW2LFDDvb5U3ETZJBICDAJ3Csaw0zxX40TQLfxWbTS/C2nx2rT2MF1DcNqrxsDGXBAVYDkny33MCPnHKsg73OuU1yyUYvdddOvkaXhv4q+HPFUcNnG11pd8Ws5IrfU5ngaaJJkJlQjKFcEnAbKhWYDAJrt7rXtHt40mn1fTIokdyzvquFUeevJJ6D37j5uorlviv4ch8VeFYRbzGHX7L7K2lXpmjja1n8wDh1O9V5Ge4wGIyqkYSnXviJd6HaeJbW+0nSNKlMmr28vkCPU7wSxsYkQk7rYH597FlfoB8u4GtyZSlFcrjfXR3fZbry+W51lz428KG/jYeKPD5UWt6pI1xSMmSMgdepwcD+LGTW9c6xphlvMalp5zHJjGpls/JH0P8X0PXBH8Irmrjwb4N/tCJF8OaKAba7O37DZ4JEke3ovoT78/LxVG5+H9hpN7rF74C1S68L395C8cpt1t5raUZjbDQMdv98Dy9pG7jPzAiuNKceVzV9Hs2uvmR/EN9P1d0sBqNkEvNUuIty6mW+V9Gnj3Angjccbj3+XpWz8MtV06LwF4USTUbBHWxtAyvqZQri0QHI/h54z2Py9Kp+G9L8RJr8E3iDxdFqsen6s12XXT7e3lldrEwj5llKKoWTpsOSPvZOBP8JNftX+F3hq8kvjDb21pGskhlhRIxFb+WzEvjGChBJ4wPWlFMzaXO3KLV4/zeS8jY0TVdOj0XTkk1GwV1tbNWVtTKkEHkEdiO4/h6ii91XTnsbdV1GwLBrEkDUzkYnBPHbA5I/hHIrmtA+K3g9dBQTeIXtnsLKzaaK5RYHIA3jy0kUNKNvK7AxORngjPGf8IzqHxBt5/E/iq+1DTrxHitfDluCLd9Kj+0bBO6b1YzcBvvYxglsFdprynS6kJVn7NXfN/N6eR7G+saZui/4men/6x/8AmJk/8tlP4eue4+bqKqXOracb+NhqNgVFreqSNTJ5MkeB7k4OB/FjJrmvBvxDjm8NT/8ACV3VzZ694fiLa5G0aYjbzd3mIQoVw4jMgCbhyAMjrT0jxR4y1q7Gq2+naSdFvrO4l0yC51EQXSwO8ZLTbY5FLP8AIwRcEAkZ4pu5NGpTbTSfXq+z8v6+R3lzrGmGW8xqennMcmMamWz8kfQ/xfQ9eR/CK8s+IU0Nx4w1CW3limiby8PFOZlP7tRw56/5Fdv4Z8YX2s3mp2WuaLq2i6pFA7yLI0M9tIGCACO5UBJDgLuUYYdADtY1xfxIl87xpqLh2kB8v5mKEn92vdPl/Ksq1+VHtcOuLxF4r7L636x8kemaHdXq6JpqrYaqyi0sgGVrbBGeCMvnHpnn+9Re3V61hbj7DqqjOnkHdbY/142gfPnrwue/3uKk0GCQ6Fph+xwnNpZnPkJzk8H7/fofXvt60ahBIbC3Is4Tl7A58hDnM64P3+/Q+vfb1rS3u7nlOUPbPSPxLv3XmTyXd9vg/wCJdq3+tkxlrXr9oTp8/XOPbOMcZqpdXV79uRjY6rxaX42lrbkebHuPD9M9e+SNvGa0Hgk3Rf6HCMyOP9QnP75Rj7/rx9DjkHIp3UEg1KImzhGLS+OfITjEsWT9/t0Hp23dabXmZ0pQutI9e/Z+Zh/E3SdR8U+Ftf0iK11a3uZYmkilaS2XbJH5EiFir8DciZK84xjnNc9bfD+XSPEtlqfgi1v9J1TTHGmL50dvNFLbG2RikkYmQGQEmTcDyT8xJ6ek3MEgmvAbOFdschIECDbhI+R8/GM54zjJ65IEVjbS/wBq6gPsEGft4G37OmM/ZYzjHmdO+M4zznPFJx21M4qm4t2j8Pn3Xmea6f8ADzUtY8W6Z4g8Z3mt63LY3Eb6faW8Vta29uRH5g+QzNuPEXJIJEYDlug7/Q7q9XRNNVbDVWUWlkAytbYIzwRl849M8/3q0LGCRlt8WcL5kUcwIc/uc45cZ457c89eKp6DBIdC0w/Y4Tm0sznyE5yeD9/v0Pr329adtdyl7OMZWUd49/PzI726vWsLcfYdVUZ08g7rbH+vG0D589eFz3+9xVuS7vt8H/Eu1b/WyYy1r1+0J0+frnHtnGOM1BqEEhsLcizhOXsDnyEOczrg/f79D699vWrjwSbov9DhGZHH+oTn98ox9/14+hxyDkFtdynKFlpHd9+y8zPurq9+3IxsdV4tL8bS1tyPNj3Hh+mevfJG3jNW7u7vvPv92natnypd25rXONkWc4fp0zjnGMc5qC6gkGpRE2cIxaXxz5CcYliyfv8AboPTtu61cuYJBNeA2cK7Y5CQIEG3CR8j5+MZzxnGT1yQBLV6g5Q93SOz7/zepVsJruPWNSePTtVEkupB32m0DF/ska8/NgttA9Rtx3qXTru+2W23TtW/1q42Na9fs46Zfrj14x70WNtL/auoD7BBn7eBt+zpjP2WM4x5nTvjOM85zxUtjBIy2+LOF8yKOYEOf3OccuM8c9ueevFCWm5M5U0to/Cu/b1M/Q7q9XRNNVbDVWUWlkAytbYIzwRl849M8/3qL26vWsLcfYdVUZ08g7rbH+vG0D589eFz3+9xUmgwSHQtMP2OE5tLM58hOcng/f79D699vWjUIJDYW5FnCcvYHPkIc5nXB+/36H177etK3u7mzlD2z0j8S7915k8l3fb4P+Jdq3+tkxlrXr9oTp8/XOPbOMcZqpdXV79uRjY6rxaX42lrbkebHuPD9M9e+SNvGa0Hgk3Rf6HCMyOP9QnP75Rj7/rx9DjkHIp3UEg1KImzhGLS+OfITjEsWT9/t0Hp23dabXmZ0pQutI9e/Z+ZPd3d959/u07Vs+VLu3Na5xsiznD9Omcc4xjnNeF/EPRNW1f9ojSIpba4/szVzHBcW04t5HuVtRHcyRMu7Z08vnOMNjn5lr3m5gkE14DZwrtjkJAgQbcJHyPn4xnPGcZPXJAzU0O3u/EjXlzpFq95Y6iTbObdAYy9miso/edCpyVJxnB6gAJrbUxlyyptLlWnn3j57HManoutWmqweJvBWl30evF4orq1ea3jt9ShEOdr/MdsyqW2SkHAO1sgkCl8Jk128hn8S6/pN+t5cRWtlpyrDbxPBp8cp8tSJCHDO+5zyQ3yHoBj0axgkZbfFnC+ZFHMCHP7nOOXGeOe3PPXiqegwSHQtMP2OE5tLM58hOcng/f79D699vWm1ruW1DWVlvHTXz13/r1I726vWsLcfYdVUZ08g7rbH+vG0D589eFz3+9xVuS7vt8H/Eu1b/WyYy1r1+0J0+frnHtnGOM1BqEEhsLcizhOXsDnyEOczrg/f79D699vWrjwSbov9DhGZHH+oTn98ox9/wBePoccg5BbXctyhZaR3ffsvMz7q6vftyMbHVeLS/G0tbcjzY9x4fpnr3yRt4zVu7u77z7/AHadq2fKl3bmtc42RZzh+nTOOcYxzmoLqCQalETZwjFpfHPkJxiWLJ+/26D07butXLmCQTXgNnCu2OQkCBBtwkfI+fjGc8Zxk9ckAS1eoOUPd0js+/8AN6ngMgi1Lwh4w0PU4dTWDWviK1j+7MAYu80JZAc8SbFfn7me9e86dd32y226dq3+tXGxrXr9nHTL9cevGPevFdAt/J+JNt4du9MtLpbrxtqmqB/LVtjRWSSImNwHBnU4zgFBy1e32MEjLb4s4XzIo5gQ5/c5xy4zxz25568UJeZw4acHCV1HRefm+/mZ+h3V6uiaaq2GqsotLIBla2wRngjL5x6Z5/vUXt1etYW4+w6qozp5B3W2P9eNoHz568Lnv97ipNBgkOhaYfscJzaWZz5Cc5PB+/36H177etGoQSGwtyLOE5ewOfIQ5zOuD9/v0Pr329aVvd3PScoe2ekfiXfuvM+ZfF/i3xj8IPHlxY6fNcDQJZGubGwvisqJEZclV2khNroRhTjgEgg17l4G8X3/AIv0HT9bfRtUthcWV+Qgkt2V18yLc6klTszwcgHP3eKu+NPAGkeL7rR5dc00SGxuJXjREVBLmVVKPh8suSOMjpjJBJrCuoJfh/qiu9uZfCssN2FH2dWOlnzIwTkMT5IbbgnPl7jjK9BrzOGgvZVeZtcuunyfz/E7+7u77z7/AHadq2fKl3bmtc42RZzh+nTOOcYxzmuA+JupajZ6r4cmit9SjkbxpYxnebfJ32uwr8rY3lWOP4MEZOc16FLGXa6eO1gKGKRgUhTAGyM5GHOOoIIz97POSB43+0ld3Wi+GodTtrW3iuLLxTazxk26bQ6We4KQHORwCV6H17USW2pdSUPYuyjt+sfM6j4QzXV/LrfidbGeeXV9XaKK4sJICj21tEYIR8743AK5yMqQ2QegHXaHdXq6JpqrYaqyi0sgGVrbBGeCMvnHpnn+9VP4caFLovgvw7pr6XbxTwQQpNGIY3Hmm3DSciTDZYsx7EnOe1aGgwSHQtMP2OE5tLM58hOcng/f79D699vWi2u5pTlD2Wqj9nv5+ZHe3V61hbj7DqqjOnkHdbY/142gfPnrwue/3uKtyXd9vg/4l2rf62TGWtev2hOnz9c49s4xxmoNQgkNhbkWcJy9gc+QhzmdcH7/AH6H177etXHgk3Rf6HCMyOP9QnP75Rj7/rx9DjkHIdtdy3KFlpHd9+y8zPurq9+3IxsdV4tL8bS1tyPNj3Hh+mevfJG3jNW7u7vvPv8Adp2rZ8qXdua1zjZFnOH6dM45xjHOaguoJBqURNnCMWl8c+QnGJYsn7/boPTtu61cuYJBNeA2cK7Y5CQIEG3CR8j5+MZzxnGT1yQBLV6g5Q93SOz7/wA3qV7O6vxq1+RYauWOoAkBrXcD9lTg/Pjdj8MH1r5/8Fm91n4HeC/B9gtysmu6pPFKI54omktY2lkuPKJO4PtAX5lKYfB6ivoOxtpf7V1AfYIM/bwNv2dMZ+yxnGPM6d8ZxnnOeK8C/ZcZtcuLIpiaHw9ZPai2ltY3BmupppGcMWB4SCMYPHLYx/FKXmcuIlDniklrFd/Lz7XPWLfw7pWqaRo7al4SXUGg0+yghkntLGTbFn5VTechOTgcdTuGK2r26vWsLcfYdVUZ08g7rbH+vG0D589eFz3+9xUmgwSHQtMP2OE5tLM58hOcng/f79D699vWjUIJDYW5FnCcvYHPkIc5nXB+/wB+h9e+3rTt7u523pqs0lH4l+a8zkvGvgLT/F2uWWpatp3iITKrWs0cN1bJHdwrdq4ilXfhlDknt8xB6AY6m6ur37cjGx1Xi0vxtLW3I82PceH6Z698kbeM1oPBJui/0OEZkcf6hOf3yjH3/Xj6HHIORTuoJBqURNnCMWl8c+QnGJYsn7/boPTtu602vMzo+zUrpR1v37PzJ7u7vvPv92natnypd25rXONkWc4fp0zjnGMc5ryj4kPLJ401Fp454pD5eUnKbx+7XrsJX8j+teuXMEgmvAbOFdschIECDbhI+R8/GM54zjJ65IHkfxIRo/Gmoq0SxEeX8ioEA/dr2BIH51lWXurU9nh5xeI0S+F7esfNnouiQXR0XTiklgFNrZkBtKkY8nud/J9T/F0FLfW919hgLyWDDdY9NKkzkzrznfz2yf4xwMVa0FW/sLTP3s3/AB6WfSKb1/3u3bHB/hwaNQVvsFv+9mHz2H/LKb/nuvo3btjg/wAODWlvdPNdV+2ev2l0XdeQPb3m6L97p/8ArH/5hMo/5bKP+enPHGOw+XqaqXMF0L+P95Yb/st6QRpUgAxJH/t9emD/AA9DnNa7qd0X72b/AFj/APLKb/nsv+1+PHOeD82DVO6Vv7Si/ezH/RL7/llN/wA9Yv8Aa7988D+LJptGdKq7rXv0XZ+QXNveCW8xLp4xHJjGkyrj5I+g8z5fqemSf4hUdnb3P9qX4V9PH+nANnR5SD/oyHhfM4HT5eufm6cVoXKt515+9mP7uTrFMM/JH1y3H45HAzwRiKxRv7V1H9/P/wAf458m4z/x6x8/ezntjrjnOOKGtiY1XyPX7PZd15EFjb3hW3zLp5zIuc6TK+f3Oe0nPrjufm6VU0SC6Oi6cUksAptbMgNpUjHk9zv5Pqf4ugrXsVJW3/ezDMi9Ipjj9z7N+HHOOfu8VT0FW/sLTP3s3/HpZ9IpvX/e7dscH+HBoa1KdV8r9Y9F5+RVvre6+wwF5LBhusemlSZyZ15zv57ZP8Y4GKtPb3m6L97p/wDrH/5hMo/5bKP+enPHGOw+XqaNQVvsFv8AvZh89h/yym/57r6N27Y4P8ODVx1O6L97N/rH/wCWU3/PZf8Aa/HjnPB+bBotqDqvlWvV9F2XkZFzBdC/j/eWG/7LekEaVIAMSR/7fXpg/wAPQ5zVu5t7wS3mJdPGI5MY0mVcfJH0HmfL9T0yT/EKLpW/tKL97Mf9Evv+WU3/AD1i/wBrv3zwP4smrlyredefvZj+7k6xTDPyR9ctx+ORwM8EYEtQdV+7r0fRd/Qz7O3uf7Uvwr6eP9OAbOjykH/RkPC+ZwOny9c/N04qSxt7wrb5l085kXOdJlfP7nPaTn1x3PzdKnsUb+1dR/fz/wDH+OfJuM/8esfP3s57Y645zjipbFSVt/3swzIvSKY4/c+zfhxzjn7vFCWhM6rtv9lfZXb0MjRILo6LpxSSwCm1syA2lSMeT3O/k+p/i6Clvre6+wwF5LBhusemlSZyZ15zv57ZP8Y4GKtaCrf2Fpn72b/j0s+kU3r/AL3btjg/w4NGoK32C3/ezD57D/llN/z3X0bt2xwf4cGlb3TZ1X7Z6/aXRd15A9vebov3un/6x/8AmEyj/lso/wCenPHGOw+XqaqXMF0L+P8AeWG/7LekEaVIAMSR/wC316YP8PQ5zWu6ndF+9m/1j/8ALKb/AJ7L/tfjxzng/Ng1Tulb+0ov3sx/0S+/5ZTf89Yv9rv3zwP4smm0Z0qrute/Rdn5Bc294JbzEunjEcmMaTKuPkj6DzPl+p6ZJ/iFR2dvc/2pfhX08f6cA2dHlIP+jIeF8zgdPl65+bpxWhcq3nXn72Y/u5OsUwz8kfXLcfjkcDPBGIrFG/tXUf38/wDx/jnybjP/AB6x8/ezntjrjnOOKGtiY1XyPX7PZd15EFjb3hW3zLp5zIuc6TK+f3Oe0nPrjufm6VU0SC6Oi6cUksAptbMgNpUjHk9zv5Pqf4ugrXsVJW3/AHswzIvSKY4/c+zfhxzjn7vFU9BVv7C0z97N/wAeln0im9f97t2xwf4cGhrUp1Xyv1j0Xn5FW+t7r7DAXksGG6x6aVJnJnXnO/ntk/xjgYq09vebov3un/6x/wDmEyj/AJbKP+enPHGOw+XqaNQVvsFv+9mHz2H/ACym/wCe6+jdu2OD/Dg1cdTui/ezf6x/+WU3/PZf9r8eOc8H5sGi2oOq+Va9X0XZeRkXMF0L+P8AeWG/7LekEaVIAMSR/wC316YP8PQ5zVu5t7wS3mJdPGI5MY0mVcfJH0HmfL9T0yT/ABCi6Vv7Si/ezH/RL7/llN/z1i/2u/fPA/iyauXKt515+9mP7uTrFMM/JH1y3H45HAzwRgS1B1X7uvR9F39DyTwtpupTftH+MrlLm1+x2cEELxNYymPzJ7eJsrBu44t+TuycKcEdPT7G3vCtvmXTzmRc50mV8/uc9pOfXHc/N0rJ8PeHTY/EHxbrf2+d21O6tYjF9lnBj8m067t+5ifM6dQBnoTXRWKkrb/vZhmRekUxx+59m/DjnHP3eKElY5qTlTg0+uuy63t07dDI0SC6Oi6cUksAptbMgNpUjHk9zv5Pqf4ugpb63uvsMBeSwYbrHppUmcmdec7+e2T/ABjgYq1oKt/YWmfvZv8Aj0s+kU3r/vdu2OD/AA4NGoK32C3/AHsw+ew/5ZTf8919G7dscH+HBpW907XVftnr9pdF3XkD295ui/e6f/rH/wCYTKP+Wyj/AJ6c8cY7D5epqneWtw94qSNp7brS+HOkyAY8yMYOX+mD/DyDnNbDqd0X72b/AFj/APLKb/nsv+1+PHOeD82DVO6Vv7Si/ezH/RL7/llN/wA9Yv8Aa7988D+LJptGdKq7rXv0XZ+QxrK4txcQ250yKGKF1jjj0eRFQBI8BV8z5Mduw6/xCvI/2ltLuLj4d6vcFrXbZazbzOIrB4Cc26JwWY4H7wfL1J5zg4r2u5VvOvP3sx/dydYphn5I+uW4/HI4GeCMYWu+H4fEqahpl9NI1o2sW000clpNKsqxRwSlGVmPDBNvqAc8jilJbGFSUp0ZRX8vZd15GjY294Vt8y6ecyLnOkyvn9zntJz647n5ulVNEgujounFJLAKbWzIDaVIx5Pc7+T6n+LoK17FSVt/3swzIvSKY4/c+zfhxzjn7vFU9BVv7C0z97N/x6WfSKb1/wB7t2xwf4cGm1qbuq+V+sei8/Iq31vdfYYC8lgw3WPTSpM5M685389sn+McDFWnt7zdF+90/wD1j/8AMJlH/LZR/wA9OeOMdh8vU0agrfYLf97MPnsP+WU3/PdfRu3bHB/hwauOp3RfvZv9Y/8Ayym/57L/ALX48c54PzYNFtQdV8q16vouy8jIuYLoX8f7yw3/AGW9II0qQAYkj/2+vTB/h6HOat3NveCW8xLp4xHJjGkyrj5I+g8z5fqemSf4hRdK39pRfvZj/ol9/wAspv8AnrF/td++eB/Fk1cuVbzrz97Mf3cnWKYZ+SPrluPxyOBngjAlqDqv3dej6Lv6GfZ29z/al+FfTx/pwDZ0eUg/6Mh4XzOB0+Xrn5unFeM/s36JPp3iXx1HZwxRafFqi2cLzWMlwjeX9oyikMOVDISMk/Mp7c+42KN/auo/v5/+P8c+TcZ/49Y+fvZz2x1xznHFeffAhSbfxdiSVf8Airr8YWOVsfu15+RgM+w598UkjmxErzhLsl0/u+h1+iQXR0XTiklgFNrZkBtKkY8nud/J9T/F0FLfW919hgLyWDDdY9NKkzkzrznfz2yf4xwMVa0FW/sLTP3s3/HpZ9IpvX/e7dscH+HBo1BW+wW/72YfPYf8spv+e6+jdu2OD/Dg0W907XVftnr9pdF3XkD295ui/e6f/rH/AOYTKP8Also/56c8cY7D5epqpcwXQv4/3lhv+y3pBGlSADEkf+316YP8PQ5zWu6ndF+9m/1j/wDLKb/nsv8Atfjxzng/Ng1Tulb+0ov3sx/0S+/5ZTf89Yv9rv3zwP4smm0Z0qrute/Rdn5Bc294JbzEunjEcmMaTKuPkj6DzPl+p6ZJ/iFeWfENWTxhqCyeUWHl58qAwL/q16IxJH589e9ev3Kt515+9mP7uTrFMM/JH1y3H45HAzwRjyP4kAjxpqILMx/d8srKf9WvZyW/M1nWXuo9jh+bliLP+V9EusfJHouiWls+i6czXDhja2ZIGrTrg554BwMeg4XqKL60tksbci4fO6xGG1af/nuueM8Een8HUc0aJqunR6LpySajYK62tmrK2plSCDyCOxHcfw9RRe6rpz2Nuq6jYFg1iSBqZyMTgnjtgckfwjkVXu8p5zVb2z0lbmXV915lt7K13Rf6RJ/rH/5jE5/5bKfXjjnPcfN1FVbm0tvt8aCd8G1vT/yFpyc+ZHjHPfPTo/U9BVp9Y0zdF/xM9P8A9Y//ADEyf+Wyn8PXPcfN1FVLnVtON/Gw1GwKi1vVJGpk8mSPA9ycHA/ixk03ykUlWutJder7PzLdzZWplvCLiQ5jkxjWJ2z8kfQ5+b6HryP4RUdna2rapfZuGwt8MEazOOPsycls5PJxu6/w9KkudY0wy3mNT085jkxjUy2fkj6H+L6HryP4RUdnq2mrql8zalp4Vr4MpOqnBH2ZBkN6ZBG71G2h8uhMVW5HpL4e77rzJLGytQtvm4kGJF66xOmP3OOzcemex+XpVTRLS2fRdOZrhwxtbMkDVp1wc88A4GPQcL1FW7HWNMC2+dT08YkXrqZTH7nHbpzxnsfl6VU0TVdOj0XTkk1GwV1tbNWVtTKkEHkEdiO4/h6ih8tymq3K9Jbx6vz8wvrS2SxtyLh87rEYbVp/+e654zwR6fwdRzVprK13Q/6RKcSPz/bE/wDz2X349c9x83UVVvdV057G3VdRsCwaxJA1M5GJwTx2wOSP4RyKtvrGmbov+Jnp/wDrH/5iZP8Ay2U/h657j5uoo924NVrLSW76vsvMq3Npbfb40E74Nren/kLTk58yPGOe+enR+p6CrVzZWplvCLiQ5jkxjWJ2z8kfQ5+b6HryP4RVS51bTjfxsNRsCotb1SRqZPJkjwPcnBwP4sZNW7nWNMMt5jU9POY5MY1Mtn5I+h/i+h68j+EULluDVb3dJbPq+/qR2dratql9m4bC3wwRrM44+zJyWzk8nG7r/D0qSxsrULb5uJBiReusTpj9zjs3Hpnsfl6VHZ6tpq6pfM2paeFa+DKTqpwR9mQZDemQRu9RtqSx1jTAtvnU9PGJF66mUx+5x26c8Z7H5elC5bEzVa20vhXV9vUqaJaWz6LpzNcOGNrZkgatOuDnngHAx6DheoovrS2SxtyLh87rEYbVp/8AnuueM8Een8HUc0aJqunR6LpySajYK62tmrK2plSCDyCOxHcfw9RRe6rpz2Nuq6jYFg1iSBqZyMTgnjtgckfwjkUvd5TVqt7Z6StzLq+68y29la7ov9Ik/wBY/wDzGJz/AMtlPrxxznuPm6iqtzaW32+NBO+Da3p/5C05OfMjxjnvnp0fqegq0+saZui/4men/wCsf/mJk/8ALZT+HrnuPm6iqlzq2nG/jYajYFRa3qkjUyeTJHge5ODgfxYyab5SKSrXWkuvV9n5lu5srUy3hFxIcxyYxrE7Z+SPoc/N9D15H8IqOztbVtUvs3DYW+GCNZnHH2ZOS2cnk43df4elSXOsaYZbzGp6ecxyYxqZbPyR9D/F9D15H8IqOz1bTV1S+ZtS08K18GUnVTgj7MgyG9Mgjd6jbQ+XQmKrcj0l8Pd915kljZWoW3zcSDEi9dYnTH7nHZuPTPY/L0qpolpbPounM1w4Y2tmSBq064OeeAcDHoOF6irdjrGmBbfOp6eMSL11Mpj9zjt054z2Py9KqaJqunR6LpySajYK62tmrK2plSCDyCOxHcfw9RQ+W5TVblekt49X5+YX1pbJY25Fw+d1iMNq0/8Az3XPGeCPT+DqOatvZWu6L/SJP9Y//MYnP/LZT68cc57j5uoqpe6rpz2Nuq6jYFg1iSBqZyMTgnjtgckfwjkVbfWNM3Rf8TPT/wDWP/zEyf8Alsp/D1z3HzdRR7twarWWkt31fZeZVubS2+3xoJ3wbW9P/IWnJz5keMc989Oj9T0FWrmytTLeEXEhzHJjGsTtn5I+hz830PXkfwiqlzq2nG/jYajYFRa3qkjUyeTJHge5ODgfxYyat3OsaYZbzGp6ecxyYxqZbPyR9D/F9D15H8IoXLcGq3u6S2fV9/Ujs7W1bVL7Nw2FvhgjWZxx9mTktnJ5ON3X+HpUljZWoW3zcSDEi9dYnTH7nHZuPTPY/L0qOz1bTV1S+ZtS08K18GUnVTgj7MgyG9Mgjd6jbUljrGmBbfOp6eMSL11Mpj9zjt054z2Py9KFy2Jmq1tpfCur7epU0S0tn0XTma4cMbWzJA1adcHPPAOBj0HC9RRfWlsljbkXD53WIw2rT/8APdc8Z4I9P4Oo5o0TVdOj0XTkk1GwV1tbNWVtTKkEHkEdiO4/h6ii91XTnsbdV1GwLBrEkDUzkYnBPHbA5I/hHIpe7ymrVb2z0lbmXV915lt7K13Rf6RJ/rH/AOYxOf8Alsp9eOOc9x83UVVubS2+3xoJ3wbW9P8AyFpyc+ZHjHPfPTo/U9BVp9Y0zdF/xM9P/wBY/wDzEyf+Wyn8PXPcfN1FVLnVtON/Gw1GwKi1vVJGpk8mSPA9ycHA/ixk03ykUlWutJder7PzLdzZWplvCLiQ5jkxjWJ2z8kfQ5+b6HryP4RUdna2rapfZuGwt8MEazOOPsycls5PJxu6/wAPSpLnWNMMt5jU9POY5MY1Mtn5I+h/i+h68j+EVHZ6tpq6pfM2paeFa+DKTqpwR9mQZDemQRu9RtofLoTFVuR6S+Hu+68ySxsrULb5uJBiReusTpj9zjs3Hpnsfl6VU0S0tn0XTma4cMbWzJA1adcHPPAOBj0HC9RVux1jTAtvnU9PGJF66mUx+5x26c8Z7H5elVNE1XTo9F05JNRsFdbWzVlbUypBB5BHYjuP4eoofLcpqtyvSW8er8/ML60tksbci4fO6xGG1af/AJ7rnjPBHp/B1HNW3srXdF/pEn+sf/mMTn/lsp9eOOc9x83UVUvdV057G3VdRsCwaxJA1M5GJwTx2wOSP4RyKtvrGmbov+Jnp/8ArH/5iZP/AC2U/h657j5uoo924NVrLSW76vsvMq3Npbfb40E74Nren/kLTk58yPGOe+enR+p6CrVzZWplvCLiQ5jkxjWJ2z8kfQ5+b6HryP4RVS51bTjfxsNRsCotb1SRqZPJkjwPcnBwP4sZNW7nWNMMt5jU9POY5MY1Mtn5I+h/i+h68j+EULluDVb3dJbPq+/qR2dratql9m4bC3wwRrM44+zJyWzk8nG7r/D0qLQ9D0nTkAskS0E919omEWpzQ+ZI0I3SNtP3ierdc/L0qWz1bTV1S+ZtS08K18GUnVTgj7MgyG9Mgjd6jbUljrGmBbfOp6eMSL11Mpj9zjt054z2Py9KFy2Jmq1tpfCur7epU0S0tn0XTma4cMbWzJA1adcHPPAOBj0HC9RRfWlsljbkXD53WIw2rT/891zxngj0/g6jmjRNV06PRdOSTUbBXW1s1ZW1MqQQeQR2I7j+HqKL3VdOext1XUbAsGsSQNTORicE8dsDkj+Ecil7vKatVvbPSVuZdX3XmW3srXdF/pEn+sf/AJjE5/5bKfXjjnPcfN1FVbm0tvt8aCd8G1vT/wAhacnPmR4xz3z06P1PQVafWNM3Rf8AEz0//WP/AMxMn/lsp/D1z3HzdRVS51bTjfxsNRsCotb1SRqZPJkjwPcnBwP4sZNN8pFJVrrSXXq+z8y3c2VqZbwi4kOY5MY1ids/JH0Ofm+h68j+EV5Z8QkRPGGoLE+9B5eG+0NPn92v8bcn8enTtXqdzrGmGW8xqennMcmMamWz8kfQ/wAX0PXkfwivLPiFNDceMNQlt5Ypom8vDxTmZT+7UcOev+RWda3KrHrZAqn1j30/he/rHzP/2Q==);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Electrocardiogram showing inverted U waves superimposed at the end of the T waves (arrows) in the lateral precordial leads. This finding is most often a subtle sign of ischemia. An unrelated complete right bundle branch block is also present (rSR' in lead V1 with prolonged QRS interval).",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Ary Goldberger, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f38_20_39238=[""].join("\n");
var outline_f38_20_39238=null;
var title_f38_20_39239="Central sleep apnea: Treatment";
var content_f38_20_39239=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/wk_utd-rgb.myextg\" width=\"220px\">",
"   </img>",
"  </div>",
"  <div id=\"printHeaderText\">",
"   Official reprint from  UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"   <a href=\"file://www.uptodate.com\">",
"    www.uptodate.com",
"   </a>",
"   <br>",
"    &copy;2013 UpToDate",
"    <sup>",
"     &reg;",
"    </sup>",
"   </br>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"5\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Central sleep apnea: Treatment",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?38/20/39239/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?38/20/39239/contributors\">",
"     M Safwan Badr, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?38/20/39239/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?38/20/39239/contributors\">",
"     Robert C Basner, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?38/20/39239/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?38/20/39239/contributors\">",
"     April F Eichler, MD, MPH",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"mobipreview.htm?38/20/39239/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Jan 15, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Central sleep apnea (CSA) is a disorder characterized by repetitive cessation or decrease of both airflow and ventilatory effort during sleep. It can be primary (ie, idiopathic CSA) or secondary. Examples of secondary CSA include CSA associated with Cheyne-Stokes breathing, a medical condition, a drug or substance, or high altitude periodic breathing [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/20/39239/abstract/1\">",
"     1",
"    </a>",
"    ]. CSA associated with Cheyne-Stokes breathing is particularly common, especially among patients who have heart failure or have had a stroke. It is characterized by central apneas that occur during the decrescendo portion of the cyclic crescendo-decrescendo respiratory pattern. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?11/2/11301?source=see_link&amp;anchor=H5#H5\">",
"     \"Classification of sleep disorders\", section on 'Sleep related breathing disorders'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?8/43/8888?source=see_link\">",
"     \"Cheyne-Stokes breathing and obstructive sleep apnea in heart failure\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    CSA can alternatively be categorized as hyperventilation- or hypoventilation-related. Hyperventilation-related CSA encompasses most of the types of CSA mentioned above, with CSA associated with a drug or substance being a notable exception. Hypoventilation-related CSA occurs in disorders in which there is alveolar hypoventilation that is so severe that central apneas occur when the patient falls asleep because the wakefulness stimulus to breathe disappears. Central apneas tend to be a minor component of such disorders. Examples of contexts in which hypoventilation-related CSA may occur include central nervous system diseases, central nervous system suppressing drugs or substances, neuromuscular diseases, and severe abnormalities in pulmonary mechanics (eg, kyphoscoliosis). (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?18/44/19140?source=see_link&amp;anchor=H2#H2\">",
"     \"Central sleep apnea: Pathogenesis\", section on 'Central apnea due to hyperventilation'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?18/44/19140?source=see_link&amp;anchor=H3#H3\">",
"     \"Central sleep apnea: Pathogenesis\", section on 'Central apnea due to hypoventilation'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In this topic review, we present an approach to treating CSA and then we describe the evidence supporting each intervention. The definition, risk factors, clinical presentation, diagnosis, and pathogenesis of CSA are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?43/29/44502?source=see_link\">",
"     \"Central sleep apnea: Risk factors, clinical presentation, and diagnosis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?18/44/19140?source=see_link\">",
"     \"Central sleep apnea: Pathogenesis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9079958\">",
"    <span class=\"h1\">",
"     NATURAL HISTORY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Untreated CSA disrupts sleep; therefore, sequelae may include excessive daytime sleepiness, inattention, poor concentration, morning headaches, difficulty maintaining sleep (ie, awakenings), and increased risk for a motor vehicle crash or a workplace accident. These symptoms are likely to persist if the underlying condition also persists and the CSA is not treated. However, CSA may improve if the underlying condition also improves.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9079968\">",
"    <span class=\"h1\">",
"     GENERAL APPROACH",
"    </span>",
"    &nbsp;&mdash;&nbsp;This section presents an approach to treating patients with CSA.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4898695\">",
"    <span class=\"h2\">",
"     Indications",
"    </span>",
"    &nbsp;&mdash;&nbsp;All patients with CSA should receive initial treatment directed at conditions that may be causing or exacerbating CSA (eg, heart failure). If the CSA persists despite such therapy, CSA-specific therapies are indicated for patients who have symptoms or significant physiological sequelae attributable to CSA (eg, daytime sleepiness, prolonged or repetitive oxyhemoglobin desaturation during sleep).",
"   </p>",
"   <p>",
"    An exception to this approach exists in decompensated patients with severe consequences of CSA (eg, prolonged severe oxyhemoglobin desaturation precipitating myocardial ischemia or arrhythmias during sleep). In such cases, treatment directed at the underlying cause of the decompensation and CSA-specific therapy may be initiated concomitantly.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4898702\">",
"    <span class=\"h2\">",
"     Choice of therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;CSA-specific therapy depends upon whether the patient&rsquo;s central apneas are hyperventilation- or hypoventilation-related:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Hyperventilation-related CSA (ie, high loop gain CSA) is most common. It includes primary CSA and CSA associated with Cheyne-Stokes breathing, a medical condition, or high altitude periodic breathing. Initial treatment consists of continuous positive airway pressure therapy (CPAP). Those who fail CPAP should receive a trial of adaptive servo-ventilation (ASV) instead, and those who also fail ASV should be given a trial of bilevel positive airway pressure (BPAP) with a backup respiratory rate before abandoning positive airway pressure therapy. BPAP without a backup respiratory rate should not be used because it may worsen the CSA. In addition, all patients with hypoxemia during sleep should receive supplemental oxygen during sleep. It is important to realize that this approach is largely based upon the extrapolation of evidence from studies that focused on patients who have CSA associated with Cheyne-Stokes breathing due to heart failure [",
"      <a class=\"abstract\" href=\"mobipreview.htm?38/20/39239/abstract/2\">",
"       2",
"      </a>",
"      ]; there is a paucity of data regarding the treatment of patients with other types of hyperventilation-related CSA. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?18/44/19140?source=see_link&amp;anchor=H2#H2\">",
"       \"Central sleep apnea: Pathogenesis\", section on 'Central apnea due to hyperventilation'",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Hypoventilation-related CSA is less common and includes CSA associated with central nervous system diseases, central nervous system suppressing drugs or substances, neuromuscular diseases, or severe abnormalities in pulmonary mechanics. Patients whose central apneas are due to hypoventilation should be initially treated with BPAP with a backup rate. The backup rate ensures adequate ventilation if the patient's ventilatory motor output is insufficient to reliably trigger mechanical inspiration. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?18/44/19140?source=see_link&amp;anchor=H3#H3\">",
"       \"Central sleep apnea: Pathogenesis\", section on 'Central apnea due to hypoventilation'",
"      </a>",
"      .)",
"      <br/>",
"      <br/>",
"      Management of patients with severe alveolar hypoventilation, with or without CSA, is described in greater detail separately. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?26/29/27095?source=see_link\">",
"       \"Types of noninvasive nocturnal ventilatory support in neuromuscular and chest wall disease\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?40/36/41543?source=see_link\">",
"       \"Practical aspects of nocturnal noninvasive ventilation in neuromuscular and chest wall disease\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Patients who do not tolerate or fail positive airway pressure therapy may benefit from supplemental oxygen during sleep. They may also benefit from treatment with a pharmacological respiratory stimulant, such as",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?5/39/5752?source=see_link\">",
"     acetazolamide",
"    </a>",
"    , but such medications can have harmful side effects and should be monitored closely. (See",
"    <a class=\"local\" href=\"#H9080828\">",
"     'Supplemental oxygen during sleep'",
"    </a>",
"    below and",
"    <a class=\"local\" href=\"#H7\">",
"     'Pharmacologic therapy'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9080532\">",
"    <span class=\"h1\">",
"     TREATMENT MODALITIES",
"    </span>",
"    &nbsp;&mdash;&nbsp;In this section, we review the modalities used to treat CSA. These include positive airway pressure, nocturnal supplemental oxygen, and, occasionally, respiratory stimulant medication.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h2\">",
"     Positive airway pressure",
"    </span>",
"    &nbsp;&mdash;&nbsp;Types of positive airway pressure therapy used to treat CSA include continuous positive airway pressure (CPAP), adaptive servo-ventilation (ASV), and bilevel positive airway pressure (BPAP).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h3\">",
"     Continuous positive airway pressure (CPAP)",
"    </span>",
"    &nbsp;&mdash;&nbsp;CPAP is first-line therapy for patients with hyperventilation-related CSA (ie, most types of CSA, including primary CSA and CSA associated with Cheyne-Stokes breathing, a medical condition, or high altitude periodic breathing). (See",
"    <a class=\"local\" href=\"#H9079968\">",
"     'General approach'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    CPAP provides a constant level of positive airway pressure throughout inspiration and expiration. There is no established method for initiating CPAP therapy in patients with CSA. Titration of the CPAP until central apneas are eliminated during polysomnography is preferable, but the method used during the Canadian Positive Airway Pressure (CANPAP) trial described below is an acceptable alternative if titration during polysomnography is not possible. In the trial, CPAP was initiated over two to three nights in the hospital or in an unmonitored sleep laboratory. The initial pressure was 5 cm of water, which was increased in increments of 2 or 3 cm of water until 10 cm of water or the highest pressure tolerated was reached [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/20/39239/abstract/3\">",
"     3",
"    </a>",
"    ]. CPAP is generally well tolerated. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?10/3/10296?source=see_link\">",
"     \"Initiation of positive airway pressure therapy for obstructive sleep apnea in adults\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?42/62/44006?source=see_link\">",
"     \"Adherence with continuous positive airway pressure (CPAP)\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    CPAP reduces the frequency of central apneas, probably by preventing pharyngeal airway narrowing and occlusion during a central apnea. The mechanism of action can be conceptualized as follows. The pharyngeal airway typically narrows and may occlude during a central apnea [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/20/39239/abstract/4\">",
"     4",
"    </a>",
"    ]. As a result, greater negative airway pressure must be generated for breathing to resume [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/20/39239/abstract/5\">",
"     5",
"    </a>",
"    ]. The greater negative airway pressure induces airway deformation, which can trigger hyperpnea, ventilatory overshoot, hypocapnia, and additional central apneas [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/20/39239/abstract/6\">",
"     6",
"    </a>",
"    ]. By preventing pharyngeal airway narrowing, CPAP mitigates the need for greater negative airway pressure and its sequelae. The observation that arterial carbon dioxide tension increases after CPAP therapy is initiated supports this theory [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/20/39239/abstract/7\">",
"     7",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Randomized trials have consistently demonstrated that CPAP decreases the frequency of central apneas in patients with CSA associated with Cheyne-Stokes breathing due to heart failure [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/20/39239/abstract/3,7-10\">",
"     3,7-10",
"    </a>",
"    ]. The impact of CPAP on patient-important outcomes has been less extensively studied; however, it appears that CPAP improves exercise capacity and transplant-free survival [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/20/39239/abstract/3,11,12\">",
"     3,11,12",
"    </a>",
"    ]. This was demonstrated by the CANPAP trial, which randomly assigned 258 patients who had CSA associated with heart failure (mean apnea hypopnea index of 40 events per hour) to receive CPAP or no CPAP for two years [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/20/39239/abstract/3\">",
"     3",
"    </a>",
"    ]. The CPAP group had greater improvement in the six-minute walk distance than the control group, but there were no differences in transplant-free survival, hospitalizations, or quality of life. When a post hoc analysis subsequently stratified the patients according to whether or not the CPAP had sufficiently treated the CSA (defined as reducing the apnea hypopnea index to fewer than 15 events per hour three months after randomization), there was significantly better transplant-free survival among patients who were adequately treated with CPAP than among patients who had not received CPAP (hazard ratio 0.37, 95% CI 0.14-0.97) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/20/39239/abstract/12\">",
"     12",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The effect of CPAP on heart failure-related outcomes (eg, ejection fraction) is described separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?8/43/8888?source=see_link&amp;anchor=H9#H9\">",
"     \"Cheyne-Stokes breathing and obstructive sleep apnea in heart failure\", section on 'Positive airway pressure'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In contrast to CSA associated with Cheyne-Stokes breathing due to heart failure, there is a lack of data regarding the impact of CPAP on other types of CSA.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H902709\">",
"    <span class=\"h3\">",
"     Adaptive servo-ventilation (ASV)",
"    </span>",
"    &nbsp;&mdash;&nbsp;ASV is the preferred therapy for patients with hyperventilation-related CSA (ie, most types of CSA, including primary CSA and CSA associated with Cheyne-Stokes breathing, a medical condition, or high altitude periodic breathing) who have failed or not tolerated CPAP. (See",
"    <a class=\"local\" href=\"#H9079968\">",
"     'General approach'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    ASV provides a varying amount of inspiratory pressure superimposed on a low level of CPAP, with a backup respiratory rate. The magnitude of the inspiratory pressure is reciprocal to the amount of respiratory effort, determined over a three to four minute moving window (",
"    <a class=\"graphic graphic_figure graphicRef84026 \" href=\"mobipreview.htm?5/35/5680\">",
"     figure 1",
"    </a>",
"    ). Despite providing ventilatory assistance, ASV does not appear to worsen hyperventilation and has not been shown to exacerbate the types of CSA characterized by central apneas due to hyperventilation [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/20/39239/abstract/2\">",
"     2",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Both randomized trials and uncontrolled trials in patients with CSA associated with Cheyne-Stokes breathing due to heart failure have consistently demonstrated that ASV decreases the frequency of central apneas [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/20/39239/abstract/13-21\">",
"     13-21",
"    </a>",
"    ]. In a systematic review, a meta-analysis of nine trials (127 patients) found that ASV decreases the apnea hypopnea index a mean of 30 events per hour [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/20/39239/abstract/2\">",
"     2",
"    </a>",
"    ]. ASV also appears to improve symptoms of disrupted sleep [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/20/39239/abstract/13\">",
"     13",
"    </a>",
"    ], left ventricular ejection fraction and exercise capacity [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/20/39239/abstract/22,23\">",
"     22,23",
"    </a>",
"    ]. However, the impact of ASV on other patient-important outcomes (ie, mortality, quality of life) is uncertain because such outcomes have not been studied.",
"   </p>",
"   <p>",
"    Fewer studies have directly compared ASV to CPAP in heart failure patients with SDB [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/20/39239/abstract/20,24\">",
"     20,24",
"    </a>",
"    ]. A meta-analysis of randomized studies found a small advantage to ASV over CPAP in two studies (weighted mean difference in AHI of -0.65",
"    <span class=\"nowrap\">",
"     events/hour",
"    </span>",
"    favoring ASV, 95% CI -1.06 to -0.25) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/20/39239/abstract/23\">",
"     23",
"    </a>",
"    ]. No randomized studies have compared the two treatments directly in heart failure patients with predominantly Cheynes-Stokes breathing (as opposed to obstructive sleep apnea (OSA) or a combination of obstructive and central breathing patterns).",
"   </p>",
"   <p>",
"    <br/>",
"    There is a paucity of data regarding the effects of ASV in patients with other types of CSA.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h3\">",
"     Bilevel positive airway pressure (BPAP)",
"    </span>",
"    &nbsp;&mdash;&nbsp;The use of bilevel positive airway pressure (BPAP) depends upon whether the patient has hyperventilation-related CSA (ie, most types of CSA, including primary CSA and CSA associated with Cheyne-Stokes breathing, a medical condition, or high altitude periodic breathing) or hypoventilation-related CSA (ie, CSA due to central nervous system disease, central nervous system suppressing drugs or substances, neuromuscular disease, or severe abnormalities in pulmonary mechanics). (See",
"    <a class=\"local\" href=\"#H9079968\">",
"     'General approach'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    BPAP delivers positive airway pressure at different levels during inspiration and expiration; the level during inspiration is called the inspiratory positive airway pressure (IPAP) and the level during expiration is called the expiratory positive airway pressure (EPAP). BPAP has two major effects. First, it splints the upper airway open. Second, it increases alveolar ventilation by augmenting the tidal volume. The tidal volume is directly related to the difference between the IPAP and EPAP. As an example, the tidal volume is greater when the IPAP is set at 15 cm H",
"    <sub>",
"     2",
"    </sub>",
"    O and the EPAP at 5 cm H",
"    <sub>",
"     2",
"    </sub>",
"    O (difference of 10 cm H",
"    <sub>",
"     2",
"    </sub>",
"    O), than when the IPAP is set at 10 cm H",
"    <sub>",
"     2",
"    </sub>",
"    O and the EPAP at 5 cm H",
"    <sub>",
"     2",
"    </sub>",
"    O (difference of 5 cm H",
"    <sub>",
"     2",
"    </sub>",
"    O). A backup respiratory rate may be set on most BPAP devices.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In patients with CSA whose central apneas are due to hyperventilation, trials of BPAP are reserved for those who have failed or not tolerated trials of CPAP and ASV. In these patients, BPAP should only be used with a backup respiratory rate because BPAP without a backup rate may exacerbate hyperventilation, hypocapnia, and central apnea by augmenting the tidal volume [",
"      <a class=\"abstract\" href=\"mobipreview.htm?38/20/39239/abstract/25,26\">",
"       25,26",
"      </a>",
"      ]. Two uncontrolled trials and one nonrandomized controlled trial evaluated the effects of BPAP with a backup respiratory rate in patients with CSA associated with Cheyne-Stokes breathing due to heart failure [",
"      <a class=\"abstract\" href=\"mobipreview.htm?38/20/39239/abstract/27-29\">",
"       27-29",
"      </a>",
"      ]. A meta-analysis of these three trials reported a mean decrease in the apnea hypopnea index of 44 events per hour [",
"      <a class=\"abstract\" href=\"mobipreview.htm?38/20/39239/abstract/2\">",
"       2",
"      </a>",
"      ]. In addition, improved exercise capacity was reported with BPAP in the only trial that measured this outcome [",
"      <a class=\"abstract\" href=\"mobipreview.htm?38/20/39239/abstract/28\">",
"       28",
"      </a>",
"      ]. There is a paucity of data regarding the effects of BPAP in patients with hyperventilation-related CSA other than CSA associated with Cheyne-Stokes breathing due to heart failure. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?18/44/19140?source=see_link&amp;anchor=H2#H2\">",
"       \"Central sleep apnea: Pathogenesis\", section on 'Central apnea due to hyperventilation'",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      In patients with CSA whose central apneas are due to hypoventilation, BPAP is first-line therapy. In such patients, BPAP may be used with or without a backup respiratory rate, but we advocate using a backup rate to ensure adequate ventilation if the patient's ventilatory output is insufficient to reliably trigger mechanical inspiration. Most patients with ventilatory failure tolerate BPAP well; however, it may rarely worsen alveolar ventilation by narrowing the laryngeal aperture and decreasing the tidal volume [",
"      <a class=\"abstract\" href=\"mobipreview.htm?38/20/39239/abstract/30\">",
"       30",
"      </a>",
"      ]. Although rare, clinicians need to be aware of this phenomenon so that it can be readily identified and corrected by adjusting the volume, flow, or inspiratory time [",
"      <a class=\"abstract\" href=\"mobipreview.htm?38/20/39239/abstract/31\">",
"       31",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?18/44/19140?source=see_link&amp;anchor=H3#H3\">",
"       \"Central sleep apnea: Pathogenesis\", section on 'Central apnea due to hypoventilation'",
"      </a>",
"      .)",
"      <br/>",
"      <br/>",
"      Management of patients with severe alveolar hypoventilation, with or without CSA, is described in greater detail separately. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?26/29/27095?source=see_link\">",
"       \"Types of noninvasive nocturnal ventilatory support in neuromuscular and chest wall disease\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?40/36/41543?source=see_link\">",
"       \"Practical aspects of nocturnal noninvasive ventilation in neuromuscular and chest wall disease\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9080828\">",
"    <span class=\"h2\">",
"     Supplemental oxygen during sleep",
"    </span>",
"    &nbsp;&mdash;&nbsp;Supplemental oxygen during sleep is indicated for patients with hyperventilation-related CSA who have hypoxemia during sleep (it is used with the positive airway pressure therapy). It is also indicated for patients who do not tolerate or fail positive airway pressure therapy. (See",
"    <a class=\"local\" href=\"#H9079968\">",
"     'General approach'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    Supplemental oxygen during sleep not only mitigates hypoxemia during sleep, but it may also reduce the apnea hypopnea index. This has been demonstrated by at least five randomized trials [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/20/39239/abstract/32-36\">",
"     32-36",
"    </a>",
"    ] and one non-randomized trial [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/20/39239/abstract/37\">",
"     37",
"    </a>",
"    ] in patients with CSA associated with Cheyne-Stokes breathing due to heart failure. It seems reasonable that supplemental oxygen during sleep may reduce the symptoms of disrupted sleep since it improves the apnea hypopnea index, but this has not been measured directly. There are few data regarding the effects of supplemental oxygen during sleep in patients with other types of hyperventilation-related CSA.",
"   </p>",
"   <p>",
"    The mechanism by which supplemental oxygen during sleep improves CSA is unknown. It has been hypothesized that supplemental oxygen during sleep either increases the cerebral carbon dioxide tension, thereby preventing the hyperventilation and ventilatory overshoot that results in central apneas, or reduces carbon dioxide chemoreflex sensitivity [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/20/39239/abstract/2\">",
"     2",
"    </a>",
"    ]. However, additional research is needed to elucidate the precise mechanism of action.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Pharmacologic therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients who do not tolerate or benefit from positive airway pressure therapy or supplemental oxygen during sleep may benefit from treatment with a respiratory stimulant, such as",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?5/39/5752?source=see_link\">",
"     acetazolamide",
"    </a>",
"    or",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?29/31/30200?source=see_link\">",
"     theophylline",
"    </a>",
"    ; however, such medications can have harmful side effects and should be monitored closely. (See",
"    <a class=\"local\" href=\"#H9079968\">",
"     'General approach'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?5/39/5752?source=see_link\">",
"     Acetazolamide",
"    </a>",
"    is a carbonic anhydrase inhibitor and a weak diuretic. It causes mild metabolic acidosis, which stimulates respiration and decreases the frequency of central apneas [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/20/39239/abstract/38,39\">",
"     38,39",
"    </a>",
"    ]. Acetazolamide has been studied in patients with hyperventilation-related CSA, specifically CSA associated with Cheyne-Stokes breathing and primary CSA:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A crossover trial randomly assigned 12 patients with CSA associated with Cheyne-Stokes breathing due to heart failure (mean apnea hypopnea index 55 events per hour) to receive",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?5/39/5752?source=see_link\">",
"       acetazolamide",
"      </a>",
"      or placebo for six nights [",
"      <a class=\"abstract\" href=\"mobipreview.htm?38/20/39239/abstract/39\">",
"       39",
"      </a>",
"      ]. Acetazolamide decreased the apnea hypopnea index (34 versus 57 events per hour for placebo), while improving subjective sleep quality, restfulness, and fatigue.",
"     </li>",
"     <li>",
"      Two non-randomized trials have evaluated the use of",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?5/39/5752?source=see_link\">",
"       acetazolamide",
"      </a>",
"      to treat primary CSA. In both trials, acetazolamide was associated with reduction of the apnea hypopnea index and less daytime sleepiness [",
"      <a class=\"abstract\" href=\"mobipreview.htm?38/20/39239/abstract/38,40\">",
"       38,40",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?29/31/30200?source=see_link\">",
"     Theophylline",
"    </a>",
"    is another respiratory stimulant that has been studied in patients with CSA associated with Cheyne-Stokes breathing due to heart failure, with both a randomized crossover trial and a before-and-after trial finding similar results [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/20/39239/abstract/41,42\">",
"     41,42",
"    </a>",
"    ]. The former study randomly assigned 15 such patients (mean apnea hypopnea index 47 events per hour) to receive either theophylline or placebo orally twice daily for five days [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/20/39239/abstract/41\">",
"     41",
"    </a>",
"    ]. Theophylline reduced the apnea hypopnea index to 18 events per hour, whereas placebo reduced the apnea hypopnea index to only 37 events per hour.",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?29/31/30200?source=see_link\">",
"     Theophylline",
"    </a>",
"    has not been evaluated in patients with other types of hyperventilation-related CSA, and neither theophylline nor",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?5/39/5752?source=see_link\">",
"     acetazolamide",
"    </a>",
"    have been studied in patients with hypoventilation-related CSA (ie, central nervous system disease, central nervous system suppressing medications).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Central sleep apnea (CSA) can be primary (ie, idiopathic CSA) or secondary. Examples of secondary CSA include CSA associated with Cheyne-Stokes breathing, a medical condition, a drug or substance, or high altitude periodic breathing. CSA associated with Cheyne-Stokes breathing is particularly common, especially among patients who have heart failure. (See",
"      <a class=\"local\" href=\"#H1\">",
"       'Introduction'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      It is important to realize that the treatment of CSA is largely based upon the extrapolation of evidence from studies that focused on patients with CSA associated with Cheyne-Stokes breathing due to heart failure; there is a paucity of data regarding the treatment of patients with other types of CSA. (See",
"      <a class=\"local\" href=\"#H9079968\">",
"       'General approach'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      An important distinction that guides clinical decision-making is whether the patient&rsquo;s central apneas are likely due to hyperventilation or hypoventilation. Most types of CSA are hyperventilation-related, including primary CSA and CSA associated with Cheyne-Stokes breathing, a medical condition, or high altitude periodic breathing. Hypoventilation-related CSA is less common and includes CSA associated with central nervous system disease, central nervous system suppressing drugs or substances, neuromuscular disease, or severe abnormalities in pulmonary mechanics. (See",
"      <a class=\"local\" href=\"#H9079968\">",
"       'General approach'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Initial treatment of CSA should be directed at any condition that may be causing or exacerbating the CSA. If the CSA persists despite such therapy, CSA-specific therapies are indicated for patients with symptoms or significant physiological sequelae attributable to CSA (eg, daytime sleepiness, prolonged or repetitive oxyhemoglobin desaturation during sleep). (See",
"      <a class=\"local\" href=\"#H9079968\">",
"       'General approach'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The following recommendations are pertinent to patients with HYPERventilation-related CSA for whom it has been decided that CSA-specific therapy is indicated:",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      For patients with CSA associated with Cheyne-Stokes breathing due to heart failure, we recommend a trial of continuous positive airway pressure (CPAP) (",
"      <a class=\"grade\" href=\"._grade_2?title=Grade 1B\">",
"       Grade 1B",
"      </a>",
"      ). For those who fail or do not tolerate CPAP, we suggest a trial of adaptive servo-ventilation (ASV) (",
"      <a class=\"grade\" href=\"._grade_5?title=Grade 2B\">",
"       Grade 2B",
"      </a>",
"      ). For those who fail or do not tolerate both CPAP and ASV, we suggest a trial of bilevel positive airway pressure (BPAP) with a backup respiratory rate (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H9079968\">",
"       'General approach'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H4\">",
"       'Continuous positive airway pressure (CPAP)'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H902709\">",
"       'Adaptive servo-ventilation (ASV)'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H5\">",
"       'Bilevel positive airway pressure (BPAP)'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      For patients with hyperventilation-related CSA other than CSA associated with Cheyne-Stokes breathing due to heart failure, we suggest a trial of CPAP (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). For those who fail or do not tolerate CPAP, we suggest a trial of ASV (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). For those who, fail or do not tolerate both CPAP and ASV, we suggest a trial of BPAP with a backup respiratory rate (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H9079968\">",
"       'General approach'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H4\">",
"       'Continuous positive airway pressure (CPAP)'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H902709\">",
"       'Adaptive servo-ventilation (ASV)'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H5\">",
"       'Bilevel positive airway pressure (BPAP)'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      For all patients with hyperventilation-related CSA and hypoxemia during sleep, we suggest supplemental oxygen during sleep (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H9079968\">",
"       'General approach'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H9080828\">",
"       'Supplemental oxygen during sleep'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      For patients with HYPOventilation-related CSA for whom it has been decided that CSA-specific therapy is indicated, we recommend BPAP as first-line therapy (",
"      <a class=\"grade\" href=\"._grade_2?title=Grade 1B\">",
"       Grade 1B",
"      </a>",
"      ). We advocate using a backup respiratory rate. (See",
"      <a class=\"local\" href=\"#H9079968\">",
"       'General approach'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H5\">",
"       'Bilevel positive airway pressure (BPAP)'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      For any patient with CSA who does not tolerate positive airway pressure therapy, we suggest a trial of",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?5/39/5752?source=see_link\">",
"       acetazolamide",
"      </a>",
"      (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H7\">",
"       'Pharmacologic therapy'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     The International Classification of Sleep Disorders, 2nd edition, Diagnostic and Coding Manual, 2nd ed, Hauri PJ (Ed), American Academy of Sleep Medicine, Westchester 2005.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/20/39239/abstract/2\">",
"      Aurora RN, Chowdhuri S, Ramar K, et al. The treatment of central sleep apnea syndromes in adults: practice parameters with an evidence-based literature review and meta-analyses. Sleep 2012; 35:17.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/20/39239/abstract/3\">",
"      Bradley TD, Logan AG, Kimoff RJ, et al. Continuous positive airway pressure for central sleep apnea and heart failure. N Engl J Med 2005; 353:2025.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/20/39239/abstract/4\">",
"      Badr MS, Toiber F, Skatrud JB, Dempsey J. Pharyngeal narrowing/occlusion during central sleep apnea. J Appl Physiol 1995; 78:1806.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/20/39239/abstract/5\">",
"      Olson LG, Strohl KP. Airway secretions influence upper airway patency in the rabbit. Am Rev Respir Dis 1988; 137:1379.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/20/39239/abstract/6\">",
"      Harms CA, Zeng YJ, Smith CA, et al. Negative pressure-induced deformation of the upper airway causes central apnea in awake and sleeping dogs. J Appl Physiol 1996; 80:1528.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/20/39239/abstract/7\">",
"      Naughton MT, Benard DC, Rutherford R, Bradley TD. Effect of continuous positive airway pressure on central sleep apnea and nocturnal PCO2 in heart failure. Am J Respir Crit Care Med 1994; 150:1598.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/20/39239/abstract/8\">",
"      Naughton MT, Liu PP, Bernard DC, et al. Treatment of congestive heart failure and Cheyne-Stokes respiration during sleep by continuous positive airway pressure. Am J Respir Crit Care Med 1995; 151:92.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/20/39239/abstract/9\">",
"      Naughton MT, Benard DC, Liu PP, et al. Effects of nasal CPAP on sympathetic activity in patients with heart failure and central sleep apnea. Am J Respir Crit Care Med 1995; 152:473.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/20/39239/abstract/10\">",
"      Granton JT, Naughton MT, Benard DC, et al. CPAP improves inspiratory muscle strength in patients with heart failure and central sleep apnea. Am J Respir Crit Care Med 1996; 153:277.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/20/39239/abstract/11\">",
"      Sin DD, Logan AG, Fitzgerald FS, et al. Effects of continuous positive airway pressure on cardiovascular outcomes in heart failure patients with and without Cheyne-Stokes respiration. Circulation 2000; 102:61.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/20/39239/abstract/12\">",
"      Arzt M, Floras JS, Logan AG, et al. Suppression of central sleep apnea by continuous positive airway pressure and transplant-free survival in heart failure: a post hoc analysis of the Canadian Continuous Positive Airway Pressure for Patients with Central Sleep Apnea and Heart Failure Trial (CANPAP). Circulation 2007; 115:3173.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/20/39239/abstract/13\">",
"      Pepperell JC, Maskell NA, Jones DR, et al. A randomized controlled trial of adaptive ventilation for Cheyne-Stokes breathing in heart failure. Am J Respir Crit Care Med 2003; 168:1109.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/20/39239/abstract/14\">",
"      Oldenburg O, Schmidt A, Lamp B, et al. Adaptive servoventilation improves cardiac function in patients with chronic heart failure and Cheyne-Stokes respiration. Eur J Heart Fail 2008; 10:581.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/20/39239/abstract/15\">",
"      Szollosi I, O'Driscoll DM, Dayer MJ, et al. Adaptive servo-ventilation and deadspace: effects on central sleep apnoea. J Sleep Res 2006; 15:199.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/20/39239/abstract/16\">",
"      Fietze I, Blau A, Glos M, et al. Bi-level positive pressure ventilation and adaptive servo ventilation in patients with heart failure and Cheyne-Stokes respiration. Sleep Med 2008; 9:652.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/20/39239/abstract/17\">",
"      Morgenthaler TI, Gay PC, Gordon N, Brown LK. Adaptive servoventilation versus noninvasive positive pressure ventilation for central, mixed, and complex sleep apnea syndromes. Sleep 2007; 30:468.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/20/39239/abstract/18\">",
"      Arzt M, Wensel R, Montalvan S, et al. Effects of dynamic bilevel positive airway pressure support on central sleep apnea in men with heart failure. Chest 2008; 134:61.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/20/39239/abstract/19\">",
"      Zhang XL, Yin KS, Li XL, et al. Efficacy of adaptive servoventilation in patients with congestive heart failure and Cheyne-Stokes respiration. Chin Med J (Engl) 2006; 119:622.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/20/39239/abstract/20\">",
"      Kasai T, Usui Y, Yoshioka T, et al. Effect of flow-triggered adaptive servo-ventilation compared with continuous positive airway pressure in patients with chronic heart failure with coexisting obstructive sleep apnea and Cheyne-Stokes respiration. Circ Heart Fail 2010; 3:140.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/20/39239/abstract/21\">",
"      Philippe C, Sto&iuml;ca-Herman M, Drouot X, et al. Compliance with and effectiveness of adaptive servoventilation versus continuous positive airway pressure in the treatment of Cheyne-Stokes respiration in heart failure over a six month period. Heart 2006; 92:337.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/20/39239/abstract/22\">",
"      Oldenburg O, Bitter T, Lehmann R, et al. Adaptive servoventilation improves cardiac function and respiratory stability. Clin Res Cardiol 2011; 100:107.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/20/39239/abstract/23\">",
"      Sharma BK, Bakker JP, McSharry DG, et al. Adaptive servoventilation for treatment of sleep-disordered breathing in heart failure: a systematic review and meta-analysis. Chest 2012; 142:1211.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/20/39239/abstract/24\">",
"      Randerath WJ, Nothofer G, Priegnitz C, et al. Long-term auto-servoventilation or constant positive pressure in heart failure and coexisting central with obstructive sleep apnea. Chest 2012; 142:440.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/20/39239/abstract/25\">",
"      Johnson KG, Johnson DC. Bilevel positive airway pressure worsens central apneas during sleep. Chest 2005; 128:2141.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/20/39239/abstract/26\">",
"      Meza S, Mendez M, Ostrowski M, Younes M. Susceptibility to periodic breathing with assisted ventilation during sleep in normal subjects. J Appl Physiol 1998; 85:1929.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/20/39239/abstract/27\">",
"      Dohi T, Kasai T, Narui K, et al. Bi-level positive airway pressure ventilation for treating heart failure with central sleep apnea that is unresponsive to continuous positive airway pressure. Circ J 2008; 72:1100.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/20/39239/abstract/28\">",
"      Kasai T, Narui K, Dohi T, et al. Efficacy of nasal bi-level positive airway pressure in congestive heart failure patients with cheyne-stokes respiration and central sleep apnea. Circ J 2005; 69:913.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/20/39239/abstract/29\">",
"      Willson GN, Wilcox I, Piper AJ, et al. Noninvasive pressure preset ventilation for the treatment of Cheyne-Stokes respiration during sleep. Eur Respir J 2001; 17:1250.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/20/39239/abstract/30\">",
"      Jounieaux V, Aubert G, Dury M, et al. Effects of nasal positive-pressure hyperventilation on the glottis in normal sleeping subjects. J Appl Physiol 1995; 79:186.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/20/39239/abstract/31\">",
"      Parreira VF, Jounieaux V, Delguste P, et al. Determinants of effective ventilation during nasal intermittent positive pressure ventilation. Eur Respir J 1997; 10:1975.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/20/39239/abstract/32\">",
"      Hanly PJ, Millar TW, Steljes DG, et al. The effect of oxygen on respiration and sleep in patients with congestive heart failure. Ann Intern Med 1989; 111:777.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/20/39239/abstract/33\">",
"      Staniforth AD, Kinnear WJ, Starling R, et al. Effect of oxygen on sleep quality, cognitive function and sympathetic activity in patients with chronic heart failure and Cheyne-Stokes respiration. Eur Heart J 1998; 19:922.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/20/39239/abstract/34\">",
"      Andreas S, Clemens C, Sandholzer H, et al. Improvement of exercise capacity with treatment of Cheyne-Stokes respiration in patients with congestive heart failure. J Am Coll Cardiol 1996; 27:1486.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/20/39239/abstract/35\">",
"      Toyama T, Seki R, Kasama S, et al. Effectiveness of nocturnal home oxygen therapy to improve exercise capacity, cardiac function and cardiac sympathetic nerve activity in patients with chronic heart failure and central sleep apnea. Circ J 2009; 73:299.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/20/39239/abstract/36\">",
"      Sasayama S, Izumi T, Matsuzaki M, et al. Improvement of quality of life with nocturnal oxygen therapy in heart failure patients with central sleep apnea. Circ J 2009; 73:1255.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/20/39239/abstract/37\">",
"      Shigemitsu M, Nishio K, Kusuyama T, et al. Nocturnal oxygen therapy prevents progress of congestive heart failure with central sleep apnea. Int J Cardiol 2007; 115:354.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/20/39239/abstract/38\">",
"      DeBacker WA, Verbraecken J, Willemen M, et al. Central apnea index decreases after prolonged treatment with acetazolamide. Am J Respir Crit Care Med 1995; 151:87.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/20/39239/abstract/39\">",
"      Javaheri S. Acetazolamide improves central sleep apnea in heart failure: a double-blind, prospective study. Am J Respir Crit Care Med 2006; 173:234.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/20/39239/abstract/40\">",
"      White DP, Zwillich CW, Pickett CK, et al. Central sleep apnea. Improvement with acetazolamide therapy. Arch Intern Med 1982; 142:1816.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/20/39239/abstract/41\">",
"      Javaheri S, Parker TJ, Wexler L, et al. Effect of theophylline on sleep-disordered breathing in heart failure. N Engl J Med 1996; 335:562.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/20/39239/abstract/42\">",
"      Hu K, Li Q, Yang J, et al. The effect of theophylline on sleep-disordered breathing in patients with stable chronic congestive heart failure. Chin Med J (Engl) 2003; 116:1711.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 7675 Version 10.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.3 - C21.34",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Morehouse School of Medicine",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0603-189.41.181.191-AA596B28AF-S473950.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f38_20_39239=[""].join("\n");
var outline_f38_20_39239=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H10\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H9079958\">",
"      NATURAL HISTORY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H9079968\">",
"      GENERAL APPROACH",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4898695\">",
"      Indications",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4898702\">",
"      Choice of therapy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H9080532\">",
"      TREATMENT MODALITIES",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      Positive airway pressure",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      - Continuous positive airway pressure (CPAP)",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H902709\">",
"      - Adaptive servo-ventilation (ASV)",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      - Bilevel positive airway pressure (BPAP)",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9080828\">",
"      Supplemental oxygen during sleep",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Pharmacologic therapy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"PULM/7675\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PULM/7675|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?5/35/5680\" title=\"figure 1\">",
"      Adaptive servo-ventilation",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?42/62/44006?source=related_link\">",
"      Adherence with continuous positive airway pressure (CPAP)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?18/44/19140?source=related_link\">",
"      Central sleep apnea: Pathogenesis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?43/29/44502?source=related_link\">",
"      Central sleep apnea: Risk factors, clinical presentation, and diagnosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?8/43/8888?source=related_link\">",
"      Cheyne-Stokes breathing and obstructive sleep apnea in heart failure",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?11/2/11301?source=related_link\">",
"      Classification of sleep disorders",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?10/3/10296?source=related_link\">",
"      Initiation of positive airway pressure therapy for obstructive sleep apnea in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?40/36/41543?source=related_link\">",
"      Practical aspects of nocturnal noninvasive ventilation in neuromuscular and chest wall disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?26/29/27095?source=related_link\">",
"      Types of noninvasive nocturnal ventilatory support in neuromuscular and chest wall disease",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f38_20_39240="NASH Light";
var content_f38_20_39240=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=GAST%2F51497%7EGAST%2F75188&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=GAST%2F51497%7EGAST%2F75188&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 563px\">",
"   <div class=\"ttl\">",
"    Nonalcoholic steatohepatitis on biopsy",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 543px; height: 165px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Histologic changes in nonalcoholic steatohepatitis (NASH). Left panel: The hepatocyte in the center contains a large vacuole of fat and deeply staining eosinophilic strands of cytoplasmic hyalin. Numerous neutrophils and phagocytic cells containing golden brown pigmented material (bile components and cellular debris) are present in the sinusoids. Right panel: NASH with cirrhosis. Trichrome stain shows regenerating nodules with fat surrounded by fibrous tissue.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Mallory-Denk bodies in alcoholic hepatitis",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 442px; height: 288px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    High power view of a liver biopsy in alcoholic hepatitis shows macrovesicular fat and Mallory-Denk bodies (arrows), which are eosinophilic accumulations of intracellular material. Similar changes can occur in nonalcoholic steatohepatitis.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Robert Odze, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f38_20_39240=[""].join("\n");
var outline_f38_20_39240=null;
var title_f38_20_39241="Actinic keratosis histopathology";
var content_f38_20_39241=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=DERM%2F76208%7EDERM%2F54208&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=DERM%2F76208%7EDERM%2F54208&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 560px\">",
"   <div class=\"ttl\">",
"    Actinic keratosis",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 540px; height: 364px; background-image: url(data:image/jpeg;base64,/9j/4AAQSkZJRgABAQAAAQABAAD/2wBDAAYEBQYFBAYGBQYHBwYIChAKCgkJChQODwwQFxQYGBcUFhYaHSUfGhsjHBYWICwgIyYnKSopGR8tMC0oMCUoKSj/2wBDAQcHBwoIChMKChMoGhYaKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCj/wAARCAFsAhwDASIAAhEBAxEB/8QAHwAAAQUBAQEBAQEAAAAAAAAAAAECAwQFBgcICQoL/8QAtRAAAgEDAwIEAwUFBAQAAAF9AQIDAAQRBRIhMUEGE1FhByJxFDKBkaEII0KxwRVS0fAkM2JyggkKFhcYGRolJicoKSo0NTY3ODk6Q0RFRkdISUpTVFVWV1hZWmNkZWZnaGlqc3R1dnd4eXqDhIWGh4iJipKTlJWWl5iZmqKjpKWmp6ipqrKztLW2t7i5usLDxMXGx8jJytLT1NXW19jZ2uHi4+Tl5ufo6erx8vP09fb3+Pn6/8QAHwEAAwEBAQEBAQEBAQAAAAAAAAECAwQFBgcICQoL/8QAtREAAgECBAQDBAcFBAQAAQJ3AAECAxEEBSExBhJBUQdhcRMiMoEIFEKRobHBCSMzUvAVYnLRChYkNOEl8RcYGRomJygpKjU2Nzg5OkNERUZHSElKU1RVVldYWVpjZGVmZ2hpanN0dXZ3eHl6goOEhYaHiImKkpOUlZaXmJmaoqOkpaanqKmqsrO0tba3uLm6wsPExcbHyMnK0tPU1dbX2Nna4uPk5ebn6Onq8vP09fb3+Pn6/9oADAMBAAIRAxEAPwD2wsP4yM9KkR1xjvnp1xVbI6nnmnrtAJA5zk9s+9SeoTTCR42WOZ4nJHzoAxGD6Hg5HFOUsU/eYL9flGB9BUJPJ24OfypC3yjBA5yaQAJN4Jy3zenB+lSA/KvTg/lUJbdggYPqKVSR8oxjPX3pgT+YyseMr2+tODYHeoQxzxj15px5wQwOP0pASb/06+1BZ8fKMnqAfT1qLPU4wacGBxzSAmL9DkntnP5UoY5GAMe/Wockc9u1NJz1waALKuqjO7vj8acXKjI79RVcHO3nIPFJLuAOAd+Dt5/SgZP5zA849j7Uqy7h9e5qmz8KvUkZI649fwqRDucEjAXnOf5UAWS/TkjPrxihWwc59/rUZLMOcc9cfypjjcm0ZCnjg4I/GpYFhnz14/HrRuwD3I5qDksScY68d6QMMtg9KAJt4DY7kdQP504sWBI/D6VFvOzoVyO46UoOSCOxx06UAS7vmByM9/enA/ifyqBenI6dOOlSDG3P4UgJd2ASoOO9NkY5/wAKYucEAj0xSlck8cn3oAQk9OoJqQDAGCOveox6dxQcg8EZ70MZY3DjdwPWomyM8dOnpTc4HX8KTPJPXFADiRgYpfTOM/ypm7gdRSgnkjrmkMVA24kHhqlB4zk4qPJJHGMd6cTgjrmgCUSfU+/WlLcdefSogcDpgfyo3cDGcH1FFybEoboefoaSRd5BONynIOOh9qj3Enkj2pedwII980BYkJ3cKeaBhc8455phJIO5hjHNK3B7YNAhXcqrNtycZCg9fal3F0BI2kgZHXFR55JOcDnmlU85ORRcLE2705zWdqtwYYOMjtirpI24zj/Gs/VVL2rd8c4qJvQuC11Pnzxlr0l3qd5NcyeXbwsVSN2+XI7iuf8ADGuvLJHqBzE0EuNqv94e4qb4g2E9ncXtrfqu2aQyxuOmO3415/ZwrZNujldpWPzHsR9PWu6m+aOjNptxaVtD648FeIl1e0SaIkBjtKt6111pMZI2EkflOrFdpbccZ4P415H8H9Ou4NPEk5wszB0XP3Vr17I25yPpiuSdlJqJnNE+7HPrxSkgAD9ars4X5iwXpyTgCnDkkHOaTMrEx4zjOelOHzA9fwqEMfrT165B5x0p7isTDO0HOOPSgnv2/nUe7jg0vfGfmoFYeDtHPPNC8dCc+9RqffHtQrAljnAqkFiUtx6H1qNQwZvnJQ8gHtSM386N2c55+npQFhx5TBxg9aR5NkkUYiJ3Zyw6Jjpn+VIPvcDGO9O3AYBxz1pA0D/MpVxnPY96iWRZFLDIwSPmGOQaeTxgkbv5CmsSTnqRzmgaQxs7wCRSMQevGfzpM/LgcH1pr9wenrTGOaU8BUJwOQOKN3A5znp7VHnDjmk3c8dRQA9gW3DeVTBBx1+oPahUUIo2KABgDGcCo9w34/iPOKMZ5wT9aAMnOAMD3oDEjI5AppOFAx/SkIbejZKqB0B4P1FaiJfmOBjg9famlufvLn9aRXDFiD90kED1pAEyHCpkgDdjBxmlcY4tgk9vpQDnOQc/ShxycdqQ54IGAP0oAkA4AI5x16USFgR5bBSCDyM5XuKaoHPBz3zSgclgcD60gHbievNPBGM9OajC8+3enpyR7UrAOJOWzg568ZzRk9+McZo564+hqLywZhLuYHbsKg8YznOPX3oGTjgAkY7/AFpxBPvTejAenWnfwjaMd/pQAwRKsrMp+d8BvwHFSKflOB78UgzkY4IpoPOcjHtSAk4IyMlu31puTk7gfrRkH0xSE4PXB/SkwF6Z+Y+/tQRgH6UpYlSOxpSOCcc+hoGIM445Xvj0pwJXg+nFIBjnOD6ihecAnJx1PFIByg5649aWNg6ZwQPQ9aaepPbHWjc3fH0pASAgn3pQMHnoelNBGAT+NKC2c8YPpTEKecjt60ueB2zxSADjcAccZoyRkkcdKBgc/KdvGfWlYc5x81Gck7SuB1wenpSZAzycHocUhig/ez+RpI3VySjAhTgkDoadkdf1oBLDrk+gNFwF6keuM07IySSQe1NA59weKMgcdfp3oAcBhjnPHSkyMj3PFBODxyB270Hp6jtQIUHHIzg8kUuBgjAz/KmnkKc8g9KBtBJyMkdT39qAH/wnjAApCcjIx7/Sjdzg+nAFG4EYwcd80gFOVHPU96ASTnGRj8aOQR3x603BU9xz29aBEhxjBHXgiomClCMDn0p+efrQwzjAH+NJq6GjkfEvhK11eNkmhV0z0I6fjWBa/DXSo7yGcWEQePpu6fiK9KxzjsOeabt4zWajJaJm3tnYp6Zp8dlGqKBu6dOAPQVfGApA6Y/KkUccAUu7jjFWkZSbbuNZFkBSRVaMjlGHBFOA4GfwHtRweCcketJGojXCBR71SJHggdOTTtx4xnNRZGCT1pM9TuGDQBLvznH0pu5umcjuD61ErYPHNLnLH1FMZKH4659DigNzjOR0zUZYdOnqKNwxtBOT0piLHmHb29KVWGBk/j2qurfwnBOPwp4fI54xQKxMGOe4HpSk5PJBrmLrxRDbeLLfQhaXEk8yb/NUfIq10W7GeR61UouNm+oEhPQnqKY7c5PX0/xpu4t9KQEjJz71IATn0571Ex3A55x+FPY5+nbmoyScg549qYDsHOR1x1FIcKDnpSKCduePoaUn5sDn39KYCNyAP4fSmFjk5UH3z1p7dc+tMYkHAAoAyv4yRz3wDSqRk8rnrTMlRxjFPUAg7QBk5JHrVCFy2Pu5I4weKbiU90xnkgHp6CnZboNuPQ08EjGQcnuOQKBhtBJyOvpSZVVA3cE9cU/Hqf1/nS9MDI5oAaQQRxz35pQOAAB9KCmcjLAkdjzThnHHShANwoA6j6U/oQO3oKQEY57HrinDheOAPXnNAXFYe5we4H9KQAcDkcU3J4A4wOuetLu4B596QDgB2IzTh90ZqIZViRjrSk/MCpOcd6BjxwOvGOKapLLhhhvTOcUbuMhQR2NIGyw7qR1J6e1TsA6Qv5bCPaZB0DdP0p2RkBcle/PSmqeBjqadz8o7/SgBVAJ6f4UvQZXk+9NI9eG7ZpcnsRx69aBigZJI+hFA2sB257dqQnvyMfrSA4OMAjvSAk4A55H8qT+PO0k9Oe1AJIwQcelPwCMg5osALvxycH26UoYA8UzIPAyDmnYO3IPPT3oAeCFAyRgd+tKGzjPbrTAeoAA/Wlz749T6UgGRW0MU008cYWaYL5jDq20YX8hUrYwMZ20g6DP4n+tB5Kg5wKADPHHFC5LAN1x64pOmT2HPvS8HH5ZpDFJ5P6jrQRyB04oBIC57daRicZBHtmgBepHQH+VKO+COOOaaM45OT1zTd2GRcZY5xg9B6mgCQYzg/iaPXpn1po4GCTx2oPzA5A96AHE7emSffmjcevSmDkHGSB60hPXnnGBQBJuyvA49BThyO2361DnOCfz/AK0oPXrTsIlVgRx370M2BnJ6UzODkcZH4GjPBPPWgB/JYHPHc0hGB14xScbs8g9xQcbSMfhRYBU5GcHrTjgZ/WmLjGDnBPJHanDnjPagQhGOnAo3DGBnNIdwGO1NbkD7xOOaAFJBwBkfWmb8ce1DNyAOR/KmE54zQMkU80oAzkEEVBIvmRMhJUn0qK0ha3iIZy2fU0LYdtC2SRnH3vSkyCeOQRSE4Ugce9JnIHGPehiHoRj5ice3OKeTwe/1qLdnBzz6ClZjxtOCOmaAFEcfmiQxoZegbA3AemfSpY5ASSuOGIH9ajB+bPc1Io44wKAY7cPUDNNY9Mkf4UDB6nvUV3PHBEzzMFjAxk+9NCHtnA5INRuVG1c/MRnHr71SOrWYXCXMRBxnnPFWQY5mR/lbb91u+KpprdDs0SbuBxkClUnuc57e1NycMQBik3E/TNK5NhwOST1J6UKNwyTg+lIzY4HP1qNmGeEZvcCmBnBucnpT1zg8cn8qhztXA4+lODHaQoOc9O9XYRMp9QDilLMeuOPboKYhBznoO3pTh14IPoaAHgnbg9M8UuQAS2AB1JPFMGQTj8qMEjB5X0IoAcfu9CKVeD7jtSE4wM9famk7ck88/hQMeThSMH1x60Mwx1OR+dNyR6k9Rz2pA2R+HSk2ApbsT9PSkDZJ+lNIAAyMdxQM4B7UmMkB6H04oPU0wN680ZyQAevrSAkyVbHQ0Hg9wSc8Go9wBOMHHFPHAIIBPagY9TxnHPt2pxO4+jetRZwc5xntT+VOe5/SkBIM9O+aMDk4JOKByeCaaxIHPBPBzSAJMlTtYA/wnHT/ABo5zjj8utGcHBPHcUA7uTg8dCKAHhsg/wCfypdxUYwBx0FR8Db1PtTscdRQA7P4jPbtShgAMcegphOAuPX86D0x+h5pNgTZOOvHcUgwQQMEjtmmZI4OMj07U4YGcAcelIY7HAxwAelAbHTJ9M0HvnANAPTkY/nQAKec+2MUq44/zmm8D0/wpQxIGeCaYD8leKBnB5z26U3px0pc8/ypAByDjv1NIMYOMn8Keeex4poPoSR79qAGjPJBz7HpTmPynrj0zzTT1B7inZz0xg+1ADHOB6k9BnAP41UnkYS7fMxn+E8Yq1FGI1wgOAehOac4DcMAVPrTTHsQIgD5MrFR2zVhWz8v6iqE6yQOGgt1ZfryPpUlnc/aYfMClRkj3yKbV1cbT3Lhz1IGPQU0MNvJJpM5I55o9j39qRI8NyMcn1NOU5zwRmmbjnnj+tAPRW7evNAiTcMkHjjgGkzjIxg0meQc0ZyBnge/rQAkirIoEg3KCCATjpSNu4J9aCwYkAgsp5Gaazbj1yB2oYxOq4UYGenpRkYxikJzg9PX3pucLtODjuKAF5PTkUbg3XoPWmE8ZAH+FKTjPY9fY0riHI2B159qUMANxyoqIn6jApwYbcE/UCgCTOBg9T+dKp9CMYxTM4IPBNHbrt/xouMlTkDkHPenpkyMdxKEAAY5Hrz3zUS4HP3TUikgZHOOwqhD3baeeR25rNu5I75jaKpkTq7dAPb3q1dRrcRbHYhf9nj865+91p4riaCxiEmwAbhwFP1q4Ru9C4Qb2KmtC0s7tILZUQuuHAGee1WdK1K8MAQWJCA8ENmubknae9kuXYhoh/q+uT3NW0uCyi4ka5t0I5wR/Kurk0szonblszqJNWEHzXcbR5+6cZBPpVb+3HD5Fq/l9dwrnrfVopZlN1cSyxjhVdPlJrorfV7GWMqWWNRwcjis5U+X7NzBxS6FyHU4pFI4DHkAnqKkhu45U3hsA9iKyRaQRSY8gywt8wkH8NV7i0HmnyJCU93wanlixcqZpJz0xn8uKeCOT0/SmcbuAM+hNSY5759aRgKo+X5trE8enFSEdhggU1eR1/CnA57flSGDD6c04H5eBgUz7oxkc9vShwSB5Z2574z+VADzgDjJ54zSdM9zjFGcnPekHHT8zQAcdDyelIevXJpTySOfbnrSHrSYxeOwz9aM9M/oOtJnoO+efakJJXNIBSRgEjv2/nQeBxkn3pBRx1z9aQxeAflGGxThgk55pO2FPB/Wl5Xt0pDHinYJO0f/AK6Yp5+UYIp3XHOKAJF5UcjJ/OkJG3nr3pMnI9D29KAeh7CgAyTjHAFA5x/jSt9444AHNKOeQR9aLAAGMgjPFKVGeme5zSqctjtS5xyT364pAG3jIAwD+tPVQW4+maMAAcLjNPXHQ4xSAYBg8jmnBcHoB2xRvAC7gTzS7uTx+NACEHIAPTtQcE8D607JI55+lJnr6/qRQAwe+PalB5bjPHNPPGM8+9Rk5Gc8g9KBgSV4OOfX+VOYY9z9KjZxnJwAOcnoKoy6xYx8faEdv7qfMaaTlsNRb2NM8D/IrLvNbsLSQxyzgN/EM52j1qvca7tQslrL5YGA0mEzXKSXK3Tts02JmJ+91JrWFK+50UqHNrM7fS9WtdTDfY33hepxir5PTnHrXE2Wpz6eMyaesa4428Gki1LVRI0whkIPK+awAFDou+g5Ye793Y7YkZJAPT1pksiohZ3VUHJJ6VyjTi5QTatfSwg9I0Uqv596xtWvY3jZLO4uZI+4UHH6040L9RQw/M7XO7vLhUt2kiePcflyzYBrnHvtQuJ3itbmAIv3pFACr7ZrjnuoTColnkml/hhySB701Fnvh5ZOyNOdgbao+vrWkaKjudtPBqK/4B2v/CUQW5WCeWNpF++UO7P0AqZfGeklW3PIP9nYa5e00i0lA+0ahFF2CxLwPxNTReF7e8L/AGXVAVBwCcVLjT6kSoYdfE2dla6/p08QaO6j2+5xSanrkNvGfI2SzbePm4P41wFx4W1S0JMOyZPVO/4VEujatdYRIWJHUNwKpUqT1voSsLSvdS0Ov0zxE8iCW+uIVnYYaIkqqntj1+tWJ9ctmwsmpKG67IRx+def3Ok6vbNGt2AFzgZ6H2zQ1jqBlMdlA+7HzBTuB/GtHTpvW5f1WHR/kdzDeoHllh1baZCPlaLgD3rOu54Bc/PqTykgtmJiu01yttc3NtLJFewsXHBUN0qxa6mY/ljjQr1wRzT9nbVM0WHcdV+h6Ro2owXtuPKkkZkGGLDBq8zbuMAdufSvLDrlzDITHIIj2A/wpU8WaknSXzCP7yisZYdt6HPLAzk7xPUN3fOCe1ZuqatHZKqLHJNMRwkYyR/gK4b/AITbUIziVbdmA9Kavi643yS7EikfhpFTJqFRa3HDL6l7yR3Wi313dpLJdRCGPdiNSfm981pggdT/AFry8a/qT5EeoAA/3o6SPUtStn3TX8pibnKc/wD6qfsbsqeXTve6R6isnzBenuKgbULdZTGz/vQcFQCTXE2niueLLvFM8eMBmA4/CoX1y7vJnaKWOzX++3GaI4d9djnWFknaR6Qs0eck/NgZB4qrd6va2qtufKqM5/pXmc2uXEbPHJK92P7yOcVj6pqV3FEZWV0jPOXbGK1jhe7H9Vtq2dxqXi0ySN9nyqYI5PH1rnbnxHHHamzhwUHzSSE43n0+leY6l4nZ8RW0Uk0nZl4U1iXWs3pCQN5axuefL9fQn1rrjh4x6B7i91HrOm+Jgz/ZbWP7XfSAopQHCitW3i1QXH2KRhMQmWklGeD7D0rnvhRYfZml1K6bbAR5YI6knsPevRBcj7RK8AIfAURIvK+mT6msqkuWVkiJ2UrLUpw2lzFarBEy7s5VlYcfgahj1HyjMlxCGmTneMDf9R0NaiafezSC6RgjsNrJu70/UrGG7064S5C+fCN4YdRWPOr66mehmWHisFmDRPHC4zEeucdiO1dBBKl1CkzwByw6xnj/APXXmmoJJot2kckgNtKRKj45TPf6ZrprL7DJAHhvJVY8yANgb+/9K0qU425okySXU7M5C9cjqaRDgY5we3+NJknnJP04p4IzycZ71zHMKCC/zEbvTv8AWnKPmyDTGUsUyq/KeSw5HHGKkHQc9TjPtSsMXjg0KD36dsUpXJAwR7UAc+2cH60WATgJ2I7c0pz0PSlIwRk00blwCoySehyAO1JjHHtge/FN7cDr70446L096Ycfh3FIBpI44NIP0pT6nkmkAY47/XqKTGOGcEtznt0oXAPHQn/JpBwOD2/GlzkHBpDHj7pwc479KMgH0pnGRux7UiyKZGQEKy8nP8qBpEp68cCjsQa53VvFNjp8pi8xZJB1APArn38crHLM5G8Nwi5xtA/rWkaUmtjojhas1dI9DLejD1o3ZJGfwrzh/HtxIVMVvCF75OatJ44uMrm1jPGThqfsJF/Ua3Y75SMYqTdyM9K4SPxvAOJrSReeoOaur440/aNscx7dOlJ0Z9iHhaq+ydivXHGMfnT1P4k+prk18ZaWVOXkB9NtSp4w0t9oErnHT5TU+zn2F9Wq/wArOnHJz19qWOQEFsHnj5u9c4vinTT91pSe4EZpy+J7Z3ytvduM9RH1qfZy7C9hU7HRZJY+tIpOAfXt3rA/t6RyfJ026fngkBf5moLrVNYI3WmnZA5wzDP0o9m+oKjJnTM2Bx0HFKx6ZrkYfFFwpK3unSwPnjnIrVtNYW8uY0slWWNc+c75GwUOnJbjlh5xV2jUuFnI2wsI++484rN1CC+KSm0YNLJwDuwB7mpLnUJ4yRHaMy5wGZsCud1PxZLbgxhI1mzyS2VH0qoRk9i6VGcn7qHanaXUVurarq5Uk42RjGfasqO8s7ePbGkFr6ySMS/4Cs4317qNwRbBri5k5MxXJHsOwFN/4RxQ/m69qEdmp5VN4Lt9a6UktJP+vQ7vZqCtUf8AXoa9rrekrJvleS7lHQtwPyq1N4itZEI8pQnZY8An8a58w+ErSPD6q5buU5FU31rwvDMVhL3GB96diAPwFPkUteVkctNvS5uJ4iit5W3Wm/PIRyWqC88QXF0DmOC2QdBjJrHbxLols25ER2xkLHGW/nVU+OofM22Om+Y46ZQACq9m91EtRprXc27e61W7LJbxTzkDq6cAe2anh0jXbgGKSPyI265OM/WuXufG3iWXCxeVbjp8iZOPeqM+ueIZkkNzqlwN/wApWNdvFV7Ob7IXNNfDFI7O50/TdAj36hfQg944zukY+lYl142eSV7fR9NhjRRxJMu4k1iaPpRnd5bsueM5fq1agsmN0jwOyoB/qwn9aFCMXrqXyTmrzZj3c+q3zvNd3kmf7kR2Kv4VHbS6lA4MTMY84IZ+fzrobqFsALATk4OOKj+zx8RuAp9jWindBGCg9CoNfmBEMn27eemJcirlpqN8iMFkmwT3kNC2iByuG3duMinoNsmwcn3HFS12Noygtx8t9rsq4iviqf3T81QpqPiKA4kn86FvvIp25/EVbjXynZ8n3X1ohVY2JLMxPIz2pbdBuFOXQbJrN1cKY7jSoYlA+UoDuH41Sl1TbtW50+R3zgEHAx71tofUj6DrTpo45Iz8q7scE+tT6IqHLHRGJHKytuWJkz0wKhuY7k5bZu+vFbiWeFXe5kP6CnRxR+YAcg9Axo0LdVJ6HMyWks6Ni1Ctj5mLHmq6Q3UQwY2dB1CtXXTQyICGGFHTPeq08PmIhicpzzs5zTViHWl0Obl1G9t4dltEI93BaUZ/AU+C412X965QAAAhRg1vyKmSuxHwOjCo0ickSY2gD7tUrW2MXOTdygNX1lcpAFBA6vggVk3194gvDtN8obr5ccfBPvW7GPtEbyQhon34Ysv3hSvGEwHLD0K8A1atHoZS945GWHU7iGJJbnyWH3zHncT9KhvNCncoLgz3O3klnLHH0rsxbfvt7M4IORjoaabTfI8hdgM5GDjmqU7ESp8y1OQ03TYBu3RSxxqcK0jYJP0rO1G0hbxDbx2yvJgAmM9M9K7mSK2W2MjxrvJ4J53eprgtr/8ACVulpvjOAUOckCri7u5hypaHsfh6yax0WF1xJcRP5sgHARPTHrXSxA3UiTWkTrEzByw4+UDufUk/pWLoc0t3Bbi5KM6wne4Xbkdh7muiLLa6fDblmDkbjj0rhqXvruYCKqxK00MkocHpngj1pqT747lhh1kILEdqpRXnnSPBa5LngbjwB61Fqt99i0ieGPyVKDDOx6k9xUuDegpKx5r8Q9Zl/ta4s02MMeWhPp/+uvPDrV2rsrLISp2naTirfii+l1HXY4LFXbafvZ5+pNRz6Te+axttPNzEekgcgGvRglFJMu7StFH1RaTrcoXQd8EHIIqyvJ5wSRj2rMtZ41dyZQXPDKgyAfetCN1cEockdcdq8pqxxSWuhYXtkgnvTjjBH86i3fMCpAFKp4wTuOaQhx9M8D9aU5zUM08cEZmlcIoOCSaa93bxq7NPHtRSzHcP1oSb2C6LB/2Tg0mTnJHQcelRxTxTxxyROHRxkEGqzIJrqCYTSRiPP7oHh/8AeFKxS1LynHUDHXFBI6nGPSo3dUVpHYADuegqhqN6yRbLV1M5P3eMfjQldjSb2L7DO7n6NjpSHHOMcVjm9v2QEW6qx65bj/61UbrVL4BkjiSV88hGyKPZtmiptnRySqsLyeik4HeuIsPGtxdazHYCxzv3fMDytaD3+vzRbYrKGAY+8TnH4ViaVcaboV9cXNxbyfb5l+dgMgn1X0zWkIpJ3V2V7CT2Zo6d4wkVLuHW7dre5jLKrJ0Y9sD1rnZtd1C5H2aF3CSHHyHMj+1Z+rTyanqUtzGCJWBIiAyF9WJ+lYtprV9Jp7WmkJFaR5PnXmN0rc9j2rohTW6VjrpQ9gtVdnRXOnW9rC8+oanYRBRlozJvdfbA71W07xLp9vxY6Z9sx9+SWML+Vc7p3h+NpGub4NKSeEJyWPqx71uQ6WoUAIqsx3bVOdo960cYdXc0cqk/iZcvNastSQR22lfZQT88oQZx6AVaSDSpIUNhqLrcD/lncrgMfTNURBslH7wCHad+6mtYRuBsUqB6Gp5YmsZSjpFmsNL1Jsq1qhAGQyMCv4nNVLnS7hMiT7Og7/vlBqLyvs0R+ZlQ9QCaVbONiGGG3epqeXzNlVkjPmRYZQGukVv9lsikS7liIaO4jcZwAvWtZ7TETbY48Y7rk1nwWFz5w8yJDEe6HBX3oSNHVXUtf2jdOFKS3G31xj8Kja7kZ8vcMoHfdWkHltrcIJX2k7SCM59DWe2no7brgsSxyV7VJrGUUhv2uYpmO4lAz1DGmx6tewOUW+kXHPzsQTT30yIfc85f909TVWfSjLx+8Yj2pWK5ovoasPiTU1wv2qQn0OGqR/EV5LG8LXDqGPzqMDP5VzVxa3dltljkPy9QwzV+28WPa4+26bZ3AJ4Zlwxpcj3QpqmldRTNSTU9Ruyqb5pQOgUnArRs9GP2J73V5ltYgMoJjgtj2rEk8cyAMbPSreCMdicVzOo6lqniO/Wa/b9yi4jjVvlApqEnvojKU5WSguU6nVvHs1u50/w1IkiEYM7xhSp9B6isfTrWS/ke51K6luZ93LN0qHTtMjjmURRBmfkse3sK6N7ZlEUZj3JuwzDgLWqUY6RMORQ16lSTSoWO7GFB9agfT7e3TcyqBnG481tmJJwYijBB3PFNdYmttsXyHGAG9fWjmBKxgy2QjkRgm6I9h3q9HYwRgN5axlunb8KllaQLGAqyt0btin3gt59qTLnkFetF7j2K5jiSUCRcjBOVot/JZvlXBbpuq0hPmyK6KEUDkVDbq8l44aSQRrwUK4yD3FArssxAInzhVI5yOgFRm7yENuGkDnGV6impujdxMqeS3CAcZ9qkgj8kSAKu3sB2paD3LKuq4R2JbGefWoHUtIjIByeSetNC7oZvKl5AI3E521PYw4t42dxJgZDg8fhRtqF+hEd6Tcnah6D3ptyrKoI+XP8AF1q0ImkZ/OPRs/QUWl0ZjNDJEVjjbCMeQ/vSuGxDCAEBGW7Zqwqg9gKfJHtBbYQCMqBVa0ln3t9otyg7YbJp3vsPyY6YuHXbtC557CkMHn3AfzQY1P3QetJf2P2tAGmaEdxtzupdO0lLTHkzPID3cYwKd1bcL2drFsMFUIMt7Co/OijYRvIA54AzzViWEHhZRH2yepqGSwtbbNzLIruf4iPu1OgOSIbm6hE628rlmf5VBqMMo8y3hyhXjkcfWobG1g1DUZLkK5ZSPmPT8KvX63cWFtLeJZG+87c8VTstCOZldopYbEBWE05bAcrjA96hjlkbUDbmL5AOZMdT7UlzJeafbNPeTwyErwkf3R9TTxq1mIYpHbYZBjGOpos35ii+5G1xh5YVINwBxkfKPrSF/NSIIEkbo5U8Cpb/AA9koMWRJwxHy5/GqcWmrpcYSB2SHgnjcWY9s000DvcWdjDICodgTgcVIFBYBieegzURXzJxJl8RjAHYmn26B5g5JU45B9aoTK2qKUspgAhYjMYzj659K890JG1DVJGRiWllCbh/IV2+vOY41iLhndXbI7DHSub8HW8cV1aFTu3vhMdj61SdkZxjeTl2TPWdJVpIysLALAAuT/FgVevL1vIdwMyE4y3YVDYRpbnavLfdPsapaq7NJmUFLdDk49PWubdnMkipNr1nplnO6uuVGGYcuxNeaeLfFH2uyMUWUiL54By1VfEV9DFJdTBmKPIcAdSM1Q0OyfUrn7Vdgsq4EcYHA/8Ar11QilqV7O2+7NPQbKeSyjdrcGVuu44AHofWuyt1MUKoqgADtTYrPCIjMVI5AHQilmm8p9mxuB6ZqZPnNYRsjt9OngXywl0cE8jAyfxraWTyH82zlaVm/gZvve3sa4qxjguLgBiIBJ88flyZ59jWvM/k/JPLiQcpLtwG+pHQ+9ZTirnnWRtXniO3gh3MkizH/lmyEYOeRmtmzuVuYElUqQeRjsa5++ki1HTFgmIHGXJ4bP8AeHrWRZy3WlYS01G2lj+9sfIrDlTVkbqhCpD3dJHc3dvDeQGG4QNE3DIe9c6dA0K0lkcj96QVwZCcA9eKbJ4igniWIv5THq6HhfXms3Uda0ayJS2gF1LjJkdjg0QhNaamUcPJ6NG9a3NlpVkLXT1aUJ93Jz+vesqe1nuLtry5uUtA3Xc2D+ArhtQ8fQxOqQqkJ5AEAzn6msufxLLegfZopTKT88kp4H0HeuiNCS1ZtGChoj1ZBbuPm1GeVO4L1FG1q3y2XkwR9JJ5n5J9AO9ePTz68LltjDyD0AHP1NVrqXW50KBtqjqcYxV+w/vD9me5JNosZPnXsc0vdnkz+lZ+p+KNG06NhCIS31wteGnTb6R/3bO0h5J80k0n9iyP/wAfUDu5GPmJOKX1aF9ZXIVN9Tvbzx5Y3cgWSeaFVbIEIJUH19TWdd+J9KiYbDezO3BkdMbfoO5rNsrL7PAiPBEiL/E7ZLD2FW3s45PnWLd7KKrliuh0KDS00Ktze3GsstvaRyWGndGRWzLP/vmta0slETRKxWIAExr0AHvTobQYQKDCe4Xkn61opD5MJ8uP5vY0m+iNFDqyHc0sQ+ycyt2YYwKu20Lxp8pHOck81EY2MRCkLM3UjmrEyuIykJxOFGAallJGfJb509rG7dnefPzoMBR2q/pdqkFlFG1y8gRdufX3NOmt7p4oTFsWdCC646r6VMYYFUQurr5gJ+XjFTJ30KgkjP017iW+vop4tsUTDyZifvithfL/AIh82OAKigjt7GBfObKlsLuq+5ii3v5JYouRjqfpUydyk0lZlYBVVjIQoxwM81VMjGVRAFcE/MQ1OMVrqlm88ErK2dpVhjafeodI0w2TOnzbVHAJzT0V77ivfbYdeW8snG6SNs8MvP4U1rI3AXzQ+BxnOKt2X2t7hxL5fkrypU8/jVoEsRsBwfUVPNbY0v5GZFcRx3Atoyxk6AZJFXVjkJOG4HUjpinrEkbs4jXewxuHU1IA0S5CkpjpmpbvqCl0KFzYiVD0b2Nc/dWMhkVTbJKmfvf3a6y4Tz4zEu4Iw5KnBFU3htrdIrbf8z/d3HrVRlYfMYH9joxxIdqN68VPHo4hUrbggjufT2rR8q4vdQSze1Vo15Vy3WtCJYxCXmHlbVOUY9MU3JrqP2ie43TrGGK0BH3gOpPNVEtUs7SVY5ZmYsX3N1OfanQxXLxzzRObiN1zDGFpJTKNPCysqzuMMY+dv40ap7mbd9yrqE8gtUhilG/oTnBNRAICkrO+FXCgn5fr71I0MTxqHBLouAc8j3pJokNttYfKOQM8mrT6ARwKy7nZjJzkdqQz7XeMO3mv0zzip1LLGDGmT6UxbjqTEoLHGSOadxX6IVEDWzRSAlj1JPJqRw7xQxBWjX1znHsaZMTtQxsoOeQe/wBKddGEhGlZ0P3flPB+tK4OxIVjfFucNInQE859aRxOWVJJAixgMZPU+lQTEwvatDF523KlwfmX3+laFwhWwSzuUEjzg5ePoO4ND0Fe7sTtZxNFJBLwWG5ggqY6fCllDIrFYo/4S3P1qO6ilktoooJlimUKA5/iA7VFc7/OHluQhQqU7MfWs9e49bjLvU7aCFZSpljchC0fIX61Fo8YZ5ZUQrGW+Rg2Qw/xqDT43trhLSBVS0GSxcZLnqQKuSRG4hBL+Vboeg4zV6LRA73LZnw4iiifOOW7VWt7fy9Rzdzlm6qo9KlhnlluSoMYt1GFA64o+xRtcQu0p3xZOAfXtSvYd2yNPs19rAYPMsUY+YdjU99cPG4OnCJ4lPzKeTimXLpawM0YXeeo7YqbRDYGMybAplU4A6k0X0uS9CWS3ivRFPMmxlA+XPT6VIsOnTsE1GcQxN0jI+Yim+buuWVnQJj5F7is3VpMTxkW6zM/A4wB+NTZy0E720LEd7DFfXVrbKqQQEAOONwPt2qtJfPcpILZJAYiRlh94/4VHbszX0sSWwSI8ySDkk4q9bvCvlPEY/IyQ8jHHPtVPToCVlqYVnbKb+a1wzqygy7jkA+1aMlnbYjdosmMkItbjwJ5TNp8UcszY+Yng1WuEjeNlkkWNhw4Jwc+1L2jkVG1tDEBhnWeS4FwyYBaAngkelXo5zPbbvJWJFGPJQ5wO340+0gtXtJFtJN7LwxBycn3NYr3X2K+FpBsEjHJBPJq/iZOm5MHdHmMgCRq2I19vWnS71h+QcucZA+6KqSxy29xMS3mSSuGYP8AwL7VKk+FcqxIVuR6VXmJ9jmvGM8tvYQuhzKxYEY6DFYfg25CXMTynbjG32Oa6XxSkclk/wAyb2Hyt9e1cPpUglto1UgvG2CM9xV30CnG7kr7o+gbSwinh+0JOPmG7O7GTXN+LdcS3RrUFSAu0le5qnDqRj0VfLmbhOY+xrz7xDr7SxpDGFDc7V7knvWMYO+upjTpNu8tkc/qjnUtSjWEZjjOPq3pXo3h6zW0sorcEl8b2XtmuR8N6TLuXzkAy5IPvXoUCrHGP4SPl+X+tby0Sihr3pObJRLKM5UCRshF/wAavWsSGEeZKjyfxEdAfSqyNl5BHHl1AJPck1o2unKkWFXgnP41jJq2pou5yWuObFw8XmfuJeQrYVh7Vt2PizSZGt2uWleNxtaFz9w/1rmfFklw5nit9j29uFMgByxBPAri7++8ubybZevHABw1dElzWRyQpxlFybtY9i1TWdH2KbW6maMniMjp9DWHP4ggLsrSN7cDJrg7G11KDMks4GV3bOOB7+la2h6dfag5bUIoIwGyh55HsaSgorcqEktLXOls9RguJTJKzpCqn7x7+2Kbc+XqJWOIuYB1UDBb8ewp8MKysVaIsIjsBPGfetmG2SKIKihSeRiolodcal9EtDIj0mzhQBtiZ+7xkg1KmmLDLmI4iPJIAyx96t3GnpMymVWyBlcHA/GrSNGJPswkUzAZK0uZi5Y9UVDF5xCkkenNUri133LW+cMo3GtlYmkdlQIZQO5x+dQ3brHLCrrIjynAKjOKSkJpIohWGAqr5YHOOpNMVmlDb42iAOBuPH1qxqEaxEq8hVJDhcetQTFfLEKkNIBkru5xTFsOeJFdGZQeMBqVYwiucsQT60yVQ8UO9SM+nbFSQszyebGGNugwwx37CgdyVQAAAVBHIXPJ+tNgeZYGLjc4PQelJcbvNQwbQ5++SMnHpSSB2h2RMF5znPJpBcfJK0O2Qh22ngDvmteGSMsXBBlK5CmsKAtDcSyO2Q4ACk1et0Lz4KNH5RBUnuPSlJDTNe3MDv5qOvmEZAJqG5WeWZWlwOv09qp3FjBNcMY8iTZtO1sEA9/wq9Zj7HbRxXcyvztDdd3p+NZ6bopaPUozndpzf2lErPC2Rg9s9at3Lvc6dJLZusbhRtZugNT3umB3MshAQoQ3PGPepRY7NLFscEMAVJPBFJyWlhSt0M/Rbe8F81xdGIWsttskVTj5/Wq1/qa27XAmlby7YiRGh+bch4wfoantYLpJpUBP2eMKqE/x+v4VLDouIZU2FkkBBwOxPSm3FO7JjHsFlfwW1hFcXb7o5nwJF5Az0qeS9MaSyzII9pwjDkMD0NTR6LGlpHarGv2YLt8tznp61UaG5VXhvIA8QPyFRjC1HNFu6Ls2WLe5j+zhbpg07HgrwMeorOnc22ohZXlkWY7cD7q1pLaxTrHOhBRPlyP5U77GsjmRtuw/dbPHFHMkIqiV0uoFtx8nKyA9x2pbsRzyyRmMCaHBRj0YGrf7raJFeNoc43e/1qdRC0CTxI8wPykoOcetJy8h3t1MnUHuTYebbLiZWViB14PNPljlmuHd5AYNmGiI656mtO78lIgIVcvKcKSvAPvVDUY5IbdpPs4kfbiUoeFxQpXKVmVZJJYzZR2beVAWMchJ+6uO1V3nZH2t8kasUwR94+tQPepJeRy3D7BbndHHjqMdTUhLSnzCMDcTz3FaWsJK5DPmVcurIu7OEPJqC41GKIcxkvjOBzipbosqZjPAHPua5q71Kezha0BWR2bGB1/GtIrmInKx0KXafZY5yGRW5wakR4rkKw5bOcg1yemeK1hlEF6kZgY7QCOV981uPMrxtcWIDRD+70NNwsRGd2aZiTK5GCp4qa5JAQKuf7wx1FVY7kFEyuN+CpNWVkaQsueQMZ96z23Nr3ICkIjlEmYTL6E/p6Vs2MjRwHPHlLgE/wBaw7tbgW8flMnmLyxcdasWCStaMrncJDlkBzgHrRJXRKdnsatu4nuwLkBkGHRl6E0SaeJ74MXKqp+XDfzqjDC32+2RCRb255XPJPvXUBIdPtmuHga6nl5VO341nKXLsU5cquZZgtY5ws74aP5lBHOT6VJEIrqJvJRtqnaQVxVnzJ54BLdonnnJVEXG0elMsvOubBmdiHbPLLgj8Km4uZ7sq/ZGtQxtkUTEEKX4H0rPitbmGzEhctMzF5FQfe9gasadBeRW8puDIMNlUJ+8PxqS11OS8ncIkSqvGA2WX3xWl2r2FzdytI17PcWseI1yf3i9cD0q0bdUvmRUIGwkMfurUg229zGWSRi55KLwKna9tmLQJ5hdeDxnB96XM+iKlZOxkNZXF1Os8yGLaNpVTyfStiOHKZkVhxx61NvURPkAqo4IPJrMs9ftZopXcSKEzkEc4HfFHvT2JlNRRZtrqJrs2wjPmAZyRgfnWnJZxvGy+WmcdGHFZsdxNJdQzW8cJsWHzMWw7H0FWYJ54hK19Iixsf3SDkr9TUtGMqknsKlvHa2HkXMmVdgmYxt69hjpVfWdM3aeYIbdZhkcs+Ccep9as2bzpA0t20cp5YeWOg+lWYbpZYVeLzACOdwxQ207kpszPDsLmGSDZsRM4Ei4Pvz3rD1u3/s+8jmRUd2Y4J6qPQV0FhrFvfTyoh2tFIUIY9T7VNqsEVxa/vFXePmBPar5nGV2jSnO/us5G9lW4uo2iJifhznv7VFKuJ2kVApbgjtS3sT+TEFYL5b5LHuKjVzh/wB4CvUH0rZbaGklYx/E0DXmkzCLAlQ7lIHce1eQxzyWF4ctzuz+Ne0XxdbVnGPMwcgdDXk/iiy8m/XYoG9dx+taU+xz1k0lOO6L8viq6SyMMJIZxjmo9DspbtpbmaZRKv3gRnAqnBoV3OyEDK4DDbziu+0SCNUKOqIwTaY1OfzouorQd51Heexd8PXBbSQSoQO2Rn+6K11kXyGdUL56e9RWcYjhPnKgRfu+lMlk82OeNX25X923QCperKSsjbsHVpYUVTvyMk989BW/Il0rYiiUqO5OK53w9C8d2jSNvRlDA5/ixjNdYrMR8wGfrisKjsyZXeh574pYadYRSWMUCyXINmwfoG65/GvK9Pa5l1ApOQB5+1gF+bPfFez6/Y2klsRdphrebzY2zw4HVT745FeNTGW21u5ubWQFGlIyw7dv0rpps5I3aaO5t44biUTCPcUG0bx90+nvWjZC3syzM087ykhdw4T2HpWcIozax3AkELEhY93K49QPWuhhkYqgVh5eAdw6saGzaESXSJDcHZ5ZjRegPWtWXCZYkb+i8VQtzItzIOBGQNpHB96s3ihnjiXdv2793bHpWctzqhoiOyiulu7iS9bMROI19aW7RbeRrkxB5BgBu/41FdiGO5tp7iSUMg5VRwa0JpItjBVLQyjJJ65pN9RXs7GHPO00khs2TEnyyDPKtVi5Z44Lea9DtJC6qmPX/CtGz0SC2cSRx5YevOe9LdKCtwJQGhVNykUc62RNm9yleOk9zIhj3GJQ+R03Gs+eAGaWWNWFwQOfQVaSdLKANtyZFzk9SeyioruXZG6SHc8q8ADHP1prQbd1qNJZYmmXLvxhT2xT98otkKqolbll9KZEG8pAQUwvT0xSRMkp85sqOgz3o6h0HSPiRlAwxHUjjNMVSqIZ3JdDkleBilmlj86OKRuWPAFLjIYkDA/WgNyKS5kEqufLSE8hh3HtVuaVryyYByCx3I0Z5HoahRlfHylsDOCOBUiFNwBGRuBBUfcpAXleWSOKaPZ5gxHNngsKu6Pb2+nWdxJK7SRb8gn5iPoKpbEuo/ILgBmGCvfvWzpwBhdJolManGG6H0rKb0LW1zoLS1sr60W4kmdFP8JGCR6EetVbmMuhWO3zCTjDNg49apaldx2LwM8pgiClfKA4YnpVmCOS58meO5lAzkI3AP1FY8tveuYKTWrY3SIzMj5tXt40k2oJOSR659KjY341xrd4h9jAz5yP39CK2suuwMMr3UGo2MYmfbtEp5KZ5xUqV22JzIXUITjOQOaydQvJptPVrCNnmwRIJhtCCtyW9e1tZCtkbkt8o5xj6+1ZFta3FuxuLmcPsQ706rg/4CnHuwUmRafEYLaCVN90kvD4OdvuK0VtII1KRoqsTnaemfWksZopIVa3wYiMqVGODVa/vY4ZpLW4kMEm3Imxjd9KNZOw+ZjraCSGMrdusuWLBQoAx2AFXbXTzNMJoCcqMbA2FH4Vn2VlGhgm8+aU8sW8zKn0zWtpdxcQNLgJszlRjIx6n3pTvrYHJ20IzCVDLMfnz0I6VBd/ZBbtFFGyTKNzk/d/OrF7vmV3SZUmcjDHp9MVi31vMlwZZrljFIwCKRgIcc0RjfdmkJXaOcubcPNdSIR5knyoWHAApFLlTETkjgse9PuXSa8MkEcjhSI1PQY/vY9KS3WRmKl13Z4I710mzZDOziWOJFLMe3vXN+IbDfcyRWx23EnDueqjvzW3qwD3qqZfLYLnqRgDvXEQai11cTzZLSBzknoVB6CtIqy5jNJzmoG1YeGkmuLOHUJImhQjdIOM1oanZx+Ebkt5u7T5nAYoN2z/AHhSaPfSlPMnhd7MIA+wDIU9/rWXqgkc3IsJnKSj/VzKCXUdvrURnJy97Y6K2GX2N0dQkiScIRtAymOhFXFZSN3yjC5xXKaDM8OnwBWZ45JNuX6qO3+FdPEgZlOCMHPTrTkktDnjJtDRb+dDzKXJBI4qXSojBbGByFf1H8Q9jUdzvKhYSokByc9x6VWnlFxZyq7jepyhU4OR2os2inZGzbxxyX0dpvYzRkMzN/EO3PeuieKZru1dpRtCFZUA4yOhFcxpQdhFc4J+UCT2PrXQ298TqQhKHYyZU9ckVjNO+hM78txxWeK7URxboMHq3U0i26T3X2udCkxAAQMfLUeuKltrtbqKVxuWMNt+YYORTkk82RrcowAH3iMDH1qNVuY8wx1LghSJnZtgI5GapizvoLhVktbe2AO5sYLSLnk1bS3hs7dre0Lpt5EgOSGPepIt25pblnnkVAoduSKd7D5mR3Lsjs8SF0C/MBVKS1N/teCaaBJRgoAFLH3NXI7qS4CmK2kUEnJfggD0qQ3HkhQyjaeoxjBp6oSkZ01qmlWwCLJKyjkZzzUOm6WPIPmRF/MYsyj1PrVm91a2sZ40mI/eklSRx9KsCRpxv3rGp7Dg+2KfvWu+ouZiI7vJ5AgZPLwo3LgE+1TBGSVVlC5J4PY0uxwP9YWkDYUf1zVcyzrGwn2B0YgKvII+tK1yfQg1fUk06VY3j3yOcLHGOTVddZmnt5VsICbwdIpvl4p3+i3lzG97Ad8Z+QnIz9KbcmNpGu9OZ7pYxs8rA59efatElazQ7W3KuiyXMlwGudNtraRSfu9c1b1OI6yZYYpGt5YnGStXXAQxcbHYbuecD0pmVWR/L2jjJb1NLmu7lq3Q5jxBA9vaOYtzuAEKH+dYRjuVeIQOFhI4DdQfSu0v7V7iNntijHueu4Vwetu9nfOkxcRE8P6H2ram+hs2pK5JeQyvuQOAp4GKw7vT7eQbbsB3H3dw6VZj1GNI3aSUy88so6e/tUk7rInz7ipGVcdxWmqE0nqiK2S4hgQW5VFHAQDjFaljFDGjNAnlk/eOOTUFlPCsSgAYXgAnOKvCYRtnZwT2GaTCxcgmiaTySdwA5yO1VJWkEj26KCgyyOBxSXJZpIXBKrn+Hp+NQ+ZNJayxR8MpwSB69KEiXozstEjVre3YZU7fyNbTLk9z71kaGCbVFyS4Az6itcSBeHOD71yzepFTQq31hb/Y54JyrQt827OQpH9K8F12yW3u763UExli8eDk4Br3p7Iu8lv5+7zAdu4YAPpXlHjvSV069tr1AVhmIRx/cYHDCt6TtdXOak1zalDwxe/arb7PLD59t93nsw9q7WwZJEQhNm3pj8q4fRIhBq1xbKC8UL74mzjcD/8AWrttNlR4/lB2A4WtZ66o1ppxdmWmA+0rOzlQPlxjrWtE/wBotBJFg8EevIrKkjNwERXK4bdj29KXTXktluIixRCdyN6c1lJXR0JstG8t5BHHeFDIfuDFaUQbfsjj4KZ3YyB9RVNrWFiDtVmGGDEdfetJOXS1DOjum4SqMhf9k/WpdiZOyuXksp7XT1lvHjaTH8BxuHoBWTbwR3R85PNCAFdhGAB7iuj13zW+wm3KgAfPkdV9veqD3lwzNa29pHFEuC05PLeoxWUW2rmUKjsnY5zUrGKS5tiPuQA7V7E1kBHhSd7g+ZhsoB/CK1pI5IXu7y5kYqM+Wi9B9KxomWWUXEiSCRsbUJzj8K3hsbTauI6j92290I+Yqx5x71bV1cDHK9elRSQCaYvOvT5RjuPeo7WQx+Z5owM4UU3qJD3P7070wvTcOtSoMqAnIxUcn7sbRn58cnnFHnRRvwwyP4R2pWFezFm3R3BDOPLKcrjoakwyqpd8HYcKBnd9KkYRzRFiuQ64PrVcJJCkccY3RgfLuPIPpRe5VuosQMZjuTI37vlRj5hn19q6rRZEnkd5WJdwM4/hFctpsAIuby5eSOXbjYBuJ+grX0WTyL5IJ2BmZMjI2smeQCKioroSa2OuktoZAEkQSAEHnn8fwq9lXeNUXA6bjXNTXry2MZCTxy3IMeVH3D6k1d0S/FzbBASs8Y8uVG6qR3Nc7g7XMZbmsu2FWWNi/HLE89aRRbPN5yD5tuN+MmqOlWawXMygmR3XzA5OUf1GO1SKYnuRAmVUnjHFTbXQVjSIj8tGjyOPmRqo3AiCYVmcMMkY4pkVvqCM8d48cixyZV0HUds1A1+shcQwSKWcxlWX7h9fpSUewLQi0+DdcyTfaJFiVcLblMAGpJII7gSJeWhkhB4L9GPt7VOmVYGQk7jzj9KdEZQHG7cW5Ibqfp6U229SttjOmtSbdLW3BtIlIZWj7nPSrM8s0KK1somkyAVBx9aq+ILi5msUCIRLJIqpsGduOv0rVs0V1WOXjAzu9apt2TYepHd7/JhkEQeRGDBeAAfU1ka45EQkfL7eB7Z6mt/aoRtzMSfujHFcrrUszxmKIA7Sflz1op7m1JdTARQ8aOzMiCUsMPnirdshW7Zt2Sy5xjAFQ2OPLZXiVX3c4BAP59KehIlNwwZCPk2nuPWul6mi2MzX7Rp7kyB9n7thn39K5bSbMFoYoUErqu07RnJzXaaykhmdRt2lQy5PWsf4czxPq22WNxIsjqyL97mlK/IXRmoVL+R1Wg6Uul2iStgvLksrdl9MVm+K4ImVLu2g8qNyAuOua9CubS3LJIgVWQDbnscVg+OFX+xVIEYUEMWx0PtXLGd2mKlWvUv3PNNEZwl4RHut95AJPRuw/Gui026lJgMqkApyP7prkvC8ssl7cxEnyXmLbCOoHeuwtWIIDbeG213zRzxeo8yFXYvwxyFyeM1Su7YyLBbzR458zzUOCprTmMUkyqFOFGST3NVp1EMwe7k3wMeBnGDUpmjWho6TqNulpcxM4M8S/MQMEA8DitBI1lt9Lijlk+zhfMkdPvhgeBWX4Zje482WWOJrgo4J9VHrXT6THbQabGzMITNhdzH7hPasZtJ6Ey+HUtkZ2rtCjNMlMjeZ5kqFVwqqeCP8aZEXS3VbgI0oONydDURshb27STyBpNxO49SPSs0jnHNBGk6CWWRIwpbIHDGnO3moPKbA4DY/iqCzlTULffG5MBJALcDIqbyygAiyNvTPr6inbowuPUGMMXdGTP5Gq9+UWPeccjDAnirMN+BHIJYldmGWI6Gq6wxXm8CHam3tzQrrVlJ2epz8OnzatZSC/QqkMuY2UZOOxFaultbQvHbz3LTyJ8pY9x7iob69nAmsbEN56qQuFwD9TVez0iR9PMjMLa4Zf3j98+1adPeZUmpPsbEVwRJcRS20iMh+Vi3ykZ7VQW6ulvZ4LqEbeNjeo+lWbGJdN+z27BpWk58125z703VYY5I5f3rRvINvPBX3FJWvYhaFbV5r57C4RPLXyJkVNgyWB65FRKj6fNAltbSPBcOWZ1PyoauabYiK0uUikYv5YDTP95j61VutRnsbuzt1mzFEm2QlcnJ6HjtVR7IbZqXdvNOx8pyikYBPX61Wt7N/J8m7mVy3DMeM0kmsxxSSq9zGxhXb06Z6UyK+tbizCkb1kYcipUZJFLYk/s5YLYxxMEhOc4OMVyuseHUckiVyqEsC5yK6fUxb3kHky7wh6ENiq86xNb+SrnywMNITyBTTa1Nab6M8+a0t7FxDIwKynIfgFvw9Khkl+wQNJcI0sZOAuOQPpWrq/hIXgluNLui3yn5WOc/T0rGt7g+THbajC8cnTc46Y75roTUth6x3Ltla20iia2Vvn5Cnn9KkLA3AQMQE+8o61BYRraXkc1oDOj8shfp713WlDSboeY8arcNw6EcqaUny6kudtGchPhiFDsyyEAqP4D61dVbiW5torfBhYjJA4XHY/wCNRaz5OnajKkA3NP0bsPatXSdNuYdLWWE5ndgA3ovek5aJiavdmvYadNBcl45jh2ywI4x6CtC4ureCTZccvjPTtU8W0qpbOe4qK48tpMyJubHXGa5733M73ZZvrR5I4SCfOxuLYx1rivHkQv8ATpbcp8xYMTjIDY/rXouny/a9PtZCBnO1sHGKw9UsImt7zzF5V9rEdTnpThPlepyReuvQ8KVriKS2c5XAaDcByMd67zT5I0WCNFCswyfQn1rn/EHmQzahprOBKkiTRlejH/64rY0GR71YZJRtKAgjGCfTFdbs4nTf3ubuaszMm4ohIC7gwNSXNxHDEjzxs6S4RiP4cjg1IE25VR8mMhT61ZSOOR445FB3JwD0JFZNnRHqaGlW6i3jjP7wA/Ln0NWr+4i0yRZTggNgoOTgelZVjf3Jt7h2jiWSJTtVGyfbjtXSaKoaBZ7tY3khj3MwGfmI96yl7ruzKUrIZJcBBG81wNxQbVbjr0qpc2MUzCdLiRJA2WJO38vWqdnpsk2p3N/qP752YeSmeEHrWndB3EaIVaMk7gTz+FJ2T0ZnG/Uw9YgeFZfs8g3OBtL8qprmYLERvNLvMjkZyWIO49SPauuvliNs5iZWVDg4OefT61yyQyhxshITaxwTyCfetYN2Nn0Y+3VjFEkIKxqcMXOSacuFmXzSNzN8uRnFFqWNtEJIDA458snk075pJlfyuB3bqDVdQWw+6aPyGUuqMp+8fWsffDbSNPIJZYicNIowo/8ArVZ1uNp2iRSfM3Ar6Y75qheyPHLHY2+x3flgx+VaqKREmzfVRKge2f8Ad43fWhHSRwejr0FVNK/dgxOm10GMA8Yq7Mka4ZQd7HbgVDWppF6Eahy8cu/ZOp5dR29KjDyrdteXK7PMYAtu+YkdOafA6QwngAbjkse9RzTSWqsVOSi7mXAKAepzR1Brqdzptwl1aKMklPlJPb8KV2FtqkflIUeU5eRUyHwOhPasXwpMzkzxSq8ch/eIBxn1zXSLcqL2O3kjZwy7uBhVA9fxrnkuWTSIkhILqWa/H2CSKRI1PmKykMpPp7VPcwyzRobZkEsYwpBxjPeoJp4ob2WR4DDsQ7JWP8PcVFbXUAhQ2JjdPmyVJ5bHFTbqkZkl/JcxrhT8yMN4zkY74qW1czjziGETjPv+VVZ0jjurc310Y1cgGI9C3YU1VNtG8Sq0aNITjrjPrRo0NdkWgW2yTg4SJSzMTwoHrT7WSO5jWSOTzY3wQVxVSwidrGWKeZZZAx8xiMDHpinWaWunRqqbV3nAVRwpNJrcdrlu5jaMlshB0Uk4+lFstxCTFfbBKDyFORim30KXXlIQVUsGYg8cGpry5MkztbKkkjMAFJ6465NSuw2hi3kTXEtqGzMgDMB2zXL61IhuXLK4ONoZRnHocV0likk9xfM8CJIGIRwRllHc1yWsTw3ZYQgPLG5DDcVxitKa941p7Mrw+fFAUuJUkkJyGK4BH+NRtPtuzDKCwDAbf7tMVmhjG1t7y8KCdyipGPltvYiSTOGI7fWt+potht0wkH7wZ2njPSuasnbRfFcOohSInkAbHoehrq5ZEUuCAWZTgVg34F7KqyQvtSPG5ehPaqgtLMmTV7s9H1a9c25khVm85O4xXNXK3c1tFZ30bC1mhMsRY/6uQZwvuDWnol1c3fh+3u7UJNMo8kK3RWHTNc1qr3t14ntWv98U1qvzRA5UZNY04bxMZPla5Tj9K0+4TVdsMmJUy5U8Z55FdxbiMLGWPzMM5PXNZHiaBrbxWohwy3KgFV4285zW0/lrCvT5TgHpWzlzJM2soydhZwwUBDjB/Os+5ErGF2jQkNg7j2qzIJI4vlIklJzgdhUVzJIkbvGAuE643EH6UkN7FjT98c8u6RY1ccnd79K6A2yPqCQliba4BYxueu0cY9MGuQQRwXEazbFa4A3puxuPrXX6fM0920ZhGLaMFZO5Ddaid1qRL4TUkDCNkGSSOD6VmXLWzqkVxd7STyobkn0z2FXzKsuBGcjoSO1YVxpUc+rG4uERoQBhPVvU1nDfUwOx0qCC4WOCGILZqvTGMH2p0/hxXaZlvJwzcpu5CGseLUbmMBY5gFxhQBgiorO5ureSR2vriQy84ds7ajkne6diGpX0NCDRJNMjPnytco5+/txj2xVUIVlA3sIoyWxnqtXhrNyLUxSYfcCu4H5vrVScRWlg8sxkMafMXY/Mf8aa5r+9uUr9TKhjln/tCBbeSGFj5guN+W+o9KtWjAW0UBleUwgfM6/eNEE8OpWsqspt4ZVyOeQvrUGq6itjp6eSruIsKH/ve5rTVuxVuxNcmPG532Akcseh9KZrUunpFF/abbAMBXJzurHhuRrbtYX6wwyIBIhBOHFbaeUzJDdxRyw4woYBgaGuW1w1LUFk9zamS3YLleCTwy+1Zj/abCWN7o24SZcBmGTnoFqe6u7bTrVZFmAjQ7cLzj0FVxqdve2hF9EVRCDETjAPqKUU9+g0myV4oZLZlCW4D/LIHTOf/rVSeytrNFW0UKo6gHitDENyoWCaMsRu2ZwTTRCqDKoM4IYZzk+tUnYtPQzr+0llty9tJGr7flLHI/GuWFldG/kt5rq5feAZChGxfYV0evXMcMyxW+0M7AeXyAc9eagayhlWNzNIiRHGVb7x9K0Umlc0hHnNjTWS3gjgiVSFHU9TWZ4r0aG6spZVRiWHzgdSKvR3cYjUxpwKsPdQ+UzFhtUYIzWOqd0bSR5BYpcpcxq6PGzHYpC84HY1qvfyK4MDnzgOqj9a0tYu2jvHFvlUxh2xjg9wfX2rM8owxpEZfNtm4h3rhhnrk12J31ZytWdkaOhS3Gq3fm3mx0TCqduOf6138DCOIKqgKBwB2rldDiS0SENuKg7d5/Q10zSQRgs74Xu2a56juzRxtGwfbkNwIPKlDH+IL8v50ydLhpP3UiIvoalRkAO1wyE9Qc4NOGV481fxqfQ53ZPQ2LZzHp8m3GI13Ky9GP0qvqQS6hYK4CzqC+e1JZ6jbyzLGVVn5VyB97I6kVMUj+z4fBZVAOOSOeKh6PU47WZ4h4vtGGtXBcjKxkM2OGH8J/pT/Cl6WQIpLKQAcnlD2x7V2Pj+2SMw3VmB5wydjLw395DXlltJJpd1HesWFpcqWUIeQQeRj2rug+dGyl7l+x6lDKwZ1nOxVPBPcU61ZmfeXyit+7Pf3qGxuBeWcTgKQycepNTr5UW2Z38tVPzA+npWT7HXB21LJd4HLSRBvNbAaMdR710ehXke42r7f32QxzjjtiuduLwQGOGWSSGFz8lwnO09s1qWSRWt7bC5k8xGy3mY5wOprGa5lqE0rNM0lEyXVxDOgCpgKwP3lNAhIQR7gcHggYqxqMLpem4WTzLWZRs2nOCPT2qu9wEl8nJEjc7etZrXU507oztVs47aAyRjYvLMo6ZJ6/WuTRAbgy7CgfPO/IPvXbyEXVs4KgZJX5q4Y2TW1zeWlwTGJG+SQcAewFbUnumbL4UOtkZY2DyiWfJwx6qKnjm+YwlSdo5aq9tiN08qFnblHduDxViOIrM8pl3Rt1A7Voy7FK9mjgkE8i5ZRhR6VymoWrtflo+WI3eduzgn1FdRq6vKCnC4XIIHWpPD1pHc6rZ2f2fzI7g5d1PI2impcsbmbs5e9sNS0vNNs4ryVgVKBjuTG8etXobzz41lRSocZHFd/wCJfD8d/pSwQkRmEEop6EY6V5XotzNZ7LS7jAYFjFKD1AOOfesaVVVot9R8y3jsbFxAJUBTHUEgioWVWsiHZkUnkMOcelWULHO7hgevY1DMk9xOrPCp2nh89u9WaGn4Qmti+22b5lBBQjrz1rrg4KgryenNcNoLRRau5WRAGOCN3P5V2rFByFA6DnpWNW3MRLYeFhvF8q4UsTwyr3FRxWlvAAVCwRKd4B4BNTx26W8jyxhHZwFdz2I9qmiiN1drG8PmwJwRj+dZc33GXMyC6CXWGngV3BBT2PanIsgkCF4vQ9yTVm8tlihdZZ0C5woBxgd+e9Z0KxidURGj3DESsDyPXNJaocXbYhjuFWa4LRlF3YLn+M+uO1Ja2yQjZFGVDN5mGP6ioJrS3neYSTXDRkYWNeBuHvVi00WNNUsIopJ2iwclnyfXHParukikaFrFNNJs8vC9D6n6Vz8WiXEWptHHIUiQblmMnzLhskFe+elenxQRqMIg+XgetchryrBrM0iwlnWPIKgls5rOlVbbSIU+fQl0KCNUukRiSUbOeoNcjrMKwB3VVXd9/jrXTrdzR3MUfkkyzJmSTGFUe/qaxfE8INsxDlAP4v6VcLqV31N6d9V3OYiBEcZ8wLEr8gL1qe4RzLGbcKEJ+cHqff6YqpYzGXesd3GHz/qzhqthoC/m5JkJ2cf4V0vcuLuhzywo0YYgknAYdapTqJpgsQYMeOBwfrVuQJ5oLhWx39KbdNu8vBOwnJCjBP40IJE3gK8Nrearpf3sruRfRu1PW3lN+bi53/az94se2a5/WLK4aYXGmO8NySMENyPrVpdY1x4PLlijkdRtMjcE/Whx15l1M3FNmd4ia9vNU+02xXhvKHHJ+ntWxC7SRYmVfMVuVA6GoNOspLa3E1xzcvlj83C59KtwgRxZXB9T3zTbVrGlryuEUQiMhLhyeSM9Kqs00gJicCMD05p3nx7m2IWkJw2TxUc6mOdhHub5eI1oBjLmZYxDOYRM2dpzjcPcV0mgOZZbgiTa0sasqnr8p5rk5baOZSZi0Tuvy54x9Peun8M2gtMylml8uEomeuT1NTO3KRK7TOhiVTAfLALdW5qGeBQikNkt0WszSJFe6nmjkIEoCsp6jFTJffapZYlDKqHYTjkc1k4tPQwtqW5FtGcxtOVfAYH0HvVWQQI/mRSF9rAFW4zVGeePTruaNYWeQDKM5++56Cq+o3kclhjVojb32DkI2CfTAq4xdxrzL0siXshEM5huIyQIj/FnoQKsWel6gliItYmErO2V44x6VQ8Msb+bzEiVSo43ghyAO9atxc3DLGjsCm7BOcBRTk2nyoXmUdZhkgt1jtxJ5m8bRF91h6Grc1nFNarHM2OjYPIJ9DUs6CNYwkn3ScBSTj602MqwaSaQsMYAAxU3dh8zepzWvaNczX8awO9sCu0On8XtWxcMIWgsY3ZriVdiOASMgdT6VsC6LuFlbjoGUZwKguoo2iIjEiH7vmDnFL2jdkwvd36mBp+iy2rSRXjxTNP1QHJJ9RVzxVpKz2O22R08oBhg9x1zSatog1DVIJpZpVMQBi8l9o9ya07Nbq5uZ49223QbVbru45pue0rj5n8jm9Ls4o7Bb2zyshBByTn6V1OmPJHZAtt343EEZ4qi0Ys7UM0TbISSMc/LUN1b3nkm507dI+AUQ9gacnzbs0vdamZ4zvV06zDmNDK5HlrjnJ71X0K7t5rSIysRMrEfU+tdB4n8OzXVhAblA5EYYNnlX9PpUunaZa/ZY4TGiGAYyooVSPIOEutzL1KSO1VNqgq3JrlJbhbiZ7pVm2RtgqcqAfX3FdbqyPP5kEckWQPTp71z80EkZe3eQBwmdzdG9qum9DWb8ymEkmjTdgq/zbepQ+tWLSz8uY+epWItkvnqO30rOs08qeGTewWTO/vvxwD7VoXpuNNmUQRG6SXljjgD0rV9jKLbdzp7eyAUEMHQD73FXYrNDE7nBVhyDXLxa0lwtvBahkCuA+1cDPpXUNd28EyrOJMP0GOKwlGSLnU5tijm0tZJWjt33p82Yx96rtu8NzCsql1DDoR0qvbG8nnlkeKOO3DHb6mmmZwzfPGBnjb6U9zCyb1NCJbe1vIZI0Ls4OcjA2+tS395Hb2/z78gbkmiOSfQEdxVq6td8cCt5ca7TgseWA7VkXWkST2oCjyiW6ocqBUJp6s5vdb1MvVbw6loxlvUWGNmIYoPusBwR9a8xMcUlnLpl8FYK5nhmXgg+n416P4lAgsvskBZyQH81+FPqQK82k3y3DJkFgCykDHNdEF7tzSik5cvRnU+FNQSfS7dJAIypKADtjpWoC237NMPN35zxx9K5fwyLeQQO8jK0jAlT2auynQwedKsqqSMKG6A05aMune2pIRJLDFDFF8pUptYZ2sKdYi+VZVcIwVSFx1PsR2qr9qmg2GB2S6JDlSMq3sPrXT2aQ3O+7tdg8zlwv8ACw6gis5PlRalZ2ZoWLiXw3YSwDEcXyMD1GOtY8n2qXW8J5sFnEo+Y4xIxrqfD48/R5A0exWY4T0rIm2SwmMjdubIx2rnhKzaMY7tCMYplItXVwjYZe+ax9dszOPMztIGBgcrWxYm3Ecqx28kBZi2SmAxBwTn3qlqwuRa3UghL+W67UUcsvc1UdJGkJ9zlozFNJ5C+YhgP38531KBi5ZdoIUbgD0/GpLq2gjIL7ozKflKdQP8apOJCXgBkKLyjKeW/wAa6NGarQtOAwU7Q207hUEOoSeHr1dQgG63Zsj5ckE9QasxbhCkhUhsZx3qvcgz4hWJiGG4k9M0rLqDVzV1zxbf6rp32jRsR2bL5bnPJb+lccieXNGxbc6MN+7nOewqa1huNPDQeVA0cmSNx6Z74qzFb29rgyHcepanCEYaRFa6StaxqpL5kswXaUVQMUxspJCY3ZF7xt/F7VA/72NDBIYstu6cmlujLyJADEoyrlsEn0pJFsgsoVtNXN5eZEm7IVOn416E0sL20Jkx5DkMnPU9v/1VwFwqPbRF5FS7kOVQ/MK6Pw5JLDbJBqh813mwmBwnpUVVzJPsZtbo6uMMXleErFu+bYx68daS3u5TfBVON+A4Tv8AWs15HW9kXaSm3IfufatGKKZYISFWMbt3J5rmasjJxsQXkgcuqwlpjIcc8VDcXN48CQDzM7MGUqAIh7H1qVIJ3uQwdCjEl2b09RWgYYzA9srMCFzvccEf40NqNhqxg20psrdfNvPNcKckrjd9PetjRtRRruKa5Cxqic88qD0zTFtba+gceSERvkV8ck+xqpDa2WluPOBWeQbEjGTlfem+WSae4tDvYbiGeASxSK8WM7lPasJLtd1xJNgRlWYkjk/SsKby9OnhEk8lvC+R5IztJPr6Gp7uVRaNLLNtjjGdoHIH9ayVK3ox04JXuyjqOpx21il0SzpIRsXoT7U851CyPnRBN3Vc5yKngi82FJHKSI/I4zxj0pQCjoVxHGOQMfMfcVq7WsjWLtqmefXlrHp+q7liHlnhtoAIH171ekMSy+Ykg+z/AMO7qD7mrHjKzeW0adI1d1HUDJGa5+0dxYrBcF5JH42lQpUfSuiPvK5o9Gakm4rKpVQG6MDnNJG52bVQsQPSoJBERBDE7KcdcdanuWZEdQcAd880xoa08RbONjr0Ip3nEKSPmbHUDJqtEXKFguCfUdRTgsi4MT53HB9AKLCt1K8j3Bdt4wp6c1I0Tkq7PwO3rUh3PJkMWK+neiVf3TZIDHkE+tO4DowjBygwO59arTS+REbhVOQcH/HFEamQR5LKqHgdiaWSCaMzyKzyHpjGAKWwmY8skt1coZLjLplvJYcSDtj3rrdGWW+s4E5tnTErBTyCOg+lcxDH5+qCGdGlcY2MV2gH6iu4tLYxyO0BPzKA31FTUlZWIS0ZBJNcMbn9x5ZU4QryX9617EPLpiedGYmYDKjhj7mmQwRxZlUMGkOXJ5BOO1NnMn2aSVZP3ir8oJ+8KyeuhmyxcW4bY0tum0fdK8tVC60u0vrpJZbdGeMZXfyatWzJBbxfaJJJ5AdzMgxj2zTry+WCGeTTrdpZD91WOSKSunoJ8y3GQAxJJLjDgYXacbR6YqvLbXLxBrR1lmAyInqa0S4njLXS+VMwzsY5/HNWWMu2PciIwwu7ptqr2dhXe5StRP5Qlu1CykYYL0Bqfcy27eYu4N0bb0NQ3kQa55kXzPQtzipl88RjOBH1btke1Dd9WILWeGKFiIskjBOc4+lNku2VQsbbGPzbM8t71KbeOCVXmAMRPIDc4pLnTbW6VrhASBhdz8E+goTje7DqNit55c3G7hflZR/KrsMFxDdws3yQBclc9M96htbeXTXuJWkEqEgIuOBVjaJI3muC5yQRjgk/4VMnf0HcQyQOZTEjMRyBnIY/SrGnXrWaqZ7fy3kPJPfNU2tLiaTdbDytvRi2Kq6lqEQzbyM8hjIbf3yPT2qLKWiHyOS0Otvlh1LSpVZtqupG/wDumuQ8QQLBbW1ta3YaTaAxB5cVTn1qW708xO/2fLDCg5JxWbaXlompbJps3JHChctV06TiOnTcdWQ6LbTjW7j7S3ysgGM5FS69ZvHNDtiMik8FeduKsaxmK8gaEMskgBLDpj0NLG8QvQwuH5XHlnoK2u3aR1NX2MIRkzQsZNuAVKhevPH0q9q2nzSWC/YpGDq351oJZxi4yjfuR0X3+veo9XsriQQOkjJCnzGOPq9Pn1QrWRHY6SktpEl0R5if3eOfWrGp3Z021RVUPhgAWOSTVSDWxC7fbbeSKA5Cvtz/AN9elXbjS7fULm3upH3GH5kJPAH070Wad5bGUpr5k2p37iGJYodzhQZdrY2j1qtbLCFZjK/zsWAIBwPQU290hrprhHkdVlYFnHAwB0+lOitHaJAkQdFG0MT1AprlS0M7HZ38Zk0oP/FExwD7GqLkrE0kB8kumdvZvX8av6mJoYCmAYZPmPoD6VnzxeRo5lkkWYN8gjbOAT2z2rCJxLY5TxrZJJbpdbliIAR0QEgrjhvavMlZF1G3bcQgJGT1HHX869ne1jjsrlmkkkkjUYjfkbD1GPavMPE9nBbQ2U0KlROjMB1xhiOlddOXu8ptSklJFfQ1ht7q6jZpHkRRIUK88+ldazKdNLSL5nGcN3FcZqW6LUrC+jLDdAEkA6EA8122npBdW6ywM3C7QN3y4Pr703smbXtNoilZyse1SDImAR/yzPuaXRNRljsLm3iXyrlQcMrj5mz3olnlRQrR8k7AE5BrNaVYoGCR5mjbGFGQCf50t0U1c9I0HxBHHKIblGUuo3rjlTjrVfWLn7FeDyhE0c0gEeQTkHkmuf8ADepeeRbXAXzidoIPIHpmrIuoWtAkk7SqZTHvK7WjfPGRWHJaTdhKMb+Zp687LHHKbsGHIVlHSI9vwJ4qW0upb3SYWlbybgE7lHUD0/Gq8sk40Z0uoY5Z0jZwUXhj2z+FVdLVbdWuLpyklyyhkByqkjjFFtLDUNL9i1qVqt0sgQbmC54FcwC2m+XHcFSgBAY9SxPAFdo1uLWdUjbbvX+HuKralZQ3agui/u2DKxH3D60RnbR7Gl7nHXsn+lDa+4xHBRG59xjvRbXTEsD5ik87GHT8afrGn/Z7jYYQDISVkQnc341DseKyEUEySsxwQzAke2a3TTQdSOUiS4VsMZGGwK3epYBGeSi7sYxmnLII4t8ithOOBzTGt9yoschVQd2BSKXkQpcB42ZlZ3U4VSNufpVxP9ItSXKxSryM84qrclpLpAZBGOgHTNWWs7tpEAR/IYZ3xjIb2NDaHbQhk32xiMAEk05wZN3C1oQH+zp1gEd1dPLgtJvyF9qjtbd4NoZY9rP+6Cjp9ae93BY3I+0ExpI5UnJ3MfQe1K99CHFbnZ27+YqSYADde+01euJoZyJJWIdONwPQ+4rgdN1S6S7mNuVay3/cJ5APU4rqNPhjlRplkyrnJyePxrnnT5dyLXd0T212stqUtZmZiSFfHA57VoC7IiPnEFimNr8DNU7GQNFGIkSNC52MBzx3ptzvluAn2aRwSWM+fkU9h9TUNJsl2LkN/E9vbxQMEOehXGz2quLqaWeT7XAUdTtRwdxI/pUybINwMfmMOCSOM0RtPEReySgQRAgxsvBPrmkrdBWsVFg1C5RBO9swLkuxU5Ydse9TXlxDp+2OaZELjGcH8quNJcy2rOSFV/u47elUpYleNY7qZZMcl5V5zTT7glYS1u4rmMiCZcDgkdRVq7ijkgwJAjop28c59aqRaLHatFJp6t5AJLqOhJ65p11aTs0extjrwyA5O33objfRlXXQrTRqzKD+8jKDJPBJ7muP1SySLUWumtnEaA7ZQ/X6iuqWSOzEMMeVeQkKCMqD6VDeWM8spOB+8B3R5yCexz2NaRlyu7NIu/unPRXIkiDtEFCjIc88UkywiNmeXBbBOeaJojby28SNuw/71VbJFSqoZWSfywzPwMVttqik7ld43O1Ivu980sFsQ25XcjoI/WpnSVmcFSka4w2fvVt+HYoDdqLhugyvsamUuVXG9jMi8P6hKu8ukIPr2rKvNIvradjNdJcWx4DJ0Vh6+lej3U0UMHmXYZowwRcDP/AqzZ2gQ3qS2b/ZnAPmRjdvz3A9RWUasuxi53ZxAEYt44wS7buWU9adI12sEp81xkf6s8jAqW6t/wCz9iR8ZkJJxzjtxVaSQxRMTM0rueoXJAra99UX01INM1O2EyN5bpKp4DD7x9hXZWcjvawyTNtZ1EhH1/lXnqSr/bMYZmQAnJAHT3rvoU3XBZHLxyIMqemMVNVWsTB3T1LbXA+zmaJmlj3DgHmrFykE4XcpK4zgnaR7UWsMcVqVhRAg+UA81YNussbFlDYHzeo+lYXRncakbC0ZViRI2IAAOTiqskiQ7TcHYrttUdzV+zMJtpN0jAA/i1QxTRyXHnSLuVTtw4wBx1oW4nK5Wkd2RwFZlQcbj0qe1KzwRrdbzEvVunPYZq291HNEAkLrIg5cD5R9fUVVFu8h3nbtAzhTwTRe+5JUure3t5zJC6yBvlVn6qfarQRJbeUsjyyrgnJxke1VJmtyqLdLJNsOQEXIFWLKaJtSNuqTBSoO/GAM9KuzsFwl8u6tXUIQ3AU5xtHtVyHYYC4iZigGEz1PrUkiq0jBxujAHKjG6o7azcXsssEBjDgKWZ+G/CouupVtNAtbO5leWS9MEVrwY9uS340+4vbe3YxQI7FxtDn0p1/dHzwrKu1Dhk96oz798mSSSPkIXj6UW5tWEbdTH1O+mt5BHsldSeQrdKTUwsCRF0YburdSK0RbKY2Bk8ueXBVfSmW33khuU81gxfbV37I2ukro56JJY08yZ1Mmc5AxgZ4wKmsjGLhpnhVpJG++Rz9a2pLiyvPNRLZVmLbQe4rAudPfT75pkYlHHKg8A+tWnzaS0GqjN27sXlVJdu5V53Z4rPe0ZLrAC+VtBDkc1lal4hkgK2cZJkYbh/dX3NPiuZ/Igjk1Jstku4Hr2HtTUZLc0g5PSxqXlz9l2QxQPNuHzFei+9UdJeV9dhs/tBw6najjj6A1PfXtkbbyIbnEnC7lOSTWdPaXFpOq29yUlIz5kjcCiK6MJSvF23OjbRGtLae2uH837QxLZP6U238P3tvcrBFbzrEygB9+V/Wsu3ll01Vku2uLm4Jz8p3Z96699Su57NVWUxRbQ5d+CB6Gk3JbMwkns7FdPDd5IiWz3vkxscsSMlvbNWx4X0y1+SS4nyfm5kx+lV4dY1QwuJntYzjERfqvo1JHpt1dRJJe34mmIxuA4x7VD518UrGLUn5I2ppJkIeMb7VjhkI5T607UdNh/s248tTh0ztzkZHORUltIN4WKXeH+8rcZp+pxs9qbS1bEpwACcce1Rs10OW9tDnIbd5L8NJMogZ1BB+nH61wPjBoxo8dpwt/ZtIrN6xk/rnNelavDHZoySqrbURwn9/HBryrxfb6hJqHmaukcUMvMbLncuOgPrxjNdFL3ncqD95HFpqMttqmnmZN0L7ldjyMHArt9GH2OXyt++Mxk5zx1/wrg9Uikls2W1bMolyYSOvHOD610fhTVoZ7dElGyWL5dkh598V02vDQ6JytWaZ073PklfOZcM3ylR27VRMsU7sI0k7kNjA/Gr++GdsoA0eNwYHP/wCqs+8jZyXVgGjGQpbCk+9Zo36FK2u/JiGVHlbsb8c59h3rq9DurS/srm2nVpDI4y4HzE+v1rlLu5jUMpOPlwVA6n1FO0TS7kK62azrOemwFlBPfNOUU1roTu9Du4b26traSB/LimjQhXcZQj39eKsKYRZnUIJRJpMoXzVVcmNwex9KxdN0TV7y0kt72OZJ1kBSXHX8/Wuy0jSLiztBbzxqzMoDqgGz3GPSuabjHqDlZpkHmJdqhi5li6MOd6npTJIyYQHyuTzUGp6PqEErS2EbKqZXanINZlxq2p291YRahYm3jHyyFudw/pRGKl8LCaSs46mneWKyL5LjjOzOevuK4O90ybRdSeGNR5fJEh6rXolwzeVEbdllTGcetQ30Bv4ZQAhuAAQW6rThJx9C077nntveJ5YN3cS8sRuZeT+FWYRFbg+WhQMRkls59/aszU7W+g1Ui6iIhQ/Lg4Dn1+lEsxls3WICYSNskVOGArosmJOzsatypmjH7mNuTtYHO33NaXhy7SOJIfO2xA/L8xAZvSqGmSWYsXt45gs0QAORnB96Wzty9z5uoS20YRh5RCHcT6+lZys7pl2ejOlWWSd7jzlhSAfcAXLD61k3SPOwVoF8xB8jFc7RV7TLSPUY5rjTtRDxCTYyzDy8N3A9auXWl6gksaJjeoLhVYHev+FY3UXYcZRktGcrPFIhuFjQrG6ZJTAZvapvDuryWdxumkjayzgqT93HrXVx+GtSuki86O3hhkB8wZyw9wahuvh9E1gYEvYxKXyXcZ/CqdenblkzKUlfRmwVt9ShMlm4w2CNp6elSHiDaThUxvwOp9a8/ji1TwrrAtwGNuvzGUDKv7Cu003UI9Uh8yMr5qnLJ61lKHLqndBa5opNCsqR5O1iDg46VX1kQFMxwyXMjMAsbPtVfc+v0qjcJc3l5EtqI44gDmdh8yY6qR7jvWokti5hjilLSlchSuMVHwtNE8pCC5j5LKEGSF5J+grHuTeapZ3C6hB5VsZAYofuyMAf4j7109vbtKRsYc87if61Heq9uoBUySsv3EG449aanZ+YXWxyVjqWoQ6nLZwQ3EkTMGORkDI6A1rNYyQ3rXTMyXDjDDPb0NLE2oTMrzafPaoxwvGWI9TjpVA6jfjXGtvsUj2wAxI/etG23pYEl0LpMqlpZ4gUAyCi5OfYU+1lZrcO8TRjrtb71SyagLeCRpkl8oYJwM5+lSwSGUklGjQfd4qXtqilozlr+KAT+fZsGuJQThhgAd+PWs+4aDYsUKHzDySzYx712aafZiVpyFYAkADsTWVr/gkS+Q1iVLseGJweev1rSNWKdmN1FcwJI5CiyXDYSPn5G/zmptMN39vBhw9vgFlYYOPXNXtU8OTaHHGZJGuUI6k9TRpaO7FpovKheP8AeDd2quZON0VzJrQ27q4d5oEiCCzIIn3Hn8Kqq08FygjjElvK42FDhkTHJNV7y6SzRBAhmDfLhecL60OtxNc2zWso8qPiQdmX0H0rC1tyeUo68oluLgwr8qfKCBmsvT9Mmkt3Ox1lIJUkYJrpbqUpPAbVlS3disoI6+9Qy3MwnR7WISwltsjFuQKqM3ayKuc5NotqjF5YnMoTl93ANWtKuHt5hbjd5bDALcbvYVa1hleFs+YkcjFVKjJB96w1nmjQMUUvA4AbOQRWqvKOpGiZ1sJwuEkkeKQ/uio79wfpVi2mk37ZW27R8xPf0p0UsLxJOi7YZQH2j1702CAXLMUBz2B71hfuRJ20FlWVJgy8RMw3H0BqfUZoILjY8DhTyp39fetGHSI5YP3zNuYhiPSpZNDhuFYTsS38LDjAqfaxvqZtx6MjtY7jULOTKjyHTyypOMj/ABqHTrWeAmOPA2rsVnH5Z96vaPpU1jMXNwXjAwqdhW0Y1dcOob1zWcqiTstiOa2hzktnIv8Aqk8uQDdIwGVFMjsLq4tkZId0j8FjxxXWKvyjjpwRT1AB9v0oVV9Bc5hWmnXkcDf6s9PkPOari2vn1B0aMrAq5DA5+b0rqQOwp2zn/PFR7SQKZyknhtriV7l5GjlcbT3yOxq1b6G1vbtG1w0x6b2GDXRAcU0qQM4weuPWj2s31DnZ5vqmgX8Vx58G0yMwB35I2+3vVtdMPnSPAXjfy8YPf15rt3QAcLwOx5qB443IJUFsY5q/byasyvaHnS2YjmkmnlO4dEA5NTqizQkyDKL7ck+ldfLodnId23GT9RViLSbZWXKDCjAHarddNFxrJO7POjosmoyMRYMFXoxXg+9R6roMljYebMjYxyyL92vWERY1AUfL7U2eFJYykiqyNwQan6y77aF/XJX0PFtNj8+UR2unq23BLngk+tbE+nzMC13b5CchT2rpPEvheOWFZNNP2a5UjocA1jiy1+N0SfdMrDaSOa6VVU7NOxUatxkKhQSpC474zSvcmceW5yvfC8HFbEelXCQhXgbPdlqS30nZCzSwfMCcZPQeuKSnHcbqIxILhLqCRYU8/koSB3+tOt2ksIEtmlMewcBjk4qOzvbhc2i25QBjjauADnrU17K5n4g3YAGcZrS3S2gm+rOvtz9puJoyAYQoZTj7pNT2gP2qYFgQAPm+nFRaRG0cQZl4cAH8KtuBCwcIzMeNiDJNckmtjzmyjqsIaW2Z0+Qlo2HsRXA62E1OO9sLnBeBV+zEjk46/jivTbmFZBkj5hgjHfFcH4gsd9rbTRsxuZNxKKueh46c+1a0JK9mNPseW3+iDS2S4RGvNOuR+9GeV9eex965zW7aK11REiLmB8TRGUYcjpj3r1HTtO1eRJY4dLmSKU7ZA3fPVhmuu8NeCobW6gvdURLm6hUrEDgpCD7dzXS68aN23c3qS54JvRo5bw54X1C5t1kSDyoZlDb3+XGfatrSvh8qvLLqk20HKBIzncnqfevRlTC4IwPalKAkZXkcCuKWJm9tCXWfQ53RfCmi6eN9paqxA4aT5sfTNbdnBDCzRwwCPacnauA3vVkjrxT/ALoBweOvcVi25PUhzk+o0IAvI/GlC5JyMnufSn9R6g9aZkcjg+vNSK4hAycDnr1okhikA8xFbnPzAGnDjGePrQ2Nx9frTsFzK1bRY7wRvA/2eeM5V4x19jQuhW7EyupErcMynAP0Fa2R1IIyM4PUUvbvn0p88krXNPayta5yWoeENO1EhZ2mEq5CsW5+ornp/hkIQ/8AZ940bE5JYZLfjXpjorAgrn+lKVHcf/qqlXqR2ZSqyPHp/hzq8dlNFFPbybjkDO0/nWZqHgjxNcPaKIIlhtjwBJ8zj1Jr3MAduKQBRliMGrWLqLsV7ZvRnir+E9V0e0kVIGnVm+0Eg7ljb0x3rTF/d6TGpmZoHniIiaRec+gJ6V6ttBDfyqvdWtvdDZcwxSqOgdQRT+tN/GrjjVsrWPLNGvNSgs3nvbiTa5LEO3C+30qvrd+wtmnV3cuo27efxr0+fQNNuAwktEYMNpAOAc1lQ+CNPghdIZLjaTlVLZCj0HtVLEQ3a1N41oLSxxGkXV3Jpd7b3o+0fZYTLDPIfuseoq78OLNZbC5Z0lVIHEvmDo/r9RWzH4Lu7O8jm0+/UKzZdJUJBHcV2NvZJHamI4G8YbaMD8BRUrxs1HqZSml8LMbT3tr90kshvjc5V2HGO/FJfaLGdThZYpMFuGU5A+tbVhYQ2aBIkACghMDoKsXEC3MBjfeFcYyhwR+NYOpr7uxKquL3OMuPEkf9pGy+zmMxybSCQfl9cV0gVo3M3ykMflCjJxVQeFNO/tNL9oyZRnr3PvW7FbIjs0Y5PUHpTnODsooUpR6FR9QiQHcHD+hoNvFeRfvIhtJzip5rKJ5xKy5I4HHFOS3MeFibgnoegrP3ehF10KEWjQQyB4yzA8bGORT7fSreCWaRNx3/AMLcha0WOCik/Mx498Up+7yDRzvuHPI811Mtp6XizxPGoctvTkDPNLpkX2myUWutLLKSHVJv4D6VseLk1CHUre6TbNpIB+0Qkc59vWudgun1W6uI9O0WSBFA2Ntxu575rsg3KN/6/E6U1JK6L/iGa9s9KkXVhFLaykLHLH/A3v7VkaZYQyEyNcPMoj2M27I+hqtdXbyarc6WRPHGY8yxy8oG9B6VV0MR2GoT2KSL5chGI+dzcetaRi1G3UajyrQ3Gs2h0oQaeV3Fs4Y7iKszTtawxqsSM3CkJ1HqaoTXqC8eBSyuoB/4DUFzdTJeSQCVZbYLkMh+bPoankb3LsWruURzFAodTy4z9361VgW20u1keBHneQlm+Y4HsKjuJRbrJ9rUYdNxZDiqL6pGbEyWEm8KudhPLfSkoMba6luK9NxZu7Q+XvJwhHOKxJZYobCeU24iaQ4dM5yP8ak0qdpbmRpHdVddyJsJA9vrWppPhybVL77TcI9vbM+SHPzPj27CrvGF2zJvQ6HR7YDTrCNI9yhcf7tatraQLOVWR2kQZIHTB7VegiSFAiLhQMClhiSL7i4zySO9cLqXMJSuTjG3p+dSg88D9KgQjqcEU9TlickjrWVzMsKwB9/WplzgY6/yqoG6/wAqkDEY9+tMRbUj1p4Kn2qsknAx3PepUIwecnsapCLAwPXI7GpQmfmyc4wMGoIzk4xjtVhcZx+lJgKBtJVh7daac4BYYAp5GMA5PsaRycYXr0+tICCVQUyDgGqLybXC469zWi+XGMjpULQoXGR09RTTGmQnHGOmP1qRQSOTT/KAIJzyeadtC9OvTmhiAjOSenfNIV3Z2k+/tT+p2jkmkI5HYgcCmBBJEsgIPQ9qS2txEpUHPOfpVrGcMBx1xRhs56kcmgL9CNF4yQKbLbq/U4OMZPWphwB3z1JpeOhzjr+FFwuY19o63IfDbM/3R1PvVGHQLmNNoukAz0Yc105wF96QJno2PYitVUktB87KasAvPQU8Hg8j6YqKOEKD87Mcd6nAwDk8+tIwGjHQnqMYPao/KRSGjRVxxnHSpsZBBxg9u1IxVAxdgqD7zE4ApDuJszgZpyrx0H40qZA9v50oAJDfr6VNh3E4A9CaccgcDJ9KTgkHP4f0oJ5OcDGOlOwXFHAzigdcnt0oUgZ4PHrQuD8oJyKLAOJydvI/rTfl5IwT9MYox2JOOfwp20HOPxpDuNA3N6jqKRutSFQW6cdBQQPoe2DSGMHPHTjilBzye9KQcc8fhQpA46D09KYwOc4Gfc+lBIyAeO+R0oIYfX+dJ1BAAGelSAclhnke9OwM8L1FISMduTSY+VduTzQMF4I9TnpTdvGSPzp7ckkHHrxSHO7kfSkMaTtJ7/Skydo4+Wlbpx06H2qPPeiwDskgfypwY7e5JqIjn0Ymnq34E/pQMlB4BBBz1py9eDjjn2qFGO79KlHXrtK9PegCTHAGcYPQilGOp5/GmJjbhQQoHSnHIPH6UhAc9/WkYkEY5J6e1KzfkRSHPfB9KLgN4GDjcfpSOw53ZpT17UmPu5JH1o3GV7qBLgKrdN27FPjQKo2gDtn1p5G04P8APvTlUZA45PU0mO+hl32j2V4HM0CebIPvgcn61yGo+Dp45I5dOkCvE+5Q3OfbNehsBjrx0pskYI6GtYVZQ2ZcarjoeZ3FrezS4TR2iuc5Zi2VeqqaLcx3hlg06cyv1ViFUe+fSvT5FB+8MnoKryqBkjg/yrZYiVtEP2vQ80n8KalO21jF5TYB+fnHfFXYPAmnRyqZHmZFHyoDjGe2e4rtZBnqMe9QTMFU7gT2xUOvUezE6jZQSG3tykMQiV+ynriraMp+5ziq8lrFNKskkYMq8Kx6gVKgVCSBjmsmS23uSFj0PrkY7UoOBn+tRrzgDj6UpIyOlIkk3cYx154p4bsTx61ChHIBz9acGxyME/yoC5PuG6nZ5H1zioAzEdPc0/JwewHFCEWVbn5ucelSo44Gf0qqG7jn8alVtoP14qhF1G5AznPbvVhW4AJH1qijYAz1qwr4GT9fekwLIbI69elKDxjP6VHGTg+h/OnnAzj8KVhCYyCARQeT0zj04pTjd0NLnkHHTuKdgADA6ZJ6800rngc07IPf5e3rTeQQD9c0Ahp7cf8A1qXAzxz6UEYG7jPY0nUYz74oAdwDzmgKM5AGe9HXOPwpCTgfnincBw55XNL156jFIBnrkDkUbiOCc/SgQh68nimeai8NIqn0LYp3puGTim5B/hB+ozTAg7A4P+FOLAZK8jpTQTnGTx1xS5JY569xWjMhTjcD0FJkNncufbqMUuD7Y96Qcnpk9MUgHDA+XPHXrRg4wDSEZ6jI7jrRzng9uABSYxeo46elAY9QOnGDSY6jv+eaCMqOeM0hjugH8hTgMj61Gx2qTgkHAwBk08jOOeT+VAwBIXH6elLjJJ6Hp0pcjgdCe/0o52gjj0pDAZx9fwp+eRjuO1NB4zwfel6qeRzSAU5wGHP1pDjk549xzS98k9Oc5pGbklu1IYhPXH4nFIBkj370o4U46jrRx3A+lAxp9+tLyTg5A9BQO4Ofzpp4ycGgBThMHBBpuSG6/jTGby5W3fccjnPQ/wD16R89e/Tp0oQx7NnaM4Y9PemEAMcGlzk57Ypmc9DxjoaBigjDYxmnKTkZODTVPH9KcPQ96AHLz64NPUbsZPHtUYJzjgE81InAywxn3pWC49SSeOfWpBgEdCKjU5I47084yABg0hA3LH1+lI3HIBHPSjOARg/40g5PQ4HOaBiMu4EAkY6470uMjtk9aMkt7Hp70AAgnv296AGv6tnHalwdnbJ9aMnnBOfpSY7d/WgB3bDdfp0phIxkHg+lPC4yMZHfNNO0gAY6cZoQEMhLPkEHA54qtIMZwMn0qy3fp+dV5O4B5IqgKjkg4JzxnmoXxg7eR71O4+hqu+FGAf8A61IZE+TwaiJ5Of8A9dPPIPQ/WmN83+FK4DQf7vfmnAjP/wBemnrxwaaH5IzyKEK5KpyeOtPHI47VWEmOBTw3B5/GnYLlhfmb37ml3e/NQBs88U/PHH5CkBYDkAc8VIjZxzj6VU3Z5GBipUcEf0q0IvxON2R6d6sx9M9fQ1nW7HB3beDwR6f41ejxjIzzTEWEwSCKnQAknIzmq6nHTj2qZMcAfhx0pNASEdDgfXNM+gAUjtS5B4Y4xSNk9MUgEPTGBxSA8gnHpj1p2ckED6Ypf5H3oEN6tx685pTxkA8+tKQc9OO3NAA3BiOnf0oAQ8LjGexpAegHQdqcSMnr60n1GfqaLCuIQOcD3xQDwOMc8YpegyOaQ9M54PamAhwcAqeTSMOex+ops/nLHm12Fwc7W6MO4z2PvTuOeKYXIP4ue9KMgY6d6QYGN3TrTmPPPNaGQnOOG69KFXauc5x6UhYBsNgMc7R3OOtPzz8p59cdaTGIOB0JB557U7ucj8TQB8/GcDnrQcEcUAIuR9CKO3TjtTunfHPSjJJORnntSGCgZHTHpTlHOPX1pvXB557etKBxkZyeaQxc46HJNIep2g80oPBxjPUUmemc5PoaTGKck456UA5UccDpijOee9IT8vHA9aQx47HpSdc8c00ZOOuOnFALdWGG+tIaHHjGCeRmlPPt7U0nIyenT6UdsA89KAFZhgk8Gm/w98e9L069v1pvPOMf4UDG4yOmfWkI4wenSnEdeSB3pjnGSc49hSGN5XPb6DpTeDgE4x3pW5+Unj+dJ7kZGe9MBTgnP6U4EZBHehRk9vYYpcDvSC47J+v0p/O3oDxSLnj5SKcAcZAxQAucEAg4HWnFmJyMkU3jb6gdCKCOP/r0gHgnjnPfFJzz1xmkzxnBA60cDjbRYAbGSeTS4weMnjvTc55GeOCemaXtz0J6ZoC44crjGBjAxSbfvHHJ6nPXFBOGyWxninDpQA0DOCOPrTX6/TvTmHAUAjHeg4wC2cfWmgIG6YwM54qtJyoz0H86tMBnnA9KrvjqelMCpLx0xu5xn1qs44wQc96tyjCjjPOelVpM+tDHcrkZOKjfjBPSpG9ORz1qCQ9O/FSK4125HPHpmogzBuuD2pxPbHFRg4OM4BosFxxznH86VG/hzTD7Hp60q8Z7VQrkyt0z0NOUkHj8KiU855pwJxwfwqR3Js54POOoqWIEnBx7VXXk/Spoz71cRFuMknr0q7E2QM96z4iCMHvVyA5GONucCqQmXU5OV/HnpUgI59/aoo2B5A46kVMc7jt5x1xSYh55znrjv2oKjb169aQDnOeD608ghhgZNSADqFHI9KCPqPrTsAAdRSAcHJ/pQAcBRxgUEAZHA+vrTjg9ST7e1M544Bp2FcVsLjHTrTT7kHvQDknj8aU9WHT0xRYLjd3OR+frTWOeRk54px6+rD0pBx3wSeKdhXEJ6kgccUmD6g0mfmPPX9aGGWOM4+tFh3IB/CRxSAbVxvZgCSdx569PpQqlW+8Tznr09qce+cZHetDICSMHFKcgDPT+lIeM8Y9KQjqMkE0hj1I7dKCOGVWIB/iHUUo4UDjbjjH9Kd0I9PQ0AA6njB/lTRnAycgnvS4GCN31pQuB1P50hiHIPQ5pWG5cEArkEj2pT0zk4pBn5T0z7UmMdnv+NJyCcGggnOOgPYd6QYPI70DF4PXr70jDIzwc9sUHORxn60gAOckcGpGBxk5+uMdBTsA4Uj3B70zeoI5A/TmnFsMcnJFJjFOC2MYz60uNuAAMeuf50hxg5z17dqccAYBwKAI26njI9vWlwAfX6noaAR0B49Ka2AuBnb/KgBTuDc8knj3prckkcc0uRnGPbNDHCjb1FDGNAOSRijAPPUUDAIIBHbHanAcAjH4daQwUYPHT1p4XHYkZo43AfljrSsuWOB0piAD5sDFPA+YkdMfnTVOWz2zwfSnrjqR2pWHcRiO1IVyPlIyeTRuBIyc5oIxx26nI6UAM+6cjdg9QTwPpSliD7n2oOSeSaQAkgdCaLAOH15PqaFyOW4JppwCCR26mlGWByMgmgB5AKndgr6EU484z0FMyCOccU9ckdTjtSAQnC5GD7HvSN0AwSe+RTzz657A0wqAcFgT3phcibAzjOB1qCRfXn0+tWmHBwO3Sq0ucYAAHb2qhFR92QDyPTtVWXjvwKtzYA9u9VZuOhI+tA7lSQ4IAPB6ZqF+nbNTPnHIAx0qvJ054FSBC3y9Dmmup4p+eg9elNYfTHoaAEJx0xj0xTg3zDjPPUUwDt6elOGd3t04pCuOByDzgU5WOee9R859/Sng46ce1MLko6jJx71Mp53dRmoFJ24x+NTKDxyCO9NAWIzhiMZz2FWomwR/KqkYHGCM/WrEWQRx9SatCL8bZxtPGasKeQPwqnExDA56cZqwhHoaALSMOMnvSsQRyQo9aiU8AY5qVQB6EZxjHSpaEL9PxpeeT6etJnnGOc88UnJH07UxDgcL1FIR7cUnX1x60Hkn+HPcUAAJxg8fSk6c4NO/h7D8aaRjPP+fSgQ0sATjqPypgOCPrkUpO4DrxUexQ7SKF3NgMfXHSqAdgZzkbu1ISScgE/pR0TI7cfhTS5HH8qaQriD6/4f8A16MYznkinBTj69D2FIcDoRz+VMgQAAbR+HvQo/Mnmhhgkj/9VKOnB60AIrEOVIOAPvY4/P1p4BC9c8ZpFJyOMD607n0z7YqRgeB7epNOUY4HJx0P9aUYHXp7mgcZJHHf2oGM9gMH1pRkcHPFPHB6D1pDgHnB96BjSCF4JOPfrRj5iCOOuc0mOee/TH+etOzyc8D1pDEPbHJokwIzv+735xilIY5wM96UrkgcDP40hkaqNvQdOhFKg2jaowBwKcAF6mk3AkDHHWkxi9xz9KM5xnnnjPrQeQaGAz0HTFIBDzzgDFB/TvRuJHAwaByMdv5UwG8gfMOB69aQ8gEfSnOCcdeenNNx35+XtSGIV6cHntT0GG9e9MPOc8HqaVcFyM8ikMU4J4GPenk/UYqL+IdM+/enN3AbHYn0NMCQEcY57dKdzx3HuahjLBfnwWzg4704DcO2F60AP6Z9+4pNwDAEc9uaYcEZX6GkBGCQPqfSgB6tyB6+/WkzgZyfxo479expqIQzF23P2wMAD0pAOP489qUEAZY/jTRhc45pQOxwe31oC5IAD2B/Sn88+hpgwfqeOaVWDKD6UAP64wckevakPzcY560h5J6Y7YoJyAB+HpQhDCAN2ePeoip5OeKsEHAGBzUMvIOeM1SApSDPOehqpIATn8KuyAdMZ7ZqrIAVx29adhlKXpxn8qrOOT6dzVyXHAHXHbvVWU9B09KlgVW+8AATkZ9gKSQhOWyAO5qVxuPoexqN1BDBsHIxUgMxggY5BoAO7I/OlUY+XBwOMUMgcKGz+BIpiAkK6ISNzngEdcVKqkkZNKoxggdsVIF29cnjmgBVU7uO9PTnqAB9KRR13cnORTxzg/oKLgSJjGfT2qyvUZ471WTn+YqyvUCmmBZjPA6fgani644BHHB6VVTlSV/LFWEIBOBjjBNUIsLwMdx+tSpk8c8moUOTk1JHnn9fegB8m/afLAL4475oDbkDd8dR0oAxjngUKCkaqOMfpQId6D/JpGcAHd90dcUnY8c49elKCdowenGBQAjcAe1GflI/Ogj7wz+ApuOflxtpiDjdkDC+o6GmEYGP5d6a6bnVsuNucAN8p+opWPAHrTEMJJGQOehqJnXPzHk+tDE5HOfb1qF2+Y96tIRbwSM8+vFKevJ56CmqTjrSnjdikSA4B5yPSg4C/LwTxQOfzzSrkE8nsaQxRyevSnZ+br26+lDnb93AzTD/AHT0NAEm3584GT1pysABuGARTdoDDHcf0pT0x7ZpWAdkkArgH0pGbqTgH1oxgt9BTSfm6DikxocDg+mKaPUYBoLEHjHTd+NAJ2jPPzYoGOAGQen0oyAfak64BpjN8p6DDYpDJMkKSenvTAQRwDS5IwR1pCPn29iKBjsg9Bz70KBg8D6U3G2Qgd6WQkYIPJqdgDPXmmsdvLEClJI4HpmkYnGKBg2cgkDPem9yCRk0p5257gmkz8ik07BcaOODQM85wcUudp470N8iHHOB3pDHZ5OBk45NGMDPFIeAPekHGcdjT3AcCccd+9NKqWRiudp3KfQ4xmlP3yO2cUwsQzAeuKQXJG+YHOR9Dg0o6jjmm5+cDqCKD9w/XFMCQfeIP3T09RQMZ7kj26UmTyaVTnn05pWC4YYjoOaACOo4PpTX/wBW2CQSvUdqQMd4X2zQBKNoHXntzSqcccZ96YwHP0pEOI8jrgGiwE/QdenemqTt5AxnAGc0A5H1ODR3UepIosK4rHHf2qKQDPzHp+tObgH64pGAycjoKaC5WfuAOaqSAjA64/Q1ec9RgYqs4yM5OasCjIPQ9BVWRcjB6dcVbkhBmDh3AXKlAflbPqPUVWP3gPWpaGmV2XrTGB6kEe9WHGJMDtUEBLCTcc/MR+RqbBcYAaei7R9KUqNy445xUgUFh2zzQDGjryRinDJPPANKRgZHUc04NgYGMUWFcOuQRTwp6ClAzxk4pf4gPwoC4q8EDox9KnQEnAA/Ool5YggdKmUfKT3FAE6dT/OpoyQRnp296gUntx8tSxnD465GeapCJ04IxnPWpVx+FQKSIz7Gpz39PSgCYe/H9KCPbrzxTR8vA9cUZPTPtQ1YQN16jPpRweCOOuTSMT5ZbvkD9af/ABHvzQgEc7f6mmt068559aGOEHcehpM8DPfrQBGxAbOSMkDp3pjDkkdAByKlf5eB0xUDnLDPPOKtCZDJgEnPJGKqyElu1TXB/eAcc55qnjOeT+dWB//Z);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Partial thickness epidermal dysplasia and a mild lymphocytic infiltrate in the superficial dermis are present.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 524px\">",
"   <div class=\"ttl\">",
"    Actinic keratosis",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 504px; height: 327px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Partial thickness epidermal dysplasia is present.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f38_20_39241=[""].join("\n");
var outline_f38_20_39241=null;
var title_f38_20_39242="Antiplatelet agents in acute non-ST elevation acute coronary syndromes";
var content_f38_20_39242=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"6\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Antiplatelet agents in acute non-ST elevation acute coronary syndromes",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?38/20/39242/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?38/20/39242/contributors\">",
"     Michael Simons, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?38/20/39242/contributors\">",
"     Donald Cutlip, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?38/20/39242/contributors\">",
"     A Michael Lincoff, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?38/20/39242/contributors\">",
"     Section Editors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?38/20/39242/contributors\">",
"     Christopher P Cannon, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?38/20/39242/contributors\">",
"     Freek Verheugt, MD, FACC, FESC",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?38/20/39242/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?38/20/39242/contributors\">",
"     Gordon M Saperia, MD, FACC",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"mobipreview.htm?38/20/39242/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Mar 12, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Rupture of an atherosclerotic plaque is the usual initiating event in an acute coronary syndrome (ACS). Plaque rupture often leads to thrombus formation and persistent thrombotic occlusion results in acute myocardial infarction (MI). (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?25/7/25721?source=see_link\">",
"     \"The role of the vulnerable plaque in acute coronary syndromes\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The role of platelets in thrombus formation during ACS is discussed in detail elsewhere (",
"    <a class=\"graphic graphic_figure graphicRef81908 \" href=\"mobipreview.htm?7/17/7446\">",
"     figure 1",
"    </a>",
"    ). (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?29/9/29850?source=see_link&amp;anchor=H2#H2\">",
"     \"Congenital and acquired disorders of platelet function\", section on 'Normal platelet function'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?4/4/4167?source=see_link\">",
"     \"The role of platelets in coronary heart disease\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    This topic will discuss the use of antiplatelet agents in unstable angina and non-ST elevation myocardial infarction, which together are referred to as non-ST elevation ACS. All patients with non-ST elevation ACS should be treated with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?24/7/24698?source=see_link\">",
"     aspirin",
"    </a>",
"    and a platelet P2Y12 receptor blocker. The use of antiplatelet agents in ST-elevation MI is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?34/49/35610?source=see_link\">",
"     \"Antiplatelet agents in acute ST elevation myocardial infarction\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     CLASSIFICATION OF ANTIPLATELET AGENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Antiplatelet agents interfere with a number of platelet functions, including aggregation, release of granule contents, and platelet-mediated vascular constriction. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?3/32/3594?source=see_link\">",
"     \"Effect of cardiac drugs on platelet function\"",
"    </a>",
"    .) They can be classified according to their mechanism of action (",
"    <a class=\"graphic graphic_figure graphicRef75709 \" href=\"mobipreview.htm?28/48/29440\">",
"     figure 2",
"    </a>",
"    ):",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?24/7/24698?source=see_link\">",
"       Aspirin",
"      </a>",
"      blocks cyclooxygenase (prostaglandin H synthase), the enzyme that mediates the first step in the biosynthesis of prostaglandins and thromboxanes (including TxA2) from arachidonic acid (",
"      <a class=\"graphic graphic_figure graphicRef66146 \" href=\"mobipreview.htm?33/29/34269\">",
"       figure 3",
"      </a>",
"      ). &nbsp; &nbsp;",
"     </li>",
"     <li>",
"      The P2Y12 receptor blockers,",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?34/9/34969?source=see_link\">",
"       clopidogrel",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?34/27/35255?source=see_link\">",
"       ticlopidine",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?26/63/27639?source=see_link\">",
"       prasugrel",
"      </a>",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?38/0/38919?source=see_link\">",
"       ticagrelor",
"      </a>",
"      , and cangrelor block the binding of ADP to a platelet receptor P2Y12, thereby inhibiting activation of the GP",
"      <span class=\"nowrap\">",
"       IIb/IIIa",
"      </span>",
"      complex and platelet aggregation [",
"      <a class=\"abstract\" href=\"mobipreview.htm?38/20/39242/abstract/1\">",
"       1",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Anti-GP",
"      <span class=\"nowrap\">",
"       IIb/IIIa",
"      </span>",
"      antibodies and receptor antagonists inhibit the final common pathway of platelet aggregation (the cross-bridging of platelets by fibrinogen binding to the GP",
"      <span class=\"nowrap\">",
"       IIb/IIIa",
"      </span>",
"      receptor) and may also prevent adhesion to the vessel wall.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h1\">",
"     ASPIRIN",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?24/7/24698?source=see_link\">",
"     Aspirin",
"    </a>",
"    has an established benefit in a variety of cardiovascular disorders including primary and secondary prevention of coronary heart disease, transient ischemic attack, and stroke, and in the acute therapy of patients with an ACS. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?36/12/37066?source=see_link\">",
"     \"Benefits and risks of aspirin in secondary and primary prevention of cardiovascular disease\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The antiplatelet activity of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?24/7/24698?source=see_link\">",
"     aspirin",
"    </a>",
"    appears to be mediated principally through inhibition of the synthesis of thromboxane A2 (TxA2), a potent stimulator of platelet aggregation (see",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?26/35/27194?source=see_link&amp;anchor=H8#H8\">",
"     \"Overview of hemostasis\", section on 'Platelet aggregation'",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/20/39242/abstract/2\">",
"     2",
"    </a>",
"    ]. Since platelets do not synthesize new enzymes, the functional defect induced by aspirin persists for the life of the platelet. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?36/12/37066?source=see_link&amp;anchor=H2#H2\">",
"     \"Benefits and risks of aspirin in secondary and primary prevention of cardiovascular disease\", section on 'Mechanisms of action'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Evidence of benefit",
"    </span>",
"    &nbsp;&mdash;&nbsp;The Antithrombotic Trialists' Collaboration reviewed the effect of antiplatelet therapy, mostly",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?24/7/24698?source=see_link\">",
"     aspirin",
"    </a>",
"    (in doses ranging from 75 to 1500 mg daily) in nearly 200,000 patients [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/20/39242/abstract/3\">",
"     3",
"    </a>",
"    ]. Antiplatelet therapy produced a significant 46 percent reduction in the combined end point of subsequent nonfatal myocardial infarction (MI), nonfatal stroke, or vascular death (8.0 versus 13.3 percent) in patients with unstable angina, and a 30 percent reduction in patients with acute myocardial infarction (10.4 versus 14.2 percent) (",
"    <a class=\"graphic graphic_table graphicRef56243 \" href=\"mobipreview.htm?42/34/43564\">",
"     table 1",
"    </a>",
"    ). There was no significant difference in efficacy between lower and higher daily doses (75 to 325 versus 500 to 1500 mg). Another important contribution of this analysis was the finding that the addition of a second antiplatelet agent (eg,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?40/25/41366?source=see_link\">",
"     dipyridamole",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?34/27/35255?source=see_link\">",
"     ticlopidine",
"    </a>",
"    , or intravenous glycoprotein",
"    <span class=\"nowrap\">",
"     IIb/IIIa",
"    </span>",
"    inhibitor) significantly lowered the combined end point.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Dose",
"    </span>",
"    &nbsp;&mdash;&nbsp;An initial loading dose of 162 to 325 mg of uncoated",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?24/7/24698?source=see_link\">",
"     aspirin",
"    </a>",
"    should be given as soon as possible to any patient thought to have an ACS. At this dose, aspirin produces a rapid antithrombotic effect due to immediate and almost complete inhibition of thromboxane A2 production. The first tablet should be chewed or crushed to establish a high blood level quickly. More rapid absorption occurs with nonenteric coated formulations. There is no evidence that higher doses are more effective but they may lead to greater gastric irritation. Aspirin (75 to 100 mg once a day) should be continued indefinitely for secondary prevention [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/20/39242/abstract/4\">",
"     4",
"    </a>",
"    ]. The upper limit of 100 mg is based on the observation of a dose dependent increase in the rate of major bleeding in the CURE trial: 2, 2.3, and 4 percent at doses of than 100, 100 to 200, and greater than 200 mg daily [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/20/39242/abstract/5\">",
"     5",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?36/12/37066?source=see_link&amp;anchor=H20#H20\">",
"     \"Benefits and risks of aspirin in secondary and primary prevention of cardiovascular disease\", section on 'Dosing and cardiovascular benefit'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?36/12/37066?source=see_link&amp;anchor=H6#H6\">",
"     \"Benefits and risks of aspirin in secondary and primary prevention of cardiovascular disease\", section on 'Dosing and bleeding risk'",
"    </a>",
"    and",
"    <a class=\"local\" href=\"#H16\">",
"     'Clopidogrel'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    We recommend that ACS patients be discharged on 75 to 100",
"    <span class=\"nowrap\">",
"     mg/day",
"    </span>",
"    of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?24/7/24698?source=see_link\">",
"     aspirin",
"    </a>",
"    , based principally on CURRENT OASIS 7 trial, in which there was no significant difference in cardiovascular outcomes between high or low dose aspirin irrespective of whether ACS patients received percutaneous coronary intervention or not, while gastrointestinal bleeding rates were increased with higher dose aspirin. For patients taking",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?38/0/38919?source=see_link\">",
"     ticagrelor",
"    </a>",
"    , we recommend not using doses greater than 100 mg daily. (See",
"    <a class=\"local\" href=\"#H26\">",
"     'Ticagrelor'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     Side effects",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?24/7/24698?source=see_link\">",
"     Aspirin",
"    </a>",
"    therapy may be associated with gastrointestinal intolerance or bleeding, allergy (primarily manifested as bronchospasm or asthma), and worsening of pre-existent bleeding. Gastrointestinal side effects such as dyspepsia and nausea are infrequent with the low doses. Patients who develop gastrointestinal side effects should be treated with a proton pump inhibitor and are usually able to tolerate a lower and probably still effective dose (80 to 100 mg of aspirin per day) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/20/39242/abstract/6\">",
"     6",
"    </a>",
"    ]. Enteric-coated aspirin may be of some benefit, but it does not protect against gastrointestinal bleeding. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?36/12/37066?source=see_link&amp;anchor=H21#H21\">",
"     \"Benefits and risks of aspirin in secondary and primary prevention of cardiovascular disease\", section on 'Aspirin formulation'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?20/9/20632?source=see_link\">",
"     \"Periprocedural and long-term gastrointestinal bleeding in patients undergoing percutaneous coronary intervention\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5666304\">",
"    <span class=\"h2\">",
"     Summary",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      An initial loading dose of 162 to 325 mg of uncoated",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?24/7/24698?source=see_link\">",
"       aspirin",
"      </a>",
"      should be given as soon as possible to any patient thought to have an ACS.",
"     </li>",
"     <li>",
"      We recommend that ACS patients be discharged on 75 to 162",
"      <span class=\"nowrap\">",
"       mg/day",
"      </span>",
"      of",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?24/7/24698?source=see_link\">",
"       aspirin",
"      </a>",
"      . For patients taking",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?38/0/38919?source=see_link\">",
"       ticagrelor",
"      </a>",
"      , we suggest aspirin at a dose between 75 and 100 mg daily. (See",
"      <a class=\"local\" href=\"#H26\">",
"       'Ticagrelor'",
"      </a>",
"      below.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h1\">",
"     PLATELET P2Y12 RECEPTOR BLOCKERS",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?34/9/34969?source=see_link\">",
"     Clopidogrel",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?34/27/35255?source=see_link\">",
"     ticlopidine",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?26/63/27639?source=see_link\">",
"     prasugrel",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?38/0/38919?source=see_link\">",
"     ticagrelor",
"    </a>",
"    , and cangrelor block the adenosine diphosphate receptor P2Y12 on platelets. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?1/7/1146?source=see_link\">",
"     \"Platelet biology\"",
"    </a>",
"    .) The evidence presented below supports a strong recommendation for at least one year of dual antiplatelet therapy with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?24/7/24698?source=see_link\">",
"     aspirin",
"    </a>",
"    and a P2Y12 receptor blocker in all patients with ACS. This recommendation is based principally on the results of the CURE trial, which compared dual antiplatelet therapy with aspirin and clopidogrel to aspirin alone. Evidence for the role of ticagrelor and prasugrel comes from studies which compared these newer agents to clopidogrel.",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?34/27/35255?source=see_link\">",
"     Ticlopidine",
"    </a>",
"    is rarely chosen due to the risk of thrombocytopenia. Three limitations to the use of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?34/9/34969?source=see_link\">",
"     clopidogrel",
"    </a>",
"    (delayed onset of action, large between individual variability in platelet response, and irreversibility of its inhibitory effect on platelets) led to the development of other agents, including",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?26/63/27639?source=see_link\">",
"     prasugrel",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?38/0/38919?source=see_link\">",
"     ticagrelor",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/20/39242/abstract/7\">",
"     7",
"    </a>",
"    ]. Both prasugrel and ticagrelor induce more intense platelet inhibition than clopidogrel and have been found to be both more effective and associated with higher rates of bleeding. All trials of P2Y12 receptor blockers have given these drugs in conjunction with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?24/7/24698?source=see_link\">",
"     aspirin",
"    </a>",
"    .",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h2\">",
"     Clopidogrel",
"    </span>",
"    &nbsp;&mdash;&nbsp;The benefit of dual antiplatelet was established in the CURE trial, which randomly assigned 12,562 patients who presented within 24 hours after the onset of a non-ST elevation ACS to",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?24/7/24698?source=see_link\">",
"     aspirin",
"    </a>",
"    alone (75 to 325",
"    <span class=\"nowrap\">",
"     mg/day)",
"    </span>",
"    or with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?34/9/34969?source=see_link\">",
"     clopidogrel",
"    </a>",
"    (300 mg loading dose immediately followed by 75",
"    <span class=\"nowrap\">",
"     mg/day)",
"    </span>",
"    for 9 to 12 months; both were given immediately on presentation. The majority of patients were at increased risk or an adverse outcome because of ECG changes (mostly ST depression &ge;1 mm or T wave inversion &ge;2 mm) or elevated cardiac enzymes [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/20/39242/abstract/5\">",
"     5",
"    </a>",
"    ]. Over 60 percent did not receive revascularization. The primary endpoint was cardiovascular death, myocardial infarction, or stroke.",
"   </p>",
"   <p>",
"    At an average follow-up of nine months, combination therapy led to a significant reduction in the combined primary endpoint of cardiovascular death, nonfatal myocardial infarction (MI), or stroke (9.3 versus 11.4 percent), which was largely due to fewer MIs (5.2 versus 6.7 percent) (",
"    <a class=\"graphic graphic_figure graphicRef56356 \" href=\"mobipreview.htm?40/4/41037\">",
"     figure 4",
"    </a>",
"    ). However,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?34/9/34969?source=see_link\">",
"     clopidogrel",
"    </a>",
"    therapy significantly increased the rate of major bleeding (3.7 versus 2.7 percent) but not in life-threatening bleeding or hemorrhagic stroke.",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?34/9/34969?source=see_link\">",
"     Clopidogrel",
"    </a>",
"    therapy produced a similar relative risk reduction in patients who were treated medically or underwent revascularization [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/20/39242/abstract/8\">",
"     8",
"    </a>",
"    ] and in low-, intermediate-, and high-risk patients as defined by the TIMI risk score (",
"    <a class=\"calc calc_professional\" href=\"mobipreview.htm?5/34/5665?source=see_link\">",
"     calculator 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/20/39242/abstract/9\">",
"     9",
"    </a>",
"    ]. High-risk patients derived the greatest absolute benefit.",
"   </p>",
"   <p>",
"    A subsequent analysis from CURE evaluated the time course of benefit of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?34/9/34969?source=see_link\">",
"     clopidogrel",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/20/39242/abstract/10\">",
"     10",
"    </a>",
"    ]. Evidence of benefit began to emerge within 24 hours and gradually increased in magnitude during the first 30 days (4.3 versus 5.4 percent incidence of the primary endpoint, relative risk 0.79). The benefit continued to increase from 31 days to one year (5.2 versus 6.3 percent incidence of new events, relative risk 0.82) (",
"    <a class=\"graphic graphic_figure graphicRef53809 \" href=\"mobipreview.htm?19/30/19936\">",
"     figure 5",
"    </a>",
"    ). There was no significant excess of late life-threatening bleeding, but there was a small excess of major bleeds (5 per 1000) that was much smaller than the total cardiovascular benefit at one year (22 per 1000).",
"   </p>",
"   <p>",
"    Subgroup analyses of the CURE (PCI-CURE) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/20/39242/abstract/8\">",
"     8",
"    </a>",
"    ] and the CREDO trials [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/20/39242/abstract/11\">",
"     11",
"    </a>",
"    ] have confirmed the benefit of dual antiplatelet therapy with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?24/7/24698?source=see_link\">",
"     aspirin",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?34/9/34969?source=see_link\">",
"     clopidogrel",
"    </a>",
"    in ACS patients undergoing PCI with stenting. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?40/37/41562?source=see_link&amp;anchor=H7#H7\">",
"     \"Antithrombotic therapy for intracoronary stent implantation: Clinical trials\", section on 'Timing and dose'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h3\">",
"     Dose",
"    </span>",
"    &nbsp;&mdash;&nbsp;The standard",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?34/9/34969?source=see_link\">",
"     clopidogrel",
"    </a>",
"    regimen in patients with a non-ST elevation ACS, which was used in CURE and CREDO, has been a 300 mg loading dose followed by a maintenance dose of 75",
"    <span class=\"nowrap\">",
"     mg/day",
"    </span>",
"    [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/20/39242/abstract/5,8,11\">",
"     5,8,11",
"    </a>",
"    ]. However, the benefit in CREDO was only seen in patients who had been treated at &ge;15 hours before PCI [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/20/39242/abstract/12\">",
"     12",
"    </a>",
"    ]. This concern existed for non-ACS patients as well and led to the following studies that compared a 300 mg to a 600 mg loading dose (see",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?40/37/41562?source=see_link&amp;anchor=H7#H7\">",
"     \"Antithrombotic therapy for intracoronary stent implantation: Clinical trials\", section on 'Timing and dose'",
"    </a>",
"    ):",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In the ARMYDA-trial in which 255 patients (75 percent stable angina, 25 percent non-ST elevation ACS) scheduled to undergo PCI were randomly assigned to a 300 or 600 mg loading dose four to eight hours before the procedure [",
"      <a class=\"abstract\" href=\"mobipreview.htm?38/20/39242/abstract/13\">",
"       13",
"      </a>",
"      ]. The primary end point (death, MI, or target vessel revascularization) occurred significantly less often with the 600 mg loading dose (4 versus 12 percent).",
"     </li>",
"     <li>",
"      In a single center trial in which 292 patients with non-ST elevation ACS were randomly assigned to either 300 or 600 mg at least 12 hours before scheduled stenting, the rate of recurrent cardiovascular events at 30 days was significantly lower with the 600 mg dose (5 versus 12 percent) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?38/20/39242/abstract/14\">",
"       14",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The optimal loading dose of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?34/9/34969?source=see_link\">",
"     clopidogrel",
"    </a>",
"    in patients with ACS was best addressed in the CURRENT-OASIS 7 trial, which randomly assigned 25,086 patients with an ACS (70.8 percent unstable angina or NSTEMI) referred for an invasive strategy to either clopidogrel 600 mg loading dose on day one followed by 150 mg daily for six days (and 75 mg thereafter) or clopidogrel 300 mg loading dose followed by 75 mg daily [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/20/39242/abstract/15\">",
"     15",
"    </a>",
"    ]. The interval between randomization and PCI was 3.4 hours. The following findings were noted:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The rate of the primary outcome (cardiovascular death, MI, or stroke at 30 days) was not statistically different (4.2 versus 4.4 percent respectively). However, in the subgroup of patients who underwent PCI (n = 17,263) the higher dose of",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?34/9/34969?source=see_link\">",
"       clopidogrel",
"      </a>",
"      significantly reduced the rate of the primary outcome, 3.9 versus 4.5 percent; adjusted hazard ratio 0.86, 95% CI 0.74-0.99.",
"     </li>",
"     <li>",
"      Major bleeding occurred significantly more often in patients who received the higher",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?34/9/34969?source=see_link\">",
"       clopidogrel",
"      </a>",
"      dose (2.5 versus 2.0 percent in the overall population and 1.6 versus 1.1 in the PCI subgroup).",
"     </li>",
"     <li>",
"      The higher dose of",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?34/9/34969?source=see_link\">",
"       clopidogrel",
"      </a>",
"      was associated with a significant reduction in the secondary outcome of definite or probable stent thrombosis among the 17,263 patients who underwent PCI (1.6 versus 2.3 percent) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?38/20/39242/abstract/16\">",
"       16",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?10/24/10634?source=see_link\">",
"       \"Antiplatelet therapy after coronary artery stenting\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    We recommend a 600 mg loading dose in patients who will undergo angiography and possible revascularization within 24 hours of diagnosis. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?27/8/27786?source=see_link\">",
"     \"Antithrombotic therapy for percutaneous coronary intervention: General use\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?40/37/41562?source=see_link&amp;anchor=H7#H7\">",
"     \"Antithrombotic therapy for intracoronary stent implantation: Clinical trials\", section on 'Timing and dose'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    We prefer the maintenance dose of 75 mg daily, as opposed to the higher dose of 150 mg for six days. As the evidence supporting the 150 mg dose (for one week) comes from a subgroup analysis of a negative trial (CURRENT-OASIS 7), the lower dose is preferred until further evidence is available. We are concerned of an increase in the frequency of bleeding with the higher dose.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H353597156\">",
"    <span class=\"h3\">",
"     Patients already taking clopidogrel",
"    </span>",
"    &nbsp;&mdash;&nbsp;The issue of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?34/9/34969?source=see_link\">",
"     clopidogrel",
"    </a>",
"    reloading is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?27/8/27786?source=see_link&amp;anchor=H7#H7\">",
"     \"Antithrombotic therapy for percutaneous coronary intervention: General use\", section on 'Patients already taking clopidogrel'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h3\">",
"     Duration of therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;The CURE trial discussed above provides evidence that dual antiplatelet therapy with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?24/7/24698?source=see_link\">",
"     aspirin",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?34/9/34969?source=see_link\">",
"     clopidogrel",
"    </a>",
"    should be continued for 9 to 12 months. While studies have not compared one duration of therapy to another, the continued separation of events in CURE up to 9 to 12 months (",
"    <a class=\"graphic graphic_figure graphicRef56356 \" href=\"mobipreview.htm?40/4/41037\">",
"     figure 4",
"    </a>",
"    ) makes us reasonably confident about this duration.",
"   </p>",
"   <p>",
"    This minimum duration is supported by a retrospective cohort study of ACS patients treated with stents (1569, 63 percent received bare metal stents) and without stents (1568) which evaluated the frequency and timing of both all-cause mortality or acute MI after",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?34/9/34969?source=see_link\">",
"     clopidogrel",
"    </a>",
"    cessation [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/20/39242/abstract/17\">",
"     17",
"    </a>",
"    ]. The mean duration of clopidogrel therapy was 278 and 302 days, respectively. In multivariate analysis, including adjustment for duration of clopidogrel treatment, the first 90-day interval after stopping clopidogrel treatment was associated with a small risk of adverse events in both medical and PCI groups (1.31 and 0.57 per 1000 patient-days, respectively) that was significantly higher than in the interval of 91 to 180 days (incidence rate ratios 1.82 and 1.98). This early incidence of adverse events was consistent whether patients took clopidogrel for three, six, or nine or more months.",
"   </p>",
"   <p>",
"    Evidence from randomized trials in favor of continued",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?34/9/34969?source=see_link\">",
"     clopidogrel",
"    </a>",
"    use for longer than one year in non-ST elevation ACS is lacking. However, some support comes from the CAPRIE trial, which compared clopidogrel to",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?24/7/24698?source=see_link\">",
"     aspirin",
"    </a>",
"    (but not the combination) in patients with atherosclerosis not limited to acute coronary syndromes [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/20/39242/abstract/18\">",
"     18",
"    </a>",
"    ]. Clopidogrel therapy was associated with a significant reduction in fatal or nonfatal MI; the magnitude of this benefit increased progressively over the three-year period of the study [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/20/39242/abstract/19\">",
"     19",
"    </a>",
"    ]. Support also comes from subgroup analyses from CHARISMA, where benefit was seen in patients with prior MI or stroke [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/20/39242/abstract/20\">",
"     20",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Some physicians recommend continuing",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?34/9/34969?source=see_link\">",
"     clopidogrel",
"    </a>",
"    beyond one year or even indefinitely given a continued benefit over time observed in CURE, PCI-CURE (",
"    <a class=\"graphic graphic_figure graphicRef80889 \" href=\"mobipreview.htm?17/15/17661\">",
"     figure 6",
"    </a>",
"    ), and CREDO (",
"    <a class=\"graphic graphic_figure graphicRef60895 \" href=\"mobipreview.htm?16/24/16781\">",
"     figure 7",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/20/39242/abstract/5,8,11\">",
"     5,8,11",
"    </a>",
"    ]. This approach should be considered in patients with more severe vascular disease (eg, prior MI or cerebrovascular event or peripheral vascular disease) or in those with drug-eluting stents. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?10/24/10634?source=see_link\">",
"     \"Antiplatelet therapy after coronary artery stenting\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?10/24/10634?source=see_link&amp;anchor=H1293704686#H1293704686\">",
"     \"Antiplatelet therapy after coronary artery stenting\", section on 'Duration'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1354569\">",
"    <span class=\"h3\">",
"     After CABG",
"    </span>",
"    &nbsp;&mdash;&nbsp;The use of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?34/9/34969?source=see_link\">",
"     clopidogrel",
"    </a>",
"    in patients with non-ST elevation ACS undergoing urgent coronary artery bypass graft surgery is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?39/26/40360?source=see_link&amp;anchor=H6#H6\">",
"     \"Medical therapy to prevent complications after coronary artery bypass graft surgery\", section on 'Platelet P2Y12 receptor blocker therapy'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h2\">",
"     Ticlopidine",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?34/27/35255?source=see_link\">",
"     Ticlopidine",
"    </a>",
"    compared to placebo improves outcomes in patients with unstable angina who are not treated with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?24/7/24698?source=see_link\">",
"     aspirin",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/20/39242/abstract/21\">",
"     21",
"    </a>",
"    ]. No trials have compared ticlopidine to aspirin or assessed the role of combined therapy. Side effects have limited its use compared to",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?34/9/34969?source=see_link\">",
"     clopidogrel",
"    </a>",
"    . (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?27/8/27786?source=see_link&amp;anchor=H4#H4\">",
"     \"Antithrombotic therapy for percutaneous coronary intervention: General use\", section on 'Ticlopidine'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h2\">",
"     Prasugrel",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?26/63/27639?source=see_link\">",
"     Prasugrel",
"    </a>",
"    has a more rapid onset of action and is able to achieve higher degrees of platelet inhibition than",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?34/9/34969?source=see_link\">",
"     clopidogrel",
"    </a>",
"    . Furthermore, prasugrel effectively suppresses platelet activity in a larger numbers of patients than clopidogrel, since 20 to 25 percent of patients appear to be clopidogrel-resistant. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?36/34/37418?source=see_link&amp;anchor=H2#H2\">",
"     \"Nonresponse and resistance to clopidogrel\", section on 'Definitions'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H960560098\">",
"    <span class=\"h3\">",
"     Patients undergoing PCI",
"    </span>",
"    &nbsp;&mdash;&nbsp;The TRITON-TIMI 38 trial directly compared",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?26/63/27639?source=see_link\">",
"     prasugrel",
"    </a>",
"    to",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?34/9/34969?source=see_link\">",
"     clopidogrel",
"    </a>",
"    in 13,608 moderate- to high-risk ACS patients undergoing PCI, including 10,074 with non-ST elevation ACS [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/20/39242/abstract/22\">",
"     22",
"    </a>",
"    ]. Prasugrel was given with a loading dose of 60 mg and maintenance dose of 10",
"    <span class=\"nowrap\">",
"     mg/day",
"    </span>",
"    while clopidogrel was given with a 300 mg loading dose and a 75",
"    <span class=\"nowrap\">",
"     mg/day",
"    </span>",
"    maintenance dose; the median duration of therapy was 14.5 months. For patients with unstable angina or NSTEMI, the coronary anatomy had to be known before randomization. Thus, in the majority of cases both clopidogrel and prasugrel were given after coronary angiography.",
"   </p>",
"   <p>",
"    At 15-month follow-up, the following findings were noted (the overall data are given since the benefits were similar in non-ST elevation and ST elevation syndromes):",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The primary efficacy end point (cardiovascular death, nonfatal MI, or nonfatal stroke) occurred significantly less often in patients treated with",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?26/63/27639?source=see_link\">",
"       prasugrel",
"      </a>",
"      (9.9 versus 12.1 percent; hazard ratio [HR] 0.81; 95% CI 0.73-0.90) irrespective of whether or not they underwent PCI with stenting [",
"      <a class=\"abstract\" href=\"mobipreview.htm?38/20/39242/abstract/22,23\">",
"       22,23",
"      </a>",
"      ]. This was driven primarily by a significant reduction in nonfatal MI (7.4 versus 9.7 percent).",
"     </li>",
"     <li>",
"      Among patients who sustained a nonfatal MI or stroke, the likelihood of a recurrent primary end point was significantly reduced with",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?26/63/27639?source=see_link\">",
"       prasugrel",
"      </a>",
"      compared to",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?34/9/34969?source=see_link\">",
"       clopidogrel",
"      </a>",
"      (10.8 versus 15.4 percent), as was the likelihood of cardiovascular death following the nonfatal first event (3.7 versus 7.1 percent) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?38/20/39242/abstract/24\">",
"       24",
"      </a>",
"      ]. This benefit was found in patients with either procedure-related or non-procedure related MIs and was seen irrespective of MI size or timing [",
"      <a class=\"abstract\" href=\"mobipreview.htm?38/20/39242/abstract/25\">",
"       25",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      The safety end point of a major bleeding event not associated with CABG occurred significantly more often in patients treated with",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?26/63/27639?source=see_link\">",
"       prasugrel",
"      </a>",
"      (2.4 versus 1.8 percent; HR 1.32; 95% CI 1.03-1.68). This difference was attributable to an increase in bleeding events with prasugrel after (but not before) the first three days [",
"      <a class=\"abstract\" href=\"mobipreview.htm?38/20/39242/abstract/26\">",
"       26",
"      </a>",
"      ]. The rate of life-threatening bleeding was also significantly increased with prasugrel.",
"     </li>",
"     <li>",
"      Post hoc analysis identified three predictors of less net clinical efficacy and greater absolute levels of bleeding with",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?26/63/27639?source=see_link\">",
"       prasugrel",
"      </a>",
"      : A history of stroke or transient ischemic attack (TIA); age &ge;75 years of age; and body weight &le;60 kg. In those with stroke or transient ischemic attack, the use of prasugrel was associated with harm. The United States Food and Drug administration states the following: &ldquo;Prasugrel use is contraindicated in patients with active pathologic bleeding or history or TIA or stroke&rdquo;.",
"     </li>",
"     <li>",
"      The rate of definite or probable stent thrombosis (ARC definition) was significantly reduced in the",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?26/63/27639?source=see_link\">",
"       prasugrel",
"      </a>",
"      group (1.1 versus 2.4 percent). (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?8/59/9146?source=see_link&amp;anchor=H2#H2\">",
"       \"Coronary artery stent thrombosis: Incidence and risk factors\", section on 'Definitions'",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    There are no data on the efficacy or safety of pre-PCI loading with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?26/63/27639?source=see_link\">",
"     prasugrel",
"    </a>",
"    in patients with non-ST elevation MI. We do not recommend use in that setting. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?8/59/9146?source=see_link&amp;anchor=H10#H10\">",
"     \"Coronary artery stent thrombosis: Incidence and risk factors\", section on 'Risk factors'",
"    </a>",
"    and",
"    <a class=\"local\" href=\"#H1354953\">",
"     'Timing'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H960560252\">",
"    <span class=\"h3\">",
"     Patients not undergoing PCI",
"    </span>",
"    &nbsp;&mdash;&nbsp;The TRILOGY ACS trial directly compared",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?26/63/27639?source=see_link\">",
"     prasugrel",
"    </a>",
"    to",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?34/9/34969?source=see_link\">",
"     clopidogrel",
"    </a>",
"    in 9326 patients treated with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?24/7/24698?source=see_link\">",
"     aspirin",
"    </a>",
"    with unstable angina or NSTEMI in whom PCI was not performed [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/20/39242/abstract/27\">",
"     27",
"    </a>",
"    ]. Randomization was carried out more than four days after admission. Prasugrel was given with a loading dose of 30 mg and a maintenance dose of 10",
"    <span class=\"nowrap\">",
"     mg/day",
"    </span>",
"    in patients less than 75 years or 5",
"    <span class=\"nowrap\">",
"     mg/day",
"    </span>",
"    for those 75 years or older or weighed less than 60 kg; clopidogrel was given with a 300 mg loading dose and a 75",
"    <span class=\"nowrap\">",
"     mg/day",
"    </span>",
"    maintenance dose. The primary efficacy end point was a composite of death from cardiovascular causes, nonfatal MI, or nonfatal stroke among patients under the age of 75 years. The median duration of exposure to a study drug was 14.8 months. During a median follow-up of 17.1 months, the following findings were noted:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      There was no statistically significant difference in the rate of the primary end point in the 7243 patients under the age of 75 years between those who received",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?26/63/27639?source=see_link\">",
"       prasugrel",
"      </a>",
"      and those who received",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?34/9/34969?source=see_link\">",
"       clopidogrel",
"      </a>",
"      (13.9 versus 16.0 percent; hazard ratio [HR] 0.91, 95% CI 0.79-1.05).",
"     </li>",
"     <li>",
"      The rates of severe and intracranial bleeding were not statistically significantly different. However, irrespective of which bleeding criteria was applied, the event rates at 30 days tended to be higher with",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?26/63/27639?source=see_link\">",
"       prasugrel",
"      </a>",
"      and the confidence intervals for the hazard ratios for bleeding often included upper boundaries that indicated as much as a doubling of the risk. &nbsp;",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H26\">",
"    <span class=\"h2\">",
"     Ticagrelor",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?38/0/38919?source=see_link\">",
"     Ticagrelor",
"    </a>",
"    differs from the thienopyridines (",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?34/9/34969?source=see_link\">",
"     clopidogrel",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?26/63/27639?source=see_link\">",
"     prasugrel",
"    </a>",
"    ) in that it binds reversibly rather than irreversibly to P2Y12 platelet receptor and has a more rapid onset of action than clopidogrel [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/20/39242/abstract/7\">",
"     7",
"    </a>",
"    ]. It has been assigned to a new chemical class of antiplatelet agents, the cyclopentyltriazolopyrimidines. Similar to prasugrel, treatment with ticagrelor leads to more intense platelet inhibition than clopidogrel.",
"   </p>",
"   <p>",
"    The efficacy and safety of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?38/0/38919?source=see_link\">",
"     ticagrelor",
"    </a>",
"    were evaluated in the PLATO trial in which 18,624 patients with ACS were randomly assigned to either ticagrelor (180 mg loading dose followed by 90 mg twice daily) or",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?34/9/34969?source=see_link\">",
"     clopidogrel",
"    </a>",
"    (300 to 600 mg loading dose followed by 75 mg daily) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/20/39242/abstract/28\">",
"     28",
"    </a>",
"    ]. Treatment was started as soon as possible after hospital admission (median of five hours); in many patients this was after diagnostic coronary angiography. The median time from the first dose of the study drug to PCI was approximately 4 hours (interquartile range [approximately] 0.45-50.8 hours).",
"   </p>",
"   <p>",
"    All patients received a loading dose of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?24/7/24698?source=see_link\">",
"     aspirin",
"    </a>",
"    , which was usually 325 mg. Subsequently, all patients received chronic aspirin therapy; the protocol-specified maintenance dose was 75-100 mg daily for patients not undergoing stenting and allowed the use of up to 325 mg daily for up to six months in those who did. &nbsp;",
"   </p>",
"   <p>",
"    The final diagnosis of STEMI, NSTEMI, or UA was present in 38, 43 and 17 percent of patients respectively. The intent to perform PCI was mandated for patients with STEMI, but not for those with NSTEMI or UA. Thus, PLATO included patients who were managed medically.",
"   </p>",
"   <p>",
"    At 12 months, the composite primary end point (first event of death from vascular causes, MI, or stroke) occurred significantly less often in patients receiving",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?38/0/38919?source=see_link\">",
"     ticagrelor",
"    </a>",
"    (9.8 versus 11.7 percent, hazard ratio [HR] 0.84, 95% CI 0.77-0.92). There was no significant difference in the rates of major bleeding between the ticagrelor and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?34/9/34969?source=see_link\">",
"     clopidogrel",
"    </a>",
"    groups (11.6 versus 11.2 percent respectively), but ticagrelor was associated with a significantly higher rate of major bleeding not related to coronary artery bypass grafting (4.5 versus 3.8 percent).",
"   </p>",
"   <p>",
"    A subsequent analysis form PLATO evaluated all events in the primary composite outcome, including first (1888 patients) and recurrent events (318 patients) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/20/39242/abstract/29\">",
"     29",
"    </a>",
"    ]. Using these additional events,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?38/0/38919?source=see_link\">",
"     ticagrelor",
"    </a>",
"    significantly reduced the total number of events (HR 0.86, 95% CI 0.79-0.93).",
"   </p>",
"   <p>",
"    A prespecified, subgroup analysis found a potentially clinically important interaction between treatment and region: the composite primary end point occurred more often with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?38/0/38919?source=see_link\">",
"     ticagrelor",
"    </a>",
"    for patients enrolled in the United States (12.6 versus 10.1 percent, HR 1.27, 95% CI 0.93-1.75) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/20/39242/abstract/30\">",
"     30",
"    </a>",
"    ]. Among 37 baseline and postrandomization factors, only",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?24/7/24698?source=see_link\">",
"     aspirin",
"    </a>",
"    dose explained a substantial fraction (80-100 percent) of the interaction (p=0.00006). The hazard ratios comparing ticagrelor and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?34/9/34969?source=see_link\">",
"     clopidogrel",
"    </a>",
"    for the primary efficacy outcome, according to region and daily dose category for median maintenance aspirin, are as follows:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      US, &ge;300 mg: 1.62 (95% CI 0.99-2.64)",
"     </li>",
"     <li>",
"      US, &le;100 mg: 0.73 (95% CI, 0.40-1.33)",
"     </li>",
"     <li>",
"      Non-US, &ge;300 mg: 1.23 (95% CI, 0.71-2.14)",
"     </li>",
"     <li>",
"      Non-US, &le;100 mg: 0.78 (95% CI, 0.69-0.87)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Until further data confirms or refutes the findings of a potential negative interaction between",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?38/0/38919?source=see_link\">",
"     ticagrelor",
"    </a>",
"    and high-dose",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?24/7/24698?source=see_link\">",
"     aspirin",
"    </a>",
"    , we suggest that when aspirin is used in conjunction with ticagrelor for the treatment of ACS, it be administered only at a daily dose of &le;100 mg, including patients who undergo stenting.",
"   </p>",
"   <p>",
"    The primary outcome was similar to the entire study population in three prespecified subgroups: patients with chronic kidney disease (17.3 versus 22 percent respectively; HR 0.77, 95% CI 0.65-0.90) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/20/39242/abstract/31\">",
"     31",
"    </a>",
"    ]; patients who underwent coronary artery bypass graft surgery and were receiving study drug treatment less than seven days before surgery (10.6 versus 13.1 percent; HR 0.84, 95% CI 0.60-1.16) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/20/39242/abstract/32\">",
"     32",
"    </a>",
"    ]; and patients with a planned non-invasive management (12.0 versus 14.3 percent; HR 0.85, 95% CI 0.73-1.00) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/20/39242/abstract/33\">",
"     33",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In addition, among patients who underwent PCI in PLATO, outcomes were similar in patients who received",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?34/9/34969?source=see_link\">",
"     clopidogrel",
"    </a>",
"    pre-randomization and those who did not [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/20/39242/abstract/34\">",
"     34",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1140488073\">",
"    <span class=\"h2\">",
"     Cangrelor",
"    </span>",
"    &nbsp;&mdash;&nbsp;Cangrelor is an intravenous P2Y12 receptor blocker that has been compared to either",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?34/9/34969?source=see_link\">",
"     clopidogrel",
"    </a>",
"    or placebo in three randomized trials that included patients with non-STEACS and evaluated 48-hour outcomes. As cangrelor has not been directly compared to either",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?38/0/38919?source=see_link\">",
"     ticagrelor",
"    </a>",
"    or",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?26/63/27639?source=see_link\">",
"     prasugrel",
"    </a>",
"    , which are preferred in this patient population (see",
"    <a class=\"local\" href=\"#H434346709\">",
"     'Invasive approach'",
"    </a>",
"    below), we do not recommend its use in patients with STEMI. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?40/37/41562?source=see_link&amp;anchor=H9#H9\">",
"     \"Antithrombotic therapy for intracoronary stent implantation: Clinical trials\", section on 'Cangrelor'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1354953\">",
"    <span class=\"h2\">",
"     Timing",
"    </span>",
"    &nbsp;&mdash;&nbsp;There are no randomized trials that have compared early (at the time of diagnosis) to late (at the time of diagnostic angiography) use of the newer P2Y12 receptor blocker in patients with non-ST elevation ACS. The use of a four hour cut-point separating early from delayed is arbitrary, but is derived in part from data in the CURE trial (",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?34/9/34969?source=see_link\">",
"     clopidogrel",
"    </a>",
"    ), in which the event rates diverged in the",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?24/7/24698?source=see_link\">",
"     aspirin",
"    </a>",
"    plus clopidogrel versus clopidogrel arms within a few hours after administration of clopidogrel [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/20/39242/abstract/10\">",
"     10",
"    </a>",
"    ]. In CURE (clopidogrel), the absolute event rates were low during the first few hours and thus the absolute number of events prevented by dual antiplatelet therapy was small. In PLATO and TRITON-TIMI 38 trials (see",
"    <a class=\"local\" href=\"#H22\">",
"     'Prasugrel'",
"    </a>",
"    above and",
"    <a class=\"local\" href=\"#H26\">",
"     'Ticagrelor'",
"    </a>",
"    above), few patients who ultimately underwent PCI received P2Y12 inhibition in advance of diagnostic angiography. As the delay to diagnostic angiography increases, the number of preventable events rises, making a recommendation for early P2Y12 receptor blocker use rational. (See",
"    <a class=\"local\" href=\"#H18\">",
"     'Dose'",
"    </a>",
"    above.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21914160\">",
"    <span class=\"h2\">",
"     Bleeding risk",
"    </span>",
"    &nbsp;&mdash;&nbsp;The most important common side effect associated with platelet P2Y12 receptor blocker therapy is bleeding. The combination of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?34/9/34969?source=see_link\">",
"     clopidogrel",
"    </a>",
"    plus",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?24/7/24698?source=see_link\">",
"     aspirin",
"    </a>",
"    in CURE (see",
"    <a class=\"local\" href=\"#H16\">",
"     'Clopidogrel'",
"    </a>",
"    above) was associated with a significant increase in major (3.7 versus 2.7 percent with aspirin alone), minor (5.1 versus 2.4 percent), and gastrointestinal bleeding (1.3 versus 0.7 percent), but not life-threatening bleeding events at 12 months [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/20/39242/abstract/5\">",
"     5",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?40/37/41562?source=see_link&amp;anchor=H4#H4\">",
"     \"Antithrombotic therapy for intracoronary stent implantation: Clinical trials\", section on 'P2Y12 receptor blockers'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Risk factors for bleeding with a P2Y12 receptor blocker include a history of transient ischemic attack or stroke, age &ge;75 years, propensity to bleed (eg, recent trauma or surgery, recent or recurrent gastrointestinal bleeding, active peptic ulcer disease, severe hepatic impairment) body weight &lt;60 kg, or concomitant use of medications that increase risk (oral anticoagulants or nonsteroidal antiinflammatory drugs). In addition the risk of bleeding is increased with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?38/0/38919?source=see_link\">",
"     ticagrelor",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?26/63/27639?source=see_link\">",
"     prasugrel",
"    </a>",
"    compared to",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?34/9/34969?source=see_link\">",
"     clopidogrel",
"    </a>",
"    .",
"   </p>",
"   <p>",
"    A history of active gastrointestinal bleeding presents a challenge to the care of the patient with ACS. The discussion of the incidence, risk factors, outcomes, prevention, and treatment of periprocedural gastrointestinal bleeding is found elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?20/9/20632?source=see_link\">",
"     \"Periprocedural and long-term gastrointestinal bleeding in patients undergoing percutaneous coronary intervention\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    One factor that influences our recommendations for the choice of P2Y12 receptor blocker is the rate of bleeding for each drug. The rate of major bleeding with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?26/63/27639?source=see_link\">",
"     prasugrel",
"    </a>",
"    was higher than that for",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?34/9/34969?source=see_link\">",
"     clopidogrel",
"    </a>",
"    in TRITON-TIMI 38 trial. In PLATO, there was no significant difference in the rates of major bleeding between the",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?38/0/38919?source=see_link\">",
"     ticagrelor",
"    </a>",
"    and clopidogrel groups, but ticagrelor was associated with a significantly higher rate of major bleeding not related to coronary artery bypass grafting.",
"   </p>",
"   <p>",
"    There are no published studies that directly compare the rates of bleeding between",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?38/0/38919?source=see_link\">",
"     ticagrelor",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?26/63/27639?source=see_link\">",
"     prasugrel",
"    </a>",
"    . However, based on pharmacokinetic data, which suggest that the duration of inhibitory effect is shorter with ticagrelor, and the findings from PLATO and TRITON-TIMI 38, we are concerned that bleeding rates are higher with prasugrel. In addition, prasugrel was given only to a subset of all non-ST elevation ACS patients (those who were post angiography about to undergo PCI) in TRITON-TIMI 38 and not at the time of presentation in the emergency department, whereas ticagrelor was given to all patients with ACS. We are concerned that patients in TRITON-TIMI 38 were a lower risk group than those in PLATO since high risk patients may have been excluded from enrollment. Thus, we have no information on the&nbsp;rate of bleeding if prasugrel were given to a higher risk group at the earlier time point, when many other antithrombotics are being given and the patients are more unstable.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1354842\">",
"    <span class=\"h2\">",
"     Early CABG",
"    </span>",
"    &nbsp;&mdash;&nbsp;The concern for an increased risk of bleeding, discussed above, is particularly relevant in non-ST ACS patients who undergo early CABG. The likelihood of life-threatening or major bleeding within seven days of CABG was non-significantly increased in patients in the CURE trial who had received",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?34/9/34969?source=see_link\">",
"     clopidogrel",
"    </a>",
"    within the five days prior to CABG (9.6 versus 6.3 percent with placebo), but not in those who had discontinued clopidogrel &ge;5 days prior to CABG (4.4 versus 5.3 percent) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/20/39242/abstract/35\">",
"     35",
"    </a>",
"    ]. This finding is supported by several observational studies [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/20/39242/abstract/36-40\">",
"     36-40",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?34/25/35226?source=see_link&amp;anchor=H8#H8\">",
"     \"Early noncardiac complications of coronary artery bypass graft surgery\", section on 'Bleeding'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In the TRITON-TIMI 38 [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/20/39242/abstract/22\">",
"     22",
"    </a>",
"    ] and PLATO [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/20/39242/abstract/28\">",
"     28",
"    </a>",
"    ] trials of P2Y12 receptor blocker therapy, the risk of CABG related major bleeding was significantly increased with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?26/63/27639?source=see_link\">",
"     prasugrel",
"    </a>",
"    but not",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?38/0/38919?source=see_link\">",
"     ticagrelor",
"    </a>",
"    compared to",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?34/9/34969?source=see_link\">",
"     clopidogrel",
"    </a>",
"    (13.4 versus 3.2 percent and 7.4 versus 7.9 percent, respectively). (See",
"    <a class=\"local\" href=\"#H22\">",
"     'Prasugrel'",
"    </a>",
"    above and",
"    <a class=\"local\" href=\"#H26\">",
"     'Ticagrelor'",
"    </a>",
"    above.) &nbsp;",
"   </p>",
"   <p>",
"    Any excess bleeding risk due to recent P2Y12 receptor blocker use in the minority of patients who will or might require CABG must be weighed against the potentially deleterious effect of delaying or not administering such therapy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/20/39242/abstract/41\">",
"     41",
"    </a>",
"    ]. In subgroup analyses of patients undergoing CABG in the ACUITY and CURE trials [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/20/39242/abstract/35,42\">",
"     35,42",
"    </a>",
"    ], patients with ACS who received",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?34/9/34969?source=see_link\">",
"     clopidogrel",
"    </a>",
"    had a lower rate of adverse outcomes than those who did not. For instance, in ACUITY, the rate of the primary composite outcome at 30 days was significantly less in those who received clopidogrel compared to those who did not (12.7 versus 17.3 percent) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/20/39242/abstract/42\">",
"     42",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?5/2/5162?source=see_link&amp;anchor=H33#H33\">",
"     \"Anticoagulant therapy in non-ST elevation acute coronary syndromes\", section on 'Bivalirudin'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    A 2011 systematic review and meta-analysis evaluated outcomes from over 10 heterogenous studies that included ACS patients who underwent CABG on or off",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?34/9/34969?source=see_link\">",
"     clopidogrel",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/20/39242/abstract/43\">",
"     43",
"    </a>",
"    ]. In those with clopidogrel exposure within five days of CABG, the rates of death, stroke, and the combined rate of death, stroke, and myocardial infarction were non-significantly higher (odds ratios 1.44, 95% CI 0.97-2.13, 1.23, 95% CI 0.66-2.29, and 1.10, 95% CI 0.87-1.41, respectively).",
"   </p>",
"   <p>",
"    We believe there is insufficient evidence to allow for firm conclusions regarding benefit to risk ratio for continuing P2Y12 receptor blocker until the time of CABG. For most patients we suggest discontinuing such therapy before CABG (at least five days for",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?34/9/34969?source=see_link\">",
"     clopidogrel",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?38/0/38919?source=see_link\">",
"     ticagrelor",
"    </a>",
"    and at least seven days for",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?26/63/27639?source=see_link\">",
"     prasugrel",
"    </a>",
"    ). As the return of normal platelet function occurs more quickly after cessation of ticagrelor than clopidogrel (as determined by measurements of platelet function), some experts are comfortable allowing patients to undergo CABG as soon as three days after cessation.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21913850\">",
"    <span class=\"h2\">",
"     Non-bleeding adverse effects",
"    </span>",
"    &nbsp;&mdash;&nbsp;Three important nonbleeding side effects of P2Y12 receptor blocker use have been identified: neutropenia and thrombotic thrombocytopenia",
"    <span class=\"nowrap\">",
"     purpura/hemolytic",
"    </span>",
"    uremic syndrome (TTP-HUS), both of which are primarily described with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?34/27/35255?source=see_link\">",
"     ticlopidine",
"    </a>",
"    , and hypersensitivity, which is more common with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?34/9/34969?source=see_link\">",
"     clopidogrel",
"    </a>",
"    . These issues are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?27/8/27786?source=see_link\">",
"     \"Antithrombotic therapy for percutaneous coronary intervention: General use\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H28\">",
"    <span class=\"h2\">",
"     Summary",
"    </span>",
"    &nbsp;&mdash;&nbsp;Outcomes after non-ST elevation ACS are better with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?24/7/24698?source=see_link\">",
"     aspirin",
"    </a>",
"    plus a platelet P2Y12 receptor blocker than with aspirin alone, irrespective of whether patients are managed with invasive or conservative strategies. Dual antiplatelet therapy should be given as soon as possible after diagnosis and continued for one year. In addition, evidence from TRITON-TIMI 38 (",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?26/63/27639?source=see_link\">",
"     prasugrel",
"    </a>",
"    ) and PLATO (",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?38/0/38919?source=see_link\">",
"     ticagrelor",
"    </a>",
"    ) provides strong support for the general idea that agents with higher levels of platelet inhibition have lower cardiovascular event rates but higher rates of bleeding compared to",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?34/9/34969?source=see_link\">",
"     clopidogrel",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/20/39242/abstract/22\">",
"     22",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In patients undergoing an invasive approach, we believe the evidence from TRITON-TIMI 38 and PLATO, which came to similar conclusions, supports the use of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?38/0/38919?source=see_link\">",
"     ticagrelor",
"    </a>",
"    or",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?26/63/27639?source=see_link\">",
"     prasugrel",
"    </a>",
"    rather than",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?34/9/34969?source=see_link\">",
"     clopidogrel",
"    </a>",
"    in most patients with non-ST elevation ACS. This preference for ticagrelor or prasugrel instead of clopidogrel is made in the 2011 European Society of Cardiology guidelines for the management of ACS in patients presenting without persistent ST-segment elevation [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/20/39242/abstract/44\">",
"     44",
"    </a>",
"    ]. However, this preference differs from recommendations made in the 2012 American College of Cardiology",
"    <span class=\"nowrap\">",
"     Foundation/American",
"    </span>",
"    Heart Association focused update of the guideline for the management of patients with unstable",
"    <span class=\"nowrap\">",
"     angina/non-ST-elevation",
"    </span>",
"    MI, which lists the three P2Y12 receptor blockers without making a preference (for patients managed with an invasive strategy) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/20/39242/abstract/45\">",
"     45",
"    </a>",
"    ]. While there are no randomized trials that compare ticagrelor to prasugrel, we prefer ticagrelor in most cases. Issues of cost or availability may influence choice. For patients managed with an invasive approach, the choice of P2Y12 receptor blocker depends on when the drug is given:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      For patients in whom the drug is withheld until the coronary anatomy is known, we prefer either",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?38/0/38919?source=see_link\">",
"       ticagrelor",
"      </a>",
"      or",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?26/63/27639?source=see_link\">",
"       prasugrel",
"      </a>",
"      to",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?34/9/34969?source=see_link\">",
"       clopidogrel",
"      </a>",
"      .",
"     </li>",
"     <li>",
"      For patients in whom the drug is given at the time of diagnosis, we prefer",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?38/0/38919?source=see_link\">",
"       ticagrelor",
"      </a>",
"      to",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?26/63/27639?source=see_link\">",
"       prasugrel",
"      </a>",
"      , as the early use of the latter has not been evaluated.",
"     </li>",
"     <li>",
"      For those patients who have received",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?34/9/34969?source=see_link\">",
"       clopidogrel",
"      </a>",
"      prior to diagnostic angiography or who have been taking clopidogrel long-term, we suggest switching to",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?38/0/38919?source=see_link\">",
"       ticagrelor",
"      </a>",
"      (with the 180 mg loading dose) prior to or after PCI.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    In patients not undergoing an invasive approach, the relative efficacy and safety of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?38/0/38919?source=see_link\">",
"     ticagrelor",
"    </a>",
"    compared to",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?34/9/34969?source=see_link\">",
"     clopidogrel",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?26/63/27639?source=see_link\">",
"     prasugrel",
"    </a>",
"    compared to clopidogrel were compared in the PLATO and TRILOGY trials respectively: In the former, ticagrelor was superior to clopidogrel, while in the latter, prasugrel was not shown to be superior to clopidogrel. Based on these studies, we recommend ticagrelor instead of clopidogrel. For patients in whom ticagrelor cannot be used, we suggest using clopidogrel instead of prasugrel. This preference is based on its lower cost, a greater experience with its use, and a trend toward higher rates of bleeding in TRILOGY.",
"   </p>",
"   <p>",
"    Major bleeding is an important concern with the use of P2Y12 receptor blockers. The following two points should be kept in mind when choosing between",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?38/0/38919?source=see_link\">",
"     ticagrelor",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?26/63/27639?source=see_link\">",
"     prasugrel",
"    </a>",
"    , and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?34/9/34969?source=see_link\">",
"     clopidogrel",
"    </a>",
"    :",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Specific relative contraindications to full dose (10 mg daily)",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?26/63/27639?source=see_link\">",
"       prasugrel",
"      </a>",
"      include patient&rsquo;s age 75 years or older or weight less than 60 kg, although the 5 mg daily dose appears to be safe in this patient population. Prasugrel is absolutely contraindicated in patients with past stroke or transient ischemic attack.",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?38/0/38919?source=see_link\">",
"       Ticagrelor",
"      </a>",
"      was not associated with an increased risk of bleeding in patients with prior stroke or TIA, but relatively few patients in the randomized trial (4 percent of the total enrolled) met this criterion and thus experience is limited;",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?34/9/34969?source=see_link\">",
"       clopidogrel",
"      </a>",
"      300 mg is preferred in these patients.",
"     </li>",
"     <li>",
"      For patients otherwise at high risk for bleeding due to prior hemorrhagic stroke, ongoing bleeding, bleeding diathesis, or clinically relevant anemia or thrombocytopenia,",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?34/9/34969?source=see_link\">",
"       clopidogrel",
"      </a>",
"      300 mg is preferred in most cases.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H434346467\">",
"    <span class=\"h1\">",
"     RESISTANCE/NONRESPONSE TO ASPIRIN OR CLOPIDOGREL",
"    </span>",
"    &nbsp;&mdash;&nbsp;The subject of",
"    <span class=\"nowrap\">",
"     resistance/nonresponse",
"    </span>",
"    to",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?24/7/24698?source=see_link\">",
"     aspirin",
"    </a>",
"    or",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?34/9/34969?source=see_link\">",
"     clopidogrel",
"    </a>",
"    , along with methods to determine in vitro platelet function following treatment with clopidogrel, are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?36/34/37418?source=see_link\">",
"     \"Nonresponse and resistance to clopidogrel\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H29\">",
"    <span class=\"h1\">",
"     GP IIb/IIIa INHIBITORS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Potent inhibition of platelet aggregation in patients with a non-ST elevation ACS can be achieved by the use of intravenous glycoprotein (GP)",
"    <span class=\"nowrap\">",
"     IIb/IIIa",
"    </span>",
"    inhibitors, which inhibit the final common pathway of platelet aggregation, the cross-bridging of platelets secondary to fibrinogen binding to the activated GP",
"    <span class=\"nowrap\">",
"     IIb/IIIa",
"    </span>",
"    receptor. The addition of GP",
"    <span class=\"nowrap\">",
"     IIb/IIIa",
"    </span>",
"    improves outcomes in some patients with non-ST elevation ACS. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?1/7/1146?source=see_link&amp;anchor=H28#H28\">",
"     \"Platelet biology\", section on 'Platelet activation'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H434345741\">",
"    <span class=\"h2\">",
"     Evidence from early trials",
"    </span>",
"    &nbsp;&mdash;&nbsp;The early randomized trials of GP",
"    <span class=\"nowrap\">",
"     IIb/IIIa",
"    </span>",
"    inhibitors are presented separately (see",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?19/31/19961?source=see_link\">",
"     \"Early trials of platelet glycoprotein IIb/IIIa receptor inhibitors in coronary heart disease\"",
"    </a>",
"    ). The following conclusions are of limited applicability to patients treated today with the routine use of P2Y12 receptor blockers and PCI with stenting:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In trials of patients treated with medical therapy:",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?6/15/6392?source=see_link\">",
"       abciximab",
"      </a>",
"      did not improve outcomes;",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?13/2/13351?source=see_link\">",
"       tirofiban",
"      </a>",
"      was of benefit in patients in troponin positive patients; and",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?31/24/32135?source=see_link\">",
"       eptifibatide",
"      </a>",
"      improved outcomes [",
"      <a class=\"abstract\" href=\"mobipreview.htm?38/20/39242/abstract/46-50\">",
"       46-50",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      In trials of intervention with balloon angioplasty, outcomes were better with",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?6/15/6392?source=see_link\">",
"       abciximab",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?13/2/13351?source=see_link\">",
"       tirofiban",
"      </a>",
"      , or",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?31/24/32135?source=see_link\">",
"       eptifibatide",
"      </a>",
"      (compared to placebo) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?38/20/39242/abstract/46,49,51\">",
"       46,49,51",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Among patients undergoing percutaneous coronary intervention with stenting, benefit has been demonstrated with",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?31/24/32135?source=see_link\">",
"       eptifibatide",
"      </a>",
"      and",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?13/2/13351?source=see_link\">",
"       tirofiban",
"      </a>",
"      [",
"      <a class=\"abstract\" href=\"mobipreview.htm?38/20/39242/abstract/52,53\">",
"       52,53",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    A 2002 meta-analysis examined individual data from six randomized trials of 31,400 non-ST elevation ACS patients treated with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?24/7/24698?source=see_link\">",
"     aspirin",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?39/34/40489?source=see_link\">",
"     heparin",
"    </a>",
"    who did not undergo early (&lt;48 hours) revascularization [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/20/39242/abstract/54\">",
"     54",
"    </a>",
"    ]. GP",
"    <span class=\"nowrap\">",
"     IIb/IIIa",
"    </span>",
"    inhibitor use was associated with a significant reduction in the combined end point (death or MI) at five days (5.7 versus 6.9 percent for",
"    <span class=\"nowrap\">",
"     placebo/control,",
"    </span>",
"    odds ratio [OR] 0.84, 95 percent CI 0.77 to 0.93) and at 30 days (10.8 versus 11.8 percent, OR 0.91, 95% CI 0.85-0.98). Benefit appeared to be limited to the highest risk patients.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H434345672\">",
"    <span class=\"h2\">",
"     Evidence from recent trials",
"    </span>",
"    &nbsp;&mdash;&nbsp;The above meta-analysis was published before the current upstream use of platelet P2Y12 receptor blockers in most or",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?17/48/18184?source=see_link\">",
"     bivalirudin",
"    </a>",
"    as the anticoagulant in some patients with non-ST elevation ACS.",
"   </p>",
"   <p>",
"    In the ISAR-REACT 2 trial, 2022 patients with a non-ST elevation ACS undergoing PCI with stenting were treated with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?34/9/34969?source=see_link\">",
"     clopidogrel",
"    </a>",
"    (600 mg loading dose at least two hours before PCI) and then randomly assigned to",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?6/15/6392?source=see_link\">",
"     abciximab",
"    </a>",
"    or placebo in the catheterization laboratory [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/20/39242/abstract/55\">",
"     55",
"    </a>",
"    ]. All patients received",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?39/34/40489?source=see_link\">",
"     heparin",
"    </a>",
"    as the anticoagulant. The following findings were noted:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?6/15/6392?source=see_link\">",
"       Abciximab",
"      </a>",
"      therapy was associated with a significant reduction in the rate of the primary end point of death, MI, or urgent target vessel revascularization at 30 days (8.9 versus 11.9 percent; relative risk [RR] 0.75, 95% CI 0.58-0.97). The lower rate was driven principally by a lower rate of myocardial infarction.",
"     </li>",
"     <li>",
"      Among patients without an elevated troponin level (about half of the study population), there was no difference in the incidence of primary end point events between the two groups (4.6 percent in both groups; relative risk 0.99, 95% CI 0.56-1.76). Among patients with an elevated troponin, the incidence of events was significantly lower in the",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?6/15/6392?source=see_link\">",
"       abciximab",
"      </a>",
"      group (13.1 versus 18.3 percent; RR of 0.71, 95% CI 0.54-0.95).",
"     </li>",
"     <li>",
"      There were no significant differences in the two groups in the risk of major bleeding.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    In the ISAR-REACT 4 trial, which compared",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?17/48/18184?source=see_link\">",
"     bivalirudin",
"    </a>",
"    to",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?39/34/40489?source=see_link\">",
"     heparin",
"    </a>",
"    plus GP",
"    <span class=\"nowrap\">",
"     IIb/IIIa",
"    </span>",
"    inhibitor in non-ST elevation MI patients receiving",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?24/7/24698?source=see_link\">",
"     aspirin",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?34/9/34969?source=see_link\">",
"     clopidogrel",
"    </a>",
"    , the rate of death, recurrent MI, or urgent target-vessel revascularization was similar between the two groups, but bleeding occurred significantly more often in those receiving heparin plus glycoprotein",
"    <span class=\"nowrap\">",
"     IIb/IIIa",
"    </span>",
"    inhibitor [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/20/39242/abstract/56\">",
"     56",
"    </a>",
"    ]. This trial is discussed in detail elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?5/2/5162?source=see_link&amp;anchor=H33#H33\">",
"     \"Anticoagulant therapy in non-ST elevation acute coronary syndromes\", section on 'Bivalirudin'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H609705878\">",
"    <span class=\"h2\">",
"     Special considerations",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H32\">",
"    <span class=\"h3\">",
"     Timing",
"    </span>",
"    &nbsp;&mdash;&nbsp;The optimal time of initiation of GP",
"    <span class=\"nowrap\">",
"     IIb/IIIa",
"    </span>",
"    inhibitor therapy in patients with an NSTEMI who are treated with an early invasive strategy was addressed in the ACUITY Timing and EARLY ACS trials; ACUITY Timing was a sub-randomization of the ACUITY trial of moderate- to high-risk ACS patients. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?40/37/41562?source=see_link&amp;anchor=H25#H25\">",
"     \"Antithrombotic therapy for intracoronary stent implantation: Clinical trials\", section on 'Bivalirudin'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In the ACUITY Timing trial, 9207 non-ST elevation ACS patients scheduled to undergo an invasive strategy were randomly assigned to either upstream GP",
"    <span class=\"nowrap\">",
"     IIb/IIIa",
"    </span>",
"    inhibitor (",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?31/24/32135?source=see_link\">",
"     eptifibatide",
"    </a>",
"    or",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?13/2/13351?source=see_link\">",
"     tirofiban",
"    </a>",
"    ) or deferred GP",
"    <span class=\"nowrap\">",
"     IIb/IIIa",
"    </span>",
"    inhibitor [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/20/39242/abstract/57\">",
"     57",
"    </a>",
"    ].The primary outcome was assessment of non-inferiority of deferred GP",
"    <span class=\"nowrap\">",
"     IIb/IIIa",
"    </span>",
"    inhibitor use compared with upstream administration for the prevention of composite ischemic events. The following findings were noted at 30 days:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The composite primary end point of death, MI, or unplanned revascularization occurred more often in patients in the deferred group (7.9 versus 7.1 percent; relative risk 1.12, 95% CI 0.97-1.29) and therefore the criteria for non-inferiority for deferred therapy were not met. The excess risk with deferred GP",
"      <span class=\"nowrap\">",
"       IIb/IIIa",
"      </span>",
"      consisted entirely of an increase rate of unplanned revascularizations, however, not death or myocardial infarction.",
"     </li>",
"     <li>",
"      Deferred use resulted in significantly reduced 30 day rates of major bleeding (4.9 versus 6.1 percent). The lower rate of bleeding with deferred therapy probably reflects selective use. With deferred therapy, a GP",
"      <span class=\"nowrap\">",
"       IIb/IIIa",
"      </span>",
"      inhibitor would only be given to those undergoing PCI, while all patients would be treated with upstream therapy.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    In EARLY ACS, 9492 non-ST elevation high-risk ACS patients scheduled to undergo an invasive strategy were randomly assigned to either early (after randomization)",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?31/24/32135?source=see_link\">",
"     eptifibatide",
"    </a>",
"    or placebo with provisional use of eptifibatide after angiography (delayed) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/20/39242/abstract/58\">",
"     58",
"    </a>",
"    ]. High risk was defined as meeting two or more of the following criteria: ischemic changes on electrocardiography, a level of troponin or creatine kinase MB that was above the upper limit of normal, and an age of 60 years or greater. Early",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?24/7/24698?source=see_link\">",
"     aspirin",
"    </a>",
"    use (initial dose of 162 to 325 mg orally) was mandated; early",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?34/9/34969?source=see_link\">",
"     clopidogrel",
"    </a>",
"    use was encouraged but not mandated. Antithrombin therapy was used in over 94 percent of patients.",
"   </p>",
"   <p>",
"    The early use of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?31/24/32135?source=see_link\">",
"     eptifibatide",
"    </a>",
"    was associated with the following findings:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      There was no significant reduction in the rate of the primary composite outcome of death from any cause, myocardial infarction, recurrent ischemia requiring urgent revascularization, or thrombotic bailout at 96 hours (9.3 versus 10.0 percent; odds ratio [OR] 0.92, 95% CI 0.80 to 1.06).",
"     </li>",
"     <li>",
"      The likelihood of TIMI major hemorrhage was significantly increased (2.6 versus 1.8 percent; OR 0.015, 95% CI 1.07 to 1.89).",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    These two large trials, of similar but not identical design, did not demonstrate a significant benefit of early compared with delayed use of glycoprotein",
"    <span class=\"nowrap\">",
"     IIb/IIIa",
"    </span>",
"    inhibitor, even in high-risk patients with non-STEMI ACS who are scheduled to undergo early PCI. The early use of GP",
"    <span class=\"nowrap\">",
"     IIb/IIIa",
"    </span>",
"    use was associated with a significantly increased risk of bleeding. (See",
"    <a class=\"local\" href=\"#H21914160\">",
"     'Bleeding risk'",
"    </a>",
"    above.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1042799215\">",
"    <span class=\"h3\">",
"     Dosing",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?6/15/6392?source=see_link\">",
"     Abciximab",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?31/24/32135?source=see_link\">",
"     eptifibatide",
"    </a>",
"    , and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?13/2/13351?source=see_link\">",
"     tirofiban",
"    </a>",
"    have been evaluated in patients with non-ST elevation ACS. We prefer eptifibatide for patients in whom GP",
"    <span class=\"nowrap\">",
"     IIb/IIIa",
"    </span>",
"    receptor blocker will be started before PCI. For patients who will undergo PCI in the catheterization laboratory, we prefer either abciximab or eptifibatide. The basis for these preferences are that abciximab use prior to coronary angiography has not been sufficiently evaluated and the optimal dosing regimen for tirofiban is less clearly defined than for either abciximab or eptifibatide.",
"   </p>",
"   <p>",
"    The dosing regimens for the first two drugs are generally agreed upon, but there is uncertainty concerning the optimal dosing regimen for",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?13/2/13351?source=see_link\">",
"     tirofiban",
"    </a>",
"    in non-ST elevation ACS patients. It should be kept in mind that each drug has not been tested in all possible clinical scenarios, such as risk level or timing of PCI. The recommendations that follow are based on dosing regimens used in clinical trials:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?6/15/6392?source=see_link\">",
"       Abciximab",
"      </a>",
"      &mdash;A bolus of 0.25",
"      <span class=\"nowrap\">",
"       mg/kg",
"      </span>",
"      should be followed by a continuous infusion of 0.125",
"      <span class=\"nowrap\">",
"       mcg/kg/min",
"      </span>",
"      (maximum: 10",
"      <span class=\"nowrap\">",
"       mcg/min),",
"      </span>",
"      which is continued for 12 hours. As most of the trials that tested abciximab started the drug in the catheterization laboratory or soon before, we recommend that it not be used in patients in whom catheterization is delayed for more than four hours.",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?31/24/32135?source=see_link\">",
"       Eptifibatide",
"      </a>",
"      &mdash;A loading dose of 180",
"      <span class=\"nowrap\">",
"       mcg/kg",
"      </span>",
"      (maximum: 22.6 mg) over one to two minutes should be followed by a continuous infusion of 2",
"      <span class=\"nowrap\">",
"       mcg/kg/min",
"      </span>",
"      (maximum: 15",
"      <span class=\"nowrap\">",
"       mg/hour),",
"      </span>",
"      which is continued for 18 to 24 hours. A second",
"      <span class=\"nowrap\">",
"       180-mcg/kg",
"      </span>",
"      bolus should be given 10 minutes after the first bolus.",
"      <br/>",
"      <br/>",
"      The continuous infusion should be reduced by 50 percent in patients with estimated creatinine clearance &lt;50",
"      <span class=\"nowrap\">",
"       mL/min.",
"      </span>",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?13/2/13351?source=see_link\">",
"       Tirofiban",
"      </a>",
"      &mdash;A loading dose of 25",
"      <span class=\"nowrap\">",
"       mcg/kg",
"      </span>",
"      (referred to as the high-bolus dose) over three minutes, which should be followed by a continuous infusion of 0.15",
"      <span class=\"nowrap\">",
"       mcg/kg/min,",
"      </span>",
"      which is continued for 18 to 24 hours. This dosing is not in United States (US) licensed product information (the US approved dose is 0.4",
"      <span class=\"nowrap\">",
"       mcg/kg/min",
"      </span>",
"      over 30 minutes and infusion of 0.1",
"      <span class=\"nowrap\">",
"       mcg/kg/min).",
"      </span>",
"      This higher dose of tirofiban has shown benefit in small studies [",
"      <a class=\"abstract\" href=\"mobipreview.htm?38/20/39242/abstract/59,60\">",
"       59,60",
"      </a>",
"      ] and is in the licensed product information for the United Kingdom and some European countries, but has not been validated in large clinical trials. We are concerned that any lower dose will not achieve adequate GP",
"      <span class=\"nowrap\">",
"       IIb/IIIa",
"      </span>",
"      receptor blocked if given soon before PCI. The optimal dose for patients not undergoing PCI within four hours is unknown, but the US approved dose may achieve adequate platelet inhibition [",
"      <a class=\"abstract\" href=\"mobipreview.htm?38/20/39242/abstract/47,48,61\">",
"       47,48,61",
"      </a>",
"      ].",
"      <br/>",
"      <br/>",
"      If tirofiban is chosen, we suggest that the infusion dose reduced by 50 percent in patients with an estimated creatinine clearance of &lt;30",
"      <span class=\"nowrap\">",
"       mL/min.",
"      </span>",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H35\">",
"    <span class=\"h3\">",
"     Serum troponins",
"    </span>",
"    &nbsp;&mdash;&nbsp;An interesting observation from the PRISM, CAPTURE, and PARAGON B trials and a meta-analysis is that the benefit from GP",
"    <span class=\"nowrap\">",
"     IIb/IIIa",
"    </span>",
"    inhibition primarily occurred in the subset of patients who had elevations in troponin T",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    I [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/20/39242/abstract/54,62-64\">",
"     54,62-64",
"    </a>",
"    ]. In PRISM, this benefit was seen whether patients were managed medically or with revascularization (",
"    <a class=\"graphic graphic_figure graphicRef75639 \" href=\"mobipreview.htm?14/32/14862\">",
"     figure 8",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/20/39242/abstract/62\">",
"     62",
"    </a>",
"    ]. The same pattern of benefit limited to patients with elevated troponins was also noted in the ISAR-REACT 2 trial of patients also treated with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?34/9/34969?source=see_link\">",
"     clopidogrel",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/20/39242/abstract/55\">",
"     55",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H434345672\">",
"     'Evidence from recent trials'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    Increases in serum troponin T and I are considered to be a surrogate marker for thrombus formation, since they are associated with complex lesion characteristics and visible thrombus [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/20/39242/abstract/65\">",
"     65",
"    </a>",
"    ]. Such patients may be most likely to benefit from a GP",
"    <span class=\"nowrap\">",
"     IIb/IIIa",
"    </span>",
"    inhibitor.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H38\">",
"    <span class=\"h3\">",
"     Combined use with enoxaparin",
"    </span>",
"    &nbsp;&mdash;&nbsp;Although most of the trials have evaluated the safety and efficacy of the GP",
"    <span class=\"nowrap\">",
"     IIb/IIIa",
"    </span>",
"    agents in patients receiving unfractionated",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?39/34/40489?source=see_link\">",
"     heparin",
"    </a>",
"    , these drugs are also safe and of benefit when used with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?35/24/36233?source=see_link\">",
"     enoxaparin",
"    </a>",
"    , a low molecular weight heparin. Enoxaparin may be associated with improved outcomes compared to unfractionated heparin, particularly in high-risk patients. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?5/2/5162?source=see_link&amp;anchor=H14#H14\">",
"     \"Anticoagulant therapy in non-ST elevation acute coronary syndromes\", section on 'Enoxaparin versus UFH'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H921624744\">",
"    <span class=\"h3\">",
"     Patients selected for CABG",
"    </span>",
"    &nbsp;&mdash;&nbsp;We agree with the recommendation made in the 2011 American College of Cardiology",
"    <span class=\"nowrap\">",
"     Foundation/American",
"    </span>",
"    Heart Association guideline CABG which states that",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?31/24/32135?source=see_link\">",
"     eptifibatide",
"    </a>",
"    or",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?13/2/13351?source=see_link\">",
"     tirofiban",
"    </a>",
"    should be discontinued for at least two to four hours before surgery and that",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?6/15/6392?source=see_link\">",
"     abciximab",
"    </a>",
"    for at least 12 hours [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/20/39242/abstract/66\">",
"     66",
"    </a>",
"    ]. These time intervals are derived from pharmacokinetic and pharmacodynamic modeling of the return of platelet function.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H39\">",
"    <span class=\"h3\">",
"     Bleeding risk",
"    </span>",
"    &nbsp;&mdash;&nbsp;Major bleeding can occur after the administration of a GP",
"    <span class=\"nowrap\">",
"     IIb/IIIa",
"    </span>",
"    inhibitor as a consequence of inhibition of platelet function or thrombocytopenia. The mechanism and frequency of thrombocytopenia, as well as recommendations for measurement of platelet count, are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?24/21/24918?source=see_link\">",
"     \"Thrombocytopenia induced by glycoprotein IIb/IIIa inhibitors\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In randomized, placebo-controlled clinical trials of the GP",
"    <span class=\"nowrap\">",
"     IIb/IIIa",
"    </span>",
"    inhibitors,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?6/15/6392?source=see_link\">",
"     abciximab",
"    </a>",
"    had a 0 to 7 percent excess risk of major bleeding compared to placebo, while",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?13/2/13351?source=see_link\">",
"     tirofiban",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?31/24/32135?source=see_link\">",
"     eptifibatide",
"    </a>",
"    had a 0 to 2 percent excess risk. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?19/31/19961?source=see_link\">",
"     \"Early trials of platelet glycoprotein IIb/IIIa receptor inhibitors in coronary heart disease\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    However, most of these trials were completed before the stent era in which the administration of both",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?24/7/24698?source=see_link\">",
"     aspirin",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?34/9/34969?source=see_link\">",
"     clopidogrel",
"    </a>",
"    has become routine. Data on the rates of major bleeding in patients with non-ST elevation ACS treated with aspirin and clopidogrel are available from the ISAR-REACT 2 trial and the CRUSADE initiative:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In ISAR-REACT 2, all patients received pretreatment with",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?24/7/24698?source=see_link\">",
"       aspirin",
"      </a>",
"      and 600 mg of",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?34/9/34969?source=see_link\">",
"       clopidogrel",
"      </a>",
"      [",
"      <a class=\"abstract\" href=\"mobipreview.htm?38/20/39242/abstract/55\">",
"       55",
"      </a>",
"      ]. The rates of major bleeding for patients receiving",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?6/15/6392?source=see_link\">",
"       abciximab",
"      </a>",
"      or placebo were not significantly different (4.5 and 4.0, respectively).",
"     </li>",
"     <li>",
"      In an analysis of 32,600 patients with a non-ST elevation ACS in the CRUSADE initiative, the rate of major bleeding, defined as a drop in hematocrit of &ge;12 percent, need for transfusion, or intracranial hemorrhage, was significantly higher in patients who received GP",
"      <span class=\"nowrap\">",
"       IIb/IIIa",
"      </span>",
"      inhibitors (10.1 versus 6.8 percent) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?38/20/39242/abstract/67\">",
"       67",
"      </a>",
"      ]. Some of this increase in risk may have been due to",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?34/9/34969?source=see_link\">",
"       clopidogrel",
"      </a>",
"      , since the rate of clopidogrel use was higher in the patients treated with a GP",
"      <span class=\"nowrap\">",
"       IIb/IIIa",
"      </span>",
"      inhibitor (63 versus 39 percent in those who did not receive a GP",
"      <span class=\"nowrap\">",
"       IIb/IIIa",
"      </span>",
"      inhibitor).",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Two groups of patients at particularly high risk for GP",
"    <span class=\"nowrap\">",
"     IIb/IIIa-induced",
"    </span>",
"    major bleeding are those with moderate to severe renal insufficiency [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/20/39242/abstract/68,69\">",
"     68,69",
"    </a>",
"    ] and women [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/20/39242/abstract/67\">",
"     67",
"    </a>",
"    ]. Although elderly patients are at increased risk of bleeding after PCI, the risk of bleeding requiring transfusion or major bleeding does not appear to be influenced by whether or not a GP",
"    <span class=\"nowrap\">",
"     IIb/IIIa",
"    </span>",
"    inhibitor is given [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/20/39242/abstract/70\">",
"     70",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H40\">",
"    <span class=\"h2\">",
"     Summary",
"    </span>",
"    &nbsp;&mdash;&nbsp;Based upon the evidence cited above, GP",
"    <span class=\"nowrap\">",
"     IIb/IIIa",
"    </span>",
"    inhibitor therapy is warranted in some ACS patients treated with PCI, particularly those not treated with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?17/48/18184?source=see_link\">",
"     bivalirudin",
"    </a>",
"    anticoagulation. For these patients, who are usually treated with unfractionated",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?39/34/40489?source=see_link\">",
"     heparin",
"    </a>",
"    , GP",
"    <span class=\"nowrap\">",
"     IIb/IIIa",
"    </span>",
"    inhibitor use should be deferred until after diagnostic angiography in most patients to decrease the risk of bleeding.",
"   </p>",
"   <p>",
"    Based primarily on the results of the ISAR-REACT 2 trial discussed above, we make the following recommendations for ACS patients scheduled for PCI in whom",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?39/34/40489?source=see_link\">",
"     heparin",
"    </a>",
"    is chosen as the anticoagulant:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      For troponin positive patients, we suggest adding a GP",
"      <span class=\"nowrap\">",
"       IIb/IIIa",
"      </span>",
"      inhibitor. The evidence to do so is of higher quality if",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?34/9/34969?source=see_link\">",
"       clopidogrel",
"      </a>",
"      is the P2Y12 receptor blocker, and of lower quality if",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?38/0/38919?source=see_link\">",
"       ticagrelor",
"      </a>",
"      or",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?26/63/27639?source=see_link\">",
"       prasugrel",
"      </a>",
"      is chosen.",
"     </li>",
"     <li>",
"      For troponin negative patients, we recommend not adding GP",
"      <span class=\"nowrap\">",
"       IIb/IIIa",
"      </span>",
"      inhibitor.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    As we prefer",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?17/48/18184?source=see_link\">",
"     bivalirudin",
"    </a>",
"    (either as the first anticoagulant or after a switch from",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?39/34/40489?source=see_link\">",
"     heparin",
"    </a>",
"    ) to heparin in patients with non-ST elevation ACS undergoing PCI, we recommend not routinely adding a GP",
"    <span class=\"nowrap\">",
"     IIb/IIIa",
"    </span>",
"    inhibitor in this setting. (see",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?5/2/5162?source=see_link&amp;anchor=H42#H42\">",
"     \"Anticoagulant therapy in non-ST elevation acute coronary syndromes\", section on 'Summary and recommendations'",
"    </a>",
"    ). The ISAR-REACT 4 trial found no significant evidence of benefit and the bleeding rate was higher with GP",
"    <span class=\"nowrap\">",
"     IIb/IIIa",
"    </span>",
"    use.",
"   </p>",
"   <p>",
"    For patients treated with either",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?17/48/18184?source=see_link\">",
"     bivalirudin",
"    </a>",
"    or a",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?39/34/40489?source=see_link\">",
"     heparin",
"    </a>",
"    and evidence of ongoing ischemia, the addition of GP",
"    <span class=\"nowrap\">",
"     IIb/III",
"    </span>",
"    inhibitor prior to diagnostic angiography is reasonable. This recommendation applies to patients who have received a P2Y12 inhibitor and to patients in whom a decision has been made to withhold P2Y12 inhibitor until diagnostic angiography.",
"   </p>",
"   <p>",
"    While there is evidence to recommend GP",
"    <span class=\"nowrap\">",
"     IIb/IIIa",
"    </span>",
"    inhibitor therapy in high-risk patients treated with a conservative approach, the evidence comes from studies performed before the routine use of P2Y12 receptor blockers. Thus, we suggest not adding a GP",
"    <span class=\"nowrap\">",
"     IIb/IIIa",
"    </span>",
"    inhibitor for these high-risk patients on dual oral antiplatelet therapy, unless there is evidence of recurrent ischemia.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7692495\">",
"    <span class=\"h1\">",
"     PAR-1 ANTAGONISTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Protease-activated-receptor 1 (PAR-1) antagonists inhibit thrombin induced platelet activation. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?26/35/27194?source=see_link&amp;anchor=H6#H6\">",
"     \"Overview of hemostasis\", section on 'Thrombin'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In the TRACER trial, nearly 13,000 patients with an acute coronary syndrome (more than 90 percent had a non-ST elevation MI) were randomly assigned to vorapaxar, an oral PAR-1 antagonist, or placebo in addition to",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?24/7/24698?source=see_link\">",
"     aspirin",
"    </a>",
"    and a platelet P2Y12 receptor blocker [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/20/39242/abstract/71\">",
"     71",
"    </a>",
"    ]. The trial was stopped early due to an increase in bleeding with vorapaxar, although the targeted number of end points had been achieved by conclusion of the trial. Voraxapar did not significantly reduce the primary composite ischemic end point in TRACER, but major bleeding and intracranial hemorrhage rates were substantially increased.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H159339577\">",
"    <span class=\"h1\">",
"     PATIENTS TAKING ORAL ANTICOAGULANTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Some patients with acute coronary syndromes are receiving oral anticoagulant therapy at the time of the event. This issue is discussed in detail elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?13/31/13818?source=see_link\">",
"     \"Triple antithrombotic therapy in patients with cardiovascular disease\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H159341032\">",
"    <span class=\"h1\">",
"     RECOMMENDATIONS OF OTHERS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Guidelines from American College of Cardiology",
"    <span class=\"nowrap\">",
"     Foundation/American",
"    </span>",
"    Heart Association (2007 and revised in 2012) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/20/39242/abstract/45,72\">",
"     45,72",
"    </a>",
"    ], the European Society of Cardiology (2011) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/20/39242/abstract/44\">",
"     44",
"    </a>",
"    ], and the American College of Chest Physicians (2012) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/20/39242/abstract/73\">",
"     73",
"    </a>",
"    ] have included recommendations for the use of antiplatelet agents in non-ST elevation ACS. Our recommendations below are generally consistent with recommendations found in these guidelines. &nbsp;",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H43\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Our recommendations for the use of antiplatelet therapy in patients with non-ST elevation acute coronary syndromes (ACS) follow. Additional recommendations for the long-term use of these drugs are found elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?10/24/10634?source=see_link&amp;anchor=H3#H3\">",
"     \"Antiplatelet therapy after coronary artery stenting\", section on 'Long-term antiplatelet therapy'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?36/12/37066?source=see_link&amp;anchor=H611367206#H611367206\">",
"     \"Benefits and risks of aspirin in secondary and primary prevention of cardiovascular disease\", section on 'Secondary prevention'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    An early step in the treatment of patients with non-ST elevation ACS is choice between choosing an invasive or a conservation strategy. This issue is discussed in detail elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?29/1/29722?source=see_link&amp;anchor=H32#H32\">",
"     \"Coronary arteriography and revascularization for unstable angina or non-ST elevation acute myocardial infarction\", section on 'Summary and recommendations'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The following comments regarding antiplatelet therapy apply irrespective of whether an invasive or a conservative approach is chosen:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      For all patients with non-ST elevation ACS, we recommend dual antiplatelet therapy with",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?24/7/24698?source=see_link\">",
"       aspirin",
"      </a>",
"      and a platelet P2Y12 receptor blocker, as opposed to single antiplatelet therapy (",
"      <a class=\"grade\" href=\"._grade_2?title=Grade 1B\">",
"       Grade 1B",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H28\">",
"       'Summary'",
"      </a>",
"      above.)",
"      <br/>",
"      <br/>",
"      We recommend aspirin and a platelet P2Y12 receptor blocker for a minimum of one year (",
"      <a class=\"grade\" href=\"._grade_2?title=Grade 1B\">",
"       Grade 1B",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H19\">",
"       'Duration of therapy'",
"      </a>",
"      above.)",
"      <br/>",
"      <br/>",
"      We recommend that aspirin be given immediately (at the time of diagnosis) (",
"      <a class=\"grade\" href=\"._grade_1?title=Grade 1A\">",
"       Grade 1A",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H10\">",
"       'Dose'",
"      </a>",
"      above.)",
"      <br/>",
"      <br/>",
"      The first aspirin tablet should be chewed and contain 162 to 325 mg. At discharge, the dose of aspirin should be 75 to 100 mg daily; if",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?38/0/38919?source=see_link\">",
"       ticagrelor",
"      </a>",
"      is chosen as the platelet P2Y12 receptor blocker, the discharge dose of aspirin should not be greater than 100 mg daily.",
"     </li>",
"     <li>",
"      With regard to P2Y12 receptor blockers:",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      The loading dose for",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?38/0/38919?source=see_link\">",
"       ticagrelor",
"      </a>",
"      is 180 mg, for",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?26/63/27639?source=see_link\">",
"       prasugrel",
"      </a>",
"      60 mg, and for",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?34/9/34969?source=see_link\">",
"       clopidogrel",
"      </a>",
"      300 to 600 mg (600 mg is preferred for patients undergoing an invasive strategy). (See",
"      <a class=\"local\" href=\"#H1354953\">",
"       'Timing'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      In deciding between one P2Y12 receptor blocker and another, the risk of bleeding needs to be taken into account. (See",
"      <a class=\"local\" href=\"#H21914160\">",
"       'Bleeding risk'",
"      </a>",
"      above.) In addition, cost or availability may enter into decision making. &nbsp;",
"     </li>",
"     <li>",
"      For those patients with a history of gastrointestinal bleeding, drugs that reduce the risk of recurrent bleeding (eg, proton pump inhibitors) should be given. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?36/20/37193?source=see_link\">",
"       \"Overview of the acute management of unstable angina and non-ST elevation myocardial infarction\"",
"      </a>",
"      .) &nbsp;",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H434346709\">",
"    <span class=\"h2\">",
"     Invasive approach",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      For patients scheduled for an invasive approach, we suggest that P2Y12 receptor blocker therapy be given at the time of diagnosis rather than after coronary angiography (",
"      <a class=\"grade\" href=\"._grade_5?title=Grade 2B\">",
"       Grade 2B",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H1354953\">",
"       'Timing'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      For patients scheduled for an invasive approach and in whom a P2Y12 receptor blocker will be withheld until the coronary anatomy is known, we recommend either",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?38/0/38919?source=see_link\">",
"       ticagrelor",
"      </a>",
"      or",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?26/63/27639?source=see_link\">",
"       prasugrel",
"      </a>",
"      as opposed to",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?34/9/34969?source=see_link\">",
"       clopidogrel",
"      </a>",
"      (",
"      <a class=\"grade\" href=\"._grade_1?title=Grade 1A\">",
"       Grade 1A",
"      </a>",
"      ). Issues such as cost and local preference may reasonably influence the choice between the two. (See",
"      <a class=\"local\" href=\"#H28\">",
"       'Summary'",
"      </a>",
"      above.)",
"      <br/>",
"      <br/>",
"      For patients who are managed with an invasive approach and who will receive P2Y12 receptor blocker prior to diagnostic angiography, we recommend ticagrelor instead of clopidogrel (",
"      <a class=\"grade\" href=\"._grade_1?title=Grade 1A\">",
"       Grade 1A",
"      </a>",
"      ).",
"      <strong>",
"      </strong>",
"      We suggest not giving prasugrel in these patients (",
"      <a class=\"grade\" href=\"._grade_5?title=Grade 2B\">",
"       Grade 2B",
"      </a>",
"      ). If prasugrel is chosen before diagnostic angiography, it should be given only to patients at low risk of bleeding. (See",
"      <a class=\"local\" href=\"#H28\">",
"       'Summary'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H21914160\">",
"       'Bleeding risk'",
"      </a>",
"      above.) &nbsp;",
"     </li>",
"     <li>",
"      We prefer",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?17/48/18184?source=see_link\">",
"       bivalirudin",
"      </a>",
"      to",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?39/34/40489?source=see_link\">",
"       heparin",
"      </a>",
"      (anticoagulant therapy) in patients with non-ST elevation ACS undergoing PCI. (See",
"      <a class=\"local\" href=\"#H40\">",
"       'Summary'",
"      </a>",
"      above.) For patients in whom bivalirudin will be used as the anticoagulant, either after a switch from heparin or as the initial anticoagulant, we recommend not adding GP",
"      <span class=\"nowrap\">",
"       IIb/IIIa",
"      </span>",
"      inhibitor to the antiplatelet regimen (",
"      <a class=\"grade\" href=\"._grade_2?title=Grade 1B\">",
"       Grade 1B",
"      </a>",
"      ).",
"      <br/>",
"      <br/>",
"      For troponin positive patients in whom heparin is chosen as the anticoagulant and",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?34/9/34969?source=see_link\">",
"       clopidogrel",
"      </a>",
"      is chosen as the P2Y12 receptor blocker, we suggest addition of a GP",
"      <span class=\"nowrap\">",
"       IIb/IIIa",
"      </span>",
"      inhibitor (",
"      <a class=\"grade\" href=\"._grade_5?title=Grade 2B\">",
"       Grade 2B",
"      </a>",
"      ). For these patients treated with heparin in whom either",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?38/0/38919?source=see_link\">",
"       ticagrelor",
"      </a>",
"      or",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?26/63/27639?source=see_link\">",
"       prasugrel",
"      </a>",
"      is chosen as the P2Y12 receptor blocker, we suggest addition of a GP",
"      <span class=\"nowrap\">",
"       IIb/IIIa",
"      </span>",
"      inhibitor (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). In most patients the GP",
"      <span class=\"nowrap\">",
"       IIb/IIIa",
"      </span>",
"      inhibitor should be started after diagnostic angiography. (See",
"      <a class=\"local\" href=\"#H29\">",
"       'GP IIb/IIIa inhibitors'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H16\">",
"       'Clopidogrel'",
"      </a>",
"      above.)",
"      <br/>",
"      <br/>",
"      For very high-risk patients (eg, markedly elevated troponin, recurrent ischemic discomfort, dynamic electrocardiographic",
"      <strong>",
"      </strong>",
"      changes, or hemodynamic instability) undergoing an invasive approach, we suggest the early (before angiography) addition of a GP",
"      <span class=\"nowrap\">",
"       IIb/IIIa",
"      </span>",
"      inhibitor (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H434345672\">",
"       'Evidence from recent trials'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      For patients in whom GP",
"      <span class=\"nowrap\">",
"       IIb/IIIa",
"      </span>",
"      inhibitor will be started before angiography, we suggest",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?31/24/32135?source=see_link\">",
"       eptifibatide",
"      </a>",
"      in preference to",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?6/15/6392?source=see_link\">",
"       abciximab",
"      </a>",
"      or",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?13/2/13351?source=see_link\">",
"       tirofiban",
"      </a>",
"      (",
"      <a class=\"grade\" href=\"._grade_5?title=Grade 2B\">",
"       Grade 2B",
"      </a>",
"      ).",
"      <br/>",
"      <br/>",
"      For patients in whom GP",
"      <span class=\"nowrap\">",
"       IIb/IIIa",
"      </span>",
"      inhibitor will be started after diagnostic angiography, we suggest abciximab or eptifibatide in preference to tirofiban (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). Cost and local practice may influence the choice of agent. (See",
"      <a class=\"local\" href=\"#H1042799215\">",
"       'Dosing'",
"      </a>",
"      above and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?27/8/27786?source=see_link\">",
"       \"Antithrombotic therapy for percutaneous coronary intervention: General use\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H112647407\">",
"    <span class=\"h2\">",
"     Conservative approach",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      For those patients managed without an invasive approach (conservative approach), we recommend",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?38/0/38919?source=see_link\">",
"       ticagrelor",
"      </a>",
"      rather than",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?34/9/34969?source=see_link\">",
"       clopidogrel",
"      </a>",
"      (",
"      <a class=\"grade\" href=\"._grade_2?title=Grade 1B\">",
"       Grade 1B",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H28\">",
"       'Summary'",
"      </a>",
"      above.)",
"      <br/>",
"      <br/>",
"      For such patients who cannot receive ticagrelor, we suggest clopidogrel rather than",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?26/63/27639?source=see_link\">",
"       prasugrel",
"      </a>",
"      (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ).",
"     </li>",
"     <li>",
"      For very high-risk patients (eg, elevated troponin, recurrent ischemic discomfort, dynamic electrocardiographic changes, or hemodynamic instability) who will be managed with a conservative approach, we suggest adding a GP",
"      <span class=\"nowrap\">",
"       IIb/IIIa",
"      </span>",
"      inhibitor (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H40\">",
"       'Summary'",
"      </a>",
"      above.)",
"      <br/>",
"      <br/>",
"      For these patients, we suggest",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?31/24/32135?source=see_link\">",
"       eptifibatide",
"      </a>",
"      or",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?13/2/13351?source=see_link\">",
"       tirofiban",
"      </a>",
"      instead of",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?6/15/6392?source=see_link\">",
"       abciximab",
"      </a>",
"      (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). The GP",
"      <span class=\"nowrap\">",
"       IIb/IIIa",
"      </span>",
"      inhibitor infusion should be initiated at presentation and continued for 48 to 72 hours. Dose adjustment may be necessary in the presence of chronic kidney disease.",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/20/39242/abstract/1\">",
"      Foster CJ, Prosser DM, Agans JM, et al. Molecular identification and characterization of the platelet ADP receptor targeted by thienopyridine antithrombotic drugs. J Clin Invest 2001; 107:1591.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/20/39242/abstract/2\">",
"      Patrono C. Aspirin as an antiplatelet drug. N Engl J Med 1994; 330:1287.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/20/39242/abstract/3\">",
"      Antithrombotic Trialists' Collaboration. Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients. BMJ 2002; 324:71.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/20/39242/abstract/4\">",
"      Wright RS, Anderson JL, Adams CD, et al. 2011 ACCF/AHA Focused Update of the Guidelines for the Management of Patients With Unstable Angina/ Non-ST-Elevation Myocardial Infarction (Updating the 2007 Guideline): a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. Circulation 2011; 123:2022.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/20/39242/abstract/5\">",
"      Yusuf S, Zhao F, Mehta SR, et al. Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation. N Engl J Med 2001; 345:494.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/20/39242/abstract/6\">",
"      Harrington RA, Becker RC, Cannon CP, et al. Antithrombotic therapy for non-ST-segment elevation acute coronary syndromes: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). Chest 2008; 133:670S.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/20/39242/abstract/7\">",
"      Sch&ouml;mig A. Ticagrelor--is there need for a new player in the antiplatelet-therapy field? N Engl J Med 2009; 361:1108.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/20/39242/abstract/8\">",
"      Mehta SR, Yusuf S, Peters RJ, et al. Effects of pretreatment with clopidogrel and aspirin followed by long-term therapy in patients undergoing percutaneous coronary intervention: the PCI-CURE study. Lancet 2001; 358:527.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/20/39242/abstract/9\">",
"      Budaj A, Yusuf S, Mehta SR, et al. Benefit of clopidogrel in patients with acute coronary syndromes without ST-segment elevation in various risk groups. Circulation 2002; 106:1622.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/20/39242/abstract/10\">",
"      Yusuf S, Mehta SR, Zhao F, et al. Early and late effects of clopidogrel in patients with acute coronary syndromes. Circulation 2003; 107:966.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/20/39242/abstract/11\">",
"      Steinhubl SR, Berger PB, Mann JT 3rd, et al. Early and sustained dual oral antiplatelet therapy following percutaneous coronary intervention: a randomized controlled trial. JAMA 2002; 288:2411.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/20/39242/abstract/12\">",
"      Steinhubl SR, Berger PB, Brennan DM, et al. Optimal timing for the initiation of pre-treatment with 300 mg clopidogrel before percutaneous coronary intervention. J Am Coll Cardiol 2006; 47:939.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/20/39242/abstract/13\">",
"      Patti G, Colonna G, Pasceri V, et al. Randomized trial of high loading dose of clopidogrel for reduction of periprocedural myocardial infarction in patients undergoing coronary intervention: results from the ARMYDA-2 (Antiplatelet therapy for Reduction of MYocardial Damage during Angioplasty) study. Circulation 2005; 111:2099.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/20/39242/abstract/14\">",
"      Cuisset T, Frere C, Quilici J, et al. Benefit of a 600-mg loading dose of clopidogrel on platelet reactivity and clinical outcomes in patients with non-ST-segment elevation acute coronary syndrome undergoing coronary stenting. J Am Coll Cardiol 2006; 48:1339.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/20/39242/abstract/15\">",
"      CURRENT-OASIS 7 Investigators, Mehta SR, Bassand JP, et al. Dose comparisons of clopidogrel and aspirin in acute coronary syndromes. N Engl J Med 2010; 363:930.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/20/39242/abstract/16\">",
"      Mehta SR, Tanguay JF, Eikelboom JW, et al. Double-dose versus standard-dose clopidogrel and high-dose versus low-dose aspirin in individuals undergoing percutaneous coronary intervention for acute coronary syndromes (CURRENT-OASIS 7): a randomised factorial trial. Lancet 2010; 376:1233.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/20/39242/abstract/17\">",
"      Ho PM, Peterson ED, Wang L, et al. Incidence of death and acute myocardial infarction associated with stopping clopidogrel after acute coronary syndrome. JAMA 2008; 299:532.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/20/39242/abstract/18\">",
"      CAPRIE Steering Committee. A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). CAPRIE Steering Committee. Lancet 1996; 348:1329.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/20/39242/abstract/19\">",
"      Cannon CP, CAPRIE Investigators. Effectiveness of clopidogrel versus aspirin in preventing acute myocardial infarction in patients with symptomatic atherothrombosis (CAPRIE trial). Am J Cardiol 2002; 90:760.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/20/39242/abstract/20\">",
"      Bhatt DL, Flather MD, Hacke W, et al. Patients with prior myocardial infarction, stroke, or symptomatic peripheral arterial disease in the CHARISMA trial. J Am Coll Cardiol 2007; 49:1982.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/20/39242/abstract/21\">",
"      Balsano F, Rizzon P, Violi F, et al. Antiplatelet treatment with ticlopidine in unstable angina. A controlled multicenter clinical trial. The Studio della Ticlopidina nell'Angina Instabile Group. Circulation 1990; 82:17.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/20/39242/abstract/22\">",
"      Wiviott SD, Braunwald E, McCabe CH, et al. Prasugrel versus clopidogrel in patients with acute coronary syndromes. N Engl J Med 2007; 357:2001.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/20/39242/abstract/23\">",
"      Wiviott SD, Braunwald E, McCabe CH, et al. Intensive oral antiplatelet therapy for reduction of ischaemic events including stent thrombosis in patients with acute coronary syndromes treated with percutaneous coronary intervention and stenting in the TRITON-TIMI 38 trial: a subanalysis of a randomised trial. Lancet 2008; 371:1353.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/20/39242/abstract/24\">",
"      Murphy SA, Antman EM, Wiviott SD, et al. Reduction in recurrent cardiovascular events with prasugrel compared with clopidogrel in patients with acute coronary syndromes from the TRITON-TIMI 38 trial. Eur Heart J 2008; 29:2473.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/20/39242/abstract/25\">",
"      Morrow DA, Wiviott SD, White HD, et al. Effect of the novel thienopyridine prasugrel compared with clopidogrel on spontaneous and procedural myocardial infarction in the Trial to Assess Improvement in Therapeutic Outcomes by Optimizing Platelet Inhibition with Prasugrel-Thrombolysis in Myocardial Infarction 38: an application of the classification system from the universal definition of myocardial infarction. Circulation 2009; 119:2758.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/20/39242/abstract/26\">",
"      Antman EM, Wiviott SD, Murphy SA, et al. Early and late benefits of prasugrel in patients with acute coronary syndromes undergoing percutaneous coronary intervention: a TRITON-TIMI 38 (TRial to Assess Improvement in Therapeutic Outcomes by Optimizing Platelet InhibitioN with Prasugrel-Thrombolysis In Myocardial Infarction) analysis. J Am Coll Cardiol 2008; 51:2028.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/20/39242/abstract/27\">",
"      Roe MT, Armstrong PW, Fox KA, et al. Prasugrel versus clopidogrel for acute coronary syndromes without revascularization. N Engl J Med 2012; 367:1297.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/20/39242/abstract/28\">",
"      Wallentin L, Becker RC, Budaj A, et al. Ticagrelor versus clopidogrel in patients with acute coronary syndromes. N Engl J Med 2009; 361:1045.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/20/39242/abstract/29\">",
"      Kohli P, Wallentin L, Reyes E, et al. Reduction in first and recurrent cardiovascular events with ticagrelor compared with clopidogrel in the PLATO Study. Circulation 2013; 127:673.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/20/39242/abstract/30\">",
"      Mahaffey KW, Wojdyla DM, Carroll K, et al. Ticagrelor compared with clopidogrel by geographic region in the Platelet Inhibition and Patient Outcomes (PLATO) trial. Circulation 2011; 124:544.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/20/39242/abstract/31\">",
"      James S, Budaj A, Aylward P, et al. Ticagrelor versus clopidogrel in acute coronary syndromes in relation to renal function: results from the Platelet Inhibition and Patient Outcomes (PLATO) trial. Circulation 2010; 122:1056.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/20/39242/abstract/32\">",
"      Held C, Asenblad N, Bassand JP, et al. Ticagrelor versus clopidogrel in patients with acute coronary syndromes undergoing coronary artery bypass surgery: results from the PLATO (Platelet Inhibition and Patient Outcomes) trial. J Am Coll Cardiol 2011; 57:672.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/20/39242/abstract/33\">",
"      James SK, Roe MT, Cannon CP, et al. Ticagrelor versus clopidogrel in patients with acute coronary syndromes intended for non-invasive management: substudy from prospective randomised PLATelet inhibition and patient Outcomes (PLATO) trial. BMJ 2011; 342:d3527.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/20/39242/abstract/34\">",
"      Steg PG, James S, Harrington RA, et al. Ticagrelor versus clopidogrel in patients with ST-elevation acute coronary syndromes intended for reperfusion with primary percutaneous coronary intervention: A Platelet Inhibition and Patient Outcomes (PLATO) trial subgroup analysis. Circulation 2010; 122:2131.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/20/39242/abstract/35\">",
"      Fox KA, Mehta SR, Peters R, et al. Benefits and risks of the combination of clopidogrel and aspirin in patients undergoing surgical revascularization for non-ST-elevation acute coronary syndrome: the Clopidogrel in Unstable angina to prevent Recurrent ischemic Events (CURE) Trial. Circulation 2004; 110:1202.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/20/39242/abstract/36\">",
"      Chu MW, Wilson SR, Novick RJ, et al. Does clopidogrel increase blood loss following coronary artery bypass surgery? Ann Thorac Surg 2004; 78:1536.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/20/39242/abstract/37\">",
"      Hongo RH, Ley J, Dick SE, Yee RR. The effect of clopidogrel in combination with aspirin when given before coronary artery bypass grafting. J Am Coll Cardiol 2002; 40:231.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/20/39242/abstract/38\">",
"      Mehta RH, Roe MT, Mulgund J, et al. Acute clopidogrel use and outcomes in patients with non-ST-segment elevation acute coronary syndromes undergoing coronary artery bypass surgery. J Am Coll Cardiol 2006; 48:281.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/20/39242/abstract/39\">",
"      Berger JS, Frye CB, Harshaw Q, et al. Impact of clopidogrel in patients with acute coronary syndromes requiring coronary artery bypass surgery: a multicenter analysis. J Am Coll Cardiol 2008; 52:1693.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/20/39242/abstract/40\">",
"      Kim JH, Newby LK, Clare RM, et al. Clopidogrel use and bleeding after coronary artery bypass graft surgery. Am Heart J 2008; 156:886.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/20/39242/abstract/41\">",
"      Bavry AA, Lincoff AM. Is clopidogrel cardiovascular medicine's double-edged sword? Circulation 2006; 113:1638.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/20/39242/abstract/42\">",
"      Ebrahimi R, Dyke C, Mehran R, et al. Outcomes following pre-operative clopidogrel administration in patients with acute coronary syndromes undergoing coronary artery bypass surgery: the ACUITY (Acute Catheterization and Urgent Intervention Triage strategY) trial. J Am Coll Cardiol 2009; 53:1965.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/20/39242/abstract/43\">",
"      Nijjer SS, Watson G, Athanasiou T, Malik IS. Safety of clopidogrel being continued until the time of coronary artery bypass grafting in patients with acute coronary syndrome: a meta-analysis of 34 studies. Eur Heart J 2011; 32:2970.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/20/39242/abstract/44\">",
"      Hamm CW, Bassand JP, Agewall S, et al. ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation: The Task Force for the management of acute coronary syndromes (ACS) in patients presenting without persistent ST-segment elevation of the European Society of Cardiology (ESC). Eur Heart J 2011; 32:2999.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/20/39242/abstract/45\">",
"      2012 Writing Committee Members, Jneid H, Anderson JL, et al. 2012 ACCF/AHA focused update of the guideline for the management of patients with unstable angina/Non-ST-elevation myocardial infarction (updating the 2007 guideline and replacing the 2011 focused update): a report of the American College of Cardiology Foundation/American Heart Association Task Force on practice guidelines. Circulation 2012; 126:875.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/20/39242/abstract/46\">",
"      Inhibition of platelet glycoprotein IIb/IIIa with eptifibatide in patients with acute coronary syndromes. The PURSUIT Trial Investigators. Platelet Glycoprotein IIb/IIIa in Unstable Angina: Receptor Suppression Using Integrilin Therapy. N Engl J Med 1998; 339:436.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/20/39242/abstract/47\">",
"      A comparison of aspirin plus tirofiban with aspirin plus heparin for unstable angina. Platelet Receptor Inhibition in Ischemic Syndrome Management (PRISM) Study Investigators. N Engl J Med 1998; 338:1498.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/20/39242/abstract/48\">",
"      Inhibition of the platelet glycoprotein IIb/IIIa receptor with tirofiban in unstable angina and non-Q-wave myocardial infarction. Platelet Receptor Inhibition in Ischemic Syndrome Management in Patients Limited by Unstable Signs and Symptoms (PRISM-PLUS) Study Investigators. N Engl J Med 1998; 338:1488.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/20/39242/abstract/49\">",
"      Effects of platelet glycoprotein IIb/IIIa blockade with tirofiban on adverse cardiac events in patients with unstable angina or acute myocardial infarction undergoing coronary angioplasty. The RESTORE Investigators. Randomized Efficacy Study of Tirofiban for Outcomes and REstenosis. Circulation 1997; 96:1445.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/20/39242/abstract/50\">",
"      Simoons ML, GUSTO IV-ACS Investigators. Effect of glycoprotein IIb/IIIa receptor blocker abciximab on outcome in patients with acute coronary syndromes without early coronary revascularisation: the GUSTO IV-ACS randomised trial. Lancet 2001; 357:1915.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/20/39242/abstract/51\">",
"      Bhatt DL, Lincoff AM, Califf RM, et al. The benefit of abciximab in percutaneous coronary revascularization is not device-specific. Am J Cardiol 2000; 85:1060.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/20/39242/abstract/52\">",
"      Kleiman NS, Lincoff AM, Flaker GC, et al. Early percutaneous coronary intervention, platelet inhibition with eptifibatide, and clinical outcomes in patients with acute coronary syndromes. PURSUIT Investigators. Circulation 2000; 101:751.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/20/39242/abstract/53\">",
"      Valgimigli M, Percoco G, Barbieri D, et al. The additive value of tirofiban administered with the high-dose bolus in the prevention of ischemic complications during high-risk coronary angioplasty: the ADVANCE Trial. J Am Coll Cardiol 2004; 44:14.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/20/39242/abstract/54\">",
"      Boersma E, Harrington RA, Moliterno DJ, et al. Platelet glycoprotein IIb/IIIa inhibitors in acute coronary syndromes: a meta-analysis of all major randomised clinical trials. Lancet 2002; 359:189.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/20/39242/abstract/55\">",
"      Kastrati A, Mehilli J, Neumann FJ, et al. Abciximab in patients with acute coronary syndromes undergoing percutaneous coronary intervention after clopidogrel pretreatment: the ISAR-REACT 2 randomized trial. JAMA 2006; 295:1531.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/20/39242/abstract/56\">",
"      Kastrati A, Neumann FJ, Schulz S, et al. Abciximab and heparin versus bivalirudin for non-ST-elevation myocardial infarction. N Engl J Med 2011; 365:1980.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/20/39242/abstract/57\">",
"      Stone GW, Bertrand ME, Moses JW, et al. Routine upstream initiation vs deferred selective use of glycoprotein IIb/IIIa inhibitors in acute coronary syndromes: the ACUITY Timing trial. JAMA 2007; 297:591.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/20/39242/abstract/58\">",
"      Giugliano RP, White JA, Bode C, et al. Early versus delayed, provisional eptifibatide in acute coronary syndromes. N Engl J Med 2009; 360:2176.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/20/39242/abstract/59\">",
"      van 't Hof AW, Valgimigli M. Defining the role of platelet glycoprotein receptor inhibitors in STEMI: focus on tirofiban. Drugs 2009; 69:85.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/20/39242/abstract/60\">",
"      Schneider DJ, Herrmann HC, Lakkis N, et al. Enhanced early inhibition of platelet aggregation with an increased bolus of tirofiban. Am J Cardiol 2002; 90:1421.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/20/39242/abstract/61\">",
"      Bolognese L, Falsini G, Liistro F, et al. Randomized comparison of upstream tirofiban versus downstream high bolus dose tirofiban or abciximab on tissue-level perfusion and troponin release in high-risk acute coronary syndromes treated with percutaneous coronary interventions: the EVEREST trial. J Am Coll Cardiol 2006; 47:522.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/20/39242/abstract/62\">",
"      Heeschen C, Hamm CW, Goldmann B, et al. Troponin concentrations for stratification of patients with acute coronary syndromes in relation to therapeutic efficacy of tirofiban. PRISM Study Investigators. Platelet Receptor Inhibition in Ischemic Syndrome Management. Lancet 1999; 354:1757.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/20/39242/abstract/63\">",
"      Hamm CW, Heeschen C, Goldmann B, et al. Benefit of abciximab in patients with refractory unstable angina in relation to serum troponin T levels. c7E3 Fab Antiplatelet Therapy in Unstable Refractory Angina (CAPTURE) Study Investigators. N Engl J Med 1999; 340:1623.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/20/39242/abstract/64\">",
"      Newby LK, Ohman EM, Christenson RH, et al. Benefit of glycoprotein IIb/IIIa inhibition in patients with acute coronary syndromes and troponin t-positive status: the paragon-B troponin T substudy. Circulation 2001; 103:2891.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/20/39242/abstract/65\">",
"      Heeschen C, van Den Brand MJ, Hamm CW, Simoons ML. Angiographic findings in patients with refractory unstable angina according to troponin T status. Circulation 1999; 100:1509.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/20/39242/abstract/66\">",
"      Hillis LD, Smith PK, Anderson JL, et al. 2011 ACCF/AHA Guideline for Coronary Artery Bypass Graft Surgery: executive summary: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. Circulation 2011; 124:2610.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/20/39242/abstract/67\">",
"      Alexander KP, Chen AY, Newby LK, et al. Sex differences in major bleeding with glycoprotein IIb/IIIa inhibitors: results from the CRUSADE (Can Rapid risk stratification of Unstable angina patients Suppress ADverse outcomes with Early implementation of the ACC/AHA guidelines) initiative. Circulation 2006; 114:1380.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/20/39242/abstract/68\">",
"      Freeman RV, Mehta RH, Al Badr W, et al. Influence of concurrent renal dysfunction on outcomes of patients with acute coronary syndromes and implications of the use of glycoprotein IIb/IIIa inhibitors. J Am Coll Cardiol 2003; 41:718.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/20/39242/abstract/69\">",
"      Best PJ, Lennon R, Gersh BJ, et al. Safety of abciximab in patients with chronic renal insufficiency who are undergoing percutaneous coronary interventions. Am Heart J 2003; 146:345.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/20/39242/abstract/70\">",
"      Sadeghi HM, Grines CL, Chandra HR, et al. Percutaneous coronary interventions in octogenarians. glycoprotein IIb/IIIa receptor inhibitors' safety profile. J Am Coll Cardiol 2003; 42:428.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/20/39242/abstract/71\">",
"      Tricoci P, Huang Z, Held C, et al. Thrombin-receptor antagonist vorapaxar in acute coronary syndromes. N Engl J Med 2012; 366:20.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/20/39242/abstract/72\">",
"      Anderson JL, Adams CD, Antman EM, et al. ACC/AHA 2007 guidelines for the management of patients with unstable angina/non ST-elevation myocardial infarction: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Revise the 2002 Guidelines for the Management of Patients With Unstable Angina/Non ST-Elevation Myocardial Infarction): developed in collaboration with the American College of Emergency Physicians, the Society for Cardiovascular Angiography and Interventions, and the Society of Thoracic Surgeons: endorsed by the American Association of Cardiovascular and Pulmonary Rehabilitation and the Society for Academic Emergency Medicine. Circulation 2007; 116:e148.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/20/39242/abstract/73\">",
"      Vandvik PO, Lincoff AM, Gore JM, et al. Primary and secondary prevention of cardiovascular disease: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest 2012; 141:e637S.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 95 Version 27.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0504-110.137.129.113-9E7C666159-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f38_20_39242=[""].join("\n");
var outline_f38_20_39242=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H43\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      CLASSIFICATION OF ANTIPLATELET AGENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      ASPIRIN",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Evidence of benefit",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Dose",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      Side effects",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5666304\">",
"      Summary",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      PLATELET P2Y12 RECEPTOR BLOCKERS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      Clopidogrel",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      - Dose",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H353597156\">",
"      - Patients already taking clopidogrel",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      - Duration of therapy",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H1354569\">",
"      - After CABG",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      Ticlopidine",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      Prasugrel",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H960560098\">",
"      - Patients undergoing PCI",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H960560252\">",
"      - Patients not undergoing PCI",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H26\">",
"      Ticagrelor",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H1140488073\">",
"      Cangrelor",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H1354953\">",
"      Timing",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H21914160\">",
"      Bleeding risk",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H1354842\">",
"      Early CABG",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H21913850\">",
"      Non-bleeding adverse effects",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H28\">",
"      Summary",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H434346467\">",
"      RESISTANCE/NONRESPONSE TO ASPIRIN OR CLOPIDOGREL",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H29\">",
"      GP IIb/IIIa INHIBITORS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H434345741\">",
"      Evidence from early trials",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H434345672\">",
"      Evidence from recent trials",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H609705878\">",
"      Special considerations",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H32\">",
"      - Timing",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H1042799215\">",
"      - Dosing",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H35\">",
"      - Serum troponins",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H38\">",
"      - Combined use with enoxaparin",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H921624744\">",
"      - Patients selected for CABG",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H39\">",
"      - Bleeding risk",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H40\">",
"      Summary",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H7692495\">",
"      PAR-1 ANTAGONISTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H159339577\">",
"      PATIENTS TAKING ORAL ANTICOAGULANTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H159341032\">",
"      RECOMMENDATIONS OF OTHERS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H43\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H434346709\">",
"      Invasive approach",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H112647407\">",
"      Conservative approach",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"CARD/95\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"CARD/95|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?7/17/7446\" title=\"figure 1\">",
"      Platelet interactions",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?28/48/29440\" title=\"figure 2\">",
"      Mechanism antiplatelet agents",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?33/29/34269\" title=\"figure 3\">",
"      Prostaglandin synthesis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?40/4/41037\" title=\"figure 4\">",
"      Clopidogrel outcome in CURE",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?19/30/19936\" title=\"figure 5\">",
"      Benefit clopidogrel over time",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?17/15/17661\" title=\"figure 6\">",
"      Aspirin 325 in unstable angina",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?16/24/16781\" title=\"figure 7\">",
"      Aspirin 75 in unstable angina",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?14/32/14862\" title=\"figure 8\">",
"      Tirofiban elevated troponin I",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"CARD/95|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?42/34/43564\" title=\"table 1\">",
"      Effect of antiplatelet therapy on vascular events",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   CALCULATORS",
"  </h1>",
"  <div id=\"relatedCalculators\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"calc calc_professional\" href=\"mobipreview.htm?5/34/5665?source=related_link\" title=\"calculator 1\">",
"      Calculator: Thrombolysis in Myocardial Infarction (TIMI) score for unstable angina or non ST elevation myocardial infarction",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?5/2/5162?source=related_link\">",
"      Anticoagulant therapy in non-ST elevation acute coronary syndromes",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?34/49/35610?source=related_link\">",
"      Antiplatelet agents in acute ST elevation myocardial infarction",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?10/24/10634?source=related_link\">",
"      Antiplatelet therapy after coronary artery stenting",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?40/37/41562?source=related_link\">",
"      Antithrombotic therapy for intracoronary stent implantation: Clinical trials",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?27/8/27786?source=related_link\">",
"      Antithrombotic therapy for percutaneous coronary intervention: General use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?36/12/37066?source=related_link\">",
"      Benefits and risks of aspirin in secondary and primary prevention of cardiovascular disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?29/9/29850?source=related_link\">",
"      Congenital and acquired disorders of platelet function",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?29/1/29722?source=related_link\">",
"      Coronary arteriography and revascularization for unstable angina or non-ST elevation acute myocardial infarction",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?8/59/9146?source=related_link\">",
"      Coronary artery stent thrombosis: Incidence and risk factors",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?34/25/35226?source=related_link\">",
"      Early noncardiac complications of coronary artery bypass graft surgery",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?19/31/19961?source=related_link\">",
"      Early trials of platelet glycoprotein IIb/IIIa receptor inhibitors in coronary heart disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?3/32/3594?source=related_link\">",
"      Effect of cardiac drugs on platelet function",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?39/26/40360?source=related_link\">",
"      Medical therapy to prevent complications after coronary artery bypass graft surgery",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?36/34/37418?source=related_link\">",
"      Nonresponse and resistance to clopidogrel",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?26/35/27194?source=related_link\">",
"      Overview of hemostasis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?36/20/37193?source=related_link\">",
"      Overview of the acute management of unstable angina and non-ST elevation myocardial infarction",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?20/9/20632?source=related_link\">",
"      Periprocedural and long-term gastrointestinal bleeding in patients undergoing percutaneous coronary intervention",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?1/7/1146?source=related_link\">",
"      Platelet biology",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?4/4/4167?source=related_link\">",
"      The role of platelets in coronary heart disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?25/7/25721?source=related_link\">",
"      The role of the vulnerable plaque in acute coronary syndromes",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?24/21/24918?source=related_link\">",
"      Thrombocytopenia induced by glycoprotein IIb/IIIa inhibitors",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?13/31/13818?source=related_link\">",
"      Triple antithrombotic therapy in patients with cardiovascular disease",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f38_20_39243="Etiology of lower extremity ischemia";
var content_f38_20_39243=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=SURG%2F75390&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=SURG%2F75390&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Etiology of lower extremity ischemia",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Major causes",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Atherosclerosis",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Thombosed aneurysm",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Arterial injury",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Arterial dissection",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Atheroembolism",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Thromboembolism",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Thromboangiitis obliterans (Buerger's disease)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Other causes",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1_start\">",
"        Aorto-iliac",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Retroperitoneal fibrosis",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Radiation fibrosis",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Tumor",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1_start\">",
"        Iliac",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Fibromuscular dysplasia",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Iliac endofibrosis (athletic injury)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1_start\">",
"        Iliofemoral",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Pseudoxanthoma elasticum",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1_start\">",
"        Popliteal",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Popliteal entrapment",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Adventitial cystic disease",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f38_20_39243=[""].join("\n");
var outline_f38_20_39243=null;
var title_f38_20_39244="Screening ECG features SCD A";
var content_f38_20_39244=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=CARD%2F59279&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=5\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=CARD%2F59279&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=5\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    ECG features of the cardiac diseases detectable at pre-participation screening in young competitive athletes",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        QTc interval",
"       </td>",
"       <td class=\"subtitle1\">",
"        P wave",
"       </td>",
"       <td class=\"subtitle1\">",
"        PR interval",
"       </td>",
"       <td class=\"subtitle1\">",
"        QRS complex",
"       </td>",
"       <td class=\"subtitle1\">",
"        ST interval",
"       </td>",
"       <td class=\"subtitle1\">",
"        T wave",
"       </td>",
"       <td class=\"subtitle1\">",
"        Arrhythmias",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\" colspan=\"7\">",
"        HCM",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Normal",
"       </td>",
"       <td>",
"        (Left atrial enlargement)",
"       </td>",
"       <td>",
"        Normal",
"       </td>",
"       <td>",
"        Increased voltages in mid-left precordial leads; abnormal Q waves in inferior and/or lateral leads;&nbsp;(LAD, LBBB); (delta wave)",
"       </td>",
"       <td>",
"        Down-sloping (up-sloping)",
"       </td>",
"       <td>",
"        Inverted in mid-left precordialleads; (giant&nbsp;and negative in the apical variant)",
"       </td>",
"       <td>",
"        (Atrial fibrillation); (PVB); (VT)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\" colspan=\"7\">",
"        Arrhythmogenic right ventricular cardiomyopathy/dysplasia",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Normal",
"       </td>",
"       <td>",
"        Normal",
"       </td>",
"       <td>",
"        Normal",
"       </td>",
"       <td>",
"        Prolonged &gt;110 ms in right precordial leads; epsilon wave in right precordial leads; reduced voltages &le;0.5 mV in frontal leads; (RBBB)",
"       </td>",
"       <td>",
"        (Up-sloping in right precordial leads)",
"       </td>",
"       <td>",
"        Inverted right in&nbsp;precordial&nbsp;leads",
"       </td>",
"       <td>",
"        PVB with aLBBB pattern; (VT with a&nbsp;LBBB pattern)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\" colspan=\"7\">",
"        Dilated cardiomyopathy",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Normal",
"       </td>",
"       <td>",
"        (Left atrial enlargement)",
"       </td>",
"       <td>",
"        (Prolonged &ge;0.21 s)",
"       </td>",
"       <td>",
"        LBBB",
"       </td>",
"       <td>",
"        Down-sloping (up-sloping)",
"       </td>",
"       <td>",
"        Inverted in inferior and/or lateral leads",
"       </td>",
"       <td>",
"        PVB; (VT)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\" colspan=\"7\">",
"        Long QT syndrome",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Prolonged",
"       </td>",
"       <td rowspan=\"3\">",
"        Normal",
"       </td>",
"       <td rowspan=\"3\">",
"        Normal",
"       </td>",
"       <td rowspan=\"3\">",
"        Normal",
"       </td>",
"       <td rowspan=\"3\">",
"        Normal",
"       </td>",
"       <td rowspan=\"3\">",
"        Bifid or biphasic in all leads",
"       </td>",
"       <td rowspan=\"3\">",
"        (PVB); (torsade de pointes)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        &gt;440 ms in males",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        &gt;460 ms in females",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Corrado D, Pelliccia A, Bjornstad HH, et al. Cardiovascular pre-participation screening of young competitive athletes for prevention of sudden death: proposal for a common European protocol. Consensus Statement of the Study Group of Sport Cardiology of the Working Group of Cardiac Rehabilitation and Exercise Physiology and the Working Group of Myocardial and Pericardial Diseases of the European Society of Cardiology. Eur Heart J 2005; 26:516. Copyright &copy; 2005 Oxford University Press.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f38_20_39244=[""].join("\n");
var outline_f38_20_39244=null;
var title_f38_20_39245="WHO MEC for women with HIV AIDS";
var content_f38_20_39245=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=OBGYN%2F75345&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=OBGYN%2F75345&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    World Health Organization medical eligibility for contraceptive use: HIV/AIDS",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tr>",
"      <td class=\"subtitle1\">",
"       Condition",
"      </td>",
"      <td class=\"subtitle1\">",
"       COC",
"      </td>",
"      <td class=\"subtitle1\">",
"       CIC",
"      </td>",
"      <td class=\"subtitle1\">",
"       P/R",
"      </td>",
"      <td class=\"subtitle1\">",
"       POP",
"      </td>",
"      <td class=\"subtitle1\">",
"       <p>",
"        DMPA",
"       </p>",
"       <p>",
"        NET-EN",
"       </p>",
"      </td>",
"      <td class=\"subtitle1\">",
"       <p>",
"        LNG/ETG",
"       </p>",
"       <p>",
"        Implants",
"       </p>",
"      </td>",
"      <td class=\"subtitle1\">",
"       Cu-IUD",
"      </td>",
"      <td class=\"subtitle1\">",
"       LNG-IUD",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"subtitle2_left\" colspan=\"1\" rowspan=\"2\">",
"       High risk of HIV",
"      </td>",
"      <td colspan=\"1\" rowspan=\"2\">",
"       1",
"      </td>",
"      <td colspan=\"1\" rowspan=\"2\">",
"       1",
"      </td>",
"      <td colspan=\"1\" rowspan=\"2\">",
"       1",
"      </td>",
"      <td colspan=\"1\" rowspan=\"2\">",
"       1",
"      </td>",
"      <td colspan=\"1\" rowspan=\"2\">",
"       1",
"      </td>",
"      <td colspan=\"1\" rowspan=\"2\">",
"       1",
"      </td>",
"      <td>",
"       Initiation: 2",
"      </td>",
"      <td>",
"       Initiation: 2",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Continuation: 2",
"      </td>",
"      <td>",
"       Continuation: 2",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"subtitle2_left\" colspan=\"1\" rowspan=\"2\">",
"       HIV-Infected",
"      </td>",
"      <td colspan=\"1\" rowspan=\"2\">",
"       1",
"      </td>",
"      <td colspan=\"1\" rowspan=\"2\">",
"       1",
"      </td>",
"      <td colspan=\"1\" rowspan=\"2\">",
"       1",
"      </td>",
"      <td colspan=\"1\" rowspan=\"2\">",
"       1",
"      </td>",
"      <td colspan=\"1\" rowspan=\"2\">",
"       1",
"      </td>",
"      <td colspan=\"1\" rowspan=\"2\">",
"       1",
"      </td>",
"      <td>",
"       Initiation: 2",
"      </td>",
"      <td>",
"       Initiation: 2",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Continuation: 2",
"      </td>",
"      <td>",
"       Continuation: 2",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"subtitle2_left\" colspan=\"1\" rowspan=\"2\">",
"       AIDS",
"      </td>",
"      <td colspan=\"1\" rowspan=\"2\">",
"       1",
"      </td>",
"      <td colspan=\"1\" rowspan=\"2\">",
"       1",
"      </td>",
"      <td colspan=\"1\" rowspan=\"2\">",
"       1",
"      </td>",
"      <td colspan=\"1\" rowspan=\"2\">",
"       1",
"      </td>",
"      <td colspan=\"1\" rowspan=\"2\">",
"       1",
"      </td>",
"      <td colspan=\"1\" rowspan=\"2\">",
"       1",
"      </td>",
"      <td>",
"       Initiation: 3",
"      </td>",
"      <td>",
"       Initiation: 3",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Continuation: 2",
"      </td>",
"      <td>",
"       Continuation: 2",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent1\" colspan=\"1\" rowspan=\"2\">",
"       Clinically well on ARV therapy",
"      </td>",
"      <td colspan=\"6\" rowspan=\"2\">",
"       See Antiretroviral therapy (ARV)",
"      </td>",
"      <td>",
"       Initiation: 2/3",
"      </td>",
"      <td>",
"       Initiation: 2/3",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Continuation: 2",
"      </td>",
"      <td>",
"       Continuation: 2",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"subtitle1_left\" colspan=\"9\">",
"       Other infections",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"subtitle2_left\" colspan=\"9\">",
"       Schistosomiasis",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent1\">",
"       Uncomplicated",
"      </td>",
"      <td>",
"       1",
"      </td>",
"      <td>",
"       1",
"      </td>",
"      <td>",
"       1",
"      </td>",
"      <td>",
"       1",
"      </td>",
"      <td>",
"       1",
"      </td>",
"      <td>",
"       1",
"      </td>",
"      <td>",
"       1",
"      </td>",
"      <td>",
"       1",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent1\">",
"       Fibrosis of the liver",
"      </td>",
"      <td>",
"       1",
"      </td>",
"      <td>",
"       1",
"      </td>",
"      <td>",
"       1",
"      </td>",
"      <td>",
"       1",
"      </td>",
"      <td>",
"       1",
"      </td>",
"      <td>",
"       1",
"      </td>",
"      <td>",
"       1",
"      </td>",
"      <td>",
"       1",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"subtitle2_left\" colspan=\"9\">",
"       Tuberculosis",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent1\" colspan=\"1\" rowspan=\"2\">",
"       Non-pelvic",
"      </td>",
"      <td colspan=\"1\" rowspan=\"2\">",
"       1",
"      </td>",
"      <td colspan=\"1\" rowspan=\"2\">",
"       1",
"      </td>",
"      <td colspan=\"1\" rowspan=\"2\">",
"       1",
"      </td>",
"      <td colspan=\"1\" rowspan=\"2\">",
"       1",
"      </td>",
"      <td colspan=\"1\" rowspan=\"2\">",
"       1",
"      </td>",
"      <td colspan=\"1\" rowspan=\"2\">",
"       1",
"      </td>",
"      <td>",
"       Initiation: 1",
"      </td>",
"      <td>",
"       Initiation: 1",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Continuation: 1",
"      </td>",
"      <td>",
"       Continuation: 1",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent1\" colspan=\"1\" rowspan=\"2\">",
"       Known pelvic",
"      </td>",
"      <td colspan=\"1\" rowspan=\"2\">",
"       1",
"      </td>",
"      <td colspan=\"1\" rowspan=\"2\">",
"       1",
"      </td>",
"      <td colspan=\"1\" rowspan=\"2\">",
"       1",
"      </td>",
"      <td colspan=\"1\" rowspan=\"2\">",
"       1",
"      </td>",
"      <td colspan=\"1\" rowspan=\"2\">",
"       1",
"      </td>",
"      <td colspan=\"1\" rowspan=\"2\">",
"       1",
"      </td>",
"      <td>",
"       Initiation: 4",
"      </td>",
"      <td>",
"       Initiation: 4",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Continuation: 3",
"      </td>",
"      <td>",
"       Continuation: 3",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"subtitle2_left\">",
"       Malaria",
"      </td>",
"      <td>",
"       1",
"      </td>",
"      <td>",
"       1",
"      </td>",
"      <td>",
"       1",
"      </td>",
"      <td>",
"       1",
"      </td>",
"      <td>",
"       1",
"      </td>",
"      <td>",
"       1",
"      </td>",
"      <td>",
"       1",
"      </td>",
"      <td>",
"       1",
"      </td>",
"     </tr>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     1: A condition for which there is no restriction for the use of the contraceptive method.",
"     <br>",
"      2: A condition where the advantages of using the method generally outweigh the theoretical or proven risks.",
"      <br>",
"       3: A condition where the theoretical or proven risks usually outweigh the advantages of using the method.",
"       <br>",
"        4: A condition which represents an unacceptable health risk if the contraceptive method is used.",
"        <br>",
"         COC: low-dose combined oral contraceptive; CIC: combined injectable contraceptives; P: combined patch; R: combined vaginal ring; POP: progestogen-only pill; DMPA: depot medroxyprogesterone acetate; NET-EN: norethisterone enantate; LNG: levonorgestrel; ETG: etonogestrel; ECP: emergency contraceptive pill; Cu-IUD: copper intrauterine device; LNG-IUD: levonorgestrel-releasing IUDs; E-IUD: copper-IUD for emergency contraception; BARR: barrier methods; FAB: fertility awareness-based methods; LAM: lactational amenorrhoea method; CI: coitus interruptus; STER: female and male sterilization.",
"        </br>",
"       </br>",
"      </br>",
"     </br>",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: file://www.who.int/reproductive-health/publications/mec/summary.html. Copyright &copy; 2006 World Health Organization.",
"     <br>",
"      <br>",
"       Reaffirmed February 16, 2012.",
"      </br>",
"     </br>",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f38_20_39245=[""].join("\n");
var outline_f38_20_39245=null;
var title_f38_20_39246="EMR suction technique cartoon";
var content_f38_20_39246=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=GAST%2F76963&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=GAST%2F76963&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Cartoon illustrating the cap-assisted suction technique for endoscopic mucosal resection",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 410px; height: 249px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    A submucosal saline injection (B) is used to raise the lesion (A), which is aspirated into a hood and permits snare excision of the isolated lesion (C).",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Christopher Gostout, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f38_20_39246=[""].join("\n");
var outline_f38_20_39246=null;
var title_f38_20_39247="Standard LMA";
var content_f38_20_39247=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=EM%2F63766&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=EM%2F63766&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 536px\">",
"   <div class=\"ttl\">",
"    Laryngeal mask airway",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 516px; height: 229px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     With permission from Mercury Medical.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f38_20_39247=[""].join("\n");
var outline_f38_20_39247=null;
